[
  {
    "name": "von Willebrand Disease",
    "aliases": [
      "von Willebrand Disease"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-eut88ppq4",
        "type": "regulatory_news",
        "date": "2025-09-05T21:34:10.000Z",
        "title": "FDA Approves Expanded Use of Vonvendi for von Willebrand Disease, Including for Certain Uses for Children",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-vonvendi-von-willebrand-disease-including-certain-uses-children",
        "source": "FDA Press Announcements",
        "summary": "The U.S. Food and Drug Administration today approved expanded use of Vonvendi [von Willebrand factor (Recombinant)] for routine preventative (prophylactic) use in adults (age 18 years and older) with all types of von Willebrand disease (VWD) and on-demand and treatment of bleeding episodes and perio",
        "severity": 5
      }
    ],
    "products": [
      "Administration today",
      "of bleeding"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.387Z",
    "monitoring_since": "2025-09-07T14:46:07.386Z"
  },
  {
    "name": "FDA Launches Green List to Protect Americans from Illegal Imported GLP",
    "aliases": [
      "FDA Launches Green List to Protect Americans from Illegal Imported GLP"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-4je4x7wx4",
        "type": "import_alert",
        "date": "2025-09-05T15:05:29.000Z",
        "title": "FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-launches-green-list-protect-americans-illegal-imported-glp-1-drug-ingredients",
        "source": "FDA Press Announcements",
        "summary": "The U.S. Food and Drug Administration today established a “green list” import alert to help stop potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the U.S. market.",
        "severity": 7
      },
      {
        "id": "379683e054aecfc3b3497254eacbeeeb",
        "type": "regulatory_news",
        "date": "2025-09-05T04:00:00.000Z",
        "title": "FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOeUpYZ0JlQzltX2t3WFVraHZCLWl4VEszY2N3MDAzdnVud2xxT3B5Zi1tTGx5VEU5aGFEYVlBUndraXlTU0prcU5Sd0c1SHVQN3d2aGszX0ZOUFVzcU0tOUoyRzhySzd5NkNCVzhzNDhsT0huMkpXY2d5ZjNSdDhWYkh2OGhSQUZFemw2dFdyeGd4YkxYTTRJUFljdWtMd3VFQ1ZLQzVIdkptMW9rVW5xYTN2QmJvc3hobFRlZ00yTjA2LVpQZ3dPNGFFUDVzZw?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Administration today",
      "Ingredients  fda"
    ],
    "facilities": [],
    "risk_score": null,
    "last_updated": "2025-09-08T12:30:00.134Z",
    "monitoring_since": "2025-09-07T14:46:07.387Z",
    "compliance_score": 85
  },
  {
    "name": "FDA Announces Real",
    "aliases": [
      "FDA Announces Real"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-4tkwetmy5",
        "type": "crl",
        "date": "2025-09-04T13:23:32.000Z",
        "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
        "source": "FDA Press Announcements",
        "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
        "severity": 9
      },
      {
        "id": "03c52031e82b610e2559e723c9820352",
        "type": "crl",
        "date": "2025-09-04T04:00:00.000Z",
        "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNVFdoVlBOSnBCeWZqcUs5by1MMXJwU29qMUlEelRwRFZXYk0yUUlrQmpPSmUtb0ZkNVU0SlRHeVk0bjNjbDRibVNKeTRyX3NmMU41UjREQ1NwQ1N4MC04WXBTRDZwelAydml6Q0RPV2hkME5paWxEWXlFOVR1dXBxWGlZRG9HMVVFeXJkT0NaOUdXSkNjQW90OTRVemszYm9BcUlsNmNXX01xRXBJZzhyX0dnNEltRkVtUnFoakxrSFdWS20yMFZvVzJyOG1BUTM3bE5QMEcyVVFnOU1NenM4Uw?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89  fda.gov",
        "severity": 9,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Administration today"
    ],
    "facilities": [],
    "risk_score": null,
    "last_updated": "2025-09-08T12:30:00.101Z",
    "monitoring_since": "2025-09-07T14:46:07.387Z",
    "compliance_score": 70
  },
  {
    "name": "Unknown",
    "aliases": [
      "Unknown Company"
    ],
    "violations": [
      {
        "id": "fc8b03b22be78b0462b2453f83e2531b",
        "type": "regulatory_news",
        "date": "2025-09-08T11:00:33.000Z",
        "title": "Biotech vet Harvey Berger steps into CEO role at Arena BioWorks",
        "link": "https://endpoints.news/biotech-vet-harvey-berger-steps-into-ceo-role-at-arena-bioworks/",
        "source": "Endpoints News",
        "summary": "Less than two years after making their public debut, the founders of Arena BioWorks have tapped longtime biotech pro Harvey Berger to take over as CEO.\r\n\r\n And he’s just completed his first task by narrowing ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "62470c94c51466c514deaa7ad270a3f1",
        "type": "regulatory_news",
        "date": "2025-09-08T11:00:00.000Z",
        "title": "STAT+: Biotech veteran Harvey Berger takes over as CEO of billionaire-backed Arena Bioworks",
        "link": "https://www.statnews.com/2025/09/08/arena-bioworks-harvey-berger-ceo/?utm_campaign=rss",
        "source": "STAT News Biotech",
        "summary": "Arena BioWorks, the research institute that launched last year with $500 million from a group of high-profile billionaires, has brought on a new CEO.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "bc37a2f015d208df353d7fce43977a92",
        "type": "regulatory_news",
        "date": "2025-09-08T10:55:13.000Z",
        "title": "STAT+: Rapport shares soar after successful mid-stage seizure trial",
        "link": "https://www.statnews.com/2025/09/08/rapport-rap219-focal-seizures-epilepsy-trial-results/?utm_campaign=rss",
        "source": "STAT News Biotech",
        "summary": "A Rapport Therapeutics seizure medicine succeeded in a mid-stage clinical trial, sending company shares soaring.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "c8cad5109f437956f658d6fe93ea3ac6",
        "type": "regulatory_news",
        "date": "2025-09-08T09:00:00.000Z",
        "title": "How sponsors are staying ahead in the obesity trial landscape",
        "link": "https://www.biopharmadive.com/spons/how-sponsors-are-staying-ahead-in-the-obesity-trial-landscape/759209/",
        "source": "BioPharma Dive",
        "summary": "Aligning digital innovation with thoughtful design is accelerating progress.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "2fe3c4eff8518793090a4d8b20e860df",
        "type": "regulatory_news",
        "date": "2025-09-08T08:22:44.000Z",
        "title": "#WCLC25: AstraZeneca’s Tagrisso combo extends survival by 10 months in EGFR-mutant lung cancer",
        "link": "https://endpoints.news/wclc25-astrazenecas-tagrisso-combo-extends-survival-by-10-months-in-egfr-mutant-lung-cancer/",
        "source": "Endpoints News",
        "summary": "The combination of AstraZeneca’s Tagrisso and chemotherapy cut the risk of death by 23% compared to Tagrisso alone for patients with advanced EGFR-mutant lung cancer.\r\n\r\n In the FLAURA2 study's key overall survival endpoint, patients who ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "5a342ab7d45a838c411afd67651cb192",
        "type": "regulatory_news",
        "date": "2025-09-08T07:15:52.000Z",
        "title": "#WorldSleep2025: Alkermes’ success in Phase 2 narcolepsy trial is clouded by side effects",
        "link": "https://endpoints.news/alkermes-success-in-phase-2-narcolepsy-trial-is-clouded-by-side-effects/",
        "source": "Endpoints News",
        "summary": "Alkermes’ narcolepsy drug candidate alixorexton significantly improved how long patients can stay awake in a mid-stage trial, but a high rate of vision-related side effects could cause trouble for the treatment.\r\n\r\n Back in July, the ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "221b2cb930145894c145a1893cb56e46",
        "type": "regulatory_news",
        "date": "2025-09-08T07:15:19.000Z",
        "title": "#WorldSleep2025: Takeda’s Phase 3 narcolepsy results could make it first mover in multibillion-dollar market",
        "link": "https://endpoints.news/takedas-phase-3-narcolepsy-results-could-make-it-first-mover-in-multibillion-dollar-market/",
        "source": "Endpoints News",
        "summary": "Takeda has shared detailed data from two Phase 3 trials of its orexin agonist in narcolepsy type 1, bringing the Japanese drugmaker a step closer to a market that Wall Street says could generate sales ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "e728696e7e1ef3301662ec15bd7270c9",
        "type": "regulatory_news",
        "date": "2025-09-08T07:15:00.000Z",
        "title": "STAT+: Alkermes, Takeda show encouraging data on narcolepsy drugs",
        "link": "https://www.statnews.com/2025/09/08/alkermes-takeda-narcolepsy-sleep-medicines/?utm_campaign=rss",
        "source": "STAT News Biotech",
        "summary": "Alkermes and Takeda released data on drug candidates that could fuel the race to develop a new class of therapies and transform sleep medicine.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "53e852db2201db11ae645660da994ee5",
        "type": "regulatory_news",
        "date": "2025-09-08T07:00:40.000Z",
        "title": "Mitochondrial startup gets £50M to test lead drug in ALS, Parkinson's",
        "link": "https://endpoints.news/mitochondrial-startup-gets-50m-to-test-lead-drug-in-als-parkinsons/",
        "source": "Endpoints News",
        "summary": "A British startup trying to target a mitochondrial pathway for neuro disorders has a heap of cash to work with, and it's going after a new frontier in one of the most challenging drug development ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "2db7c4aefe08d7d593286cb1017b3f6b",
        "type": "regulatory_news",
        "date": "2025-09-08T06:30:05.000Z",
        "title": "Servier buys Medicxi startup's fragile X candidate for up to $450M",
        "link": "https://endpoints.news/servier-buys-medicxi-startups-fragile-x-candidate-for-up-to-450m/",
        "source": "Endpoints News",
        "summary": "French pharma Servier will pay up to $450 million for an experimental fragile X syndrome drug from UK-based startup Kaerus Bioscience, the companies said Monday morning.\r\n\r\n The deal for KER-0193, an oral small molecule that ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "194cb31bb98de7aec22e7242ba729503",
        "type": "regulatory_news",
        "date": "2025-09-08T02:00:04.000Z",
        "title": "China biotech Epigenic raises $60M to test CRISPR epigenetic therapies",
        "link": "https://endpoints.news/china-biotech-epigenic-raises-60m-to-test-crispr-epigenetic-therapies/",
        "source": "Endpoints News",
        "summary": "Epigenic Therapeutics has raised a $60 million Series B financing to ramp up clinical tests of what it hopes could be a cure for chronic hepatitis B, using a version of CRISPR gene editing that ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "9a05a74d559d49afc87d6761a8db7d9c",
        "type": "regulatory_news",
        "date": "2025-09-07T21:31:10.000Z",
        "title": "#WCLC25: Merck and Daiichi Sankyo head to FDA with ADC for small cell lung cancer",
        "link": "https://endpoints.news/wclc25-merck-and-daiichi-sankyo-head-to-fda-with-adc-for-small-cell-lung-cancer/",
        "source": "Endpoints News",
        "summary": "Nearly half of patients with an aggressive form of lung cancer saw their tumors shrink substantially after receiving an antibody-drug conjugate developed by Daiichi Sankyo and Merck, according to the results of a mid-stage trial ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "cd8c6490f5371a8c2c0df2e9b7abc044",
        "type": "regulatory_news",
        "date": "2025-09-07T08:45:00.000Z",
        "title": "STAT+: Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster",
        "link": "https://www.statnews.com/2025/09/07/summit-therapeutics-lung-cancer-ivonescimab/?utm_campaign=rss",
        "source": "STAT News Biotech",
        "summary": "Summit Therapeutics may have a geography problem with its lung cancer drug ivonescimab.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "e775eda92abfcfb64cceb841bf2a7bc3",
        "type": "regulatory_news",
        "date": "2025-09-07T07:30:43.000Z",
        "title": "#WCLC25: Summit reports full Phase 3 data from first group of Western lung cancer patients",
        "link": "https://endpoints.news/wclc25-summit-reports-full-phase-3-data-from-first-group-of-western-lung-cancer-patients/",
        "source": "Endpoints News",
        "summary": "Summit Therapeutics released a much-anticipated cut of data in North American and European lung cancer patients on Sunday, trumpeting a new analysis in which its drug ivonescimab, when added to chemotherapy, reduced the risk of ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "8504185da035276ee016e526a939c385",
        "type": "regulatory_news",
        "date": "2025-09-06T10:00:53.000Z",
        "title": "Maraganore, Meanwell team up; FDA publishes CRLs; Endpoints 11: Where are they now?; and more",
        "link": "https://endpoints.news/maraganore-meanwell-team-up-fda-publishes-crls-endpoints-11-where-are-they-now-and-more/",
        "source": "Endpoints News",
        "summary": "Welcome back to Endpoints Weekly! It’s almost time for the Endpoints 11 event in Boston, where we’ll unveil our team’s choice of companies shaping the future of biopharma. Until then, check out Kyle LaHucik’s story ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "FDA Press Announcements-1757331501837-npiq59hhi",
        "type": "regulatory_news",
        "date": "2025-09-05T21:34:10.000Z",
        "title": "FDA Approves Expanded Use of Vonvendi for von Willebrand Disease, Including for Certain Uses for Children",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-vonvendi-von-willebrand-disease-including-certain-uses-children",
        "source": "FDA Press Announcements",
        "summary": "The U.S. Food and Drug Administration today approved expanded use of Vonvendi [von Willebrand factor (Recombinant)] for routine preventative (prophylactic) use in adults (age 18 years and older) with all types of von Willebrand disease (VWD) and on-demand and treatment of bleeding episodes and perio",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757331502593-uylbwbg0i",
        "type": "crl",
        "date": "2025-09-05T18:56:15.000Z",
        "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
        "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
        "severity": 9
      },
      {
        "id": "STAT News Pharma-1757331501944-r3snlph7x",
        "type": "regulatory_news",
        "date": "2025-09-05T18:48:39.000Z",
        "title": "STAT+: Patient groups cheer as the WHO adds diabetes and cystic fibrosis drugs to its essential medicines list",
        "link": "https://www.statnews.com/pharmalot/2025/09/05/who-medicines-pharma-biotech-diabetes-obesity-cystic-fibrosis-vertex-lilly-novo-sanofi/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "For the first time, the WHO has added various high-cost treatments for diabetes and cystic fibrosis to its list of essential medicines.",
        "severity": 5
      },
      {
        "id": "53b1ab86499c5d89cac5090f41887456",
        "type": "regulatory_news",
        "date": "2025-09-05T17:36:12.000Z",
        "title": "FDA is readying more surprise inspections for foreign drug sites, Makary says",
        "link": "https://endpoints.news/fda-is-readying-more-surprise-inspections-for-foreign-drug-sites-makary-says/",
        "source": "Endpoints News",
        "summary": "BETHESDA, MD — FDA Commissioner Marty Makary said the agency will soon begin inspecting more foreign drug manufacturers without advance notice, a move that's been in the works for years and would align its oversight of ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "8ef8b0f227fdb11dbe06e24fa0cd9443",
        "type": "regulatory_news",
        "date": "2025-09-05T16:09:17.000Z",
        "title": "Biologics Electronic Reading Room (eFOIA)",
        "link": "http://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/biologics-electronic-reading-room-efoia",
        "source": "FDA CBER Biologics",
        "summary": "The Biologics eFOI Reading Room provides access to documents posted throughout the \"Vaccines, Blood & Biologics\" and other sections related to the Center for Biologics Evaluation and Research on the FDA.gov Web site.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "STAT News Pharma-1757331501944-8r7ik91wo",
        "type": "regulatory_news",
        "date": "2025-09-05T15:36:02.000Z",
        "title": "STAT+: FDA commissioner says agency is looking into question of pediatric deaths from Covid vaccines",
        "link": "https://www.statnews.com/2025/09/05/fda-investigating-childhood-deaths-from-covid-vaccine/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Commissioner Marty Makary said the FDA will release a report within weeks on childhood deaths that he said are linked to Covid shots.",
        "severity": 5
      },
      {
        "id": "1472d50ddd180b4af5f02713dc48c67c",
        "type": "crl",
        "date": "2025-09-05T15:15:00.000Z",
        "title": "FDA to publish CRLs in real time; PEPFAR to distribute Gilead’s Yeztugo",
        "link": "https://www.biopharmadive.com/news/fda-complete-response-letters-gilead-pepfar-yeztugo-ac-immune-layoffs/759306/",
        "source": "BioPharma Dive",
        "summary": "The FDA also unveiled a batch of 89 previously unpublished complete response letters, including rejection notices to Capricor and Replimune.",
        "severity": 9,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "FDA Press Announcements-1757331501854-tzwfd9few",
        "type": "import_alert",
        "date": "2025-09-05T15:05:29.000Z",
        "title": "FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-launches-green-list-protect-americans-illegal-imported-glp-1-drug-ingredients",
        "source": "FDA Press Announcements",
        "summary": "The U.S. Food and Drug Administration today established a “green list” import alert to help stop potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the U.S. market.",
        "severity": 7
      },
      {
        "id": "Google News - Form 483-1757256367323-ix2ra13jn",
        "type": "form_483",
        "date": "2025-09-05T14:59:30.000Z",
        "title": "USFDA issues Form 483 with 8 observations to Aurobindo's Telangana unit - The Economic Times",
        "link": "https://news.google.com/rss/articles/CBMi_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?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues Form 483 with 8 observations to Aurobindo's Telangana unit  The Economic Times",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757331502651-vff4d6paz",
        "type": "regulatory_news",
        "date": "2025-09-05T14:46:24.000Z",
        "title": "Aurobindo Pharma Under US FDA Scrutiny: Eight Observations Made - Devdiscourse",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Aurobindo Pharma Under US FDA Scrutiny: Eight Observations Made  Devdiscourse",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757256367385-0h0d07c03",
        "type": "regulatory_news",
        "date": "2025-09-05T14:45:39.000Z",
        "title": "'Several concerning observations': FDA sheds more light on reasons it rejected drugs - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSnluVHU4Znp2MXRyZ2dXUDFUcXh4VTB2aXNsdzZsVHYwN2poQXZmVHc2TjNtT2xVYWRRQnZJTDlXMXFqV0FuR1NCbUVHUzE3NFFXenBVOS1abklsTDFfLWpITUhFT1FsUnoxN0toazNBYjZ3ano3V2ZJbFU3Z1JXS3VQNmtidkNZWjRBM3dLeGtKcTZEYWdzdDEyQmk5SURBR0pOcDB1bDc?oc=5",
        "source": "Google News - CRLs",
        "summary": "'Several concerning observations': FDA sheds more light on reasons it rejected drugs  Fierce Biotech",
        "severity": 5
      },
      {
        "id": "221c8cf409de77164fc5167e3a5fd650",
        "type": "regulatory_news",
        "date": "2025-09-05T14:20:24.000Z",
        "title": "Bravehart, a stealthy startup, looks to China to challenge Bristol Myers heart drug",
        "link": "https://www.biopharmadive.com/news/braveheart-hengrui-hypertrophic-cardiomyopathy-china-licensing-deal/759365/",
        "source": "BioPharma Dive",
        "summary": "Led by the former CEO of Hi-Bio and backed by notable investors, the startup licensed from Hengrui a drug it claims is superior to Bristol Myers' Camzyos as well as other, similar medicines.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "5de2564539c1b80a471e67f20fa2463d",
        "type": "regulatory_news",
        "date": "2025-09-05T14:19:49.000Z",
        "title": "Rapafusyn Pharmaceuticals' $44M raise; CAGE Bio's atopic dermatitis data",
        "link": "https://endpoints.news/rapafusyn-pharmaceuticals-44m-raise-cage-bios-atopic-dermatitis-data/",
        "source": "Endpoints News",
        "summary": "Plus, news about Octave Biosciences and Mineralys Therapeutics:\r\n\r\n 💵 Rapafusyn Pharmaceuticals closes $44M Series A: The molecular glue discovery company wrapped up an upsized and oversubscribed funding ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "STAT News Pharma-1757256366570-vfzjqg14y",
        "type": "regulatory_news",
        "date": "2025-09-05T13:49:40.000Z",
        "title": "STAT+: Up and down the ladder: The latest comings and goings",
        "link": "https://www.statnews.com/pharmalot/2025/09/05/jobs-biotech-pharma-ladder-sanofi-genmab-merck-icon-iqvia/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757331501944-hhau1e49k",
        "type": "regulatory_news",
        "date": "2025-09-05T13:32:27.000Z",
        "title": "STAT+: The FDA is getting more transparent about drug rejections",
        "link": "https://www.statnews.com/2025/09/05/biotech-news-fda-lsd-gilead-pfizer/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "And more biotech news stories brought to you by The Readout.",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757256366570-y42g0bd2s",
        "type": "regulatory_news",
        "date": "2025-09-05T13:11:53.000Z",
        "title": "STAT+: Pharmalittle: We’re reading about PEPFAR and a Gilead drug, the FDA’s rejection letters, and much more",
        "link": "https://www.statnews.com/pharmalot/2025/09/05/medicare-trump-gilead-pepfar-hiv-aids-fda-crl-cvs-wegovy-zepbound-novo-lilly-jnj-bristol-india-weight-obesity/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "The FDA said it would start releasing rejection letters soon after they are provided to drugmakers, a victory for those who wanted more transparency.",
        "severity": 5
      },
      {
        "id": "4c61abeb7474118a6c2fc54e537ebaaa",
        "type": "regulatory_news",
        "date": "2025-09-05T12:28:26.000Z",
        "title": "Drugs@FDA Data Files",
        "link": "http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files",
        "source": "FDA CBER Biologics",
        "summary": "Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "660eb04dd8b1c8917974128a0fad7f92",
        "type": "regulatory_news",
        "date": "2025-09-05T11:04:34.000Z",
        "title": "BioNTech and DualityBio’s ADC hits in late-stage breast cancer trial in China",
        "link": "https://endpoints.news/biontech-and-dualitybios-adc-hits-in-late-stage-breast-cancer-trial-in-china/",
        "source": "Endpoints News",
        "summary": "BioNTech said its most advanced antibody-drug conjugate has succeeded in a Phase 3 China-based trial in hard-to-treat breast cancer patients. The win will raise expectations for an ongoing global late-phase trial of the drug.  ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "8550b6995ae73ef28dbed8e3cf4161bd",
        "type": "regulatory_news",
        "date": "2025-09-05T11:00:32.000Z",
        "title": "Merck KGaA finds its next R&D leader; Exelixis retools management team as medical chief leaves",
        "link": "https://endpoints.news/merck-kgaa-finds-its-next-r-exelixis-retools-management-team-as-medical-chief-leaves/",
        "source": "Endpoints News",
        "summary": "→ Merck KGaA has selected David Weinreich as global R&D chief and CMO for the healthcare business sector. Weinreich’s experience with larger pharmas goes back to his days at Amgen as ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "Google News - Form 483-1757331502657-nidtufoo4",
        "type": "regulatory_news",
        "date": "2025-09-05T08:54:26.000Z",
        "title": "Biocon Biologics’ Bengaluru Unit Gets 5 US FDA Observations, Shares Up 1% - Equitypandit",
        "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPamxjOEVXM2RYbDhPdnpRaXNCNTk1b05RV0lCMU0tYzg2Ml9KMEZ0QURRbzVfa0xZMnR6azBOQ2xrWWdqWlNFWER2bEFLejBpRzNmMkM4NnRZX3ZtVW9zNDl6aUUwSzlOMlphQ3NRNnF3Z04zTlhRd21pemQzMlV2MGpzTllvZERZWFowTnF4VldlVENnZEZWVFJoRkdKb1ZzTXc?oc=5",
        "source": "Google News - Form 483",
        "summary": "Biocon Biologics’ Bengaluru Unit Gets 5 US FDA Observations, Shares Up 1%  Equitypandit",
        "severity": 5
      },
      {
        "id": "af035ab0563a2a917be1f0682a74ffc0",
        "type": "regulatory_news",
        "date": "2025-09-05T08:30:00.000Z",
        "title": "STAT+: Donavon Decker knew a gene therapy experiment wouldn’t help him. To help others, he still said yes",
        "link": "https://www.statnews.com/2025/09/05/gene-therapy-pioneer-donavon-decker-remembered/?utm_campaign=rss",
        "source": "STAT News Biotech",
        "summary": "Long before there was Sarepta's gene therapy for muscular dystrophy, there was Donavon Decker and his offer to test a gene therapy.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "e5b043360911002e9b1cb5daa97f520c",
        "type": "regulatory_news",
        "date": "2025-09-05T08:01:47.000Z",
        "title": "Hengrui does another US deal, this time in Cytokinetics' cardio arena",
        "link": "https://endpoints.news/hengrui-does-another-us-deal-this-time-in-cytokinetics-cardio-arena/",
        "source": "Endpoints News",
        "summary": "Jiangsu Hengrui Pharmaceuticals, China's leading drug developer and producer of one of the largest pipelines in the entire biopharma industry, has outlicensed another candidate to a US biotech.\r\n\r\n This time, Hengrui is teaming up with ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "Google News - CRLs-1757331502601-2fxzn4jxw",
        "type": "crl",
        "date": "2025-09-05T02:37:30.000Z",
        "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
        "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
        "source": "Google News - CRLs",
        "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757331502593-i36s4jzvd",
        "type": "crl",
        "date": "2025-09-05T00:09:00.000Z",
        "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
        "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
        "source": "Google News - CRLs",
        "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
        "severity": 9
      },
      {
        "id": "STAT News Pharma-1757256366570-1zft3dhwx",
        "type": "regulatory_news",
        "date": "2025-09-04T20:56:03.000Z",
        "title": "STAT+: Trump administration confirms plan for PEPFAR to distribute Gilead’s new HIV prevention drug",
        "link": "https://www.statnews.com/pharmalot/2025/09/04/gilead-hiv-aids-pepfar-trump-lenacapavir-licensing/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "\"This is a really significant moment in the fight against HIV and AIDS.”",
        "severity": 5
      },
      {
        "id": "5944d9d3c9fa0b40fd016e8a9d6433c5",
        "type": "regulatory_news",
        "date": "2025-09-04T20:17:00.000Z",
        "title": "At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves",
        "link": "https://www.biopharmadive.com/news/kennedy-rfk-senate-hearing-vaccines-cdc-crisis-acip/759319/",
        "source": "BioPharma Dive",
        "summary": "Robert F. Kennedy Jr. faced criticism Thursday even from Republicans over changes to federal vaccine policy as well as a leadership crisis at the CDC.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "cbbbf4ae79193821fc74fe43cf695d03",
        "type": "crl",
        "date": "2025-09-04T19:20:52.000Z",
        "title": "FDA publishes drug rejection letters for ongoing applications for the first time",
        "link": "https://endpoints.news/fda-for-the-first-time-publishes-drug-rejection-letters-for-ongoing-applications/",
        "source": "Endpoints News",
        "summary": "On Thursday, the FDA finally did what several prior agency commissioners only promised to do: publish redacted complete response letters for drugs that are still under consideration by the agency despite the initial rejection.  ...",
        "severity": 9,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "192e8bf3ca2ea06c642a10ef9772e49e",
        "type": "regulatory_news",
        "date": "2025-09-04T19:03:50.000Z",
        "title": "RFK Jr. battles growing GOP frustration over vaccine policies",
        "link": "https://endpoints.news/rfk-jr-battles-growing-gop-frustration-over-vaccine-policies/",
        "source": "Endpoints News",
        "summary": "Senators on both sides of the aisle lambasted HHS Secretary Robert F. Kennedy Jr. on Thursday over the upheaval of CDC leadership and recent agency decisions that have muddled Covid-19 vaccine access in the US ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "e51086eca430748fe1ce54377dde90fb",
        "type": "regulatory_news",
        "date": "2025-09-04T18:29:54.000Z",
        "title": "J&J, Bristol Myers lose appeals cases challenging Medicare price negotiation",
        "link": "https://endpoints.news/jj-bristol-myers-lose-appeals-cases-challenging-medicare-price-negotiation/",
        "source": "Endpoints News",
        "summary": "The government won another challenge against Medicare drug price negotiations on Thursday, as an appeals court threw out cases brought by Johnson & Johnson and Bristol Myers Squibb.\r\n\r\n In a majority opinion, the US Court ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "5a9b1c61e5b265e389e097023c88caab",
        "type": "regulatory_news",
        "date": "2025-09-04T18:05:00.000Z",
        "title": "Atlas Venture reels in $400M to grow its biotech startups",
        "link": "https://www.biopharmadive.com/news/atlas-venture-opportunity-fund-3-raise-september-2025/759281/",
        "source": "BioPharma Dive",
        "summary": "The venture firm has closed its third \"Opportunity Fund,” which complements its early-stage work by supporting startups it's already backed.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "Google News - CRLs-1757331502593-178mcq3q5",
        "type": "regulatory_news",
        "date": "2025-09-04T17:45:28.000Z",
        "title": "FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPcThla0JHRzd3ci1sWnVhWUluMmliSWFmeEFQUTdNaG5WREpNU2xQZHRURGNuSFV6ZEpzaTNObDZ2OWkxWHVJS3Bvd2xmS3dfNjhiNUEyb2NKMU9CQUJTd21EbVFiVWFzak5oM1ZCcllXVnNDN2VqNHoxVlFDbDc0TkJQanpNd2FQbDZsZXoyVnhvZTdMRUZiQ1FqX1BqXy1JTkJaZ2FHeUZqdEc5V1RDRWFpVUhmRlN5ZFNhQ2o5ZEJxRkF0?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub  Fierce Biotech",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757331501944-5ckhl3l15",
        "type": "regulatory_news",
        "date": "2025-09-04T16:34:54.000Z",
        "title": "STAT+: In major shift, FDA to start releasing rejection letters shortly after they’re issued",
        "link": "https://www.statnews.com/pharmalot/2025/09/04/fda-crls-rejection-letters-transparency-makary/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "The FDA said it would start releasing rejection letters soon after they are provided to drugmakers, a victory for transparency advocates.",
        "severity": 5
      },
      {
        "id": "f14768fb610b96fc80330f4a72cb2bdc",
        "type": "regulatory_news",
        "date": "2025-09-04T16:16:12.000Z",
        "title": "AstraZeneca ends manufacturing license at Indian plant as it exits the site ",
        "link": "https://endpoints.news/astrazeneca-ends-manufacturing-license-at-indian-plant-as-it-exits-the-site/",
        "source": "Endpoints News",
        "summary": "AstraZeneca is terminating a manufacturing license at its factory in Bengaluru, India, after announcing its plans to sell the facility last year, a company spokesperson confirmed to Endpoints News.\r\n\r\n The manufacturing license at the site ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "Google News - CRLs-1757331502593-i0ije9ceb",
        "type": "crl",
        "date": "2025-09-04T16:10:06.000Z",
        "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
        "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
        "source": "Google News - CRLs",
        "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
        "severity": 9
      },
      {
        "id": "STAT News Pharma-1757331501944-d1zqgixun",
        "type": "regulatory_news",
        "date": "2025-09-04T15:35:54.000Z",
        "title": "STAT+: Swing Therapeutics raises $11 million, adds former Pear CEO to board",
        "link": "https://www.statnews.com/2025/09/04/swing-therapeutics-raises-11-million-adds-former-pear-ceo-to-board/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Former Pear CEO joins Swing board — did he invest? My colleague Allison DeAngelis spotted a familiar character pop up in a fresh SEC filing from Swing Therapeutics, developer of…",
        "severity": 5
      },
      {
        "id": "6eedde6daf9b144b581e8d5231ce6cdc",
        "type": "regulatory_news",
        "date": "2025-09-04T15:16:00.000Z",
        "title": "Sanofi’s touted eczema drug hits study goal, but data fall short of expectations",
        "link": "https://www.biopharmadive.com/news/sanofi-amlitelimab-eczema-atopic-dermatitis-study-results-disappoint-analysts/759231/",
        "source": "BioPharma Dive",
        "summary": "Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug class once viewed as particularly promising.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "9d04d90e91d1ddc797bbf3bae5e9988b",
        "type": "regulatory_news",
        "date": "2025-09-04T15:04:00.000Z",
        "title": "A drug discovery startup banks $150M for immune and obesity drugs",
        "link": "https://www.biopharmadive.com/news/enveda-series-d-immune-obesity-dolsten-board/759080/",
        "source": "BioPharma Dive",
        "summary": "Enveda Biosciences has raised $300 million over the last year to make drugs to treat atopic dermatitis, asthma and more.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "c961a285a6fca73a76e5a8140cc14f73",
        "type": "regulatory_news",
        "date": "2025-09-04T14:47:45.000Z",
        "title": "What’s New for Biologics",
        "link": "http://www.fda.gov/vaccines-blood-biologics/news-events-biologics/whats-new-biologics",
        "source": "FDA CBER Biologics",
        "summary": "Latest news from the Center for Biologics Evaluation and Research",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "1b43c247b48adff0698d7abd69596ad4",
        "type": "regulatory_news",
        "date": "2025-09-04T14:25:57.000Z",
        "title": "TACHOSIL",
        "link": "http://www.fda.gov/vaccines-blood-biologics/approved-blood-products/tachosil",
        "source": "FDA CBER Biologics",
        "summary": "Product approval information is indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "Google News - Form 483-1757331502651-qth54cikd",
        "type": "regulatory_news",
        "date": "2025-09-04T14:19:05.000Z",
        "title": "Biocon Biologics’ Bengaluru facility gets five observations from US FDA inspection - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Biocon Biologics’ Bengaluru facility gets five observations from US FDA inspection  CNBC TV18",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757256366570-47nmbn1bc",
        "type": "regulatory_news",
        "date": "2025-09-04T13:41:43.000Z",
        "title": "STAT+: Treeline expands Series A another $200 million",
        "link": "https://www.statnews.com/2025/09/04/biotech-news-treeline-atlas-sanofi-pfizer-agios/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Plus more biotech news from The Readout newsletter.",
        "severity": 5
      },
      {
        "id": "FDA Press Announcements-1757331501854-0h6vtsx25",
        "type": "crl",
        "date": "2025-09-04T13:23:32.000Z",
        "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
        "source": "FDA Press Announcements",
        "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
        "severity": 9
      },
      {
        "id": "STAT News Pharma-1757256366570-xmazt7nt2",
        "type": "regulatory_news",
        "date": "2025-09-04T12:58:36.000Z",
        "title": "STAT+: Pharmalittle: We’re reading about FDA and Covid shots, a Sanofi setback, and much more",
        "link": "https://www.statnews.com/pharmalot/2025/09/04/pfizer-bourla-trump-covid-vaccines-nobel-sanofi-eczema-amneal-contamination-novartis-argo-cardiovascular-jobs-layoffs-fda-prasad/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "FDA memos show that the agency’s vaccine chief overruled staff scientists who favored widespread access to Covid shots",
        "severity": 5
      },
      {
        "id": "e93cc943881ed1c27a9ccb5eb83ea9fa",
        "type": "regulatory_news",
        "date": "2025-09-04T11:00:00.000Z",
        "title": "STAT+: Biotech VC raises $400 million ‘opportunity’ fund in sign of possible industry rebound",
        "link": "https://www.statnews.com/2025/09/04/atlas-venture-biotech-opportunity-fund/?utm_campaign=rss",
        "source": "STAT News Biotech",
        "summary": "Prominent biotech VC firm Atlas Venture has another $400 million to invest in drug companies.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "STAT News Pharma-1757256366570-11yja0eke",
        "type": "regulatory_news",
        "date": "2025-09-04T10:33:01.000Z",
        "title": "STAT+: Sanofi shares drop after disappointing trial results",
        "link": "https://www.statnews.com/2025/09/04/sanofi-amlitelimab-immunology-atopic-dermatitis-eczema/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Sanofi shares slid Thursday after the company reported underwhelming results from a closely watched trial in the skin condition atopic dermatitis.",
        "severity": 5
      },
      {
        "id": "c4556ac670d7f73cb378185a3b3d8355",
        "type": "regulatory_news",
        "date": "2025-09-04T10:30:00.000Z",
        "title": "STAT+: Is biotech back? Don’t jinx it, but the signs are encouraging",
        "link": "https://www.statnews.com/2025/09/04/biotech-back-encouraging-signs/?utm_campaign=rss",
        "source": "STAT News Biotech",
        "summary": "Is biotech back? Industry stocks, collectively, return to positive territory for the year.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "STAT News Pharma-1757331501944-y82nh9oas",
        "type": "regulatory_news",
        "date": "2025-09-03T20:54:12.000Z",
        "title": "STAT+: Amneal Pharma is scolded by FDA for using contaminated bags for a sterile injectable drug",
        "link": "https://www.statnews.com/pharmalot/2025/09/03/amneal-infusion-sterile-epidural-injectable-fda-contamination/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "A pharmaceuticals company relied on contaminated bags for a sterile injectable drug, among other infractions, the FDA found.",
        "severity": 5
      },
      {
        "id": "FDA Press Announcements-1757256366574-o8x9ppp1k",
        "type": "regulatory_news",
        "date": "2025-09-03T17:59:25.000Z",
        "title": "FDA Advances Rare Disease Drug Development with New Evidence Principles",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-advances-rare-disease-drug-development-new-evidence-principles",
        "source": "FDA Press Announcements",
        "summary": "FDA advanced Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability for the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.",
        "severity": 5
      },
      {
        "id": "9064c3f70fd8787a78bacb9c6e8ea0c6",
        "type": "regulatory_news",
        "date": "2025-09-03T17:07:21.000Z",
        "title": "Recently Issued Guidance Documents",
        "link": "http://www.fda.gov/vaccines-blood-biologics/biologics-guidances/recently-issued-guidance-documents",
        "source": "FDA CBER Biologics",
        "summary": "This page lists Recently Issued CBER and Cross-Center Guidance Documents.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "STAT News Pharma-1757256366570-b9qfr6uzv",
        "type": "regulatory_news",
        "date": "2025-09-03T16:03:08.000Z",
        "title": "STAT+: Why biotech stocks did unusually well yesterday",
        "link": "https://www.statnews.com/2025/09/03/biotech-news-xbi-index-acip-rsv-gilead/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "And more biotech stories brought to you by The Readout.",
        "severity": 5
      },
      {
        "id": "a396acc5c9f4e7691235697b66cb8dd2",
        "type": "regulatory_news",
        "date": "2025-09-03T15:53:06.000Z",
        "title": "Patient Engagement Collaborative",
        "link": "http://www.fda.gov/patients/learn-about-fda-patient-engagement/patient-engagement-collaborative",
        "source": "FDA CBER Biologics",
        "summary": "The Patient Engagement Collaborative (PEC) is an advancement in the FDA’s efforts to strengthen its relationship with patient communities and is being coordinated by the FDA’s Public Engagement Staff.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "5b3cd084b02693cb2030ee35e16daf47",
        "type": "recall",
        "date": "2025-09-03T15:26:00.000Z",
        "title": "Endico Potatoes Inc. Recalls 2.5lb Bags of Frozen “Peas And Carrots” and “Mixed Vegetables” Because of Possible Health Risk - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxPeVU5TjBJMEMwSlUxLU5xODJHZDU1RlJyVjVZRFA4Z0hVZ3NBNUhOOVNXbXJaM3ladTFpS1h0UDJJWXdOakx1RThaVnhPeEcwbDBoUjAtLXY4aXBKTHVuSDYtU2tTMnlsUDgtMUxxWjVsVVlLUTc1UURzSERDR3piNGY3dFVFWEtyNVJucXkybzd4c3lyWk10b1ZwdFFOUm1aYlhjZnZVZ041dzdVTkdiZnVaYXc1dVFGaG9fUUFkRVJNNEJTRmNJb2hvVzBmRnlNa1Z1WXBTUi1JRllaRXZyQnUtcHZPdWhqT0xtaHc2N2VkcHBmSldXYk1aUQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Endico Potatoes Inc. Recalls 2.5lb Bags of Frozen “Peas And Carrots” and “Mixed Vegetables” Because of Possible Health Risk  fda.gov",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "STAT News Pharma-1757256366570-cqk2q817m",
        "type": "regulatory_news",
        "date": "2025-09-03T15:10:19.000Z",
        "title": "STAT+: Pfizer’s CEO defends Covid vaccines, suggests Trump may deserve a Nobel Peace Prize",
        "link": "https://www.statnews.com/2025/09/03/pfizer-responds-trump-covid-vaccine-safety-effectiveness/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Pfizer CEO Albert Bourla defended the development of Covid vaccines and suggested President Trump may deserve a Nobel Peace Prize because of Operation Warp Speed.",
        "severity": 5
      },
      {
        "id": "02b5ecdcc7dfdc186a1ab8a803b6afd4",
        "type": "regulatory_news",
        "date": "2025-09-03T13:54:40.000Z",
        "title": "CDER/CBER Rare Disease Evidence Principles (RDEP)",
        "link": "http://www.fda.gov/industry/fda-rare-disease-innovation-hub/cdercber-rare-disease-evidence-principles-rdep",
        "source": "FDA CBER Biologics",
        "summary": "CDER and CBER propose a new regulatory process for the approval of drugs to treat rare diseases with very small patient populations with significant unmet medical need.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "STAT News Pharma-1757331501945-rzfex0r0d",
        "type": "regulatory_news",
        "date": "2025-09-03T13:11:33.000Z",
        "title": "STAT+: Pharmalittle: We’re reading about Gilead price hikes for HIV drugs, a Novartis China deal, and more",
        "link": "https://www.statnews.com/pharmalot/2025/09/03/gilead-hiv-drugs-novartis-china-deal-cdc-novo-vaccines/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Gilead is seeking to boost prices significantly for several HIV treatments distributed by state AIDS Drug Assistance Programs",
        "severity": 5
      },
      {
        "id": "e80990ef2d37e4bf80c22b8cb019867d",
        "type": "regulatory_news",
        "date": "2025-09-03T00:00:00.000Z",
        "title": "CDER/CBER Rare Disease Evidence Principles (RDEP) - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQbUFhbXdHeEgxS1BpSVBIVTU1emVXV1FMTWhHREhpRWhtWFM1amE1NTVpVzFlZUhaU1p4MlVGM2c5eEpqa1Z0TW1xM3EzS0E4ZENkSnBfZzhudUVNbFdWX2lLNk5QZy0yLUU3Y2Zna21walJkbTZWLWpXTG1Cb1BMMVJObkZHbXBvVVNiemdHMUZoUmdmcjFuQ2h2aF96cjBzTXdMcmduU3Q1U2s?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "CDER/CBER Rare Disease Evidence Principles (RDEP)  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "Google News - CRLs-1757331502593-vhgj6k8wm",
        "type": "crl",
        "date": "2025-09-02T21:45:00.000Z",
        "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
        "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757256367385-4byyrb05q",
        "type": "crl",
        "date": "2025-09-02T17:28:42.000Z",
        "title": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter - Yahoo Finance",
        "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZmF0a0F4VGs4MjA3QlpBRGJxcjlzODF4dlN6XzVYbnN4OElBWFdxNUpNOTBvZG9ya2JWWWVDV1VfdjNyUkpLSW41QmYxSGdGSWZESzA3emJGQUROcnpfU0JKa3RvT1JHN0JLaEc0SlJBSHlSU1ZwcHZZcFpfVHd6Q3NfYmxzSkh1?oc=5",
        "source": "Google News - CRLs",
        "summary": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter  Yahoo Finance",
        "severity": 9
      },
      {
        "id": "STAT News Pharma-1757331501945-czpgke49i",
        "type": "regulatory_news",
        "date": "2025-09-02T15:47:01.000Z",
        "title": "STAT+: Gilead wants state AIDS drug programs to pay significant price hikes for HIV meds",
        "link": "https://www.statnews.com/pharmalot/2025/09/02/hiv-aids-drugs-medicines-pharma-gilead-adap-prices-inflation-descovy/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Gilead Sciences is seeking to boost prices significantly for several treatments that are widely distributed by state AIDS Drug Assistance Programs.",
        "severity": 5
      },
      {
        "id": "6a182572306d61a274b01563a54e166f",
        "type": "regulatory_news",
        "date": "2025-09-02T15:10:26.000Z",
        "title": "Consumer Updates",
        "link": "http://www.fda.gov/consumers/consumer-updates",
        "source": "FDA CBER Biologics",
        "summary": "Science-based health and safety information you can trust.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "FDA Press Announcements-1757331501854-bp9kcr4kt",
        "type": "regulatory_news",
        "date": "2025-09-02T14:59:10.000Z",
        "title": "FDA Urges Nicotine Pouch Manufacturers To Use Child-Resistant Packaging Following Increasing Reports of Accidental Exposure  ",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-urges-nicotine-pouch-manufacturers-use-child-resistant-packaging-following-increasing-reports",
        "source": "FDA Press Announcements",
        "summary": "The U.S. Food and Drug Administration calls on nicotine pouch manufacturers to use child-resistant packaging to protect American children from accidental, harmful exposure.",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757256366570-bvvlbrd21",
        "type": "regulatory_news",
        "date": "2025-09-02T13:36:00.000Z",
        "title": "STAT+: Trump pressures drugmakers amid CDC turmoil",
        "link": "https://www.statnews.com/2025/09/02/biotech-news-corsera-ionis-replimune-cytokinetics/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "And other biotech news brought to you by The Readout.",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757256366570-krs2qgzmg",
        "type": "regulatory_news",
        "date": "2025-09-02T13:24:36.000Z",
        "title": "STAT+: Pharmalittle: We’re reading about Trump’s post on Covid data, a Merck cholesterol pill, and more",
        "link": "https://www.statnews.com/pharmalot/2025/09/02/fda-teva-saxenda-novo-wegovy-lilly-mounjaro-glp-china-trump-covid-vaccines-merck-cholesterol-sanofi-ionis-triglycerides-pancreas/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "President Trump called on pharmaceutical companies to publicly prove that their Covid-19 products work",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757331502604-io1by1w61",
        "type": "crl",
        "date": "2025-09-02T12:56:17.000Z",
        "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
        "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
        "source": "Google News - CRLs",
        "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757331502593-u4lypsjbb",
        "type": "crl",
        "date": "2025-09-02T12:44:00.000Z",
        "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
        "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
        "source": "Google News - CRLs",
        "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
        "severity": 9
      },
      {
        "id": "STAT News Pharma-1757331501945-1d7slgfdw",
        "type": "regulatory_news",
        "date": "2025-09-02T12:37:42.000Z",
        "title": "STAT+: The key health care fights to watch in Congress",
        "link": "https://www.statnews.com/2025/09/02/cdc-in-crisis-trump-rfk-jr-healthcare-policy-congress-dc-diagnosis-newsletter/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.",
        "severity": 5
      },
      {
        "id": "d5d577fa8864ff9a896b397caf8e9b03",
        "type": "regulatory_news",
        "date": "2025-09-02T11:00:00.000Z",
        "title": "STAT+: Ionis drug lowers triglycerides, reduces pancreas damage in late-stage studies",
        "link": "https://www.statnews.com/2025/09/02/ionis-olezarsen-triglycerides-drug-study/?utm_campaign=rss",
        "source": "STAT News Biotech",
        "summary": "Ionis Pharmaceuticals released new data on a rare disease drug that opened up the possibility it could become a blockbuster opportunity for the biotech.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "fabe169044daddeb0cf4dd235de7f4e1",
        "type": "regulatory_news",
        "date": "2025-09-02T10:30:00.000Z",
        "title": "STAT+: Biotech veterans John Maraganore, Clive Meanwell launch new heart disease startup with lofty goals",
        "link": "https://www.statnews.com/2025/09/02/biotech-corsera-maraganore-meanwell/?utm_campaign=rss",
        "source": "STAT News Biotech",
        "summary": "Biotech veterans John Maraganore and Clive Meanwell are launching Corsera, a new heart disease startup with lofty goals.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "9669f713e22cc605e6c54bc55f9417f3",
        "type": "regulatory_news",
        "date": "2025-08-30T14:30:00.000Z",
        "title": "STAT+: Alnylam’s hypertension treatment did not significantly lower blood pressure in mid-stage study",
        "link": "https://www.statnews.com/2025/08/30/alnylam-hypertension-treatment-study/?utm_campaign=rss",
        "source": "STAT News Biotech",
        "summary": "An investigational therapy from Alnylam did not significantly lower blood pressure in a key Phase 2 trial, new data show, but the drug is being advanced to a late-stage study.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "09dd6bb69cc29eeec555fb5b53c33fd5",
        "type": "regulatory_news",
        "date": "2025-08-30T07:18:00.000Z",
        "title": "STAT+: Cytokinetics drug yielded benefits over common therapy in patients with heart condition, study shows",
        "link": "https://www.statnews.com/2025/08/30/cytokinetics-aficamten-hcm-study/?utm_campaign=rss",
        "source": "STAT News Biotech",
        "summary": "An experimental medicine from Cytokinetics showed strong results in patients newly diagnosed with a common, inherited heart condition, according to new study results.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "Google News - Form 483-1757256367323-br0hvmtz8",
        "type": "regulatory_news",
        "date": "2025-08-30T06:03:00.000Z",
        "title": "U.S. FDA issues five observations to Aurobindo Pharma arm’s API plant - The Hindu",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "U.S. FDA issues five observations to Aurobindo Pharma arm’s API plant  The Hindu",
        "severity": 5
      },
      {
        "id": "80a5c5a23a7e5254ac4752286887ee0c",
        "type": "regulatory_news",
        "date": "2025-08-29T17:09:00.000Z",
        "title": "Coronavirus (COVID-19) | CBER-Regulated Biologics",
        "link": "http://www.fda.gov/vaccines-blood-biologics/industry-biologics/coronavirus-covid-19-cber-regulated-biologics",
        "source": "FDA CBER Biologics",
        "summary": "This page and the associated links provide information on guidance and advice relevant to the development of therapies to treat or prevent COVID-19, and contact information for developers seeking additional information or assistance.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "8424560ec8427f83a4edde94f5781a0a",
        "type": "regulatory_news",
        "date": "2025-08-29T16:39:27.000Z",
        "title": "Health Fraud Scams",
        "link": "http://www.fda.gov/consumers/health-fraud-scams",
        "source": "FDA CBER Biologics",
        "summary": "Learn how to spot health fraud and avoid it.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "STAT News Pharma-1757256366570-5f2g1ngi4",
        "type": "regulatory_news",
        "date": "2025-08-29T13:12:12.000Z",
        "title": "STAT+: Pharmalittle: We’re reading about Lilly and a China tech giant, Cassidy and a CDC vaccine panel, and more",
        "link": "https://www.statnews.com/pharmalot/2025/08/29/astrazeneca-lilly-virginia-manufacturing-obesity-diabetes-china-cassidy-rfk-cdc-vaccines-uk-gsk-uti-antibiotics-alzheimers-fda/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "The chair of the U.S. Senate health committee called for delaying a federal vaccine advisory panel meeting after a mass exodus of CDC leaders",
        "severity": 5
      },
      {
        "id": "604dedd3115e35e822a412225db0573d",
        "type": "regulatory_news",
        "date": "2025-08-29T04:00:00.000Z",
        "title": "Green Lumber Holding, LLC Issues Consumer Alert on Counterfeit Products  Following FDA Findings",
        "link": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/green-lumber-holding-llc-issues-consumer-alert-counterfeit-products-following-fda-findings",
        "source": "FDA MedWatch Safety",
        "summary": "Costa Mesa, California August 28, 2025 - Green Lumber Holding, LLC (“Green Lumber”) is alerting consumers that counterfeit products misrepresented as genuine Green Lumber have been identified and may pose health risks.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "ba77eb42c5672efa587de3ae4e1b43df",
        "type": "regulatory_news",
        "date": "2025-08-28T19:19:13.000Z",
        "title": "Roster of the Vaccines and Related Biological Products Advisory Committee",
        "link": "http://www.fda.gov/advisory-committees/vaccines-and-related-biological-products-advisory-committee/roster-vaccines-and-related-biological-products-advisory-committee",
        "source": "FDA CBER Biologics",
        "summary": "This is the Roster of the Vaccines and Related Biological Products Advisory Committee",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "cb4fc4534dd44ab15e7f76c4d53f4706",
        "type": "regulatory_news",
        "date": "2025-08-28T19:19:07.000Z",
        "title": "Roster of the Cellular, Tissue and Gene Therapies Advisory Committee",
        "link": "http://www.fda.gov/advisory-committees/cellular-tissue-and-gene-therapies-advisory-committee/roster-cellular-tissue-and-gene-therapies-advisory-committee",
        "source": "FDA CBER Biologics",
        "summary": "This is the Roster of the Cellular, Tissue and Gene Therapies Advisory Committee.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "095e94bf0ddbf3ccd43e90833a4a97a9",
        "type": "regulatory_news",
        "date": "2025-08-28T19:19:04.000Z",
        "title": "Roster of the Blood Products Advisory Committee",
        "link": "http://www.fda.gov/advisory-committees/blood-products-advisory-committee/roster-blood-products-advisory-committee",
        "source": "FDA CBER Biologics",
        "summary": "This is the Roster of the Blood Products Advisory Committee (BPAC).",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "a2296bfa5585418e040beced66fe714c",
        "type": "regulatory_news",
        "date": "2025-08-28T17:56:16.000Z",
        "title": " NUVAXOVID",
        "link": "http://www.fda.gov/vaccines-blood-biologics/vaccines/nuvaxovid",
        "source": "FDA CBER Biologics",
        "summary": "NUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\n\nNUVAXOVID is approved for use in individuals who are:\n\n65 years of age and older, or\n\n12 years through 64 years of age with",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "d2b88658140179ea65f71f62dcf41240",
        "type": "regulatory_news",
        "date": "2025-08-28T17:51:53.000Z",
        "title": "SPIKEVAX",
        "link": "http://www.fda.gov/vaccines-blood-biologics/spikevax",
        "source": "FDA CBER Biologics",
        "summary": "For active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\n\nSPIKEVAX is approved for use in individuals who are:\n\n65 years of age and older, or\n\n6 months through 64 years of age with at least one underlying condition",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "1fb1b4de872d336f716d43bf88d37740",
        "type": "regulatory_news",
        "date": "2025-08-28T17:38:50.000Z",
        "title": "COMIRNATY ",
        "link": "http://www.fda.gov/vaccines-blood-biologics/comirnaty",
        "source": "FDA CBER Biologics",
        "summary": "COMIRNATY is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID 19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\n\nCOMIRNATY is approved for use in individuals who are:\n\n65 years of age and older, or\n\n5 years through 64 years of age with",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "Google News - CRLs-1757256367385-a8y2cdikn",
        "type": "regulatory_news",
        "date": "2025-08-28T14:55:37.000Z",
        "title": "Outlook Therapeutics’ outlook dims as FDA snubs reformulated Avastin in eye disease—again - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOdnhCOEtJcEJFMEd0VEFDdjB5R3k3ZG1ZcUxvNHhSX0tSeXpmSWNkczA0ZGVST0swdkJoNmV3X05XYkpZZXBzVHdfNzFiVnZGZUNGWHVYNGpKSFVGNElKRFZtM01NVFhrZ1pFTUpEWWlTTURseWFIV2RQdlBoaEt4OU5mb2dDRkdTSXF4VzN3TEg2Tjh2MDhGZGdCSUJWbk11SDBDMzlkdjEwcWR1aTd4NEVOTEZhelV5YWc?oc=5",
        "source": "Google News - CRLs",
        "summary": "Outlook Therapeutics’ outlook dims as FDA snubs reformulated Avastin in eye disease—again  Fierce Pharma",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757331502650-i5de8f2qb",
        "type": "form_483",
        "date": "2025-08-28T14:08:33.000Z",
        "title": "FDA 483 Observations Highlight Ongoing Issues in Quality Control and cGMP Compliance - geneonline.com",
        "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOeU9EMEZNc0kxSG8wekZiUWtmWVlxVHNhelFmck9IYlcyeFhBYl85UnJqWUh3M0JDNW00UWVnZi1BNENYdFBaRzRlcm9jeHp5MHphTGE4R1dWTGRMUnJLWERBZ0FOM3A1U2dISjU1VXMxNk9iemx1VnF4U05PZmdPVzNPT1BaYUtGeVZVM1drOTZsT3VwakpsS3ZKUUZZMmViYzMzajFISnBKQmdTM2h2XzJB?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA 483 Observations Highlight Ongoing Issues in Quality Control and cGMP Compliance  geneonline.com",
        "severity": 6
      },
      {
        "id": "329e4ee9524de0943da0f0f832a2c4c1",
        "type": "regulatory_news",
        "date": "2025-08-28T10:30:00.000Z",
        "title": "STAT+: An under-the-radar biotech finds FDA more receptive to an alternative to Covid vaccines",
        "link": "https://www.statnews.com/2025/08/28/covid-invivyd-monoclonal-antibody-moonlake/?utm_campaign=rss",
        "source": "STAT News Biotech",
        "summary": "Invivyd's CEO doesn’t want to see Covid vaccines disappear, but he does believe the monoclonal antibody candidate his company is developing can be an effective alternative.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "Google News - CRLs-1757331502593-h93lb4x37",
        "type": "crl",
        "date": "2025-08-28T07:00:00.000Z",
        "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
        "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
        "severity": 9
      }
    ],
    "products": [
      "Administration",
      "rejection letters",
      "refusal process",
      "Rejection Letters",
      "Fierce Biotech",
      "Investing",
      "and Diagnostic",
      "Food and",
      "for animal",
      "for use",
      "Administration today",
      "Labeling to",
      "Opioid Pain",
      "and beverage",
      "Evaluation and",
      "Center for",
      "that counterfeit",
      "include additional",
      "lots of",
      "approval information",
      "approval of",
      "Related Biological",
      "the Blood",
      "candidates that",
      "data on",
      "ivonescimab",
      "lung cancer",
      "for muscular",
      "companies",
      "invest in",
      "that opened",
      "rare disease",
      "from Alnylam",
      "is being",
      "but the",
      "it claims",
      "Hengrui a",
      "class once",
      "about a",
      "to make",
      "cut the",
      "candidate alixorexton",
      "narcolepsy",
      "for the",
      "the Japanese",
      "development",
      "most challenging",
      "from UK",
      "syndrome",
      "conjugate developed",
      "which its",
      "manufacturers without",
      "more foreign",
      "conjugate has",
      "of the",
      "developer and",
      "leading",
      "letters for",
      "price negotiations",
      "against Medicare",
      "Targeted Oncology",
      "light on",
      "Approval Process",
      "Into the",
      "FDA Reveals",
      "Deramiocel Slammed",
      "Tabelecleucel for",
      "kidney",
      "Products with",
      "Approved Drug",
      "Manufacturers  Pharmaceutical",
      "For Sterile",
      "of certain",
      "Aarti",
      "critical",
      "Law Institute",
      "pump  MassDevice",
      "SynchroMed II",
      "APPROVED BY"
    ],
    "facilities": [
      "Telangana  The, Hi",
      "Hyderabad, ge"
    ],
    "risk_score": null,
    "last_updated": "2025-09-08T13:00:22.627Z",
    "monitoring_since": "2025-09-07T14:46:07.387Z",
    "compliance_score": 0
  },
  {
    "name": "FDA Urges Nicotine Pouch Manufacturers To Use Child",
    "aliases": [
      "FDA Urges Nicotine Pouch Manufacturers To Use Child"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-p1r35wt6w",
        "type": "regulatory_news",
        "date": "2025-09-02T14:59:10.000Z",
        "title": "FDA Urges Nicotine Pouch Manufacturers To Use Child-Resistant Packaging Following Increasing Reports of Accidental Exposure  ",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-urges-nicotine-pouch-manufacturers-use-child-resistant-packaging-following-increasing-reports",
        "source": "FDA Press Announcements",
        "summary": "The U.S. Food and Drug Administration calls on nicotine pouch manufacturers to use child-resistant packaging to protect American children from accidental, harmful exposure.",
        "severity": 5
      },
      {
        "id": "d6dd2e7f6cb52f84a83e609ea2a94215",
        "type": "regulatory_news",
        "date": "2025-09-02T04:00:00.000Z",
        "title": "FDA Urges Nicotine Pouch Manufacturers To Use Child-Resistant Packaging Following Increasing Reports of Accidental Exposure - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPMnR2SDZWaGg0eGFiMGdrcERVdkNqQldUVG9XTndsaWxsajdfc3lrcm43emlBXzRLUjlHODJrLV8ySXp5Z2pnZ0t3ZXQzRnRrdVlDdHFuOW92Z1BDWGdYcTdQeDYzbVFhWFFldXJIaFBaU3ZMallyZXhkcjdTWGZqMnJjYVdQZWZGcGI5M19xdGZ2dUhFQk9PaldRZmN0cXhILURpeW9zb1JYTmRkeFZsSTNQM1g2VmNKYzJ5VU1za3RfYVNJRTBISldQRERCeF9KSUNfckRkZ1Bfbk40ejlqbjVjaw?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "FDA Urges Nicotine Pouch Manufacturers To Use Child-Resistant Packaging Following Increasing Reports of Accidental Exposure  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Administration calls"
    ],
    "facilities": [],
    "risk_score": null,
    "last_updated": "2025-09-08T12:30:00.165Z",
    "monitoring_since": "2025-09-07T14:46:07.387Z",
    "compliance_score": 90
  },
  {
    "name": "FDA Begins Real",
    "aliases": [
      "FDA Begins Real"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-snmqby5ot",
        "type": "regulatory_news",
        "date": "2025-08-22T15:46:16.000Z",
        "title": "FDA Begins Real-Time Reporting of Adverse Event Data",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-begins-real-time-reporting-adverse-event-data",
        "source": "FDA Press Announcements",
        "summary": "The U.S. Food and Drug Administration (FDA) today began publishing adverse event data on a daily basis, giving the public faster access to information on serious medication errors and product quality complaints for prescription drugs and therapeutic biologics.",
        "severity": 5
      }
    ],
    "products": [
      "Administration",
      "errors and",
      "quality complaints"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.387Z",
    "monitoring_since": "2025-09-07T14:46:07.387Z"
  },
  {
    "name": "Combat New World Screwworm",
    "aliases": [
      "Combat New World Screwworm"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-4cjupsezz",
        "type": "regulatory_news",
        "date": "2025-08-19T12:45:21.000Z",
        "title": "HHS Allows FDA Emergency Use of Animal Drugs to Combat New World Screwworm, Protect U.S. Food Supply",
        "link": "http://www.fda.gov/news-events/press-announcements/hhs-allows-fda-emergency-use-animal-drugs-combat-new-world-screwworm-protect-us-food-supply",
        "source": "FDA Press Announcements",
        "summary": "The U.S. Department of Health and Human Services (HHS) today issued a declaration that allows the U.S. Food and Drug Administration (FDA) to issue Emergency Use Authorizations (EUAs) for animal drugs to treat or prevent infestations caused by the New World Screwworm (NWS).",
        "severity": 5
      }
    ],
    "products": [
      "Administration"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.387Z",
    "monitoring_since": "2025-09-07T14:46:07.387Z"
  },
  {
    "name": "Recurrent Respiratory Papillomatosis",
    "aliases": [
      "Recurrent Respiratory Papillomatosis"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-b1aoglmvz",
        "type": "regulatory_news",
        "date": "2025-08-14T22:11:48.000Z",
        "title": "FDA Approves First Immunotherapy for Recurrent Respiratory Papillomatosis",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-immunotherapy-recurrent-respiratory-papillomatosis",
        "source": "FDA Press Announcements",
        "summary": "FDA approved Papzimeos, the first-of-its-kind non-replicating adenoviral vector-based immunotherapy for use in adults with recurrent respiratory papillomatosis.",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.387Z",
    "monitoring_since": "2025-09-07T14:46:07.387Z"
  },
  {
    "name": "Statement from FDA Commissioner Marty Makary, M.D., M.P.H., on Florida Restriction of 7",
    "aliases": [
      "Statement from FDA Commissioner Marty Makary, M.D., M.P.H., on Florida Restriction of 7"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-cos7p9vzv",
        "type": "regulatory_news",
        "date": "2025-08-13T18:43:49.000Z",
        "title": "Statement from FDA Commissioner Marty Makary, M.D., M.P.H., on Florida Restriction of 7-OH Opioid Products",
        "link": "http://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-marty-makary-md-mph-florida-restriction-7-oh-opioid-products",
        "source": "FDA Press Announcements",
        "summary": "Statement from FDA Commissioner Marty Makary, M.D., M.P.H., on Florida Restriction of 7-OH Opioid Products",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.387Z",
    "monitoring_since": "2025-09-07T14:46:07.387Z"
  },
  {
    "name": "Benefit American Growers",
    "aliases": [
      "Benefit American Growers"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-0pdxisytv",
        "type": "regulatory_news",
        "date": "2025-08-08T19:30:37.000Z",
        "title": "FDA Commissioner Makary, USDA Secretary Rollins Celebrate Proposed Modernization of Orange Juice Regulations to Benefit American Growers",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-commissioner-makary-usda-secretary-rollins-celebrate-proposed-modernization-orange-juice",
        "source": "FDA Press Announcements",
        "summary": "U.S. FDA Commissioner Dr. Marty Makary, M.D., M.P.H., and U.S. Secretary of Agriculture Brooke L. Rollins this week announced plans to support American citrus growers and cut bureaucratic barriers by proposing an update to the standard of identity (SOI) for pasteurized orange juice.",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.387Z",
    "monitoring_since": "2025-09-07T14:46:07.387Z"
  },
  {
    "name": "A Statement from FDA Commissioner Marty Makary, M.D., M.P.H.",
    "aliases": [
      "A Statement from FDA Commissioner Marty Makary, M.D., M.P.H."
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-swmifcdfe",
        "type": "regulatory_news",
        "date": "2025-08-08T15:25:35.000Z",
        "title": "A Statement from FDA Commissioner Marty Makary, M.D., M.P.H.: Announcing Resolution of the IV Saline Solutions Shortage",
        "link": "http://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-marty-makary-md-mph-announcing-resolution-iv-saline-solutions-shortage",
        "source": "FDA Press Announcements",
        "summary": "A Statement from FDA Commissioner Marty Makary, M.D., M.P.H: Announcing Resolution of the IV Saline Solutions Shortage",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.387Z",
    "monitoring_since": "2025-09-07T14:46:07.387Z"
  },
  {
    "name": "Boost U.S. Drug Manufacturing",
    "aliases": [
      "Boost U.S. Drug Manufacturing"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-7r2txqa2f",
        "type": "regulatory_news",
        "date": "2025-08-07T13:32:05.000Z",
        "title": "FDA Announces New FDA PreCheck Program to Boost U.S. Drug Manufacturing",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-new-fda-precheck-program-boost-us-drug-manufacturing",
        "source": "FDA Press Announcements",
        "summary": "The U.S. Food and Drug Administration today announced FDA PreCheck, a new program to strengthen the domestic pharmaceutical supply chain by increasing regulatory predictability and facilitating the construction of manufacturing sites in the United States.",
        "severity": 5
      }
    ],
    "products": [
      "Administration today"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.387Z",
    "monitoring_since": "2025-09-07T14:46:07.387Z"
  },
  {
    "name": "Opioid Pain Medication Labeling to Emphasize Risks",
    "aliases": [
      "Opioid Pain Medication Labeling to Emphasize Risks"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-gd963mrzo",
        "type": "regulatory_news",
        "date": "2025-07-31T19:24:28.000Z",
        "title": "FDA Requires Major Changes to Opioid Pain Medication Labeling to Emphasize Risks",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-requires-major-changes-opioid-pain-medication-labeling-emphasize-risks",
        "source": "FDA Press Announcements",
        "summary": "FDA Requires Major Changes to Opioid Pain Medication Labeling to Emphasize Risks",
        "severity": 5
      }
    ],
    "products": [
      "Labeling to"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA Takes Steps to Restrict 7",
    "aliases": [
      "FDA Takes Steps to Restrict 7"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-2k74kfvsr",
        "type": "regulatory_news",
        "date": "2025-07-29T14:41:37.000Z",
        "title": "FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-takes-steps-restrict-7-oh-opioid-products-threatening-american-consumers",
        "source": "FDA Press Announcements",
        "summary": "FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "Elevidys for Ambulatory Patients",
    "aliases": [
      "Elevidys for Ambulatory Patients"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-vlusqo4o9",
        "type": "regulatory_news",
        "date": "2025-07-28T20:21:55.000Z",
        "title": "FDA Recommends Removal of Voluntary Hold for Elevidys for Ambulatory Patients",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-recommends-removal-voluntary-hold-elevidys-ambulatory-patients",
        "source": "FDA Press Announcements",
        "summary": "FDA Recommends Removal of Voluntary Hold for Elevidys for Ambulatory Patients",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA Investigating Death of 8",
    "aliases": [
      "FDA Investigating Death of 8"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-9p807ktma",
        "type": "regulatory_news",
        "date": "2025-07-25T21:25:06.000Z",
        "title": "FDA Investigating Death of 8-Year-Old Boy Who Received Elevidys",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-investigating-death-8-year-old-boy-who-received-elevidys",
        "source": "FDA Press Announcements",
        "summary": "The U.S. Food and Drug Administration is investigating the death of an 8-year-old boy who received Elevidys, a Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy.",
        "severity": 5
      }
    ],
    "products": [
      "Administration is"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "HHS, FDA and USDA Address the Health Risks of Ultra",
    "aliases": [
      "HHS, FDA and USDA Address the Health Risks of Ultra"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-9cfzkii5y",
        "type": "regulatory_news",
        "date": "2025-07-23T21:44:12.000Z",
        "title": "HHS, FDA and USDA Address the Health Risks of Ultra-Processed Foods",
        "link": "http://www.fda.gov/news-events/press-announcements/hhs-fda-and-usda-address-health-risks-ultra-processed-foods",
        "source": "FDA Press Announcements",
        "summary": "HHS, FDA and USDA Address the Health Risks of Ultra-Processed Foods",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "Drug Evaluation and Research",
    "aliases": [
      "Drug Evaluation and Research"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757256366574-v030abs7w",
        "type": "regulatory_news",
        "date": "2025-07-21T10:57:14.000Z",
        "title": "Stanford faculty member George Tidmarsh, M.D., Ph.D. named Director of Center for Drug Evaluation and Research",
        "link": "http://www.fda.gov/news-events/press-announcements/stanford-faculty-member-george-tidmarsh-md-phd-named-director-center-drug-evaluation-and-research",
        "source": "FDA Press Announcements",
        "summary": "The U.S. Food and Drug Administration today announced the appointment of George Francis Tidmarsh, M.D., Ph.D., as Director of the Center for Drug Evaluation and Research (CDER).",
        "severity": 5
      }
    ],
    "products": [
      "Administration today",
      "Evaluation and"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "its essential medicines list",
    "aliases": [
      "its essential medicines list"
    ],
    "violations": [
      {
        "id": "STAT News Pharma-1757256366552-mukj1dpwb",
        "type": "regulatory_news",
        "date": "2025-09-05T18:48:39.000Z",
        "title": "STAT+: Patient groups cheer as the WHO adds diabetes and cystic fibrosis drugs to its essential medicines list",
        "link": "https://www.statnews.com/pharmalot/2025/09/05/who-medicines-pharma-biotech-diabetes-obesity-cystic-fibrosis-vertex-lilly-novo-sanofi/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "For the first time, the WHO has added various high-cost treatments for diabetes and cystic fibrosis to its list of essential medicines.",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "question of pediatric deaths from Covid vaccines",
    "aliases": [
      "question of pediatric deaths from Covid vaccines"
    ],
    "violations": [
      {
        "id": "STAT News Pharma-1757256366570-3ykb7ptcl",
        "type": "regulatory_news",
        "date": "2025-09-05T15:36:02.000Z",
        "title": "STAT+: FDA commissioner says agency is looking into question of pediatric deaths from Covid vaccines",
        "link": "https://www.statnews.com/2025/09/05/fda-investigating-childhood-deaths-from-covid-vaccine/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Commissioner Marty Makary said the FDA will release a report within weeks on childhood deaths that he said are linked to Covid shots.",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "The FDA is",
    "aliases": [
      "The FDA is"
    ],
    "violations": [
      {
        "id": "STAT News Pharma-1757256366570-n2k5qfgl0",
        "type": "regulatory_news",
        "date": "2025-09-05T13:32:27.000Z",
        "title": "STAT+: The FDA is getting more transparent about drug rejections",
        "link": "https://www.statnews.com/2025/09/05/biotech-news-fda-lsd-gilead-pfizer/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "And more biotech news stories brought to you by The Readout.",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "re",
    "aliases": [
      "re"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268589619-y7gyzxq5s",
        "type": "crl",
        "date": "2025-09-05T18:56:15.000Z",
        "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
        "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268589620-ybywcc9re",
        "type": "regulatory_news",
        "date": "2025-09-05T14:45:39.000Z",
        "title": "'Several concerning observations': FDA sheds light on rejections - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSnluVHU4Znp2MXRyZ2dXUDFUcXh4VTB2aXNsdzZsVHYwN2poQXZmVHc2TjNtT2xVYWRRQnZJTDlXMXFqV0FuR1NCbUVHUzE3NFFXenBVOS1abklsTDFfLWpITUhFT1FsUnoxN0toazNBYjZ3ano3V2ZJbFU3Z1JXS3VQNmtidkNZWjRBM3dLeGtKcTZEYWdzdDEyQmk5SURBR0pOcDB1bDc?oc=5",
        "source": "Google News - CRLs",
        "summary": "'Several concerning observations': FDA sheds light on rejections  Fierce Biotech",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589619-w6vkumgjx",
        "type": "crl",
        "date": "2025-09-05T13:49:44.000Z",
        "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
        "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
        "source": "Google News - CRLs",
        "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
        "severity": 9
      },
      {
        "id": "STAT News Pharma-1757268588855-xfild8sdw",
        "type": "regulatory_news",
        "date": "2025-09-05T13:11:53.000Z",
        "title": "STAT+: Pharmalittle: We’re reading about PEPFAR and a Gilead drug, the FDA’s rejection letters, and much more",
        "link": "https://www.statnews.com/pharmalot/2025/09/05/medicare-trump-gilead-pepfar-hiv-aids-fda-crl-cvs-wegovy-zepbound-novo-lilly-jnj-bristol-india-weight-obesity/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "The FDA said it would start releasing rejection letters soon after they are provided to drugmakers, a victory for those who wanted more transparency.",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589558-bbt65i2yw",
        "type": "regulatory_news",
        "date": "2025-09-05T08:54:26.000Z",
        "title": "Biocon Biologics’ Bengaluru Unit Gets 5 US FDA Observations, Shares Up 1% - Equitypandit",
        "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPamxjOEVXM2RYbDhPdnpRaXNCNTk1b05RV0lCMU0tYzg2Ml9KMEZ0QURRbzVfa0xZMnR6azBOQ2xrWWdqWlNFWER2bEFLejBpRzNmMkM4NnRZX3ZtVW9zNDl6aUUwSzlOMlphQ3NRNnF3Z04zTlhRd21pemQzMlV2MGpzTllvZERZWFowTnF4VldlVENnZEZWVFJoRkdKb1ZzTXc?oc=5",
        "source": "Google News - Form 483",
        "summary": "Biocon Biologics’ Bengaluru Unit Gets 5 US FDA Observations, Shares Up 1%  Equitypandit",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589620-070qud861",
        "type": "crl",
        "date": "2025-09-05T02:37:30.000Z",
        "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
        "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
        "source": "Google News - CRLs",
        "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268589619-eeht0sbzx",
        "type": "crl",
        "date": "2025-09-05T00:09:00.000Z",
        "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
        "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
        "source": "Google News - CRLs",
        "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
        "severity": 9
      },
      {
        "id": "STAT News Pharma-1757268588855-ax02xx6bg",
        "type": "regulatory_news",
        "date": "2025-09-04T20:56:03.000Z",
        "title": "STAT+: Trump administration confirms plan for PEPFAR to distribute Gilead’s new HIV prevention drug",
        "link": "https://www.statnews.com/pharmalot/2025/09/04/gilead-hiv-aids-pepfar-trump-lenacapavir-licensing/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "\"This is a really significant moment in the fight against HIV and AIDS.”",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589619-jsw2aq6rf",
        "type": "regulatory_news",
        "date": "2025-09-04T17:45:28.000Z",
        "title": "FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPcThla0JHRzd3ci1sWnVhWUluMmliSWFmeEFQUTdNaG5WREpNU2xQZHRURGNuSFV6ZEpzaTNObDZ2OWkxWHVJS3Bvd2xmS3dfNjhiNUEyb2NKMU9CQUJTd21EbVFiVWFzak5oM1ZCcllXVnNDN2VqNHoxVlFDbDc0TkJQanpNd2FQbDZsZXoyVnhvZTdMRUZiQ1FqX1BqXy1JTkJaZ2FHeUZqdEc5V1RDRWFpVUhmRlN5ZFNhQ2o5ZEJxRkF0?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub  Fierce Biotech",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757256366570-iv3fcjpi1",
        "type": "regulatory_news",
        "date": "2025-09-04T16:34:54.000Z",
        "title": "STAT+: In major shift, FDA to start releasing rejection letters shortly after they’re issued",
        "link": "https://www.statnews.com/pharmalot/2025/09/04/fda-crls-rejection-letters-transparency-makary/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "The FDA said it would start releasing rejection letters soon after they are provided to drugmakers, a victory for transparency advocates.",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757268588855-z267fq9lr",
        "type": "regulatory_news",
        "date": "2025-09-04T13:41:43.000Z",
        "title": "STAT+: Treeline expands Series A another $200 million",
        "link": "https://www.statnews.com/2025/09/04/biotech-news-treeline-atlas-sanofi-pfizer-agios/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Plus more biotech news from The Readout newsletter.",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757268588855-22lg4ryfr",
        "type": "regulatory_news",
        "date": "2025-09-04T12:58:36.000Z",
        "title": "STAT+: Pharmalittle: We’re reading about FDA and Covid shots, a Sanofi setback, and much more",
        "link": "https://www.statnews.com/pharmalot/2025/09/04/pfizer-bourla-trump-covid-vaccines-nobel-sanofi-eczema-amneal-contamination-novartis-argo-cardiovascular-jobs-layoffs-fda-prasad/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "FDA memos show that the agency’s vaccine chief overruled staff scientists who favored widespread access to Covid shots",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757268588855-wltat5fqi",
        "type": "regulatory_news",
        "date": "2025-09-04T10:33:01.000Z",
        "title": "STAT+: Sanofi shares drop after disappointing trial results",
        "link": "https://www.statnews.com/2025/09/04/sanofi-amlitelimab-immunology-atopic-dermatitis-eczema/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Sanofi shares slid Thursday after the company reported underwhelming results from a closely watched trial in the skin condition atopic dermatitis.",
        "severity": 5
      },
      {
        "id": "FDA Press Announcements-1757268588771-7eevpg58r",
        "type": "regulatory_news",
        "date": "2025-09-03T17:59:25.000Z",
        "title": "FDA Advances Rare Disease Drug Development with New Evidence Principles",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-advances-rare-disease-drug-development-new-evidence-principles",
        "source": "FDA Press Announcements",
        "summary": "FDA advanced Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability for the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757268588856-ro7d1smxc",
        "type": "regulatory_news",
        "date": "2025-09-03T13:11:33.000Z",
        "title": "STAT+: Pharmalittle: We’re reading about Gilead price hikes for HIV drugs, a Novartis China deal, and more",
        "link": "https://www.statnews.com/pharmalot/2025/09/03/gilead-hiv-drugs-novartis-china-deal-cdc-novo-vaccines/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Gilead is seeking to boost prices significantly for several HIV treatments distributed by state AIDS Drug Assistance Programs",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589620-7g26onv09",
        "type": "crl",
        "date": "2025-09-02T17:28:42.000Z",
        "title": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter - Yahoo Finance",
        "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZmF0a0F4VGs4MjA3QlpBRGJxcjlzODF4dlN6XzVYbnN4OElBWFdxNUpNOTBvZG9ya2JWWWVDV1VfdjNyUkpLSW41QmYxSGdGSWZESzA3emJGQUROcnpfU0JKa3RvT1JHN0JLaEc0SlJBSHlSU1ZwcHZZcFpfVHd6Q3NfYmxzSkh1?oc=5",
        "source": "Google News - CRLs",
        "summary": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter  Yahoo Finance",
        "severity": 9
      },
      {
        "id": "STAT News Pharma-1757268588856-w02ogpp4c",
        "type": "regulatory_news",
        "date": "2025-09-02T13:36:00.000Z",
        "title": "STAT+: Trump pressures drugmakers amid CDC turmoil",
        "link": "https://www.statnews.com/2025/09/02/biotech-news-corsera-ionis-replimune-cytokinetics/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "And other biotech news brought to you by The Readout.",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757268588856-i8j9z379e",
        "type": "regulatory_news",
        "date": "2025-09-02T13:24:36.000Z",
        "title": "STAT+: Pharmalittle: We’re reading about Trump’s post on Covid data, a Merck cholesterol pill, and more",
        "link": "https://www.statnews.com/pharmalot/2025/09/02/fda-teva-saxenda-novo-wegovy-lilly-mounjaro-glp-china-trump-covid-vaccines-merck-cholesterol-sanofi-ionis-triglycerides-pancreas/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "President Trump called on pharmaceutical companies to publicly prove that their Covid-19 products work",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589619-hwrqba7b8",
        "type": "crl",
        "date": "2025-09-02T12:44:00.000Z",
        "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
        "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
        "source": "Google News - CRLs",
        "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
        "severity": 9
      },
      {
        "id": "STAT News Pharma-1757268588856-1gdb154ao",
        "type": "regulatory_news",
        "date": "2025-09-02T12:37:42.000Z",
        "title": "STAT+: The key health care fights to watch in Congress",
        "link": "https://www.statnews.com/2025/09/02/cdc-in-crisis-trump-rfk-jr-healthcare-policy-congress-dc-diagnosis-newsletter/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589621-0qm40rbwz",
        "type": "regulatory_news",
        "date": "2025-09-02T12:00:00.000Z",
        "title": "Critical FDA Meeting Scheduled: Replimune's Advanced Melanoma Treatment Faces Decisive Moment - Stock Titan",
        "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPcjN0dnpXQVJhNmxlNEVPRjBNdmF5bGFnWE84TF9ncFZ5OWpGZktEbWpJNzhGMWRfVC1ld190dG56anBLNGpZXzRBWElMMmpYTVNwU2p6dzRjQzI2Zlk3MTRwNzBmdV9NQ2xJUUFrWlhHaXhSNklYbWhMcXY4WlpNMVdZbGZIcVdscUYwc1pFQ2JMZFNPa09idmpLc1R0dTdMM2ViUnNSRQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "Critical FDA Meeting Scheduled: Replimune's Advanced Melanoma Treatment Faces Decisive Moment  Stock Titan",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757268588856-2b64w6u1d",
        "type": "regulatory_news",
        "date": "2025-08-29T13:12:12.000Z",
        "title": "STAT+: Pharmalittle: We’re reading about Lilly and a China tech giant, Cassidy and a CDC vaccine panel, and more",
        "link": "https://www.statnews.com/pharmalot/2025/08/29/astrazeneca-lilly-virginia-manufacturing-obesity-diabetes-china-cassidy-rfk-cdc-vaccines-uk-gsk-uti-antibiotics-alzheimers-fda/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "The chair of the U.S. Senate health committee called for delaying a federal vaccine advisory panel meeting after a mass exodus of CDC leaders",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589620-qtdx1dwvv",
        "type": "crl",
        "date": "2025-08-28T21:22:30.000Z",
        "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
        "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
        "source": "Google News - CRLs",
        "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268589621-wv8sch8aa",
        "type": "regulatory_news",
        "date": "2025-08-28T14:55:37.000Z",
        "title": "Outlook Therapeutics’ outlook dims as FDA snubs reformulated Avastin in eye disease—again - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOdnhCOEtJcEJFMEd0VEFDdjB5R3k3ZG1ZcUxvNHhSX0tSeXpmSWNkczA0ZGVST0swdkJoNmV3X05XYkpZZXBzVHdfNzFiVnZGZUNGWHVYNGpKSFVGNElKRFZtM01NVFhrZ1pFTUpEWWlTTURseWFIV2RQdlBoaEt4OU5mb2dDRkdTSXF4VzN3TEg2Tjh2MDhGZGdCSUJWbk11SDBDMzlkdjEwcWR1aTd4NEVOTEZhelV5YWc?oc=5",
        "source": "Google News - CRLs",
        "summary": "Outlook Therapeutics’ outlook dims as FDA snubs reformulated Avastin in eye disease—again  Fierce Pharma",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589619-h5t5vzxdp",
        "type": "crl",
        "date": "2025-08-28T07:00:00.000Z",
        "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
        "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268589620-z9do6p8jk",
        "type": "regulatory_news",
        "date": "2025-08-28T07:00:00.000Z",
        "title": "FDA flags issues in review of Telix's PET diagnostic agent for kidney cancer - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOem9yN0VVLVNDdDBEbHdycExVVDhVZ1BEZk1JWEJ2X0xab1FFWTdLRXZHWmZYdVdMUWRlWUdwU1RTM21LbnU0bXIwVTBnYkdWSVZPVGJmVDNSc1MwNVhhNkR2SjdzTW03UXk0LTJVVUFnMVcyX1NqUG1BUjV5NjR6VTdPNkZPeHZiYnYtRHpOZm9uS3RtWV9URlIzdVBkMHVkVUYzVXZn?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA flags issues in review of Telix's PET diagnostic agent for kidney cancer  Fierce Biotech",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589622-nes1btxkq",
        "type": "regulatory_news",
        "date": "2025-08-28T07:00:00.000Z",
        "title": "FDA Requests More Efficacy Data: Outlook Therapeutics' Novel Bevacizumab Eye Drug Hits Regulatory Roadblock - Stock Titan",
        "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTkhRc0ZnakRlRHJUNWwxTGNmZXJQYWo5X1g5NV9sRmdwU3BjN0E3UlBQRVczMG9WUDNpbnZYZnNIdVZtUzgwLXdQc0p6ZGtCYW14TDAyNWtpem1qdHpLNzJkSmVnR2d6eE1iQk1Ja2w5UGtXZ25vRUM2SnJNcjJzeGdNalJTV1A5M3BFZmpMd1lNU0NFSWVmTncwb1FRc2RHN3FWVkcySDJOekQ3eHZGcnpNeUNJdzRLTjNkSmt2YzI?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Requests More Efficacy Data: Outlook Therapeutics' Novel Bevacizumab Eye Drug Hits Regulatory Roadblock  Stock Titan",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589620-o3cuk7pk0",
        "type": "crl",
        "date": "2025-08-27T22:51:27.000Z",
        "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
        "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268589621-758p1ha7q",
        "type": "crl",
        "date": "2025-08-21T07:00:00.000Z",
        "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
        "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757330791536-53rpnsdum",
        "type": "regulatory_news",
        "date": "2025-08-21T07:00:00.000Z",
        "title": "FDA accelerates Stealth Bio's rare disease application with a decision slated for next month - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQcHpvelRIeWdVRzktOEN6bkRKOUhBaEo3YzJFMkpna1pReW1RSHJyeUFwX280RjhuaVU3QTFVMHhsQ3lXT09ucnB0NjI3M09Sa21OVVlhckh6M00waENmUnJoWWpDd0plODctYnVsOUozeTVEcVlTQkNxNEZpTzlhR0JsaW9RNmVSVFRIZ0hFS3NSZjdNNTZ4WE5GdmtBLUdrS0llQS02YmpFVWR3ZzlPU21IVEN2bFM0OWc?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA accelerates Stealth Bio's rare disease application with a decision slated for next month  Fierce Biotech",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589620-sisz3wzuc",
        "type": "crl",
        "date": "2025-08-20T07:00:00.000Z",
        "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
        "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268589620-cgtex8fdk",
        "type": "crl",
        "date": "2025-08-19T13:56:19.000Z",
        "title": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA - Contract Pharma",
        "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPN1Zpanp6WWlzNWUzRnl4NXRpOFdWWVRRRE1laGZZdGRJbDVzWFZ6Q0N5T1F0MkRQbEgwc1FmNzB3X1Jqc1lTa3VEMm1vMExiRUFtNENZRUNabWR4anQzMWJGcXZHcXV5NUI5QjZBQmxINnQxMnJlN0JOTEh2aXJpUGVqczFPTU01N1QtUFdBNjhzNHN1VVlFOTZ0WjdtcUlTSWxBWA?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA  Contract Pharma",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268589620-qsna3qr1s",
        "type": "regulatory_news",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed - Neurology live",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPUjVKMU9XR0ZDSjNDOFdNYV9NX19CbXp4QnhkWm1qNV9ZZUoxVTlheHJBNjBlZUkxQW1EdVdDREJndTdxdnU4OVZDQTdycEk5dkx3ZnFQajlNM0FWYmhfMy1TQjJwS0JXOXQ4WVR6SE9TUmhSalZndzhrWjlMLUtyYV9sbWhDTGluWEtXV25Bakt4akZlMEZHenhnLWxJclBPbjBnTTFwQXNfejZMYnc3X2p6WXZFRWg2MXc?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed  Neurology live",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589620-90n50veiy",
        "type": "regulatory_news",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "FDA Denies Approval: PTC Therapeutics' Vatiquinone for Rare Genetic Disease Friedreich's Ataxia Hits Setback - Stock Titan",
        "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOeVZPeDFtLTdjUkpQVjA1Q1U1LTExRUZ1UU9YMHo3Nk1fcXczeW9EeXhMSWlFdk5CWkc1Smk2WS1CY2I5OUgyNjlSVE51Q1lXcGVuaWtYM1dJcTJEODZOWHZHQjVEdWE4WVd0WEM4RjU2ZUtNNHRBR1pHTDR6YmJlcFlEVHB1UHpuSHo4ZVBUSnVGN09vSHRialR2a1RjcjFZd2ozcGhfWWFNNklHUDFCSWxZUEFYMU1WbEc0Vkxn?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Denies Approval: PTC Therapeutics' Vatiquinone for Rare Genetic Disease Friedreich's Ataxia Hits Setback  Stock Titan",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589620-k72h60lsw",
        "type": "regulatory_news",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder - Reuters",
        "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOMng1aGpKMmxPMmxqSVN5X3ZFWG5YY19QemEta0l3MVRsMjZBLWE0RWVzQ1hVNTUwTzdaWl9zN0ZUQl85Njg0SVhNZFMwc0dLWGdWaHdFMnJMb0dtTGYyU2plN1lBUWVOTUZHVXBjblRtNVZ4eHRvcldkV3Z5SXdEWTJtX1FjTTMtVkxXelRTdF8xMzV1djN4bV9ON2hBME5CME5aT3IzVXlJdkFaQ2JaVTR4eGw1RmtzY2dnVDYyenhoMGxqcnVtQTNBRG1jYlNWZ0gzV2dKT2dNN2M5?oc=5",
        "source": "Google News - CRLs",
        "summary": "US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder  Reuters",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589621-200442403",
        "type": "regulatory_news",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "Interest In PTC’s Sephience Launch Overshadows FDA’s Vatiquinone Rejection - insights.citeline.com",
        "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNZU4tTHNKWEJ1NHh4WUVuR0lVT3laZHFxSldwUHk0OC1ka2M0WkRMWjNjcnpWOUdTY1BUNDZkYWdSRFRrcFlmXzI4bjRoMWlDZlhpM1ZoaWlKQjRDMTU5LU5qNzZPSzRLVVl4VENuaTZzVkJfVXRKbl9lU1FpMWs5Z3N5bE9IZUhXMVZwRkRPTExhcjA3XzU5emxuU0V4QUxlVVFXWG9QeGFDREstVGRaeTVTS3BNcjRkd19hZ2VsRFc1dFZRYU04ekE1U05BaXg1VzFLR2ZydXltVk1rQVNISGxIYUVuaXlOQWtLSmZjcUdmUQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "Interest In PTC’s Sephience Launch Overshadows FDA’s Vatiquinone Rejection  insights.citeline.com",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589621-14dhb0iur",
        "type": "crl",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "PTC Therapeutics Receives FDA Complete Response Letter - TipRanks",
        "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNN0lZVHJyMzNVT2duUjBScTZ3SEQzeDZ6UXc4NjNnNmt6bGJDZENoOUxJc09HeEZXcGR5UW11Z1pxdVUteDR4dWFjV1ZxYXE4UzhSZU1JTUdXamtmbFBkTU1iX0xINHpPalV5clNleDZGVXlib0l6aDJRbkRFT1l6aFV0NzBycXlkemdnZmpXbnlMdFViT2MzbG40Z1dBRkRfRmVZRlJ3RkxGdw?oc=5",
        "source": "Google News - CRLs",
        "summary": "PTC Therapeutics Receives FDA Complete Response Letter  TipRanks",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268589621-68qfu7opy",
        "type": "regulatory_news",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "FDA rejection derails PTC Therapeutics' rare disease hopeful - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOek1NVEJyLTYtTGwzcHlZUzRyUWF6eUtIclc5Zl9vQ1dnUjNvODVrb0xVSmxLbjRZRXB6bklCRlpoOXRCTExIVlU2d3dFcTJMV0xiUzNZeWluaGpab1BjYy12YUFuNjZPeXktTm1jNi1VUmNjQ2xFX3pYeGZVcE5UQ2NfYThRTDBoS2JqNUM4ODFhNmRsOEtSaU1ZdnY?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA rejection derails PTC Therapeutics' rare disease hopeful  Fierce Biotech",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589558-seph3t94e",
        "type": "warning_letter",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "Staying Ahead of Enforcement: Executive Strategies To Prevent FDA Warning Letters - Med Device Online",
        "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOMlh0TnFnZkd6d2hLOEF3dUhfN1RKQmZQQ3J0UGl6SXdraUhiWXZYd2JZMVltRzRJRkZXUWQ0NU5ncE1UcUIyalVEcU1sQnpfQXdYZEdONzhySk9uMUJvakRGNmhtd0xYVGhMbXA4WnJmZ0RaWWF4ZE1IaVhQaEhiZmFrZEFUN0ZMcHdKdGxIdzdmY29qRHJpRXdLcGJ6VVFzWWgzd1J6VXdCWF9fVnZJdzdFZjZxVU8wMnRSellR?oc=5",
        "source": "Google News - Form 483",
        "summary": "Staying Ahead of Enforcement: Executive Strategies To Prevent FDA Warning Letters  Med Device Online",
        "severity": 8
      },
      {
        "id": "Google News - CRLs-1757330791535-adwymcxn3",
        "type": "crl",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "PTC Therapeutics Receives FDA Complete Response Letter - MSN",
        "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZmI0WlRSMDNhNURtOWxSbkJrLVY3UFFNODhiTmxEc3NxeTB6VEhVSURFWEh5VUxCTFZKLUJsT2lEZjVlcEhlM3Rpb2htdjdLcnVoLURIcHhxaDcxVFI2YVRtOWNET0Q0OVVEU3ZtQkZVaGpTQWNuUXR2anotbHdpY3ZGTkZzU2V3OGQ2bFoxVDdtaG5CWDgyRnhHRXNkWXJqY2lpVzlKeEc?oc=5",
        "source": "Google News - CRLs",
        "summary": "PTC Therapeutics Receives FDA Complete Response Letter  MSN",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268589622-75svog6qm",
        "type": "regulatory_news",
        "date": "2025-08-18T07:00:00.000Z",
        "title": "Stealth Bio submits third FDA application for rare disease candidate - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNMDQ0VjFsZEhhcHYzM1IzMHJrZWNvd3FsSkItRDJHZ2hvcnVsZ19PNGllNmt6OW81TE9qTFh6VkZlUlVIUk5PSTBsWHd3WXQwXzBmc01iWmNialhJcDVNRGxxTl9XRzZFNGFjNEppV28xUUVfWFlkeTRORXJ2OVp4YkVxdmJIZXdoaW93Rl9XeWdEaXM2czBCcGxqVTF1TGpNdmVaVEF4WExTWXprNEE?oc=5",
        "source": "Google News - CRLs",
        "summary": "Stealth Bio submits third FDA application for rare disease candidate  Fierce Biotech",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589621-m1kfbfbgz",
        "type": "regulatory_news",
        "date": "2025-08-08T07:00:00.000Z",
        "title": "Stealth Bio questions its own viability as FDA directs rare disease biotech to resubmit drug application - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPNnN5SE0yeE5kaTB2Sk1hVEdGaVREMjVEME56M3dNQkhkdXM5UjZ6SGFteUFVZjdVaG5wbUdYM0dmdzJIWFJJdGE3b2Z3VW5rX3pmaFAtSm5ua2I3MzhJQ19kYkxnUGpSaWUwODJCdHc5anFFRUxsN2ZINGhDVkZMRGdLLWxGcnpSbVhkZmdqei1HMkZUWHhrUmNYUXNxN3VWRS0zUW5CeTJVUTJYdEZfX1c0QmRaYUxIOGc?oc=5",
        "source": "Google News - CRLs",
        "summary": "Stealth Bio questions its own viability as FDA directs rare disease biotech to resubmit drug application  Fierce Biotech",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589621-83bw8dxyw",
        "type": "regulatory_news",
        "date": "2025-08-01T07:00:00.000Z",
        "title": "Regeneron says Novo plant problems caused another CRL and will delay 2 Eylea decisions - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQQWlnbWlmSFhGYXBOTHc3MkRaMTB3QXIxbHdZU2VEMklXVVJ1X0tHZVZJRUxHMXJDU21fQjgtY2x1YlBzRWpWZlBUS19FZkF2Z2M5dVE4b0NPdldSemFpRUd1eERNQXZHWG1WRExuNlN4Sl9WT1pOYjRWZkx3X0ExTklVcExlWHIzc3puN1BCRVR0WEJsQmpocjUxLWl6THd2d05mVkJCSnJUcFhfLUZ0OW52bWZ3U0NoTnkydHJ3?oc=5",
        "source": "Google News - CRLs",
        "summary": "Regeneron says Novo plant problems caused another CRL and will delay 2 Eylea decisions  Fierce Pharma",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589620-p9p47i0xo",
        "type": "crl",
        "date": "2025-07-30T07:00:00.000Z",
        "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
        "severity": 9
      },
      {
        "id": "Google News - Form 483-1757268589557-7u0w2232r",
        "type": "regulatory_news",
        "date": "2025-07-29T07:00:00.000Z",
        "title": "5 Cs For Responding To FDA-483s — Strategies For Effective Compliance And Resolution - Clinical Leader",
        "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQVEgxdUZlOTlRTnhhbWcxLTFxVmxsQkxKZkRjek1CbndhMHFGME9pcF9waTExRV9hcGNTMk9VUjU3NDh1YjBuU2Rrdm1TQ2YxdHdnVXk5YmltQ2lzVG9YT2dkbDV2clFTajhuM0NLelpFclBiREh3X1h0WEF6RVdHR3ptcjU4a0h4bG82eG14Y1NTVGFRdkdHcmlGZ3dPZHlpanlQXzVxUjg1eG1qZjhLUFNONDI3d3ZT?oc=5",
        "source": "Google News - Form 483",
        "summary": "5 Cs For Responding To FDA-483s — Strategies For Effective Compliance And Resolution  Clinical Leader",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589622-n4q97f0wk",
        "type": "regulatory_news",
        "date": "2025-07-25T07:00:00.000Z",
        "title": "Replimune CRL Fallout: How Biopharma Leaders Should Manage a New Layer of FDA Uncertainty - Pharmaceutical Executive",
        "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxNTkF4SjBPS01MdURwbjNoanNMQWJTczdSY3BvU2NkS1p6S1FpUEw0eUpJdE16RnBfOHg4OEJjdmoxQVhiZFpRRUJqRjhXajBlRWtnY3ZsT0E2UUhySHNVbmRIMmN1T3dqQ2I4c1Q4bFJEUUtPS05xTHBlazRwZ01rdkhrc2dOVUpaUXpQcTFLU0RMdXF6dHhVT2daai1BQQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "Replimune CRL Fallout: How Biopharma Leaders Should Manage a New Layer of FDA Uncertainty  Pharmaceutical Executive",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589621-26sg7ddft",
        "type": "regulatory_news",
        "date": "2025-07-24T07:00:00.000Z",
        "title": "DLBCL: FDA Rejects BLA for Second-Line Glofitamab Combo - Medscape",
        "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOaVI5eGY5ZUstSlZiSHdoaEpoVGF2LUFSampJTWQ4LXpyNFlRODd6eGNzRFlUQm5nbjkyZXNzeThhOHhsUUhZSnlodmRRV25OR2MzVDRZSUVuSkxjQ2dvSS1BUUNsdk5IYUJwcEtVU0xRdUVOTl81Vm1iWUNDX3Ztblh2TXk0dkZwOXFmamY5U0xIX2M0SkVaLXpPSHp6aG51dlE?oc=5",
        "source": "Google News - CRLs",
        "summary": "DLBCL: FDA Rejects BLA for Second-Line Glofitamab Combo  Medscape",
        "severity": 5
      },
      {
        "id": "FDA Press Announcements-1757268588773-ina3ni0y5",
        "type": "regulatory_news",
        "date": "2025-07-22T18:17:07.000Z",
        "title": "HHS, FDA Praise Consumer Brands Association’s Vow to Remove Artificial Colors from America’s Food Supply ",
        "link": "http://www.fda.gov/news-events/press-announcements/hhs-fda-praise-consumer-brands-associations-vow-remove-artificial-colors-americas-food-supply",
        "source": "FDA Press Announcements",
        "summary": "Today the leadership of the U.S. Department of Health and Human Services (HHS) praised the Consumer Brands Association for its pledge on behalf of the makers of the nation’s food and beverage products to remove certified Food, Drug & Cosmetic (FD&C) petroleum-based colors from America’s food supply.",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589619-naw0ti0jk",
        "type": "crl",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
        "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268589621-n5fp33tzl",
        "type": "regulatory_news",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA rejects RP1 for advanced melanoma, says IGNYTE not a ‘well-controlled’ trial - Healio",
        "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNbWJBZlpidVZBdy1nNUVfTkJHZ0xKSlUxRHNzZkFhYzlfSk5EZXpsVmhFclFZRkFZVDJwTWh5aDZwVjNzOWpGZzFYdzFmRWQ2OGI3WDJiazVGR0dGS0ZNWWhLelJKVlczS2d5d2RhMUdDUmYzblhCM3dqWnNZZ05PelNuV1hUS1dxcFNXdDYwSTBXalRGY2hPZ01tVFJ2R19ENkNpNTduZm54SDdvaVZsZWhKY0tkRXdsNUZ0bmJOT1lVNE5DR21HejVubkE3UQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA rejects RP1 for advanced melanoma, says IGNYTE not a ‘well-controlled’ trial  Healio",
        "severity": 5
      },
      {
        "id": "ebcc641bfcab11d931a82b2473904d37",
        "type": "regulatory_news",
        "date": "2021-08-09T07:00:00.000Z",
        "title": "RE: NDA 213876 ALKINDI® SPRINKLE (hydrocortisone) oral granules MA 13 Dear Ms. Devarakonda: The Office of Prescription Drug P - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1QRjNVZnN6bmVrLTB1ZkE3OFpSOFZ3YUcyWWRYR1ZaVGxXVTZtVUMtMnE5alhBZl8tYllneDFYN3ZNcng3UXpHLWtqemw0bzJ6NHRN?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "RE: NDA 213876 ALKINDI® SPRINKLE (hydrocortisone) oral granules MA 13 Dear Ms. Devarakonda: The Office of Prescription Drug P  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Assistance Programs",
      "rejection letters",
      "Neurology live",
      "refusal process",
      "Application Rejection",
      "Rejection Letters",
      "for rare",
      "Faces Decisive",
      "Fierce Biotech",
      "Oncology News",
      "application  Fierce",
      "Administration issues",
      "Investing",
      "Hits Regulatory",
      "Manufacturers  Pharmaceutical",
      "Online",
      "of Prescription"
    ],
    "facilities": [
      "Telangana  The, Hi"
    ],
    "risk_score": null,
    "last_updated": "2025-09-08T12:30:00.784Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z",
    "compliance_score": 0
  },
  {
    "name": "board",
    "aliases": [
      "board"
    ],
    "violations": [
      {
        "id": "STAT News Pharma-1757256366570-oacuwg1th",
        "type": "regulatory_news",
        "date": "2025-09-04T15:35:54.000Z",
        "title": "STAT+: Swing Therapeutics raises $11 million, adds former Pear CEO to board",
        "link": "https://www.statnews.com/2025/09/04/swing-therapeutics-raises-11-million-adds-former-pear-ceo-to-board/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Former Pear CEO joins Swing board — did he invest? My colleague Allison DeAngelis spotted a familiar character pop up in a fresh SEC filing from Swing Therapeutics, developer of…",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "using contaminated bags for a sterile injectable drug",
    "aliases": [
      "using contaminated bags for a sterile injectable drug"
    ],
    "violations": [
      {
        "id": "STAT News Pharma-1757256366570-8zgn6kh26",
        "type": "regulatory_news",
        "date": "2025-09-03T20:54:12.000Z",
        "title": "STAT+: Amneal Pharma is scolded by FDA for using contaminated bags for a sterile injectable drug",
        "link": "https://www.statnews.com/pharmalot/2025/09/03/amneal-infusion-sterile-epidural-injectable-fda-contamination/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "A pharmaceuticals company relied on contaminated bags for a sterile injectable drug, among other infractions, the FDA found.",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "HIV drugs",
    "aliases": [
      "HIV drugs"
    ],
    "violations": [
      {
        "id": "STAT News Pharma-1757256366570-l127543v5",
        "type": "regulatory_news",
        "date": "2025-09-03T13:11:33.000Z",
        "title": "STAT+: Pharmalittle: We’re reading about Gilead price hikes for HIV drugs, a Novartis China deal, and more",
        "link": "https://www.statnews.com/pharmalot/2025/09/03/gilead-hiv-drugs-novartis-china-deal-cdc-novo-vaccines/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Gilead is seeking to boost prices significantly for several HIV treatments distributed by state AIDS Drug Assistance Programs",
        "severity": 5
      }
    ],
    "products": [
      "Assistance Programs"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "pay significant price hikes for HIV meds",
    "aliases": [
      "pay significant price hikes for HIV meds"
    ],
    "violations": [
      {
        "id": "STAT News Pharma-1757256366570-ob8r8uufz",
        "type": "regulatory_news",
        "date": "2025-09-02T15:47:01.000Z",
        "title": "STAT+: Gilead wants state AIDS drug programs to pay significant price hikes for HIV meds",
        "link": "https://www.statnews.com/pharmalot/2025/09/02/hiv-aids-drugs-medicines-pharma-gilead-adap-prices-inflation-descovy/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Gilead Sciences is seeking to boost prices significantly for several treatments that are widely distributed by state AIDS Drug Assistance Programs.",
        "severity": 5
      }
    ],
    "products": [
      "Assistance Programs"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "watch in Congress",
    "aliases": [
      "watch in Congress"
    ],
    "violations": [
      {
        "id": "STAT News Pharma-1757256366570-80qtgr1mm",
        "type": "regulatory_news",
        "date": "2025-09-02T12:37:42.000Z",
        "title": "STAT+: The key health care fights to watch in Congress",
        "link": "https://www.statnews.com/2025/09/02/cdc-in-crisis-trump-rfk-jr-healthcare-policy-congress-dc-diagnosis-newsletter/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "BREAKING",
    "aliases": [
      "BREAKING"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367384-saa9ewrwd",
        "type": "crl",
        "date": "2025-09-05T13:49:44.000Z",
        "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
        "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
        "source": "Google News - CRLs",
        "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "publish drug rejection letters in real time",
    "aliases": [
      "publish drug rejection letters in real time"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367384-8wshw8utm",
        "type": "regulatory_news",
        "date": "2025-09-04T17:45:28.000Z",
        "title": "FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPcThla0JHRzd3ci1sWnVhWUluMmliSWFmeEFQUTdNaG5WREpNU2xQZHRURGNuSFV6ZEpzaTNObDZ2OWkxWHVJS3Bvd2xmS3dfNjhiNUEyb2NKMU9CQUJTd21EbVFiVWFzak5oM1ZCcllXVnNDN2VqNHoxVlFDbDc0TkJQanpNd2FQbDZsZXoyVnhvZTdMRUZiQ1FqX1BqXy1JTkJaZ2FHeUZqdEc5V1RDRWFpVUhmRlN5ZFNhQ2o5ZEJxRkF0?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub  Fierce Biotech",
        "severity": 5
      }
    ],
    "products": [
      "rejection letters"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA Releases Complete Response Letter on Declining MDMA",
    "aliases": [
      "FDA Releases Complete Response Letter on Declining MDMA"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367384-gqoanbz2c",
        "type": "crl",
        "date": "2025-09-05T18:56:15.000Z",
        "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
        "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS",
    "aliases": [
      "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367384-zk2l23ml9",
        "type": "crl",
        "date": "2025-08-28T07:00:00.000Z",
        "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
        "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "MDMA",
    "aliases": [
      "MDMA"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367384-x10ui6u4v",
        "type": "crl",
        "date": "2025-09-05T00:09:00.000Z",
        "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
        "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
        "source": "Google News - CRLs",
        "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA issues complete response letter for 89Zr",
    "aliases": [
      "FDA issues complete response letter for 89Zr"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367384-l9ikodu42",
        "type": "crl",
        "date": "2025-08-28T07:00:00.000Z",
        "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
        "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS",
    "aliases": [
      "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-tjj72xvi5",
        "type": "crl",
        "date": "2025-09-02T12:44:00.000Z",
        "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
        "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
        "source": "Google News - CRLs",
        "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma",
    "aliases": [
      "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-o3ejkllhk",
        "type": "crl",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
        "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade",
    "aliases": [
      "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-62v66q8ls",
        "type": "crl",
        "date": "2025-07-11T07:00:00.000Z",
        "title": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade - Pharmacy Times",
        "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbF8zbDVUalRyb19zVnJOMmMxWVZWc1U3UEgtRWpWTHhUOTVzemwyQ3A3Ykw0dHlqTl92VWVRWkphZ3ZaUVEwVXd6RHIxSFZKbUw1ZDNRN0d6b2k2cl9xbmZ6UDVUTDAwcnJ2U0w1XzI4blhzMVlCQjRjX2RlVVE4V0J3bXUzRHhFOExDR1N2V09pWlZ0SU0tRGx0ckJWVDA1STh4QXJIQUdDazFMRFYzTHhObTNLQTQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade  Pharmacy Times",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA Issues Complete Response Letter to Outlook",
    "aliases": [
      "FDA Issues Complete Response Letter to Outlook"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-fa3ao3lfb",
        "type": "crl",
        "date": "2025-09-02T21:45:00.000Z",
        "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
        "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA Issues CRL for RP1 Plus Nivolumab for Advanced Melanoma",
    "aliases": [
      "FDA Issues CRL for RP1 Plus Nivolumab for Advanced Melanoma"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-nqnxh338c",
        "type": "regulatory_news",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA Issues CRL for RP1 Plus Nivolumab for Advanced Melanoma - OncLive",
        "link": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQZEl1ZFBnQWVDQlhPSWQ4N1ZwUkJuREc0WHJERS1HUV80emJFRnFmZ2F6NXA1aURxMnBiTUxUYXVtVVVIY3NMWjdWSUlVU1BNUEx3RTlDZlk0WmpUOUZacUhGZGhTTXBBajBfR2VYakhkenE2Wkt2VmpXTHAxWDVZWGJacVRnNFd6cTFHdDIyX3l2Zw?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for RP1 Plus Nivolumab for Advanced Melanoma  OncLive",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD",
    "aliases": [
      "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-i6c46nkim",
        "type": "crl",
        "date": "2025-07-02T07:00:00.000Z",
        "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
        "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
        "severity": 9
      }
    ],
    "products": [
      "for CKD"
    ],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA Issues CRL for SC Daratumumab Plus VRd for Transplant",
    "aliases": [
      "FDA Issues CRL for SC Daratumumab Plus VRd for Transplant"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-tkvu18got",
        "type": "regulatory_news",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "FDA Issues CRL for SC Daratumumab Plus VRd for Transplant-Ineligible or -Deferred, Newly Diagnosed Multiple Myeloma - OncLive",
        "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSFVVVi1aUTFZUDJYMWF3U085ODluNXUyLVNSMENQODNUQ1p5UDU5U21uMVVZZzRwOU1acWxTVlpLWWxqRlEyejFUSlV6cmhnSi05N3F5anNfcldYNDl0al9HSkNmU3JxR1RCSEtWVGJZc1ZXeGIzWnpZT3hhQ3lXQXBRenpDVV9FTGV4S213MTJzWkRmZ05iLXZhM0dpWG5hTnJoOVNkeG5PcTVCcGtKNWcxeFJKQVpyaEJKMVpJUWR1RDA?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for SC Daratumumab Plus VRd for Transplant-Ineligible or -Deferred, Newly Diagnosed Multiple Myeloma  OncLive",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen",
    "aliases": [
      "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-f9meg4qmi",
        "type": "crl",
        "date": "2025-08-20T07:00:00.000Z",
        "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
        "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "kidney cancer",
    "aliases": [
      "kidney cancer"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-9v6fywo0r",
        "type": "regulatory_news",
        "date": "2025-08-28T07:00:00.000Z",
        "title": "FDA flags issues in review of Telix's PET diagnostic agent for kidney cancer - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOem9yN0VVLVNDdDBEbHdycExVVDhVZ1BEZk1JWEJ2X0xab1FFWTdLRXZHWmZYdVdMUWRlWUdwU1RTM21LbnU0bXIwVTBnYkdWSVZPVGJmVDNSc1MwNVhhNkR2SjdzTW03UXk0LTJVVUFnMVcyX1NqUG1BUjV5NjR6VTdPNkZPeHZiYnYtRHpOZm9uS3RtWV9URlIzdVBkMHVkVUYzVXZn?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA flags issues in review of Telix's PET diagnostic agent for kidney cancer  Fierce Biotech",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757256367385-ac4fnrr04",
        "type": "regulatory_news",
        "date": "2025-08-28T18:33:45.000Z",
        "title": "FDA issues CRL to Telix's radiopharmaceutical diagnostic for kidney cancer - FirstWord Pharma",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE56TnB2NUk2UGhDS1FNZ295TEtPekRPV3RTQTlEOHJQdEtLX1BqdUhyUDhRNjBRSGtFVFNwNHRKYThIeDlUUktxSncxZHhJaHQyM0pB?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA issues CRL to Telix's radiopharmaceutical diagnostic for kidney cancer  FirstWord Pharma",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA received complete response letter from FDA for Columvi in DLBCL",
    "aliases": [
      "FDA received complete response letter from FDA for Columvi in DLBCL"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-9272w75rj",
        "type": "crl",
        "date": "2025-08-27T22:51:27.000Z",
        "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
        "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "Ultragenyx receives complete response letter for UX111 BLA",
    "aliases": [
      "Ultragenyx receives complete response letter for UX111 BLA"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-l6g77hkc9",
        "type": "crl",
        "date": "2025-07-14T07:00:00.000Z",
        "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
        "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
        "source": "Google News - CRLs",
        "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment",
    "aliases": [
      "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-1sih2hucs",
        "type": "crl",
        "date": "2025-07-30T07:00:00.000Z",
        "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
        "severity": 9
      }
    ],
    "products": [
      "Neurology live"
    ],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "the Drug Approval Process",
    "aliases": [
      "the Drug Approval Process"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-atu565ukw",
        "type": "regulatory_news",
        "date": "2025-07-16T07:00:00.000Z",
        "title": "FDA’s Published CRLs Deliver Insight Into the Drug Approval Process - OncLive",
        "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxONjFGNFRLejRrYVdvZk5DbWlVVWNZZlZmUlpoZFUwUnBxb2w2bC04LWwxeDlpbDcxZVFoTG50MTNVTEtkWFYyeHZzRHpNOTEyc0RkbHNLcU5qT1hCNFVKM3lwZ05IaXpsb2wwTXJCVEltbHc0LW5hbHdnWmtwLWFScW9WNmcxVHRQWVBPUGxDMnFSeW1OeC1vS0J3RVU?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA’s Published CRLs Deliver Insight Into the Drug Approval Process  OncLive",
        "severity": 5
      }
    ],
    "products": [
      "Approval Process"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy",
    "aliases": [
      "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-eq75yp2ch",
        "type": "crl",
        "date": "2025-07-11T07:00:00.000Z",
        "title": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy - FirstWord Pharma",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBalJyWmlNZjQzUWxrRFpsVm9XTGhwMlFBWVd6QUw3S280U1JWX0NQbWZVTEEyVVhvVHF6VHBlenJoOTFHTlB2UnhNOHZqSW9Cck5v?oc=5",
        "source": "Google News - CRLs",
        "summary": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy  FirstWord Pharma",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS",
    "aliases": [
      "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-hugdrkzib",
        "type": "crl",
        "date": "2025-08-28T07:00:00.000Z",
        "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
        "source": "Google News - CRLs",
        "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA Crackdown on Trial Design",
    "aliases": [
      "FDA Crackdown on Trial Design"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-xfcgd0v23",
        "type": "regulatory_news",
        "date": "2025-07-25T07:00:00.000Z",
        "title": "FDA Crackdown on Trial Design: What July’s CRLs to Replimune and Capricor Mean for Sponsors - Applied Clinical Trials",
        "link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOUlFwSXd5dEk5eHNMYl8xWlk1WS0xby05a1lZNGtmQ1ZXSXRib2lxYzVqb2tWbnMyVlAzalU3eHVBSVpIRUhSQWYyVDNRUkJ3Z1VfUU1VTzRxNXhmbzVUZVpWRVY3cDFQcnA0ZTZHcmsxM1p6cUVvRWIxc2FhV1NBR2d1Z1B3ZXRJVW5NVkcwLUtOWXJRam9JdHFtcjY5STA?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Crackdown on Trial Design: What July’s CRLs to Replimune and Capricor Mean for Sponsors  Applied Clinical Trials",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.388Z",
    "monitoring_since": "2025-09-07T14:46:07.388Z"
  },
  {
    "name": "FDA hits Unicycive with manufacturing",
    "aliases": [
      "FDA hits Unicycive with manufacturing"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-8q7mhuxla",
        "type": "crl",
        "date": "2025-06-30T07:00:00.000Z",
        "title": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHNsMWNuaTNURmo2SVJ0MkZwczNsNkREY2g1bG1XRnRZREUyTlFreVZNYXdlNkJYMjZBV3FwQ2twZmQtOHRPUzNvR2tRNVpFbWxVT01paU9VcGFSQjhMblpFZzg3U25iRlNIZGxaQXFVUTBYb1R6dTVrbzYxamZtUERSazFfS2xIY0g5dGR5ekI0RndTM0lyN3pPc2pnTGhPaklOUVJpZ0FfbW04eUNwVW1kMDAxSmh6QnhRYXlkS18?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect  Fierce Pharma",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "FDA Releases CRLs for Previous Drug and Biologic Product Applications",
    "aliases": [
      "FDA Releases CRLs for Previous Drug and Biologic Product Applications"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-fih7wxjw3",
        "type": "regulatory_news",
        "date": "2025-07-10T07:00:00.000Z",
        "title": "FDA Releases CRLs for Previous Drug and Biologic Product Applications - OncLive",
        "link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNWVh2d1FXVWZSeWU3b2g2OFpKSTIzdEE4WHU0OVVuQUk1UGUyM2M2T1VmVXhreTllVjJUX3FOdl94clRiZXhtV0l0cE04MjhtaWtMNjdkYzhTT1gwaWt3ZWtLbUpxSXJhZVQ3Y3haSy1qWW1Bb2lZQ2g3MEdwYktZWUNmTkFVai1sR2VweHM5WEJRT2RIMFNEOUVtZm5CUUU?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Releases CRLs for Previous Drug and Biologic Product Applications  OncLive",
        "severity": 5
      }
    ],
    "products": [
      "and Biologic",
      "Applications  OncLive"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "TLX101",
    "aliases": [
      "TLX101"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-s395ap51d",
        "type": "crl",
        "date": "2025-05-06T07:00:00.000Z",
        "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
        "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZjdnbUFDSFlpQkV5UkFOcTVxYThqYWJhNm9OMEEwdlJfem9JS3dYcEZ6cXBxNnN0UkZvZ3QxQ0xVLVB2V0E1eWRmUkxJUm1lMUcxbXBnMzJFaWJVQkM0WlFUeW04R0pCSmlDbE5VOWRPYmVISWpqSGtRdi1XMlRMUnZoOG5idEdVVUhxT2FpYmJyMmprR05tc3JsaHc?oc=5",
        "source": "Google News - CRLs",
        "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
        "severity": 9
      },
      {
        "id": "3cc58d467d3d23b571713a999e0f70e7",
        "type": "crl",
        "date": "2025-05-06T07:00:00.000Z",
        "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
        "link": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxQVmIyemZUbEpPZmx3cGNyNTg1blVBQ1hUNEN1R0JXRDlST05aNzVuTTU3ZXJHbW5LREFmdnU0c3pad0lmN0pycnY5ZW0yU2lBLWgtY0R1aHpnbkNLQktHTlp3eW5GSkoxWDdfcm1fcmMxWnVYcGFRdGh0c29kWWNrMWw1NENHS0RKMVFsdTIwV2JmU0NWTUJ0by1QWXp1Qmd6ZmhWYlducDBaYTlkX19UcU41NzN4LUo2MWpKb0FpMUhNTU40aGczVTJOZ2dhZm1GT1VldExRNkhLalMxSk42TXF4WFFFRVA4S0FqZw?oc=5",
        "source": "Google News - CRLs",
        "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
        "severity": 9,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": null,
    "last_updated": "2025-09-08T12:30:00.071Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z",
    "compliance_score": 70
  },
  {
    "name": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA",
    "aliases": [
      "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-2oodglvmz",
        "type": "crl",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
        "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
        "source": "Google News - CRLs",
        "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "FDA Issues CRL to Glofitamab Plus GemOx in ASCT",
    "aliases": [
      "FDA Issues CRL to Glofitamab Plus GemOx in ASCT"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-cnzn1mfrh",
        "type": "regulatory_news",
        "date": "2025-07-21T07:00:00.000Z",
        "title": "FDA Issues CRL to Glofitamab Plus GemOx in ASCT-Ineligible R/R DLBCL - CancerNetwork",
        "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQQVhucUF6ZTNFTW5XS2hKcGVxRG9HeUFsb2dpR0l0S2tHWi05SXAwaVQyY1JaaWRZTWliM2c0WFFCTGRyVjh4UDNBc3U1TVVZQW04N0JXYkVRRjY4V2pJV28za0R1cG9TMHhzdEhFZ1VVNWVBUjF2V1FKaUpXUnBnQkdTTjZ2bGRZR3BtSy1Kak95c3JlbU02LVBLSHJvSXpGSGFOdVV3?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL to Glofitamab Plus GemOx in ASCT-Ineligible R/R DLBCL  CancerNetwork",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "FDA Issues Complete Response Letter for Glofit",
    "aliases": [
      "FDA Issues Complete Response Letter for Glofit"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-2e7xars6r",
        "type": "crl",
        "date": "2025-07-18T07:00:00.000Z",
        "title": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL - Pharmacy Times",
        "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOEp5QUp6MFBYajNKQlptc0lpeWc2MGZYb3E1ckR5MW1GUUhDS2w0TWhWdjFpeVpUbWh3THZPRWJaeDZQWFloem5sZnJUaHh1cTFtWDd4dnJBb2h3MTdWTDBHVnd6cjdtREt0MGFiWjJWcEF5dldvajV5ZlFyQjRKRDBxYTNtUGg3ZHljdnBhdEo5UmFibE1CcVFnNFVBaWhnaHc?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL  Pharmacy Times",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Unapproved Drugs",
    "aliases": [
      "Unapproved Drugs"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-04nw9yfnf",
        "type": "crl",
        "date": "2025-09-05T02:37:30.000Z",
        "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
        "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
        "source": "Google News - CRLs",
        "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "FDA Issues CRL to TLX101",
    "aliases": [
      "FDA Issues CRL to TLX101"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-c55e1t1yi",
        "type": "regulatory_news",
        "date": "2025-05-01T07:00:00.000Z",
        "title": "FDA Issues CRL to TLX101-CDx for Glioma Imaging - OncLive",
        "link": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOcU9TZGNfSjhtUTZsWTNYQ0NiNUR6YmhGQW5vVjZEY3FSMFg0UmZ1RXBoSWhaSlRzYUtSeXFUcEdNSnVPQ1Nlank3blAtQjhrdlJlSGNzd3Utb0dldUV1dlNFUlZrM1pzNnREWmtTQUhBQUVVdlBJUFdFSkZvZzBKanlR?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL to TLX101-CDx for Glioma Imaging  OncLive",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Telix stock plunges after FDA issues Complete Response Letter",
    "aliases": [
      "Telix stock plunges after FDA issues Complete Response Letter"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-w9m13npwx",
        "type": "crl",
        "date": "2025-08-28T21:22:30.000Z",
        "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
        "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
        "source": "Google News - CRLs",
        "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Stealth hit by FDA rejection to twice",
    "aliases": [
      "Stealth hit by FDA rejection to twice"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-8ljve3x27",
        "type": "regulatory_news",
        "date": "2025-05-29T07:00:00.000Z",
        "title": "Stealth hit by FDA rejection to twice-delayed filing as it lays off staff - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOcXpCbnZPTFRLNmNrOHpMVGFzZm1KX1ZJUHZFMVNSVmM3ckYzRTJJLVdZUldFMXpNdXdERkRPc1VmSElTaDkteV9vVUEwaHRJbGRVendaQU9aQmJTbWo5RHNhSXpzbTNtYllxRHVuUi1XaW5GT0JFTEcwNC1CcW9JRDhfaDZhS1o4aUdySHRyal96RGVibGpnSkRZVXVhT0R6WEwzUGZnVjNWV0EybnVBaDBTSQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "Stealth hit by FDA rejection to twice-delayed filing as it lays off staff  Fierce Biotech",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "FDA issues complete response letter for Ultragenyx gene therapy application",
    "aliases": [
      "FDA issues complete response letter for Ultragenyx gene therapy application"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-m6jrpsqlw",
        "type": "crl",
        "date": "2025-07-11T07:00:00.000Z",
        "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
        "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "FDA Issues Complete Response Letter for Tab",
    "aliases": [
      "FDA Issues Complete Response Letter for Tab"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-bh5unbh9g",
        "type": "crl",
        "date": "2025-01-16T08:00:00.000Z",
        "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
        "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "New FDA Initiative Reveals Common Reasons for Drug Application Rejection",
    "aliases": [
      "New FDA Initiative Reveals Common Reasons for Drug Application Rejection"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-kl9s24kqk",
        "type": "regulatory_news",
        "date": "2025-07-11T07:00:00.000Z",
        "title": "New FDA Initiative Reveals Common Reasons for Drug Application Rejection - Applied Clinical Trials",
        "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPN0xiLW1pcG5NdDB0cmhKWUpNLXRZN0ktMmdqZWJqRlg0OFByX3hCQWlvSzJra3hkVzhsQnk3U2QyOURiZGlDRDJteEM1SS1EdVA3N0ZpdW1raFlaRXRPMlExc3FQRnE2R1dBamdjZDRPWC1ZMnhqQVo0aDFGUFdGbEI2bzUzRU1YMVc0UHhoRC1QYkM1T2s2MUNKeU1taG4wcl9SbHJHNnJHdzE1ckVDZTlld21BWkw1?oc=5",
        "source": "Google News - CRLs",
        "summary": "New FDA Initiative Reveals Common Reasons for Drug Application Rejection  Applied Clinical Trials",
        "severity": 5
      }
    ],
    "products": [
      "Application Rejection"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Ultragenyx Receives Complete Response Letter from FDA for",
    "aliases": [
      "Ultragenyx Receives Complete Response Letter from FDA for"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-9hi3a8j02",
        "type": "crl",
        "date": "2025-07-11T07:00:00.000Z",
        "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
        "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
        "source": "Google News - CRLs",
        "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed",
    "aliases": [
      "FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-7o2kblevn",
        "type": "regulatory_news",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed - Neurology live",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPUjVKMU9XR0ZDSjNDOFdNYV9NX19CbXp4QnhkWm1qNV9ZZUoxVTlheHJBNjBlZUkxQW1EdVdDREJndTdxdnU4OVZDQTdycEk5dkx3ZnFQajlNM0FWYmhfMy1TQjJwS0JXOXQ4WVR6SE9TUmhSalZndzhrWjlMLUtyYV9sbWhDTGluWEtXV25Bakt4akZlMEZHenhnLWxJclBPbjBnTTFwQXNfejZMYnc3X2p6WXZFRWg2MXc?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed  Neurology live",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "FDA Denies Approval",
    "aliases": [
      "FDA Denies Approval"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365422-doe58fdt7",
        "type": "regulatory_news",
        "date": "2025-08-06T07:00:00.000Z",
        "title": "For a Second Time, FDA Denies Approval of Odronextamab in Lymphoma - Targeted Oncology",
        "link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNb21KUHZqZjMxc3ZZSXlKbVpzSmdkSU5iak9xN2ZReVVjY2l4eVZ5WmdnZ3JJeTJkZ1JUektHR1dwZ1JwQ2p0aUdiU0M4OVhpcU5aYXloVG1nWnNldjFMRGhwVEh6a1VEOUtmclRSSlBmUWpmZ3AzUWRNSFVGT3E2ekdXeXdPZ1BQOThnT182Sk1oSzFPMk1ISDFkT1RYZG8?oc=5",
        "source": "Google News - CRLs",
        "summary": "For a Second Time, FDA Denies Approval of Odronextamab in Lymphoma  Targeted Oncology",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757256367385-obyld9xcf",
        "type": "regulatory_news",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "FDA Denies Approval: PTC Therapeutics' Vatiquinone for Rare Genetic Disease Friedreich's Ataxia Hits Setback - Stock Titan",
        "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOeVZPeDFtLTdjUkpQVjA1Q1U1LTExRUZ1UU9YMHo3Nk1fcXczeW9EeXhMSWlFdk5CWkc1Smk2WS1CY2I5OUgyNjlSVE51Q1lXcGVuaWtYM1dJcTJEODZOWHZHQjVEdWE4WVd0WEM4RjU2ZUtNNHRBR1pHTDR6YmJlcFlEVHB1UHpuSHo4ZVBUSnVGN09vSHRialR2a1RjcjFZd2ozcGhfWWFNNklHUDFCSWxZUEFYMU1WbEc0Vkxn?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Denies Approval: PTC Therapeutics' Vatiquinone for Rare Genetic Disease Friedreich's Ataxia Hits Setback  Stock Titan",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:06:05.521Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma",
    "aliases": [
      "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-ead3m4u8o",
        "type": "crl",
        "date": "2025-09-02T12:56:17.000Z",
        "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
        "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
        "source": "Google News - CRLs",
        "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy",
    "aliases": [
      "Ultragenyx stock falls after FDA issues complete response letter for gene therapy"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-ppvxno023",
        "type": "crl",
        "date": "2025-07-11T07:00:00.000Z",
        "title": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy - Investing.com",
        "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPWmFTT2hrVEZfZ0NuZ2x0aWFmSmNDMEQ4Nk1XYUFpc3lJTHAtOEFYS2R5SkhOc19vX05MUkpGVmNucEFrdTZqVERncEg2ejlTWjU0cnVRUllNWGt2N0lQM1NaV2puaERWZVNFMXYwbDA3M2tFSDc3b3MwakhLYlA4TkZnbThXUm1XQTFjVFZkVjYzMnZXbW1SanZWRGlmNlF3SnpINndMdlhqb3VPXy1LaGNudkFoWGdVUjF3cWhfeF9FY21vUktJNUtlOWJucklqb1gzWWcxU2pxbEU?oc=5",
        "source": "Google News - CRLs",
        "summary": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy  Investing.com",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "rare genetic disorder",
    "aliases": [
      "rare genetic disorder"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-oia9sozko",
        "type": "regulatory_news",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder - Reuters",
        "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOMng1aGpKMmxPMmxqSVN5X3ZFWG5YY19QemEta0l3MVRsMjZBLWE0RWVzQ1hVNTUwTzdaWl9zN0ZUQl85Njg0SVhNZFMwc0dLWGdWaHdFMnJMb0dtTGYyU2plN1lBUWVOTUZHVXBjblRtNVZ4eHRvcldkV3Z5SXdEWTJtX1FjTTMtVkxXelRTdF8xMzV1djN4bV9ON2hBME5CME5aT3IzVXlJdkFaQ2JaVTR4eGw1RmtzY2dnVDYyenhoMGxqcnVtQTNBRG1jYlNWZ0gzV2dKT2dNN2M5?oc=5",
        "source": "Google News - CRLs",
        "summary": "US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder  Reuters",
        "severity": 5
      }
    ],
    "products": [
      "for rare"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease",
    "aliases": [
      "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-10flohsaf",
        "type": "crl",
        "date": "2025-04-03T07:00:00.000Z",
        "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
        "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Complete Response Letter, Warning Letter and Shareholder Lawsuit Follow FDA Data Integrity Findings",
    "aliases": [
      "Complete Response Letter, Warning Letter and Shareholder Lawsuit Follow FDA Data Integrity Findings"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-weu198iyi",
        "type": "warning_letter",
        "date": "2025-01-15T08:00:00.000Z",
        "title": "Complete Response Letter, Warning Letter and Shareholder Lawsuit Follow FDA Data Integrity Findings - JD Supra",
        "link": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQUGhhVWRtUDA3TEtVa0p6VElTMGE1eXNMcl9mMG1fY3FsdU1xSFdIODBGNWdMVlUtekUxUVFDbFVtZmpxVTF5WVdEblE0MTI0aFllWHJ2ZEM0UkhRcWNYRUdwbTlibUlJUzdPMmEwOUFRdWlTVXZGc2VMa0tvS3NaRXhRRHM4SGQwZGc?oc=5",
        "source": "Google News - CRLs",
        "summary": "Complete Response Letter, Warning Letter and Shareholder Lawsuit Follow FDA Data Integrity Findings  JD Supra",
        "severity": 8
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 8,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Milestone submits response to FDA Complete Response Letter over Cardamyst",
    "aliases": [
      "Milestone submits response to FDA Complete Response Letter over Cardamyst"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-n9jlbcvla",
        "type": "crl",
        "date": "2025-06-16T07:00:00.000Z",
        "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
        "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
        "source": "Google News - CRLs",
        "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "FDA Issues Complete Response Letter for Etripamil for PSVT",
    "aliases": [
      "FDA Issues Complete Response Letter for Etripamil for PSVT"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-vkqrqkow0",
        "type": "crl",
        "date": "2025-03-28T07:00:00.000Z",
        "title": "FDA Issues Complete Response Letter for Etripamil for PSVT - Yahoo Finance",
        "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRTF1MV9aZ28xSjc4c2dMQ1ZEaFlqa0tHQUZBMkhnY1R6Y0x6eC1aVnQtVV9rQVpWeFpPOFo4MldTRlgwN3MtMWdJZ1pLVVJsUFBWeFBqejVPQTBkMEdrUDNKYURTeTBaR3RLVlBqdTZmWkJIdWhDMDdiTEIxUDBRNGVfUENPeHJM?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter for Etripamil for PSVT  Yahoo Finance",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "advanced melanoma",
    "aliases": [
      "advanced melanoma"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-hrm8ldtwo",
        "type": "regulatory_news",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA rejects RP1 for advanced melanoma, says IGNYTE not a ‘well-controlled’ trial - Healio",
        "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNbWJBZlpidVZBdy1nNUVfTkJHZ0xKSlUxRHNzZkFhYzlfSk5EZXpsVmhFclFZRkFZVDJwTWh5aDZwVjNzOWpGZzFYdzFmRWQ2OGI3WDJiazVGR0dGS0ZNWWhLelJKVlczS2d5d2RhMUdDUmYzblhCM3dqWnNZZ05PelNuV1hUS1dxcFNXdDYwSTBXalRGY2hPZ01tVFJ2R19ENkNpNTduZm54SDdvaVZsZWhKY0tkRXdsNUZ0bmJOT1lVNE5DR21HejVubkE3UQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA rejects RP1 for advanced melanoma, says IGNYTE not a ‘well-controlled’ trial  Healio",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "For a Second Time, FDA Denies Approval of Odronextamab in Lymphoma",
    "aliases": [
      "For a Second Time, FDA Denies Approval of Odronextamab in Lymphoma"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-of7blhfbk",
        "type": "regulatory_news",
        "date": "2025-08-06T07:00:00.000Z",
        "title": "For a Second Time, FDA Denies Approval of Odronextamab in Lymphoma - Targeted Oncology",
        "link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNb21KUHZqZjMxc3ZZSXlKbVpzSmdkSU5iak9xN2ZReVVjY2l4eVZ5WmdnZ3JJeTJkZ1JUektHR1dwZ1JwQ2p0aUdiU0M4OVhpcU5aYXloVG1nWnNldjFMRGhwVEh6a1VEOUtmclRSSlBmUWpmZ3AzUWRNSFVGT3E2ekdXeXdPZ1BQOThnT182Sk1oSzFPMk1ISDFkT1RYZG8?oc=5",
        "source": "Google News - CRLs",
        "summary": "For a Second Time, FDA Denies Approval of Odronextamab in Lymphoma  Targeted Oncology",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Regeneron says Novo plant problems caused another CRL and will delay 2 Eylea decisions",
    "aliases": [
      "Regeneron says Novo plant problems caused another CRL and will delay 2 Eylea decisions"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-g24d6kqh4",
        "type": "regulatory_news",
        "date": "2025-08-01T07:00:00.000Z",
        "title": "Regeneron says Novo plant problems caused another CRL and will delay 2 Eylea decisions - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQQWlnbWlmSFhGYXBOTHc3MkRaMTB3QXIxbHdZU2VEMklXVVJ1X0tHZVZJRUxHMXJDU21fQjgtY2x1YlBzRWpWZlBUS19FZkF2Z2M5dVE4b0NPdldSemFpRUd1eERNQXZHWG1WRExuNlN4Sl9WT1pOYjRWZkx3X0ExTklVcExlWHIzc3puN1BCRVR0WEJsQmpocjUxLWl6THd2d05mVkJCSnJUcFhfLUZ0OW52bWZ3U0NoTnkydHJ3?oc=5",
        "source": "Google News - CRLs",
        "summary": "Regeneron says Novo plant problems caused another CRL and will delay 2 Eylea decisions  Fierce Pharma",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "FDA Issues CRL for RP1 in Advanced Melanoma",
    "aliases": [
      "FDA Issues CRL for RP1 in Advanced Melanoma"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-46qtktjyl",
        "type": "regulatory_news",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA Issues CRL for RP1 in Advanced Melanoma - Targeted Oncology",
        "link": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPNUp3Q2hzNDdZejRfTHhjYmRhUHpvXzRVYXRUa1JhM2p0X1l2ZUJCZlNEWHlVLTNfM2ZVU2JGZmw1R0RQbEptUS0zRlJ6Z0doQzdEZGMteVFEWndESER6MGpqTXRreHBwd1lFQlJPMG43TjU2dVh6YkFHbXF2X0QteUpR?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for RP1 in Advanced Melanoma  Targeted Oncology",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A",
    "aliases": [
      "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-nkvotmj90",
        "type": "crl",
        "date": "2025-07-11T07:00:00.000Z",
        "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
        "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
        "source": "Google News - CRLs",
        "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Ultragenyx takes another hit as FDA snubs AAV gene therapy over manufacturing issues",
    "aliases": [
      "Ultragenyx takes another hit as FDA snubs AAV gene therapy over manufacturing issues"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-wvouar6rf",
        "type": "regulatory_news",
        "date": "2025-07-14T07:00:00.000Z",
        "title": "Ultragenyx takes another hit as FDA snubs AAV gene therapy over manufacturing issues - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPRktpSHB2MXBlSHhSUGhMdVpISE55Z0MtZl9iV1BwaUpmbEdHVjBBUU44R0pMcDQtMDdxZk9xcjRwNUwxV1ZKeHFlYWhubzQ1ZXNyZjFRUXg4QTFrN0c3Z1ZBcG5mUHpkdDVydDRfUHZlSm4zQzQzRTI5MXRfZ04yaHVoTzYzUm1OczJzQWs5WDJVNWRPY1hTdXkzVkp6S1B2YW5lWmRjQS0tQVZ1Q3UtUGxQUkc5cjFJ?oc=5",
        "source": "Google News - CRLs",
        "summary": "Ultragenyx takes another hit as FDA snubs AAV gene therapy over manufacturing issues  Fierce Pharma",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Unicycive Therapeutics Announces Receipt of Complete",
    "aliases": [
      "Unicycive Therapeutics Announces Receipt of Complete"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-9yr6xh3n7",
        "type": "regulatory_news",
        "date": "2025-06-30T07:00:00.000Z",
        "title": "Unicycive Therapeutics Announces Receipt of Complete - GlobeNewswire",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - CRLs",
        "summary": "Unicycive Therapeutics Announces Receipt of Complete  GlobeNewswire",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "FDA Issues Complete Response Letter for Much",
    "aliases": [
      "FDA Issues Complete Response Letter for Much"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-disme9cn8",
        "type": "crl",
        "date": "2024-12-21T08:00:00.000Z",
        "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
        "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Capricor",
    "aliases": [
      "Capricor"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365422-k8o407elr",
        "type": "regulatory_news",
        "date": "2025-07-11T07:00:00.000Z",
        "title": "Capricor’s BLA for DMD Cardiomyopathy Cell Therapy Deramiocel Slammed With CRL - CGTLive®",
        "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOSHMyUkY1Nlp0Zi15dm9VeVZCRTVIeXBPSi1PVDhnemVpNVd0MlJHbjk3ZDMwemYxYlExYWJUVDFEMWplWnhvdlFTbXNOZXFlQTF3VmZTeFpzbTdiTkRVUENHaXlUNGZLMGsyb1pSZkRhTndwRTg1V2Rna0lual9SQVJtaFFHaEFfLW5Tb3htTDZDYTBUMDJieFBfNVU?oc=5",
        "source": "Google News - CRLs",
        "summary": "Capricor’s BLA for DMD Cardiomyopathy Cell Therapy Deramiocel Slammed With CRL  CGTLive®",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757256367385-3tciib58r",
        "type": "crl",
        "date": "2025-07-14T07:00:00.000Z",
        "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
        "source": "Google News - CRLs",
        "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 14,
    "last_updated": "2025-09-07T18:06:05.523Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "FDA Issues CRL for RP1 and Nivolumab in Melanoma",
    "aliases": [
      "FDA Issues CRL for RP1 and Nivolumab in Melanoma"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-17k4ugw0h",
        "type": "regulatory_news",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA Issues CRL for RP1 and Nivolumab in Melanoma - Dermatology Times",
        "link": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNVjFfVW80YVZIT1NnUVdMS0ljYU5JTzFQaDExX2JpUmRfMHk2LTZEdjZqV0JoeGhOcmhrTG1wSGZIV1lDcnI2SnBYWDlxVUNGQjJmcXljdEh0WENsYUVTeEpwanNWZndEdnlqa3hVWWFGdXNydEVrbmZxRDBJM01tcWFMS2FJUmJzMndzMUFqcw?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for RP1 and Nivolumab in Melanoma  Dermatology Times",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Capricor Plunges on FDA Rejection of DMD Cell Therapy",
    "aliases": [
      "Capricor Plunges on FDA Rejection of DMD Cell Therapy"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-4d8b2vu32",
        "type": "regulatory_news",
        "date": "2025-07-11T07:00:00.000Z",
        "title": "Capricor Plunges on FDA Rejection of DMD Cell Therapy - biospace.com",
        "link": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQMUlxSDhVN0UtanB6bm9WUzZzOXpNY29QdHk4NUVDZ083WFBEZjJPSjV1eDRMNnVEVHNtRl9rRWI4N2YxR1lLaXY3R09WaTgxMGw1d0pQZGtJYldMSWlZMGhmckFFeXllMG4wVDNVQU9hTDJ0UXR6aDBXaUNkOGdaX1ZLZTUzTVB0VlE?oc=5",
        "source": "Google News - CRLs",
        "summary": "Capricor Plunges on FDA Rejection of DMD Cell Therapy  biospace.com",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "PTC Therapeutics Receives FDA Complete Response Letter",
    "aliases": [
      "PTC Therapeutics Receives FDA Complete Response Letter"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-rhca20f58",
        "type": "crl",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "PTC Therapeutics Receives FDA Complete Response Letter - TipRanks",
        "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNN0lZVHJyMzNVT2duUjBScTZ3SEQzeDZ6UXc4NjNnNmt6bGJDZENoOUxJc09HeEZXcGR5UW11Z1pxdVUteDR4dWFjV1ZxYXE4UzhSZU1JTUdXamtmbFBkTU1iX0xINHpPalV5clNleDZGVXlib0l6aDJRbkRFT1l6aFV0NzBycXlkemdnZmpXbnlMdFViT2MzbG40Z1dBRkRfRmVZRlJ3RkxGdw?oc=5",
        "source": "Google News - CRLs",
        "summary": "PTC Therapeutics Receives FDA Complete Response Letter  TipRanks",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757330720403-r828szn74",
        "type": "crl",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "PTC Therapeutics Receives FDA Complete Response Letter - MSN",
        "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZmI0WlRSMDNhNURtOWxSbkJrLVY3UFFNODhiTmxEc3NxeTB6VEhVSURFWEh5VUxCTFZKLUJsT2lEZjVlcEhlM3Rpb2htdjdLcnVoLURIcHhxaDcxVFI2YVRtOWNET0Q0OVVEU3ZtQkZVaGpTQWNuUXR2anotbHdpY3ZGTkZzU2V3OGQ2bFoxVDdtaG5CWDgyRnhHRXNkWXJqY2lpVzlKeEc?oc=5",
        "source": "Google News - CRLs",
        "summary": "PTC Therapeutics Receives FDA Complete Response Letter  MSN",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 18,
    "last_updated": "2025-09-08T11:25:20.491Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Astellas receives Complete Response Letter from FDA for Izervay sNDA",
    "aliases": [
      "Astellas receives Complete Response Letter from FDA for Izervay sNDA"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-3zbl1psej",
        "type": "crl",
        "date": "2025-09-04T15:41:33.000Z",
        "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
        "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis",
    "aliases": [
      "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-ff6cgfif5",
        "type": "crl",
        "date": "2025-04-03T07:00:00.000Z",
        "title": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis - Pharmacy Times",
        "link": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNLTlmaDFOclA3OUhtMkdzQjBtQXk3S1JKbl93VzJBM3R2bGRDRUpWQWQxQnZhY05qS0pOTXhNcnJpZE5jTVJnbmlvR1pGa1EweWc2aFkxTldEUEQ2RDZOaTZsS184ZUYxVHN0YmNEOXZlUUt1N3hqNl9VVjJNQ3BKZ19HQkxYbFBRNWdMYnZ1aWJVdlJxb2RweTBfendMM2NQU2I4NVd0MUo1M21Kc3FqS1oyVWwxWE5pZVVzVHVuZUk2dHJiSmhVcGRicDMyMlNVRVE5b1YyRmRIT3BXRzBCOEZDRzA4TWtFNGc?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis  Pharmacy Times",
        "severity": 9
      }
    ],
    "products": [
      "for Dry"
    ],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "DMD Cardiomyopathy Cell Therapy Deramiocel Slammed With CRL",
    "aliases": [
      "DMD Cardiomyopathy Cell Therapy Deramiocel Slammed With CRL"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-l9mb9mtxe",
        "type": "regulatory_news",
        "date": "2025-07-11T07:00:00.000Z",
        "title": "Capricor’s BLA for DMD Cardiomyopathy Cell Therapy Deramiocel Slammed With CRL - CGTLive®",
        "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOSHMyUkY1Nlp0Zi15dm9VeVZCRTVIeXBPSi1PVDhnemVpNVd0MlJHbjk3ZDMwemYxYlExYWJUVDFEMWplWnhvdlFTbXNOZXFlQTF3VmZTeFpzbTdiTkRVUENHaXlUNGZLMGsyb1pSZkRhTndwRTg1V2Rna0lual9SQVJtaFFHaEFfLW5Tb3htTDZDYTBUMDJieFBfNVU?oc=5",
        "source": "Google News - CRLs",
        "summary": "Capricor’s BLA for DMD Cardiomyopathy Cell Therapy Deramiocel Slammed With CRL  CGTLive®",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "DLBCL",
    "aliases": [
      "DLBCL"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-nnogtg3d1",
        "type": "regulatory_news",
        "date": "2025-07-24T07:00:00.000Z",
        "title": "DLBCL: FDA Rejects BLA for Second-Line Glofitamab Combo - Medscape",
        "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOaVI5eGY5ZUstSlZiSHdoaEpoVGF2LUFSampJTWQ4LXpyNFlRODd6eGNzRFlUQm5nbjkyZXNzeThhOHhsUUhZSnlodmRRV25OR2MzVDRZSUVuSkxjQ2dvSS1BUUNsdk5IYUJwcEtVU0xRdUVOTl81Vm1iWUNDX3Ztblh2TXk0dkZwOXFmamY5U0xIX2M0SkVaLXpPSHp6aG51dlE?oc=5",
        "source": "Google News - CRLs",
        "summary": "DLBCL: FDA Rejects BLA for Second-Line Glofitamab Combo  Medscape",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Diffuse Large B",
    "aliases": [
      "Diffuse Large B"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-3j78youz6",
        "type": "regulatory_news",
        "date": "2025-07-21T07:00:00.000Z",
        "title": "FDA Rejects Glofitamab (Columvi) for Diffuse Large B-cell Lymphoma Indication - Oncology News Central",
        "link": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNZlJkekliM19uc0dzTm9pMGlUSXRVRjdZLW9GS1VuR1JCTU5hbi1RTmN4Z3dta1cwbnhSNXBtWngyQ3dRWGFJTHZQc0JlQUYtUHdJYWpheXRGWGZkS1dNTXBZS1JKTHVyNWlvUG9oMVlKdXVRLUhZb0x6d3p1SGsta1d4Yk51OWp2dm4tOG5ydjM4STQtVWczM1Y2NHJ6ZFRnT2U4UjhTY1FGbWZRckZyRUJySlk?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Rejects Glofitamab (Columvi) for Diffuse Large B-cell Lymphoma Indication  Oncology News Central",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Updated",
    "aliases": [
      "Updated"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-nsi55dt21",
        "type": "regulatory_news",
        "date": "2025-07-10T07:00:00.000Z",
        "title": "Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future - Endpoints News",
        "link": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNa1NadUpmeHdvZW54R1NsLWs3MGVzS3o1WHlFcmczOTdxMkRJVGVsNmo4Um1BUmQ3eDlSSFdFTGZ6dkJncHNBSW9kZGN2VlZud2VtbTR5RUJMaGVnYzlTWmFxLVJlWWVGOTR5WHctd09KbGtRMFRodUpOaThuSW1kUlNMSHVBVkk?oc=5",
        "source": "Google News - CRLs",
        "summary": "Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future  Endpoints News",
        "severity": 5
      }
    ],
    "products": [
      "rejection letters"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Stealth Bio questions its own viability as FDA directs rare disease biotech to resubmit drug application",
    "aliases": [
      "Stealth Bio questions its own viability as FDA directs rare disease biotech to resubmit drug application"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-yyfmc329z",
        "type": "regulatory_news",
        "date": "2025-08-08T07:00:00.000Z",
        "title": "Stealth Bio questions its own viability as FDA directs rare disease biotech to resubmit drug application - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPNnN5SE0yeE5kaTB2Sk1hVEdGaVREMjVEME56M3dNQkhkdXM5UjZ6SGFteUFVZjdVaG5wbUdYM0dmdzJIWFJJdGE3b2Z3VW5rX3pmaFAtSm5ua2I3MzhJQ19kYkxnUGpSaWUwODJCdHc5anFFRUxsN2ZINGhDVkZMRGdLLWxGcnpSbVhkZmdqei1HMkZUWHhrUmNYUXNxN3VWRS0zUW5CeTJVUTJYdEZfX1c0QmRaYUxIOGc?oc=5",
        "source": "Google News - CRLs",
        "summary": "Stealth Bio questions its own viability as FDA directs rare disease biotech to resubmit drug application  Fierce Biotech",
        "severity": 5
      }
    ],
    "products": [
      "application  Fierce"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "U.S. Food and Drug Administration issues Complete Response",
    "aliases": [
      "U.S. Food and Drug Administration issues Complete Response"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367385-29roz4jhk",
        "type": "regulatory_news",
        "date": "2024-12-19T08:00:00.000Z",
        "title": "U.S. Food and Drug Administration issues Complete Response - GlobeNewswire",
        "link": "https://news.google.com/rss/articles/CBMiwgJBVV95cUxNT01UMVJNcTcyXzlxd00tdlE4SjRBNTUxYkNvS25IUjlHSXRWa0hpdnlDX01vMjBxcDdMbTM2eTBlTjhZTWM1UDBSVnlOSkZvLWVGcTNJeW1yZGhPeG5wVEhLXzFXdmpxTjk2cENnSk5YaGlnbDNkMEtNYWpFMWYzRHRZSTI1SHdZZElFOVoxRFJOemZyaXN0RkJwcndWQ3F3dmx0cjQ3QTVLc2tOWi1FOE4xNWNBWldWR2p3dUFjMFE0dGI0UW1DaWlSQVRWODdYV1pPc0V6dU1ON19kUGJPX3JYc2N0Qk1SYnM1Vkl3QWh3Y2VMRVBUcE1SZUIzb0FiTkpUV3lpeWlpTC1lSlF6RVROLUs4NHZjLVczOXEtMzNBZ1lETFhkTWhKNEZ5YWE3R3NYNkhFb3NHRllnb1FKcXNB?oc=5",
        "source": "Google News - CRLs",
        "summary": "U.S. Food and Drug Administration issues Complete Response  GlobeNewswire",
        "severity": 5
      }
    ],
    "products": [
      "Administration issues"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.389Z",
    "monitoring_since": "2025-09-07T14:46:07.389Z"
  },
  {
    "name": "Unicycive stock falls as FDA plans complete response letter for OLC",
    "aliases": [
      "Unicycive stock falls as FDA plans complete response letter for OLC"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367386-tsi23eb8e",
        "type": "crl",
        "date": "2025-07-01T07:00:00.000Z",
        "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
        "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
        "source": "Google News - CRLs",
        "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Replimune receives complete response letter from FDA for RP1 BLA",
    "aliases": [
      "Replimune receives complete response letter from FDA for RP1 BLA"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367386-1lgemu1sf",
        "type": "crl",
        "date": "2025-08-15T13:11:52.000Z",
        "title": "Replimune receives complete response letter from FDA for RP1 BLA - MSN",
        "link": "https://news.google.com/rss/articles/CBMiygJBVV95cUxNNUIxb2dzdnM4OC1ERlo2MFpMOFZzZl9IaUNJcVhtSFc5cTd0Nkl4Qmd0T1RXanh0alZDQS12MWlwRDZGdWd1WEo1VHRSUFlXZTF0VElxOUdaVDdUQmE2WUJWZzhoSVFORm1BTmdlZFN0S3VzYy1NZWl5dnZ4RWxpSzF2WWQzT1IwOWN6OTVqUDhJck01VGljOVhvM1VhVGI1WnlOSExhNWV1Nnp5SG1xam9DZjZmZWVDdEFUT3owNnltSUdfM0pnREhxVDhCY01GaFlaLTVOdkhsNlhENlRfUzBEa3BZQXJnelRPWl9MMWVyRlVER093blRHV1JObnJBclRSOWRVem83elV4WE1TVElwb2l3REY3WWxINGtYVm03dS1DWE8tUlRBaHlnaXBVUDdwWVEtV2hUS1I0Z3VqQmhHeTBwVjd1UFE?oc=5",
        "source": "Google News - CRLs",
        "summary": "Replimune receives complete response letter from FDA for RP1 BLA  MSN",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma",
    "aliases": [
      "FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367386-6l4jzwar5",
        "type": "regulatory_news",
        "date": "2025-08-04T07:00:00.000Z",
        "title": "FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma - CancerNetwork",
        "link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPUC1mb1Z3UGRULXVCa1YyQ2NYbmRQOC05TnFTODg1RmhfcHAwU1hueGRzRG42aVBydTBsOGtJQkk3Skk3LTlpb1l2WnNVT09BVEkzbHRBV0N0NDZVYzFCbVgwRnBKaFMtQXlIQmtDaGdHdUVDSlNkeW1zc2M0bWYzSmRROGExMXhSYUR4QmtTSXFMemR3eVRUR1UzX0NjSk9K?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma  CancerNetwork",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Replimune CRL Fallout",
    "aliases": [
      "Replimune CRL Fallout"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367386-o8mrta0ee",
        "type": "regulatory_news",
        "date": "2025-07-25T07:00:00.000Z",
        "title": "Replimune CRL Fallout: How Biopharma Leaders Should Manage a New Layer of FDA Uncertainty - Pharmaceutical Executive",
        "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxNTkF4SjBPS01MdURwbjNoanNMQWJTczdSY3BvU2NkS1p6S1FpUEw0eUpJdE16RnBfOHg4OEJjdmoxQVhiZFpRRUJqRjhXajBlRWtnY3ZsT0E2UUhySHNVbmRIMmN1T3dqQ2I4c1Q4bFJEUUtPS05xTHBlazRwZ01rdkhrc2dOVUpaUXpQcTFLU0RMdXF6dHhVT2daai1BQQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "Replimune CRL Fallout: How Biopharma Leaders Should Manage a New Layer of FDA Uncertainty  Pharmaceutical Executive",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Stealth Bio submits third FDA application for rare disease candidate",
    "aliases": [
      "Stealth Bio submits third FDA application for rare disease candidate"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367386-k27kono7e",
        "type": "regulatory_news",
        "date": "2025-08-18T07:00:00.000Z",
        "title": "Stealth Bio submits third FDA application for rare disease candidate - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNMDQ0VjFsZEhhcHYzM1IzMHJrZWNvd3FsSkItRDJHZ2hvcnVsZ19PNGllNmt6OW81TE9qTFh6VkZlUlVIUk5PSTBsWHd3WXQwXzBmc01iWmNialhJcDVNRGxxTl9XRzZFNGFjNEppV28xUUVfWFlkeTRORXJ2OVp4YkVxdmJIZXdoaW93Rl9XeWdEaXM2czBCcGxqVTF1TGpNdmVaVEF4WExTWXprNEE?oc=5",
        "source": "Google News - CRLs",
        "summary": "Stealth Bio submits third FDA application for rare disease candidate  Fierce Biotech",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "FDA Issues CRL for Vusolimogene Oderparepvec in Advanced Melanoma",
    "aliases": [
      "FDA Issues CRL for Vusolimogene Oderparepvec in Advanced Melanoma"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367386-puogwjn6b",
        "type": "regulatory_news",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA Issues CRL for Vusolimogene Oderparepvec in Advanced Melanoma - AJMC",
        "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNM251Q1hxcTBwYmhzMnc3d3V2TWdKbWF5aTdnc0p1QVhnSzFfQTZhTjhYN3p4S0lTQXdoMl9IUlBrc25BMTVtY2x4dHRfVXNNLXYyT3ZFSUVkN2ZwQnpMbFc1cURwc0ZRWVg5eTdrWHpZSlNUVjFGeTJkWXpHZ1JFcENsSkJDeTZQWHVtbDhUcDNwN3V5cXc?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for Vusolimogene Oderparepvec in Advanced Melanoma  AJMC",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "FDA Delivers Blow to ImmunityBio",
    "aliases": [
      "FDA Delivers Blow to ImmunityBio"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367386-827op7rb8",
        "type": "regulatory_news",
        "date": "2025-05-19T07:00:00.000Z",
        "title": "FDA Delivers Blow to ImmunityBio - Los Angeles Business Journal",
        "link": "https://news.google.com/rss/articles/CBMifEFVX3lxTE5RVktfaXR0Zm9RYUY2a2RsWDFua2FrdW9IbHgwSVBnMlRKbmdpODU2QzFzTjBZTDlCd2N1SllJbUNzTXBROHBnblhFQXU4M0pNa2E0QU02MkRXcHViaWVWanA0QzFaZUlTdTVYUE5TYjBkWXVpYldHcHQ0VDE?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Delivers Blow to ImmunityBio  Los Angeles Business Journal",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Ultragenyx Gene Therapy Faces FDA Delay",
    "aliases": [
      "Ultragenyx Gene Therapy Faces FDA Delay"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367386-jbu1hod0z",
        "type": "regulatory_news",
        "date": "2025-07-11T07:00:00.000Z",
        "title": "Ultragenyx Gene Therapy Faces FDA Delay: Clinical Data Strong, Manufacturing Issues Fixable - Stock Titan",
        "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNRjFYdWEzT0pObThZbExVVTc0RS1SQjhhZGs0NGRETFkwbnRrSmRsWnc3dmVYaU9sTUhUdTRnY2FzQ0U2WVhheVBhZ3dRSzVwa0hISWJhUzBaczZxLXhqb2RGanlLMnF4S2lIeG9GNkJ1ZUg5RW8zQW9Db1ZaSUhpWXpnVTBPVWZaazdkYTRxS2RxMU91UFJyWVNmNlVjTlZKRHZ5eFBHSUkzTFRRYkR2dENQU2xDUE9vbTBodUNJUQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "Ultragenyx Gene Therapy Faces FDA Delay: Clinical Data Strong, Manufacturing Issues Fixable  Stock Titan",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "FDA Requests More Efficacy Data",
    "aliases": [
      "FDA Requests More Efficacy Data"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757256367386-nj9kfsrq2",
        "type": "regulatory_news",
        "date": "2025-08-28T07:00:00.000Z",
        "title": "FDA Requests More Efficacy Data: Outlook Therapeutics' Novel Bevacizumab Eye Drug Hits Regulatory Roadblock - Stock Titan",
        "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTkhRc0ZnakRlRHJUNWwxTGNmZXJQYWo5X1g5NV9sRmdwU3BjN0E3UlBQRVczMG9WUDNpbnZYZnNIdVZtUzgwLXdQc0p6ZGtCYW14TDAyNWtpem1qdHpLNzJkSmVnR2d6eE1iQk1Ja2w5UGtXZ25vRUM2SnJNcjJzeGdNalJTV1A5M3BFZmpMd1lNU0NFSWVmTncwb1FRc2RHN3FWVkcySDJOekQ3eHZGcnpNeUNJdzRLTjNkSmt2YzI?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Requests More Efficacy Data: Outlook Therapeutics' Novel Bevacizumab Eye Drug Hits Regulatory Roadblock  Stock Titan",
        "severity": 5
      }
    ],
    "products": [
      "Hits Regulatory"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Novo plant acquired in Catalent buyout faces renewed FDA scrutiny with Form 483",
    "aliases": [
      "Novo plant acquired in Catalent buyout faces renewed FDA scrutiny with Form 483"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-renpjn9g9",
        "type": "form_483",
        "date": "2025-08-22T07:00:00.000Z",
        "title": "Novo plant acquired in Catalent buyout faces renewed FDA scrutiny with Form 483: Stat - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNbHR0a3hLWml2bzhKdWl0RWszdXM3ZlQ4THY1LU05SkwzU24tbDdnaHpQeFFOSTRBemxUeFpPVWJWWG5PVWlpYmt2MFpfcXExdGk5MEVOSnFzVElGU2JJaXlEbHVGRUxiVXFvaFdPMzFrUnVMT2ZXc3FDNGJNUmpYTlh2NndnR0ZpTDJHN25TYy1PcHRPTnplVVpQc0ExTl94NHNsVHFUZzNzS2VEeVZDQ0Zjd1liNFlpdVpB?oc=5",
        "source": "Google News - Form 483",
        "summary": "Novo plant acquired in Catalent buyout faces renewed FDA scrutiny with Form 483: Stat  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Capricor says FDA inspection brought Form 483 with several observations",
    "aliases": [
      "Capricor says FDA inspection brought Form 483 with several observations"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-td9xke17w",
        "type": "form_483",
        "date": "2025-06-12T07:00:00.000Z",
        "title": "Capricor says FDA inspection brought Form 483 with several observations - Yahoo Finance",
        "link": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNODRhYzJFMkRaVEpPNHlJa2NFdl81TXdXc0Q5azc3UGJuQ1F6YnI1dnQtWk4xMEswYWNuMDR4VG12RlRpQW9UYmJhZ2ZYZ0dDaTdEaG9UYkxvUEFubzVDLXBhaVRHM0Zwd2tqTjctU1YxM1diaDRZRUZpN3lCMm95N042X1NnV2tpWmc?oc=5",
        "source": "Google News - Form 483",
        "summary": "Capricor says FDA inspection brought Form 483 with several observations  Yahoo Finance",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "FDA",
    "aliases": [
      "FDA"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268589558-oktxrgs2p",
        "type": "regulatory_news",
        "date": "2025-09-04T14:19:05.000Z",
        "title": "Biocon Biologics’ Bengaluru facility gets five observations from US FDA inspection - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Biocon Biologics’ Bengaluru facility gets five observations from US FDA inspection  CNBC TV18",
        "severity": 5
      },
      {
        "id": "092e52884d5b3821ab88b91be250a93a",
        "type": "regulatory_news",
        "date": "2025-09-03T12:06:32.000Z",
        "title": "FDA-TRACK: Prescription Drug User Fee Act Meeting Goals Summary",
        "link": "http://www.fda.gov/about-fda/fda-track-agency-wide-program-performance/fda-track-prescription-drug-user-fee-act-meeting-goals-summary",
        "source": "FDA CBER Biologics",
        "summary": "FDA-TRACK: Prescription Drug User Fee Act Meeting Goals Summary",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "636114fa305d2ac6efa1c876d317afc8",
        "type": "regulatory_news",
        "date": "2025-09-03T12:05:51.000Z",
        "title": "FDA-TRACK: Prescription Drug User Fee Act Procedural Goals Summary",
        "link": "http://www.fda.gov/about-fda/fda-track-agency-wide-program-performance/fda-track-prescription-drug-user-fee-act-procedural-goals-summary",
        "source": "FDA CBER Biologics",
        "summary": "FDA-TRACK: Prescription Drug User Fee Act Procedural Goals Summary",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "3a19e7c114ae8b1a0e85f43153e2a419",
        "type": "regulatory_news",
        "date": "2025-09-03T12:05:28.000Z",
        "title": "FDA-TRACK: Prescription Drug User Fee Act Review Goals Summary",
        "link": "http://www.fda.gov/about-fda/fda-track-agency-wide-program-performance/fda-track-prescription-drug-user-fee-act-review-goals-summary",
        "source": "FDA CBER Biologics",
        "summary": "FDA-TRACK: Prescription Drug User Fee Act Review Goals Summary",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "Google News - Form 483-1757268589558-ho8hdadbn",
        "type": "regulatory_news",
        "date": "2025-08-30T06:03:00.000Z",
        "title": "U.S. FDA issues five observations to Aurobindo Pharma arm’s API plant - The Hindu",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "U.S. FDA issues five observations to Aurobindo Pharma arm’s API plant  The Hindu",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589557-sir1ldi79",
        "type": "form_483",
        "date": "2025-08-28T14:08:33.000Z",
        "title": "FDA 483 Observations Highlight Ongoing Issues in Quality Control and cGMP Compliance - geneonline.com",
        "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOeU9EMEZNc0kxSG8wekZiUWtmWVlxVHNhelFmck9IYlcyeFhBYl85UnJqWUh3M0JDNW00UWVnZi1BNENYdFBaRzRlcm9jeHp5MHphTGE4R1dWTGRMUnJLWERBZ0FOM3A1U2dISjU1VXMxNk9iemx1VnF4U05PZmdPVzNPT1BaYUtGeVZVM1drOTZsT3VwakpsS3ZKUUZZMmViYzMzajFISnBKQmdTM2h2XzJB?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA 483 Observations Highlight Ongoing Issues in Quality Control and cGMP Compliance  geneonline.com",
        "severity": 6
      },
      {
        "id": "FDA Press Announcements-1757268588772-lmfppb2rn",
        "type": "regulatory_news",
        "date": "2025-08-04T19:42:12.000Z",
        "title": "FDA Names Top HHS Lawyer as Chief Counsel",
        "link": "http://www.fda.gov/news-events/press-announcements/fda-names-top-hhs-lawyer-chief-counsel",
        "source": "FDA Press Announcements",
        "summary": "The U.S. Department of Health and Human Services (HHS) and U.S. Food and Drug Administration (FDA) today announced that Sean Keveney has been appointed Chief Counsel at the FDA.",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757256367323-8a4ht53q3",
        "type": "regulatory_news",
        "date": "2025-07-29T07:00:00.000Z",
        "title": "5 Cs For Responding To FDA-483s — Strategies For Effective Compliance And Resolution - Clinical Leader",
        "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQVEgxdUZlOTlRTnhhbWcxLTFxVmxsQkxKZkRjek1CbndhMHFGME9pcF9waTExRV9hcGNTMk9VUjU3NDh1YjBuU2Rrdm1TQ2YxdHdnVXk5YmltQ2lzVG9YT2dkbDV2clFTajhuM0NLelpFclBiREh3X1h0WEF6RVdHR3ptcjU4a0h4bG82eG14Y1NTVGFRdkdHcmlGZ3dPZHlpanlQXzVxUjg1eG1qZjhLUFNONDI3d3ZT?oc=5",
        "source": "Google News - Form 483",
        "summary": "5 Cs For Responding To FDA-483s — Strategies For Effective Compliance And Resolution  Clinical Leader",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589562-d7egk30c0",
        "type": "regulatory_news",
        "date": "2025-06-20T07:00:00.000Z",
        "title": "Granules India's Bonthapally facility completes US FDA inspection with one observation - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Granules India's Bonthapally facility completes US FDA inspection with one observation  CNBC TV18",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589564-jy7scb38h",
        "type": "regulatory_news",
        "date": "2025-06-20T07:00:00.000Z",
        "title": "Granules Indias API Facility In Telangana Gets FDA Observation - NDTV Profit",
        "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxNMlE1bHc2MFBURzVkdzdIOTY3YTJ1aE5jYmptNmpMM2lZd2hlTTB2Q2oxVDN2MFRWYTFzdXhHRDI1cm52bnBKcklqZWRiaGdFb2hBRDgxSDBJQWR1ZjdsLWJER0xWQ08tU1dDR1BvTmwxWDNrSXRwZkNLYS0ta184TVJpZ1pTMUhoWnJ6UXhOTmhDZU1LVEwySWpIdVBlZ9IBowFBVV95cUxObmVaSjZpdmlKamp5aXlxb29uWWVleXVma0hHelE3THhHVU9LYlFDVVBrYmZIa1plX1VHaFVBelZ1ZF9hNlZrUHRzZk9EQkNub2M3cW5VZnBpRUdZMTZYOWFJOHdmYUo3WXBnek9HMHpEUzE2Q3Z1S1hWY1VLNHJnemx0ZnNldVVzVzFQbzIxZ01uLUR5OEdNbklLSDllSnVyaXBJ?oc=5",
        "source": "Google News - Form 483",
        "summary": "Granules Indias API Facility In Telangana Gets FDA Observation  NDTV Profit",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589558-eaoc7nco8",
        "type": "regulatory_news",
        "date": "2025-06-19T07:00:00.000Z",
        "title": "U.S. FDA issues 7 observations to Natco Pharma’s formulations unit in Hyderabad - The Hindu",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "U.S. FDA issues 7 observations to Natco Pharma’s formulations unit in Hyderabad  The Hindu",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589559-gvdjrv32y",
        "type": "regulatory_news",
        "date": "2025-06-19T07:00:00.000Z",
        "title": "Natco Pharmas Division In Hyderabad Gets Seven FDA Observations - NDTV Profit",
        "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxObzd2UjVFS2pSaUxQQnpwMmlvbkNGdW9KcHplaGFfTUtxaW5Pb2FMSWpSdXFVNERDSkFNYTZIN2d3SGZ6dmlsV3psaXlURzk4SGZMWFQ2OFFDUzFuLUJmOU1TSmVIRGFKUnhjRE9ieTFCbnpXTmNpYUhZLURsVXA2VERRd1c1S29MbE1CWWpJWG9sdUFVMTljNldtRnVPSXI5dVFHRG9tdGRDd9IBrwFBVV95cUxQMlY0anNaVXE3bDdLR3p0ZWNBbVFKUzdmb2RCSFZqeXRZc01QX1VUTUtndmN0ZnM4cnhkNlY5WENKZkQ3TkJDcjZiWDM4NElERlE1UzFCT1FXTDFyd19uNUl2QTBwU1ZHQndtdHVxNmtZejVuRGg4NUJ5Sm1XYldseDNIQVkyMHltWW9naTl0Ukd2dkhzeFBlSU9PVlI0YTNySDZmNDNpZjZfaTd4dDhJ?oc=5",
        "source": "Google News - Form 483",
        "summary": "Natco Pharmas Division In Hyderabad Gets Seven FDA Observations  NDTV Profit",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589561-p8k14yyhv",
        "type": "regulatory_news",
        "date": "2025-06-19T07:00:00.000Z",
        "title": "NATCO Pharma gets 7 observations from FDA for Hyderabad manufacturing unit - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "NATCO Pharma gets 7 observations from FDA for Hyderabad manufacturing unit  CNBC TV18",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589560-u7cwiuidf",
        "type": "regulatory_news",
        "date": "2025-06-18T07:00:00.000Z",
        "title": "Glenmark Pharma’s North Carolina facility gets five U.S. FDA observations - The Hindu",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Glenmark Pharma’s North Carolina facility gets five U.S. FDA observations  The Hindu",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589559-93i26t5vs",
        "type": "form_483",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit - Business Standard",
        "link": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNV3Y2eS1EMHMzN3JYVmd4VHItZ2xyQllZTW52N0hMaHNlVDZRSjBTb2F1ZzIxYU1USXlMeHNJTEh4QUFzNzctS2ptYURWUFdIN2RtNTVmREpuWFlINHU3VnBHR0lPWHYwYzNXTUF5a0hWVGMzdXgxTTI3NGd3YThONkUzdXVhZWxLYTRBOFNXVENCRmNHSXloUGdEa0RiMG5FSlRtSEVTX0hQcHJNMFBuaWctSUlnQ1RUQ24wTWRVajM3U3hBMF8ta1Qwd1hsS1IzdWxTVUp1VlFkWE8zbVhEeEtSLVQ2T2sxUjhHRGVQZ1RfTjB4OG5ER1BR0gH_AUFVX3lxTE8yTUJ4N0xocHZvdUFXOHR3aEJhdUtPRmJ4WUF0aF80elRXc2RZV0hVMURFeHUwb0QzeGFmNnFOOExyakhJU3djVDNESXR0VXZCY0xxTGVpYjhIYnBFNWNwREhDTEw3M0JDd1FabUVJQ1RiRzEtbEFDU2FkRXRjb044eXN5YmtTTkU4YTZwVXp5ZkpKTXh5OVFhNGxWMF9xakQ0UnhaVmhVd1JYOFBvZ0tKdEdRYUFrVGMybDJqbzM2TG1zVUJFT3BYRGFCV3huRFBQRWhfSm10MnZkWE1LdlNMUm15b253ZFpaTHA3RzlpQzFHTWREYWk5TmZFaUhmdw?oc=5",
        "source": "Google News - Form 483",
        "summary": "NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit  Business Standard",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757268589560-3hblljufc",
        "type": "regulatory_news",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "Syngene's Bengaluru-based facility gets 'NAi' status from US FDA - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Syngene's Bengaluru-based facility gets 'NAi' status from US FDA  Business Standard",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589561-3c3yxkox5",
        "type": "regulatory_news",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "USFDA issues one observation for Natco Pharma Mekaguda unit - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues one observation for Natco Pharma Mekaguda unit  Medical Dialogues",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589561-ptu7x2bmv",
        "type": "regulatory_news",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "Sun Pharma gets 8 USFDA observations for Halol facility - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Sun Pharma gets 8 USFDA observations for Halol facility  Medical Dialogues",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589561-3lob8plae",
        "type": "form_483",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "US FDA inspects Sun Pharma’s Halol plant, issues Form 483 with 8 observations - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "US FDA inspects Sun Pharma’s Halol plant, issues Form 483 with 8 observations  CNBC TV18",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757268589562-5o6xjydzk",
        "type": "regulatory_news",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "Natco Pharma’s API plant in Hyderabad gets U.S. FDA observation - The Hindu",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Natco Pharma’s API plant in Hyderabad gets U.S. FDA observation  The Hindu",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589563-egraexr7v",
        "type": "regulatory_news",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "Sun Pharma’s Halol facility issued eight observations by U.S. FDA - The Hindu",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Sun Pharma’s Halol facility issued eight observations by U.S. FDA  The Hindu",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589559-wfc82p8lz",
        "type": "form_483",
        "date": "2025-06-02T07:00:00.000Z",
        "title": "Piramal Pharma completes USFDA inspection of Aurora facility with Zero Form-483 observations - Indian Pharma Post",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Piramal Pharma completes USFDA inspection of Aurora facility with Zero Form-483 observations  Indian Pharma Post",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757268589564-tbwtptyjh",
        "type": "regulatory_news",
        "date": "2025-05-31T07:00:00.000Z",
        "title": "USFDA issues one observation for Cipla Bommasandra facility - Medical Dialogues",
        "link": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOdl9kV3VPeDhvbmFlalM5bTMwMlVrbDJGWEx1N0ZVMktucWRGbHBETTZwenhuYl9vN0taVHVHYXI1WF9mWGlKQXVxUExPVDM5SzM2LVRISWttcUV6Zkp5ekl2TzlUWThleTdpU0o0MU9ZRjdCMV8zVXNtaEttWHFDckRGU1lQSjlqNXh1eVFTYlkxM1Ewc2JhWVIxdmJMOXdRZklyVUtyaVZPczl3OUtFOEhpSy1LZ9IBuwFBVV95cUxPbTlSbjdWYVNwb1gzNkxXSzBYMlgySzUzZFBQYlNaRjNrLW91YzVsWnpURzhyYWQtREotMXpfSXF3NEE4WDdZZWF6cDBUeFBWempQRURnenhPVHpiMjM5dzlCeWZHcnd3N1owVWV1clRhWEc1NTBPZU04WHF0cGxEbFRDbnRSUUVibko5RXh6Ung2aVFfNDlxQW92VHJDcnhFUmxHRjlSZ3F6dzFMNDhhWXZBUEg4aDM0b2Mw?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues one observation for Cipla Bommasandra facility  Medical Dialogues",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589562-2uku50kok",
        "type": "regulatory_news",
        "date": "2025-05-30T07:00:00.000Z",
        "title": "Cipla's Bommasandra plant in Bengaluru gets single USFDA observation after cGMP inspection - CNBC TV18",
        "link": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNUHZSMS1mSWFQNkZpY2lfN0xoTmViVFJfVkJwVWFqc2lQYVBKNXJtNklyR1pwYWRYSmc2U19pWl9ySTI5ak43Z09tVjY3VndxZmE3QVJZMGtLLURvMFh4bGwzOEV2OWVWTlVXb21sbkkyenNUUy15NzlYYUk0NEZ0NmpUc1o4R3RPdFFmeEtmb2hPUXhmTDNRd3VTdXFBVDd6aE85LU9HUDZ5YmNoeGxqa3IzSnJuelNnVG9ocndwWmc2dnFrVnp2RHdKTHlEZUF5OVR2YWNhQjc4YWR5VTY1dmhHai1Jem_SAewBQVVfeXFMUFRNVUNDbE5OUFU0VnhIS1plSng2eXNHMzZ3MTd0UUxrcFVNeElnX1NIa3cya1N5aWkxaF9pZ01rSzBzWHJNSGwtbTdHcFJhVWxjcWg2V0oyTGhEbHBvcS1TcEpLR092ZXZUclVGbmdhQ3RsRFB6UjRpQzNwNEJ1bXNGbThYUG55dGFLdktiWFlWUm9TZk9fWFdvaWFLX01SU2d2SlluRTE2VWNKNFFyNDZLQmNwZmM3bnRaNkR3M01lZkdOYTRRVGVvUkttWkIwSGY2eTdIUS0xSEJ0Ym00TEl0RDlUZEZwbFFEMGY?oc=5",
        "source": "Google News - Form 483",
        "summary": "Cipla's Bommasandra plant in Bengaluru gets single USFDA observation after cGMP inspection  CNBC TV18",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589560-s2ttllckw",
        "type": "regulatory_news",
        "date": "2025-04-28T07:00:00.000Z",
        "title": "Marksans Pharma arm New York facility gets 1 USFDA observation - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Marksans Pharma arm New York facility gets 1 USFDA observation  Medical Dialogues",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589559-mglkhbslj",
        "type": "form_483",
        "date": "2025-04-11T07:00:00.000Z",
        "title": "Aurobindo Pharma's Aurolife plant in North Carolina faces US FDA scrutiny, gets Form 483 with 11 observations - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Aurobindo Pharma's Aurolife plant in North Carolina faces US FDA scrutiny, gets Form 483 with 11 observations  CNBC TV18",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757268589559-xf0uffvhu",
        "type": "regulatory_news",
        "date": "2025-04-11T07:00:00.000Z",
        "title": "Aurobindo Pharmas US Plant Gets 11 FDA Observations - NDTV Profit",
        "link": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQSlBpLXVWT0JKWmZfTi1kcXJmeC1sSld5ZGRWNjRwdXljdnZjSVlJbTNnbUM3d3dwZTJIcjRiWnVYcG1DOHg4QTNzdUF5NjBsYklydV9XbXp5ZEtTNExzM3lYLVEwdVhLMVlYX0NOdlpvcURwWE82OGd4QlREZjdITlpkZWFPTURReFFwblVmbV_SAZYBQVVfeXFMUEJDWDZEMWRHY1FUTGhjdEwxYVJIbG9CcEY3dS05QmJsS25ISkV6cHdpb1h0ZFd1RGhxVnBsYTNwZERpOWZyaDlSaU5VM1Q2ckVoSGVJOXFxcE1raFJBY1NkbUxncnRUT3FDVER3YUVnSnd2ODItNlFsMTNESzlfTXRPODQ5R2hDODlBdlZDeko4MTFYMklR?oc=5",
        "source": "Google News - Form 483",
        "summary": "Aurobindo Pharmas US Plant Gets 11 FDA Observations  NDTV Profit",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589560-v14g2hpfe",
        "type": "regulatory_news",
        "date": "2025-04-11T07:00:00.000Z",
        "title": "Aurobindo Pharma arm gets 11 USFDA observations for Raleigh Plant - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Aurobindo Pharma arm gets 11 USFDA observations for Raleigh Plant  Medical Dialogues",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589560-00gi8fbrb",
        "type": "form_483",
        "date": "2025-03-08T08:00:00.000Z",
        "title": "Alembic Pharma's Vadodara facility gets one Form 483 observation from US FDA - Business Standard",
        "link": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxNX0tfVnNXLVFrdWpDR0N1bllHalcwTG01c0hGTnN3UFV3eWJrMmNXbzZYT2owTURYT0ZHVTVVVmVsWlh1YVFLeDJxczJVanJ0MjQzSUpYbUpnM3FMODdFQ1MtSzdRUlVheFZhQ29RbFpXYjBHS1J4TVJaYWNDZ1dPa2d1NXZ5ZG95QWVYVHZuMUpHYU15MUlEclpkY01HODA3UndCeFRyWWptXzI3Wkd0eFR5R1U3ZmtncnlJbFkyMjZ3VTdkaHBheGF5cW9FWnVYWkd5ZkcxV2ExU3AtTEdqdXJxQVhiRHBob01FR0tpZ9IB9AFBVV95cUxNU0ZYNjZHaVJ2SmxBQ0VNTndfZGM1dTBMN3g1b0YxMVVNejVFMTJJTXlqSmNjS1BXSkdwVk5vd0w5R25PX1ZiWWJKX3M1a2QxTmhBQ0VYeXJkV0VxUDh5QTVkeC05bzdTVU9vb2xVemlnZjg0S0szdUdFOE1YbHpCRlpZdlhSRnFpU1FCZzJuVE1fRW9DbURnNEs1QkxrSFRhUUdzNmRCdFp2bU9ULUtPQS1KSWdfbTEwU2t0cC1lTEo1U21rYUVXSWN6bHRFWktxUDhORFNiTGpMbE9ORFJUcHJIZ1hiWDV0U2tCbm5wXzRxZnlh?oc=5",
        "source": "Google News - Form 483",
        "summary": "Alembic Pharma's Vadodara facility gets one Form 483 observation from US FDA  Business Standard",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757268589564-1y3ejuio1",
        "type": "regulatory_news",
        "date": "2025-03-07T08:00:00.000Z",
        "title": "US FDA ends Alembic Pharma's Vadodara unit inspection with one observation - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "US FDA ends Alembic Pharma's Vadodara unit inspection with one observation  CNBC TV18",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589561-merywd8pa",
        "type": "regulatory_news",
        "date": "2025-02-24T08:00:00.000Z",
        "title": "Syngene International gets 5 USFDA observations for Bengaluru facilities - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Syngene International gets 5 USFDA observations for Bengaluru facilities  Medical Dialogues",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589562-y30k2opjo",
        "type": "regulatory_news",
        "date": "2025-02-19T08:00:00.000Z",
        "title": "USFDA issues 6 observations for Piramal Pharma Turbhe facility - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues 6 observations for Piramal Pharma Turbhe facility  Medical Dialogues",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589564-tly3feytq",
        "type": "regulatory_news",
        "date": "2025-02-19T08:00:00.000Z",
        "title": "Aurobindo Pharma slips after Andhra Pradesh facility gets 5 observations from USFDA - Business Standard",
        "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxPYlF4YUtaaTdfRmMyc1Y1Q1hWUDlNbUNvMWNfMnlCbG5BMlpxSmlYZThBdGx5WThORGk0eU1sT1lfTFRxckJnek1tVlRwWGlUcXQwdHpTUzVzMzZSZFJzUEVuQ3lvUjM5NllhYlpOZ2M4Si1WZVgzSHVFbzFqZDU1SnZuY1NyWlJLNGRpYS1lSGlCRVJMaTdHRmdObjBmMVVEbXUxSHh0TkU3NjBORjJ6Wk1QS2ZNeDdfZEdhZXlzQ2dkU2dmaGRQWWVPcUxGaHMtaDlmUF9henE3TnZ6dXU5ZU5taXdyeVMzdWlFeHRUZkJEeGZHVjNpVdIB_gFBVV95cUxOdEt3MktIMVlsTVpHZUo2dVpCX053eUJRZ3hRX3F5SU9xcXNQdVZwT1BFRnVFMFZMVlV5aFFra1EydXBNVHo0OTk5cEVUMFBNQXU0cFJHNVFYYURGSDdqZ1o0S3cxZXZLam9XQkZsMTBPZUJ5SlY1MFNaN2lqcmpXMEVrcGpFbGNBWThZMWQwZHdOZEtkdVlWWlhjbHhmS1FZYmQtVDlwTEZOYjZBbHREV1N1NFBMY1c4RDM0bEV2WU1FX1ljSDd6aXN5dGplY0twVDBUTGNHa0hBYlRfQWlZd1hmR3JkQ19heUhqMmpUemxac0N2cm0wTU5iaC0wdw?oc=5",
        "source": "Google News - Form 483",
        "summary": "Aurobindo Pharma slips after Andhra Pradesh facility gets 5 observations from USFDA  Business Standard",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589560-hp5vbwa1i",
        "type": "regulatory_news",
        "date": "2025-02-18T08:00:00.000Z",
        "title": "Piramal Pharma facility gets six U.S. FDA observations - The Hindu",
        "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNQi1Nd2d4YnhRQzhvY250dXlZX0hYaUxLekhLbDc0NkFwaWNDOEFja0VWOUUtSThRNWszYXJCU2lDQllLYmJHOUc3TVZ1d0doVXNTWW9nUEZHNXZFdjJxNmxXZFpMYU05Z1h5eXdFZnc5eWlnNVBwM2VMemVKQVZjaGhuOFl0b1I3aDJLeGZvTE5YeXFaVjJRazBsWXc5bkJyVlk5SkdRWXBzUdIBsAFBVV95cUxOeC1IUDRPM1p2ZlZYc0pZdW9kdEtEajl2TnZkVjF0ck9TRFU1Y2VDdzRhQ0RGbnB1YjZlV0xkNFhKMS1ITUtFZlZrV3owUTdTNlBvY2NuSkVDSjkwdTltOVQyTzBReFNZT195NDUtbGQ0djU0MVh0Unc2MGE0MXViaW04X0Zad3ZXNDE0T0J4aXlXd2ZZWVpCekx1Y190MTJ4RDRfVmNzTkNUQ0FSUWFuNA?oc=5",
        "source": "Google News - Form 483",
        "summary": "Piramal Pharma facility gets six U.S. FDA observations  The Hindu",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589564-rpvkwc2ac",
        "type": "regulatory_news",
        "date": "2025-02-18T08:00:00.000Z",
        "title": "Piramal Pharma's Mumbai facility gets 6 observations from US FDA inspection - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Piramal Pharma's Mumbai facility gets 6 observations from US FDA inspection  CNBC TV18",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589559-drbun6yli",
        "type": "form_483",
        "date": "2025-02-03T08:00:00.000Z",
        "title": "Lupin's Somerset -based facility completes US FDA inspection with zero Form 483 observations - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Lupin's Somerset -based facility completes US FDA inspection with zero Form 483 observations  Business Standard",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757268589561-vakyifqo2",
        "type": "form_483",
        "date": "2025-01-22T08:00:00.000Z",
        "title": "Laurus Labs' US arm gets Form 483 from FDA after 'adverse experience' probe - CNBC TV18",
        "link": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQUUxUcnBhWVo0RVI3SUlKYVdxbGYtQTFrTEtKa3VnWDU4bDJ3YnFMV2pUN0l6OHFwSkh4UTN2SmExTHlTZGNkTGJCMU5JM1dIdXhEcUFQWnhKVngyY1EwSXk2T1RxWmtIeVVvdUVlSnM3Rm1Pa0NpQlZuc3huc1JfUDhjM2hzZmF2WHpxTEtZaEJfX0FTU0dMYTk0Ukl4OF84MjM4WTQwc0FMbHNXUmZGRFctaVJPU01uODFVQzhJcTdXVFE1Mi1CZ3RoVkJTZDVFRVkwTDljcFJ0WEpWN1RjcUc4dW3SAeoBQVVfeXFMTWk0M1NoUjl0TlZXV3JuQjQxcGU0dDBMNEx5blhIa1BWMlBTcmdMN0lzc2c1dTNfRjVxYzlwVGdMdG1kVHBYT2xidHBtY1FlUU5GNlZqcTlINzlNSzdFLXdIZWt5bDNYZzA1N1J3dktqLV9hS3F6NG1TcDRxTEw0UllSWi1leE1GN3g4dlNvZDNMVWg5MEJ0S3hxM3RyeXViTVdqU1VwQUtQRFA3NG1qbEJxaU1rWEk3a3JDaXpkTE9haFdpOGZaLS00MG5VUThxUmFXNVM2XzlUbFh3dmJZRXVwNW9GdElncHlR?oc=5",
        "source": "Google News - Form 483",
        "summary": "Laurus Labs' US arm gets Form 483 from FDA after 'adverse experience' probe  CNBC TV18",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757268589560-5wpkw8xn1",
        "type": "form_483",
        "date": "2025-01-21T08:00:00.000Z",
        "title": "Cipla's Goa-based facility gets one form 483 observation from US FDA - Business Standard",
        "link": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxPVGFnVEhpLWZjSkxtUGNJM1R2MXByNTFmWUUzWEliNmJMdHhHeFJmLTlhQlJ4QWJSWmdudmp1dEpWS2FzUV9hcWp4aDJ1MVZDcS1sWHhNRnlNdTBiME9UeEpWZkJpd0I3OFQyU0hFWDFOQWFTejlMcXd3MzVsMlRjQ2o5dm45MGdLLVVUeU5oNnpJaUVpWDRwLVpPX3Rkbmw0bUhieWc0UWM5ckFsbTkzeVRHRlFmWWh5REdXT3VuRDJDbW04eUlUQTdJa3BLckhONkQyb0hEREk0OV92bk10bkRhUkPSAeoBQVVfeXFMTUFWRXJscldnY3pQMWlXazFyVjBJVHM5WFlMemtiTE5HRlZLQXRaSVFMZHlpcGdtT2dXUzhOaEFFTUQ5bWJWazdseXppZ0ZxRzQyamUyZkpmZTlnN1pCM1R3Y21UYk1oRUFiQVZZak9SWDZ2WUZ1NkpyRExHMi1vUTNtd29vUTh5RjdQNVNPRkVsdGdBRU1RVnlqMWxkUXNqck9VX0YycGlxR0VPS1RxR1J4d3V2N2ExWUVZRm9GZEk4WnJTU2dDb0xlckVYTEhKalA4RkhXSXpjSTZmbEM3aWx0eDNxblNraHpR?oc=5",
        "source": "Google News - Form 483",
        "summary": "Cipla's Goa-based facility gets one form 483 observation from US FDA  Business Standard",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757268589564-4eh8h5k68",
        "type": "regulatory_news",
        "date": "2025-01-21T08:00:00.000Z",
        "title": "Cipla Goa facility gets one USFDA observation - Medical Dialogues",
        "link": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPMUdDS2ljUGlxV0p4dExEanBacGJ2dURReFRtb0hIQmNDcW1TZ1RweXc0Nm40dmNLczJwZFgyWVRqLUdPYjI1REpQSmVfZUsxRUVMM2dEOW5PR1E0OVdFck85cWNyM1hISzZrbWlwdkFTenU1OE9vb29wUWs2MWJVZFJuLXhhOEhtRDdRY2hrNVB6Z3Q2b3dPU3lxQ3hfVG5wQVBF0gGoAUFVX3lxTFBsVk1zTFZQRDdiVV9TU1NJUk13OS1MaEtMQktaRVR1RXZxdGxRVllkNFJYZUFxWWt1LVlGWXNHZGZaQzdEWUNzZG5VcmVzWmhvd2lNamxZTTBaWFBzWTJXc1hPNDloNHVkWUlRbzRfaFYzQ1JvUW1nbmgxdGtXdXJ5YmNFWUFPRWdSR3FRUS1UalhaZ2dQY3V1NHpzS2w5RnNuTFdOUm9zNw?oc=5",
        "source": "Google News - Form 483",
        "summary": "Cipla Goa facility gets one USFDA observation  Medical Dialogues",
        "severity": 5
      },
      {
        "id": "bd799d379eb3b2adfc508bb4991124c9",
        "type": "warning_letter",
        "date": "2025-01-06T08:00:00.000Z",
        "title": "FDA warning letter reveals quality control, data integrity issues at Viatris plant in India - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNLVZtZVpSekVIb2VmQXJFQzJNamNBc3Z0ek83MkNMdHp3cHlhQjhuN0NIVlFNR1pxX25FR2xkNG01X0R4cjdINUNSZGZCd3llem5fWjl0S2xHVlRVaDdjYzFoVWRjYUFhRnc3alVPa193RWVNY3BjZFVzOVQwNDQ3VkVJNUVpSWNpcVNtT1A1cDZJakVqbm4xdWZtQnVJMUJETE4yM2VtRDJrdUVwWVRJQ3FNcHpCcTBteUtZYld6Vjk0Zw?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA warning letter reveals quality control, data integrity issues at Viatris plant in India  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-01-21T08:00:00.000Z"
      },
      {
        "id": "Google News - Form 483-1757268589563-2xusx09ve",
        "type": "regulatory_news",
        "date": "2024-11-13T08:00:00.000Z",
        "title": "Cipla gets eight observations after FDA inspection at Bengaluru plant - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Cipla gets eight observations after FDA inspection at Bengaluru plant  CNBC TV18",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589564-el396d10q",
        "type": "regulatory_news",
        "date": "2024-11-13T08:00:00.000Z",
        "title": "Cipla Gets Eight Observations After FDA Inspection - NDTV Profit",
        "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxOQUpOdEJ6NDlNQ1pSTFMyYUc3ZWlKdkNjcE8tX2F5OXc5aDhIVm12aEVVS3BVMTZmWG1KbGxBUjBSQ1JKMHFNQjJFeXoxWTU1ODluelVMcVdZM2hUY1BtVmoxeEo1STBiV1hNQnIzcDJsUjJmRW1SbUZYWXlCa1Z6Y3g1U2h2S1REOWZsajBCaWJZQWZYSVZZVndRNE9NQdIBowFBVV95cUxOUzMxWUtNZEhGSGo1QVZSd3dja3dZOXRVOE1nRXl4aTRnNFBXTHBSTVIyeURLZ1psZXFkM05kUVpVdmpIX01PVTBWX0RtemJDdzA4MWJTQlA1RmZ1WGdteXZ6Q05mWWFjTko4Q0cydHg0czRiWDhaSEhFSnV4bU1ScWdMLXYxQW1KNGFoMnBuenh5YnFlbHVQM213aDh2Ukp2dU1Z?oc=5",
        "source": "Google News - Form 483",
        "summary": "Cipla Gets Eight Observations After FDA Inspection  NDTV Profit",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589558-h6r8r75w8",
        "type": "regulatory_news",
        "date": "2024-10-31T07:00:00.000Z",
        "title": "Novo Nordisk hit with FDA write-up over production issues at critical semaglutide plant - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPMWdjQXQ3ZERyalE1VkpFMDdXZVNrQWpNb3UtcXdsX3NtZ1BrcnBmMkh0WWs3MkhCTzJZc2dnVUxEbmhNbEtXclFFWjNmUW1MZDFKREliSURWMVlWNldFLTN2eGlpNGhlWHlKdHFULUZfQVN2Tk1nYnNWckpIRl9Jb2YzY2xKR0FOUkVoUlJBWDdQaEN4ZDQ4NGZTVlBDUVVDdzV3bkIzNFRyX1g3TUVuOERNWGZnQ09XMW1tSDVnSng?oc=5",
        "source": "Google News - Form 483",
        "summary": "Novo Nordisk hit with FDA write-up over production issues at critical semaglutide plant  Fierce Pharma",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589562-bvbox3vvh",
        "type": "regulatory_news",
        "date": "2024-10-17T19:27:51.000Z",
        "title": "Biocon Gets FDA Observations At Key Biosimilars Facilities - insights.citeline.com",
        "link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPdW9IWHZYMVBWaGRBdUF5OHVFV3pkZ1JDRUFZU2psYWN5NFIzY0VsVDBfaFJqNGViY0wyNllqaDRISUtTWktoSElNemhYQzZGeEdqRzEyTWwtVE5vZUVTUUxNc19SVXlGTEhCaElLTENHcEwwMGZ2a0U5QVdRS1hPNEVkLVhNNFBlR2RzTWJLSWI0ZkllWjYwWVFkRTh3UjA?oc=5",
        "source": "Google News - Form 483",
        "summary": "Biocon Gets FDA Observations At Key Biosimilars Facilities  insights.citeline.com",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268589565-vm062qqzj",
        "type": "form_483",
        "date": "2024-08-19T07:00:00.000Z",
        "title": "That Time FDA was ‘Unusually Thorough’ on a Form 483 - Medical Device and Diagnostic industry",
        "link": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPUDV4YWgyWHZ4YmNWYk8ya2lxSFNZMWozR3JmakNGU2QwSlNmOUQ4eVRjYzM4dWRTXzJaTTl5a0t0eW5EbDl1NkV2S3I0dDN2Zm9wTEl5cG9IMjRUdW40OUVSak1ULXBXdUYtdzd1MWlBRGx1RjJXQ2dYY2w5X0k3SngzQW5jNExrYjlB?oc=5",
        "source": "Google News - Form 483",
        "summary": "That Time FDA was ‘Unusually Thorough’ on a Form 483  Medical Device and Diagnostic industry",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757330791548-rgq8zufpx",
        "type": "regulatory_news",
        "date": "2023-02-28T08:00:00.000Z",
        "title": "Amneal injectables plant slapped by FDA for sanitary issues, improper working conditions - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNcW5fcmlCVDZ4Vkx1NU9mS2ViNTh3T1M4d0R2LXZwbTZRb3E1ajFJRlB6bndvOURkVnRRVVNsV0JxMkhucmhjaGxyaHV6TV90SGExRWUwc2xobGYybkk4bU9KWEQxRDJNbHV1UWlhVzNzdHgxdVRVdnM5cGx4V3JieFpFVmdJTjZtc3psZ1VTc0VmQ05ycTktZzlOcjR5SkpWT3Y4LVQ2SldMdU0?oc=5",
        "source": "Google News - Form 483",
        "summary": "Amneal injectables plant slapped by FDA for sanitary issues, improper working conditions  Fierce Pharma",
        "severity": 5
      },
      {
        "id": "4387ea0236d3caa4f485bf492a136bd3",
        "type": "warning_letter",
        "date": "2021-03-17T07:00:00.000Z",
        "title": "FDA warning letters detail violations at China, Mexico drugmakers already under import alert - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPdG5panZOR0dXUjZrbUh4VjM1c01NNnB2NzNvdHZzMWdiOXVHQm5tQVdJMWlneFJTSHAxUHppQU9mSWhQNlc5SEtTOERuMGo2Y0dORmRoYXBTMl9yNGMxaGt6bm1YNVBJN2RoeEpjc2RzNlBocmJlODZrOGpnYmdNSzAxUVFvMTd4UlpFeHBMem02SGxQS2hqbEdfb1NxaTJZTmNrSWVLOA?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA warning letters detail violations at China, Mexico drugmakers already under import alert  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2021-04-01T06:00:00.000Z"
      },
      {
        "id": "21f8aac3ba4ee1e1ba7f8937c25b9b3f",
        "type": "warning_letter",
        "date": "2018-05-10T07:00:00.000Z",
        "title": "FDA warning letter tells India's Goran Pharma to get professional help - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOcnVvdlRNOGt2dV9pa1lvS0VvT1VIQ1U2OVhXMFRUV3J6ZWJsS2RsbUdXcVo3MkNGVndBa3JCc0g5UHJrUzR0czg4TTRLRkhRbVRRSkJaN1RZVTJ2RDVvZ2JURFVRZ1NfZ0xvMDJGTjJhMkw2QnkybFNWbWN5UlhTS1hSSmstMDU2anQzQVBMYnBxYmQteEFLTWR4TndNNWd1Sk1HWDRDVlJLaW1sano2MkxHUQ?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA warning letter tells India's Goran Pharma to get professional help  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2018-05-25T07:00:00.000Z"
      }
    ],
    "products": [
      "Administration",
      "and Diagnostic",
      "User Fee",
      "Prescription",
      "Mexico"
    ],
    "facilities": [
      "North Carolina, fa",
      "Hyderabad, ge",
      "Bengaluru gets, si",
      "Telangana Gets, FD",
      "India  Fierce, Ph"
    ],
    "risk_score": null,
    "last_updated": "2025-09-08T12:30:01.283Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z",
    "compliance_score": 0
  },
  {
    "name": "Aurobindo Pharma Under US FDA Scrutiny",
    "aliases": [
      "Aurobindo Pharma Under US FDA Scrutiny"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-fsxgjgzs0",
        "type": "regulatory_news",
        "date": "2025-09-05T14:46:24.000Z",
        "title": "Aurobindo Pharma Under US FDA Scrutiny: Eight Observations Made - Devdiscourse",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Aurobindo Pharma Under US FDA Scrutiny: Eight Observations Made  Devdiscourse",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "FDA 483 Observations Highlight Ongoing Issues in Quality Control and cGMP Compliance",
    "aliases": [
      "FDA 483 Observations Highlight Ongoing Issues in Quality Control and cGMP Compliance"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-crg6sx5zq",
        "type": "form_483",
        "date": "2025-08-28T14:08:33.000Z",
        "title": "FDA 483 Observations Highlight Ongoing Issues in Quality Control and cGMP Compliance - geneonline.com",
        "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOeU9EMEZNc0kxSG8wekZiUWtmWVlxVHNhelFmck9IYlcyeFhBYl85UnJqWUh3M0JDNW00UWVnZi1BNENYdFBaRzRlcm9jeHp5MHphTGE4R1dWTGRMUnJLWERBZ0FOM3A1U2dISjU1VXMxNk9iemx1VnF4U05PZmdPVzNPT1BaYUtGeVZVM1drOTZsT3VwakpsS3ZKUUZZMmViYzMzajFISnBKQmdTM2h2XzJB?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA 483 Observations Highlight Ongoing Issues in Quality Control and cGMP Compliance  geneonline.com",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "The Warning Letter Wake",
    "aliases": [
      "The Warning Letter Wake"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-hid7hq9ee",
        "type": "warning_letter",
        "date": "2025-08-12T07:00:00.000Z",
        "title": "The Warning Letter Wake-Up Call In 2025: What FDA Enforcement Is Really Telling Us - Med Device Online",
        "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPSWFHZV9SUHFlSUYzbS1VQVlBdURxT3dXR0k5QzlYOF9fM3VzOVZ1S250V290cE9FQ21Oa1liS2VWZkliVlVRYUJGcUhJZVFpOE1pWTNpVHZXLUg1TTJSaVU2QlBpWVpTUkZJQmVVN0NsSDBnbDNZLVJZRTRodDRWV1pLZ1E0WVZUNVhuQmdUTFpxd0QwSWd4Q3p2SWlXcm5XMWRMQzFKODBteDZMS0MtRWNLZFV3MXpW?oc=5",
        "source": "Google News - Form 483",
        "summary": "The Warning Letter Wake-Up Call In 2025: What FDA Enforcement Is Really Telling Us  Med Device Online",
        "severity": 8
      }
    ],
    "products": [
      "Online"
    ],
    "facilities": [],
    "risk_score": 8,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "A Shifting Trend In FDA Form 483 Disclosure Obligations",
    "aliases": [
      "A Shifting Trend In FDA Form 483 Disclosure Obligations"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-wmm6qbk4u",
        "type": "form_483",
        "date": "2025-08-22T21:08:00.000Z",
        "title": "A Shifting Trend In FDA Form 483 Disclosure Obligations - Law360",
        "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNbjc4YTFOYWxET0dKcVZzWWdZd2dVWW55bzN5Q0djRlBYdk9Jd2JnQUl1M2lqalU2TVJ6d3RJbzcwMWthckc1OGFjejRuMEpJM0o0VTRFcVRnclVaVEFQeTJrQnFmUDFSMGROLUV1WmQtbllqVmJ6OW5rMFM1eHd1cHVkVWNfWVlPcVZNNGxVR0lld1RXLUxpTFluNlo2RU8wTFh5a19XTHF3YVVoVGFwRlhFS2stVW_SAXJBVV95cUxNN3ZYQlVIQVgtb2d3MEVsSmZyQmJqaFR2MktlbnF5MGpDVXByQUthaUNqRTFxUGgzZklraTdhLWRHai1vZ0FZS191OFZaWFlNQ1VBZWE2VW4xY1VhSnJ1QVR3SFR6YzgtSG16WThyaXFlbXc?oc=5",
        "source": "Google News - Form 483",
        "summary": "A Shifting Trend In FDA Form 483 Disclosure Obligations  Law360",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Bengaluru facility",
    "aliases": [
      "Bengaluru facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365505-n3qdaqns9",
        "type": "form_483",
        "date": "2024-10-31T07:00:00.000Z",
        "title": "Shilpa Medicare slips after US FDA issues four form 483 obersvations to Bengaluru facility - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Shilpa Medicare slips after US FDA issues four form 483 obersvations to Bengaluru facility  Business Standard",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757256367323-10iavpgw9",
        "type": "regulatory_news",
        "date": "2025-09-04T14:19:05.000Z",
        "title": "Biocon Biologics’ Bengaluru facility gets five observations from US FDA inspection - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Biocon Biologics’ Bengaluru facility gets five observations from US FDA inspection  CNBC TV18",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T18:06:05.538Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Safe Medicines",
    "aliases": [
      "Safe Medicines"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-4ya2ouesk",
        "type": "regulatory_news",
        "date": "2025-07-14T23:11:33.000Z",
        "title": "An FDA inspection revealed significant problems at Empower’s new outsourcing facility - Partnership for Safe Medicines",
        "link": "https://news.google.com/rss/articles/CBMif0FVX3lxTFByaWtYV1dtTzNHams5eWZPSDU3elRxOUxQR2toT3VWVnlnZG9oNTM0bnZ4cW1TUlMwX0xfQnBKYzFjNDI5VzU5V1RYSWY1OVJSSFBjM251dWZJN0NaZGY2MmZoVjNfclZIdGhKT1hQSnlOREtiZ1VySjY2Szg5eTQ?oc=5",
        "source": "Google News - Form 483",
        "summary": "An FDA inspection revealed significant problems at Empower’s new outsourcing facility  Partnership for Safe Medicines",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Dexcom receives warning letter based on FDA inspections of 2 plants",
    "aliases": [
      "Dexcom receives warning letter based on FDA inspections of 2 plants"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-9pmfw9pij",
        "type": "warning_letter",
        "date": "2025-03-10T07:00:00.000Z",
        "title": "Dexcom receives warning letter based on FDA inspections of 2 plants - MedTech Dive",
        "link": "https://news.google.com/rss/articles/CBMidEFVX3lxTE1kZDFOS1BEdVY5c3h0X3NBWWxRdWhpUW1VTWRldDRSVXloWDAyUTdGUGZHcDZ0YlFhLVF6TF9vVndpaXVQR3gySWNKeXlFR0t3MG9mRU1uMzRQLXcxcngxbHkwZVZzV2FwekFnZ3JfeEdfeW1t?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dexcom receives warning letter based on FDA inspections of 2 plants  MedTech Dive",
        "severity": 8
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 8,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Sterile Drug Manufacturers",
    "aliases": [
      "Sterile Drug Manufacturers"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-mn8sf5szt",
        "type": "regulatory_news",
        "date": "2025-01-30T08:00:00.000Z",
        "title": "2024 Trends In FDA Observations For Sterile Drug Manufacturers - Pharmaceutical Online",
        "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQY0gzZEdCMEdiRTZqdUFUa0w4MWtheTY0VE9VV1F5Tkt1Q3NyRmhVckZfbjdBc1RSTW1YVVVSa3VaaGtDd2pzbHBNWThnbG1RSE02MXJRTFFQakZua1owM2Zuc1R5dFlRczdyR01BV0lMV0ZRQ1pEU0VlVndzYklvSlpiZDE0c1VQQnlBWFFFeXVYN3lmck9BNzJpS1RIdG96aXI1cmNOQUJkb3M0?oc=5",
        "source": "Google News - Form 483",
        "summary": "2024 Trends In FDA Observations For Sterile Drug Manufacturers  Pharmaceutical Online",
        "severity": 5
      }
    ],
    "products": [
      "Manufacturers  Pharmaceutical"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "FDA dings Piramal API plant with Form 483 detailing problems tied to quality control, equipment cleaning and more",
    "aliases": [
      "FDA dings Piramal API plant with Form 483 detailing problems tied to quality control, equipment cleaning and more"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-x1sar7jfz",
        "type": "form_483",
        "date": "2025-02-26T08:00:00.000Z",
        "title": "FDA dings Piramal API plant with Form 483 detailing problems tied to quality control, equipment cleaning and more - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQUlJZeTVjUGkzaXhRcjcwamh2ZmxIVnFldjgxYVFTMS1TMGhBX2xTZFZQczRkMXhJYVFmNnlTWGpRSkZ2UEN2M1FWb0k4YnJpZERJVE1zQUVpSXVRbnViM1I0OVhTRW1hczdPTDJHMk5MV0VrSUVfWTRDRklkcUYtdEpYWE9HX0Z3V3FyWk9ZU3ZUbDU5bGJQMm5fM0oxcW9Bbm9aOEU3b1cweE80VzdMZFFFWnFES2dESGpN?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA dings Piramal API plant with Form 483 detailing problems tied to quality control, equipment cleaning and more  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Bengaluru Unit",
    "aliases": [
      "Bengaluru Unit"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-qppmyel5l",
        "type": "regulatory_news",
        "date": "2025-09-05T08:54:26.000Z",
        "title": "Biocon Biologics’ Bengaluru Unit Gets 5 US FDA Observations, Shares Up 1% - Equitypandit",
        "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPamxjOEVXM2RYbDhPdnpRaXNCNTk1b05RV0lCMU0tYzg2Ml9KMEZ0QURRbzVfa0xZMnR6azBOQ2xrWWdqWlNFWER2bEFLejBpRzNmMkM4NnRZX3ZtVW9zNDl6aUUwSzlOMlphQ3NRNnF3Z04zTlhRd21pemQzMlV2MGpzTllvZERZWFowTnF4VldlVENnZEZWVFJoRkdKb1ZzTXc?oc=5",
        "source": "Google News - Form 483",
        "summary": "Biocon Biologics’ Bengaluru Unit Gets 5 US FDA Observations, Shares Up 1%  Equitypandit",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "s NY API plant",
    "aliases": [
      "s NY API plant"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-kmsuq6omb",
        "type": "form_483",
        "date": "2025-05-17T07:00:00.000Z",
        "title": "Dr Reddy's NY API plant gets USFDA Form 483 with 2 observations - Times of India",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dr Reddy's NY API plant gets USFDA Form 483 with 2 observations  Times of India",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757256367324-pngcj1nql",
        "type": "form_483",
        "date": "2025-05-17T17:34:26.000Z",
        "title": "Dr Reddy's NY API plant gets USFDA Form 483 with 2 observations - MSN",
        "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQbjZjajl3ZjVoRk5BYV9nUkdRQ0twV1hVVFVJYWVmWG9IblJxV1ZQY3BCQklGSDAzWDJYdDJxT0hjLUtGX09fX0dNY2wyUVcwYlMyZzh3TW16ek0yWnhHU0x2cXF0S285WVpSWkZGblVsUU9WR0c3a25yLUpXeF9wVWxudENNaVZNMXd4NFJpd3lDbHZzVGtrajVXek1WbHF0clRHX3ExZjNOQThRZ3cyWk8xQWt5MzlkUXg1RnhVRjdfcmxfcnpMamI5aFVZaHN1RUI2QThUdWx1NFZB?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dr Reddy's NY API plant gets USFDA Form 483 with 2 observations  MSN",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 12,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Staying Ahead of Enforcement",
    "aliases": [
      "Staying Ahead of Enforcement"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-wufsk58ka",
        "type": "warning_letter",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "Staying Ahead of Enforcement: Executive Strategies To Prevent FDA Warning Letters - Med Device Online",
        "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOMlh0TnFnZkd6d2hLOEF3dUhfN1RKQmZQQ3J0UGl6SXdraUhiWXZYd2JZMVltRzRJRkZXUWQ0NU5ncE1UcUIyalVEcU1sQnpfQXdYZEdONzhySk9uMUJvakRGNmhtd0xYVGhMbXA4WnJmZ0RaWWF4ZE1IaVhQaEhiZmFrZEFUN0ZMcHdKdGxIdzdmY29qRHJpRXdLcGJ6VVFzWWgzd1J6VXdCWF9fVnZJdzdFZjZxVU8wMnRSellR?oc=5",
        "source": "Google News - Form 483",
        "summary": "Staying Ahead of Enforcement: Executive Strategies To Prevent FDA Warning Letters  Med Device Online",
        "severity": 8
      }
    ],
    "products": [
      "Online"
    ],
    "facilities": [],
    "risk_score": 8,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "USFDA issues Form 483 with 11 observations to Raleigh plant of Aurobindo Pharma arm",
    "aliases": [
      "USFDA issues Form 483 with 11 observations to Raleigh plant of Aurobindo Pharma arm"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-gp4t3rl9a",
        "type": "form_483",
        "date": "2025-04-11T07:00:00.000Z",
        "title": "USFDA issues Form 483 with 11 observations to Raleigh plant of Aurobindo Pharma arm - The Economic Times",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues Form 483 with 11 observations to Raleigh plant of Aurobindo Pharma arm  The Economic Times",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Aurobindo gets Form 483 scolding from FDA at North Carolina inhaler plant",
    "aliases": [
      "Aurobindo gets Form 483 scolding from FDA at North Carolina inhaler plant"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-c83jnto2o",
        "type": "form_483",
        "date": "2025-04-14T07:00:00.000Z",
        "title": "Aurobindo gets Form 483 scolding from FDA at North Carolina inhaler plant - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQdUNLZzdXMDZhVExlZlNXeldtWWk5RHpQTHpDQ3l5S1JqckFNNmtOUFpUX3NhU3RnNVB6ZFJ6S1U1VWItNkY5a3NuUFFLaXFENmx1WDByMmd3RkR3cmxGS0xBUkY0ZFNoLW85aG95ZlRDdUZqMzZBQUZTRC1DRGY1MzBMNVUzbFNJUmUzVXlTNmdHa29jTzVQd0lTNWtmQVdUb3FMRDdRNW9pZw?oc=5",
        "source": "Google News - Form 483",
        "summary": "Aurobindo gets Form 483 scolding from FDA at North Carolina inhaler plant  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "manufacturing facility",
    "aliases": [
      "manufacturing facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-hl93e8qkj",
        "type": "form_483",
        "date": "2025-05-26T07:00:00.000Z",
        "title": "Dr Reddys Labs' manufacturing facility gets two form 483 observations from US FDA - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dr Reddys Labs' manufacturing facility gets two form 483 observations from US FDA  Business Standard",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Novo Nordisk hit with FDA write",
    "aliases": [
      "Novo Nordisk hit with FDA write"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-k6fsl1p7b",
        "type": "regulatory_news",
        "date": "2024-10-31T07:00:00.000Z",
        "title": "Novo Nordisk hit with FDA write-up over production issues at critical semaglutide plant - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPMWdjQXQ3ZERyalE1VkpFMDdXZVNrQWpNb3UtcXdsX3NtZ1BrcnBmMkh0WWs3MkhCTzJZc2dnVUxEbmhNbEtXclFFWjNmUW1MZDFKREliSURWMVlWNldFLTN2eGlpNGhlWHlKdHFULUZfQVN2Tk1nYnNWckpIRl9Jb2YzY2xKR0FOUkVoUlJBWDdQaEN4ZDQ4NGZTVlBDUVVDdzV3bkIzNFRyX1g3TUVuOERNWGZnQ09XMW1tSDVnSng?oc=5",
        "source": "Google News - Form 483",
        "summary": "Novo Nordisk hit with FDA write-up over production issues at critical semaglutide plant  Fierce Pharma",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "How to Avoid FDA Warning Letters",
    "aliases": [
      "How to Avoid FDA Warning Letters"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-3krp7jm92",
        "type": "warning_letter",
        "date": "2025-06-17T07:00:00.000Z",
        "title": "How to Avoid FDA Warning Letters - Quality Digest",
        "link": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPUGFtcW8tNVkzQlRvell6cmZ6YU9IWlJYTkV4OHdINlcxTGRudlI1RnFLRWpXbjhYTU9fX25RbFd2UEp4dHRLcGQ2OXczNXE3eS1IWWhGMXVYRlZPS0xHOHZyVDYxQVdma19fSXBEYjhzSl9fSS1UR2dMLXJCREhReXlST2tBLTQxT2dDNGF4Z21SXy01UHZzN0R5Y05GcTI5a3Z3?oc=5",
        "source": "Google News - Form 483",
        "summary": "How to Avoid FDA Warning Letters  Quality Digest",
        "severity": 8
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 8,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Dr Reddys Gets Form 483 With Seven Observations From USFDA After Inspection At Andhra Unit",
    "aliases": [
      "Dr Reddys Gets Form 483 With Seven Observations From USFDA After Inspection At Andhra Unit"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-nxqev8fb3",
        "type": "form_483",
        "date": "2025-07-18T07:00:00.000Z",
        "title": "Dr Reddys Gets Form 483 With Seven Observations From USFDA After Inspection At Andhra Unit - NDTV Profit",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dr Reddys Gets Form 483 With Seven Observations From USFDA After Inspection At Andhra Unit  NDTV Profit",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Piramal Pharma completes USFDA inspection of Aurora facility with Zero Form",
    "aliases": [
      "Piramal Pharma completes USFDA inspection of Aurora facility with Zero Form"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-cef5ypxjg",
        "type": "form_483",
        "date": "2025-06-02T07:00:00.000Z",
        "title": "Piramal Pharma completes USFDA inspection of Aurora facility with Zero Form-483 observations - Indian Pharma Post",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Piramal Pharma completes USFDA inspection of Aurora facility with Zero Form-483 observations  Indian Pharma Post",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "s Aurolife plant in North Carolina faces US FDA scrutiny,",
    "aliases": [
      "s Aurolife plant in North Carolina faces US FDA scrutiny,"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-xlcxvm9aq",
        "type": "form_483",
        "date": "2025-04-11T07:00:00.000Z",
        "title": "Aurobindo Pharma's Aurolife plant in North Carolina faces US FDA scrutiny, gets Form 483 with 11 observations - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Aurobindo Pharma's Aurolife plant in North Carolina faces US FDA scrutiny, gets Form 483 with 11 observations  CNBC TV18",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [
      "North Carolina, fa"
    ],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.392Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit",
    "aliases": [
      "Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-kkk64jz2m",
        "type": "form_483",
        "date": "2025-07-18T07:00:00.000Z",
        "title": "Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2 - Indian Pharma Post",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2  Indian Pharma Post",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.392Z"
  },
  {
    "name": "Natco Pharmas Division In Hyderabad Gets Seven FDA Observations",
    "aliases": [
      "Natco Pharmas Division In Hyderabad Gets Seven FDA Observations"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-gmnk2twx8",
        "type": "regulatory_news",
        "date": "2025-06-19T07:00:00.000Z",
        "title": "Natco Pharmas Division In Hyderabad Gets Seven FDA Observations - NDTV Profit",
        "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxObzd2UjVFS2pSaUxQQnpwMmlvbkNGdW9KcHplaGFfTUtxaW5Pb2FMSWpSdXFVNERDSkFNYTZIN2d3SGZ6dmlsV3psaXlURzk4SGZMWFQ2OFFDUzFuLUJmOU1TSmVIRGFKUnhjRE9ieTFCbnpXTmNpYUhZLURsVXA2VERRd1c1S29MbE1CWWpJWG9sdUFVMTljNldtRnVPSXI5dVFHRG9tdGRDd9IBrwFBVV95cUxQMlY0anNaVXE3bDdLR3p0ZWNBbVFKUzdmb2RCSFZqeXRZc01QX1VUTUtndmN0ZnM4cnhkNlY5WENKZkQ3TkJDcjZiWDM4NElERlE1UzFCT1FXTDFyd19uNUl2QTBwU1ZHQndtdHVxNmtZejVuRGg4NUJ5Sm1XYldseDNIQVkyMHltWW9naTl0Ukd2dkhzeFBlSU9PVlI0YTNySDZmNDNpZjZfaTd4dDhJ?oc=5",
        "source": "Google News - Form 483",
        "summary": "Natco Pharmas Division In Hyderabad Gets Seven FDA Observations  NDTV Profit",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Mastering FDA Inspections",
    "aliases": [
      "Mastering FDA Inspections"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-r5kt6kmwk",
        "type": "regulatory_news",
        "date": "2025-02-21T08:00:00.000Z",
        "title": "Mastering FDA Inspections: The Prep Work For Regulatory Success - Med Device Online",
        "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOUEpyNGdaVlV4WkNqMnJGMUFMT3dLMGM3SnRqTVdGUzQtUEpteDNmZ1d6OVZaX19GT0txNEw4TGxVT2U5b3dlVGNOcFNYeGhIZFNXcWcyeG02TXoycHA3Z29uQ0JWZXJCMDRpaUZfWFFTdk1zUWJuSC1tVHZ1ZjNoR2lyTlJYRWVvRUs4SzVMaFNfNDhXUGVOajRUaW05LUpqS0l1dzVn?oc=5",
        "source": "Google News - Form 483",
        "summary": "Mastering FDA Inspections: The Prep Work For Regulatory Success  Med Device Online",
        "severity": 5
      }
    ],
    "products": [
      "Online"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Aurobindo Pharmas US Plant Gets 11 FDA Observations",
    "aliases": [
      "Aurobindo Pharmas US Plant Gets 11 FDA Observations"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367323-nju4bi4dq",
        "type": "regulatory_news",
        "date": "2025-04-11T07:00:00.000Z",
        "title": "Aurobindo Pharmas US Plant Gets 11 FDA Observations - NDTV Profit",
        "link": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQSlBpLXVWT0JKWmZfTi1kcXJmeC1sSld5ZGRWNjRwdXljdnZjSVlJbTNnbUM3d3dwZTJIcjRiWnVYcG1DOHg4QTNzdUF5NjBsYklydV9XbXp5ZEtTNExzM3lYLVEwdVhLMVlYX0NOdlpvcURwWE82OGd4QlREZjdITlpkZWFPTURReFFwblVmbV_SAZYBQVVfeXFMUEJDWDZEMWRHY1FUTGhjdEwxYVJIbG9CcEY3dS05QmJsS25ISkV6cHdpb1h0ZFd1RGhxVnBsYTNwZERpOWZyaDlSaU5VM1Q2ckVoSGVJOXFxcE1raFJBY1NkbUxncnRUT3FDVER3YUVnSnd2ODItNlFsMTNESzlfTXRPODQ5R2hDODlBdlZDeko4MTFYMklR?oc=5",
        "source": "Google News - Form 483",
        "summary": "Aurobindo Pharmas US Plant Gets 11 FDA Observations  NDTV Profit",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Dr Reddys Gets Two Observations From US FDA For New York API Plant",
    "aliases": [
      "Dr Reddys Gets Two Observations From US FDA For New York API Plant"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-ajs8z6x0p",
        "type": "regulatory_news",
        "date": "2025-05-17T07:00:00.000Z",
        "title": "Dr Reddys Gets Two Observations From US FDA For New York API Plant - NDTV Profit",
        "link": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE5RclFGSzNCQUZ4XzVRR3UzWTloZ0lFTXdoR2dfN0VJUWdoWnNhSGJHQnpYcWFNNHdBYnlid2ozWE5XSEs5OWcxcFB4cmZDZUxJQktuMDVtVlpfakZRZmJZ0gFkQVVfeXFMUEwxNXdZSE5pczdyUVRBRlY0c3g4d0dNRktqcHRzeDMyNUhuVjh3MlIwa3puM1M4aGZDSWZJNFlQSGpVUkJaMjJ1RVdWX2pVRDIxTzMxSllHRmE4M3lrYUU4Nm81UA?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dr Reddys Gets Two Observations From US FDA For New York API Plant  NDTV Profit",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "FDA Releases Form 483 to Taylor Farms Colorado Springs Facility",
    "aliases": [
      "FDA Releases Form 483 to Taylor Farms Colorado Springs Facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-tl8tqwxcu",
        "type": "form_483",
        "date": "2025-01-14T08:00:00.000Z",
        "title": "FDA Releases Form 483 to Taylor Farms Colorado Springs Facility - Food Safety Magazine",
        "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNTVlWEdUOXJncDJRT2dBZkc2WTZJaEwwVUVob0M1S1liRnZuN3F5U3VGQ3A1QWVSSTF5YklwUkpfbUwyNl9ZVW1wM2k3OGFUVDhaalVPVV9TRkJnenhuaDNFZS04NDdXMk5PT01rT2hXbXZGRWF3MjJYQm52blRJVDlBSk9PNldOM1BjOTBLNWl1bU1CU01XZDFfRUVEX1AxbktGbGpKVzladw?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA Releases Form 483 to Taylor Farms Colorado Springs Facility  Food Safety Magazine",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Granules arm gets U.S. FDA observation resolved",
    "aliases": [
      "Granules arm gets U.S. FDA observation resolved"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-luhcmho0i",
        "type": "regulatory_news",
        "date": "2025-06-28T07:00:00.000Z",
        "title": "Granules arm gets U.S. FDA observation resolved - The Hindu",
        "link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPTDRKT0k5c01hdFEwTnFwckFSQmR3NExWUFpldVYtWXo3SnZBQ1FWSE51RFI5bDBMNW5sSldYSU55Vk0waWFfX3Z4OGFhYnhQTFA3bm43TVlCUldMcnVDeHRXeVVRdXlzaDl1eVVTWEJHbC1PRmZZMDBSZmdsM0YzdkE1bW9YZjVXVGpnaUlDRFhvVDVPWktQQk4wR1JXNEV10gGnAUFVX3lxTFBYQlR0cnRHWDhxeUU3NTNWczdXc1REWHNzRUlXeGx1TlRNTkQ2RFVSWVh2TWlIM1FxQnJBSmc1V09xY2tCYzR5VTV4RHc0VUlKRnlDYm8ycFJpdDBkNHJ3czZud0xNU0VWZUZQS253aER1allRRm9ERmVRNVBuQ3pudDAwRnJ2SlNfRmhlLUhtOFJIZHQtMGlBMzV1cWxERzFaQTI2OTBJ?oc=5",
        "source": "Google News - Form 483",
        "summary": "Granules arm gets U.S. FDA observation resolved  The Hindu",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "What to Expect after an Inspection",
    "aliases": [
      "What to Expect after an Inspection"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-9zu8ss95l",
        "type": "regulatory_news",
        "date": "2022-12-14T08:00:00.000Z",
        "title": "What to Expect after an Inspection: 483s, Responses and Beyond - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQNmVkRWdET0F2Wm56eGFiMWY3bFpKV2VFM0YxQ05hS3luQ2lfcFdwUFlfdXc0QktYSmtpSFRwUE5rTjdJbndSOXdmMjFVS1NjcU9ndVZ3M0t5OXVZYnpGS1NCWC1RbjFQZHRrY05fMDk4X3ppRWRMQ09nUXJFd2VyU3NsSDRxUXdZdktFeThpM0F4ZVgzZUpnNmpOSEI4QTl6enNQZExKM1NCbFdZNHBWakh2WQ?oc=5",
        "source": "Google News - Form 483",
        "summary": "What to Expect after an Inspection: 483s, Responses and Beyond  fda.gov",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Piramal Pharma declines after US FDA issues Form 483 with 6 observations to Turbhe unit",
    "aliases": [
      "Piramal Pharma declines after US FDA issues Form 483 with 6 observations to Turbhe unit"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-vz8hfyfb0",
        "type": "form_483",
        "date": "2025-02-19T08:00:00.000Z",
        "title": "Piramal Pharma declines after US FDA issues Form 483 with 6 observations to Turbhe unit - Business Standard",
        "link": "https://news.google.com/rss/articles/CBMi_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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Piramal Pharma declines after US FDA issues Form 483 with 6 observations to Turbhe unit  Business Standard",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "based plant",
    "aliases": [
      "based plant"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-l6tsopviu",
        "type": "form_483",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit - Business Standard",
        "link": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNV3Y2eS1EMHMzN3JYVmd4VHItZ2xyQllZTW52N0hMaHNlVDZRSjBTb2F1ZzIxYU1USXlMeHNJTEh4QUFzNzctS2ptYURWUFdIN2RtNTVmREpuWFlINHU3VnBHR0lPWHYwYzNXTUF5a0hWVGMzdXgxTTI3NGd3YThONkUzdXVhZWxLYTRBOFNXVENCRmNHSXloUGdEa0RiMG5FSlRtSEVTX0hQcHJNMFBuaWctSUlnQ1RUQ24wTWRVajM3U3hBMF8ta1Qwd1hsS1IzdWxTVUp1VlFkWE8zbVhEeEtSLVQ2T2sxUjhHRGVQZ1RfTjB4OG5ER1BR0gH_AUFVX3lxTE8yTUJ4N0xocHZvdUFXOHR3aEJhdUtPRmJ4WUF0aF80elRXc2RZV0hVMURFeHUwb0QzeGFmNnFOOExyakhJU3djVDNESXR0VXZCY0xxTGVpYjhIYnBFNWNwREhDTEw3M0JDd1FabUVJQ1RiRzEtbEFDU2FkRXRjb044eXN5YmtTTkU4YTZwVXp5ZkpKTXh5OVFhNGxWMF9xakQ0UnhaVmhVd1JYOFBvZ0tKdEdRYUFrVGMybDJqbzM2TG1zVUJFT3BYRGFCV3huRFBQRWhfSm10MnZkWE1LdlNMUm15b253ZFpaTHA3RzlpQzFHTWREYWk5TmZFaUhmdw?oc=5",
        "source": "Google News - Form 483",
        "summary": "NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit  Business Standard",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Granules India shares in focus after US FDA flags observation at Telangana API facility",
    "aliases": [
      "Granules India shares in focus after US FDA flags observation at Telangana API facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-xk3emlev6",
        "type": "regulatory_news",
        "date": "2025-06-23T07:00:00.000Z",
        "title": "Granules India shares in focus after US FDA flags observation at Telangana API facility - The Economic Times",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Granules India shares in focus after US FDA flags observation at Telangana API facility  The Economic Times",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "s Goa facility",
    "aliases": [
      "s Goa facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-d4zdwfxmy",
        "type": "regulatory_news",
        "date": "2025-01-20T08:00:00.000Z",
        "title": "Cipla's Goa facility receives single USFDA observation following inspection - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Cipla's Goa facility receives single USFDA observation following inspection  CNBC TV18",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Aurobindo Pharma arm gets 11 USFDA observations for Raleigh Plant",
    "aliases": [
      "Aurobindo Pharma arm gets 11 USFDA observations for Raleigh Plant"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-krpsbt77f",
        "type": "regulatory_news",
        "date": "2025-04-11T07:00:00.000Z",
        "title": "Aurobindo Pharma arm gets 11 USFDA observations for Raleigh Plant - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Aurobindo Pharma arm gets 11 USFDA observations for Raleigh Plant  Medical Dialogues",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Lupin receives USFDA observations for two Pithampur manufacturing units",
    "aliases": [
      "Lupin receives USFDA observations for two Pithampur manufacturing units"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-ki73bfun4",
        "type": "regulatory_news",
        "date": "2025-07-18T07:00:00.000Z",
        "title": "Lupin receives USFDA observations for two Pithampur manufacturing units - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Lupin receives USFDA observations for two Pithampur manufacturing units  Medical Dialogues",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "based facility",
    "aliases": [
      "based facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-679cdpyhi",
        "type": "form_483",
        "date": "2025-01-21T08:00:00.000Z",
        "title": "Cipla's Goa-based facility gets one form 483 observation from US FDA - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Cipla's Goa-based facility gets one form 483 observation from US FDA  Business Standard",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757256367324-m2amdoixm",
        "type": "regulatory_news",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "Syngene's Bengaluru-based facility gets 'NAi' status from US FDA - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Syngene's Bengaluru-based facility gets 'NAi' status from US FDA  Business Standard",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Piramal Pharma facility gets six U.S. FDA observations",
    "aliases": [
      "Piramal Pharma facility gets six U.S. FDA observations"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-xh3jzqavw",
        "type": "regulatory_news",
        "date": "2025-02-18T08:00:00.000Z",
        "title": "Piramal Pharma facility gets six U.S. FDA observations - The Hindu",
        "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNQi1Nd2d4YnhRQzhvY250dXlZX0hYaUxLekhLbDc0NkFwaWNDOEFja0VWOUUtSThRNWszYXJCU2lDQllLYmJHOUc3TVZ1d0doVXNTWW9nUEZHNXZFdjJxNmxXZFpMYU05Z1h5eXdFZnc5eWlnNVBwM2VMemVKQVZjaGhuOFl0b1I3aDJLeGZvTE5YeXFaVjJRazBsWXc5bkJyVlk5SkdRWXBzUdIBsAFBVV95cUxOeC1IUDRPM1p2ZlZYc0pZdW9kdEtEajl2TnZkVjF0ck9TRFU1Y2VDdzRhQ0RGbnB1YjZlV0xkNFhKMS1ITUtFZlZrV3owUTdTNlBvY2NuSkVDSjkwdTltOVQyTzBReFNZT195NDUtbGQ0djU0MVh0Unc2MGE0MXViaW04X0Zad3ZXNDE0T0J4aXlXd2ZZWVpCekx1Y190MTJ4RDRfVmNzTkNUQ0FSUWFuNA?oc=5",
        "source": "Google News - Form 483",
        "summary": "Piramal Pharma facility gets six U.S. FDA observations  The Hindu",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "s North Carolina facility",
    "aliases": [
      "s North Carolina facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-eksg2th7y",
        "type": "regulatory_news",
        "date": "2025-06-18T07:00:00.000Z",
        "title": "Glenmark Pharma’s North Carolina facility gets five U.S. FDA observations - The Hindu",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Glenmark Pharma’s North Carolina facility gets five U.S. FDA observations  The Hindu",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Marksans Pharma arm New York facility gets 1 USFDA observation",
    "aliases": [
      "Marksans Pharma arm New York facility gets 1 USFDA observation"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-j0zb5wayu",
        "type": "regulatory_news",
        "date": "2025-04-28T07:00:00.000Z",
        "title": "Marksans Pharma arm New York facility gets 1 USFDA observation - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Marksans Pharma arm New York facility gets 1 USFDA observation  Medical Dialogues",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "s Vadodara facility",
    "aliases": [
      "s Vadodara facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-dld2682y4",
        "type": "form_483",
        "date": "2025-03-08T08:00:00.000Z",
        "title": "Alembic Pharma's Vadodara facility gets one Form 483 observation from US FDA - Business Standard",
        "link": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxNX0tfVnNXLVFrdWpDR0N1bllHalcwTG01c0hGTnN3UFV3eWJrMmNXbzZYT2owTURYT0ZHVTVVVmVsWlh1YVFLeDJxczJVanJ0MjQzSUpYbUpnM3FMODdFQ1MtSzdRUlVheFZhQ29RbFpXYjBHS1J4TVJaYWNDZ1dPa2d1NXZ5ZG95QWVYVHZuMUpHYU15MUlEclpkY01HODA3UndCeFRyWWptXzI3Wkd0eFR5R1U3ZmtncnlJbFkyMjZ3VTdkaHBheGF5cW9FWnVYWkd5ZkcxV2ExU3AtTEdqdXJxQVhiRHBob01FR0tpZ9IB9AFBVV95cUxNU0ZYNjZHaVJ2SmxBQ0VNTndfZGM1dTBMN3g1b0YxMVVNejVFMTJJTXlqSmNjS1BXSkdwVk5vd0w5R25PX1ZiWWJKX3M1a2QxTmhBQ0VYeXJkV0VxUDh5QTVkeC05bzdTVU9vb2xVemlnZjg0S0szdUdFOE1YbHpCRlpZdlhSRnFpU1FCZzJuVE1fRW9DbURnNEs1QkxrSFRhUUdzNmRCdFp2bU9ULUtPQS1KSWdfbTEwU2t0cC1lTEo1U21rYUVXSWN6bHRFWktxUDhORFNiTGpMbE9ORFJUcHJIZ1hiWDV0U2tCbm5wXzRxZnlh?oc=5",
        "source": "Google News - Form 483",
        "summary": "Alembic Pharma's Vadodara facility gets one Form 483 observation from US FDA  Business Standard",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "US arm",
    "aliases": [
      "US arm"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-wm7wetf8m",
        "type": "form_483",
        "date": "2025-01-22T08:00:00.000Z",
        "title": "Laurus Labs' US arm gets Form 483 from FDA after 'adverse experience' probe - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Laurus Labs' US arm gets Form 483 from FDA after 'adverse experience' probe  CNBC TV18",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Pharmaceutical Formulation Facilities",
    "aliases": [
      "Pharmaceutical Formulation Facilities"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-45ycpofzj",
        "type": "form_483",
        "date": "2024-08-01T07:00:00.000Z",
        "title": "2023–2024 Trends In FDA Form 483s For Pharmaceutical Formulation Facilities - Pharmaceutical Online",
        "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNRUFyTmtXYWsyTWRvX29VU1pkTUFKSkQ2amdscHQ4b0lSTDRjSVNaLVhhSEduVEJOOE5zZ2kweEFfM3JWaXFHTG5GaEdLTGZYS01NSVdURzJXXzJybVdIU2h5NDNqU2JzME5BdUgzVk16QXB1ZG5tZnhJdDlOVFRWY05IYzBOQlBrdmdrcjR0QXBhZ0VVTGdFazZueFVkcktVRnRza3c0OTFQU25GQ0pSeFFEclUtMzlMZzJGRnBB?oc=5",
        "source": "Google News - Form 483",
        "summary": "2023–2024 Trends In FDA Form 483s For Pharmaceutical Formulation Facilities  Pharmaceutical Online",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "USFDA issues one observation for Natco Pharma Mekaguda unit",
    "aliases": [
      "USFDA issues one observation for Natco Pharma Mekaguda unit"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-pds6d3g24",
        "type": "regulatory_news",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "USFDA issues one observation for Natco Pharma Mekaguda unit - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues one observation for Natco Pharma Mekaguda unit  Medical Dialogues",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "FDA issues Form 483s to Japanese, Indian drugmakers in wake of plant inspections",
    "aliases": [
      "FDA issues Form 483s to Japanese, Indian drugmakers in wake of plant inspections"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-uz9pirmt5",
        "type": "form_483",
        "date": "2024-09-10T07:00:00.000Z",
        "title": "FDA issues Form 483s to Japanese, Indian drugmakers in wake of plant inspections - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNRFZDZXhpX2U1U2RjMHN1c1B2WGY1aVIyNExmOEo5TGE0VDlQTEJfcVVwejNza0JjdTN2Y1I3Qk1jQnZ4cW4zOTRRWjJDTWVjTTNXbl9JUXU3dW9wNGlYSklOR1BOcFlCT3JRLU5xWC1vTkFSSUw4cDJUbXdlUXVCTy05UG1mMzZEVll0LVQ4SnlSWjgwOHZNbV9KRDkyMjlRd1gtX09nRVhZZTA?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA issues Form 483s to Japanese, Indian drugmakers in wake of plant inspections  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Compliance review",
    "aliases": [
      "Compliance review"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-bhegsvkq9",
        "type": "regulatory_news",
        "date": "2025-06-16T07:00:00.000Z",
        "title": "Compliance review: US FDA issues 8 observations for Sun Pharma’s Halol plant following GMP inspection - financialexpress.com",
        "link": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxOU3JpNVdJOUVuYmlJWHRxMVM4WENyVzZHM3prTFNMUW5falhsMkdZc3JwRXZKSndUSWFmc1JuR3M3RGo0bWh6YnVMSHc0VFBYMy1pOUcxWTJEci1uN21kSGt5ei0yQnJUTDJoVEZ5RWpVSVRoZDJTZTFQaGpRWHc5d1hTZWNYRFMtWS1PYnMzbzRBS0NlMnFzd3d5VWdaeUI0Y2NoYlZWa09fUElMbkpoMkw3cEhCRGZmRk1yTTFSdVNHb3ZJSy1aY05wZEdqN1M5SDNpNjAwWmJDWFVZM1hCeTRPSkl5NEJYR2h1Rmk0N1J0bG9WdUE?oc=5",
        "source": "Google News - Form 483",
        "summary": "Compliance review: US FDA issues 8 observations for Sun Pharma’s Halol plant following GMP inspection  financialexpress.com",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Sun Pharma gets 8 USFDA observations for Halol facility",
    "aliases": [
      "Sun Pharma gets 8 USFDA observations for Halol facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-piwsubz90",
        "type": "regulatory_news",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "Sun Pharma gets 8 USFDA observations for Halol facility - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Sun Pharma gets 8 USFDA observations for Halol facility  Medical Dialogues",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "s API unit",
    "aliases": [
      "s API unit"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-bc6mzujn8",
        "type": "form_483",
        "date": "2024-11-19T08:00:00.000Z",
        "title": "Dr. Reddy’s API unit issued Form 483 with 7 observations by U.S. FDA - The Hindu",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dr. Reddy’s API unit issued Form 483 with 7 observations by U.S. FDA  The Hindu",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "NATCO Pharma gets 7 observations from FDA for Hyderabad manufacturing unit",
    "aliases": [
      "NATCO Pharma gets 7 observations from FDA for Hyderabad manufacturing unit"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-eedw8pqls",
        "type": "regulatory_news",
        "date": "2025-06-19T07:00:00.000Z",
        "title": "NATCO Pharma gets 7 observations from FDA for Hyderabad manufacturing unit - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "NATCO Pharma gets 7 observations from FDA for Hyderabad manufacturing unit  CNBC TV18",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1",
    "aliases": [
      "Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-dpb0jq1vj",
        "type": "form_483",
        "date": "2025-06-23T07:00:00.000Z",
        "title": "Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1 - Indian Pharma Post",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1  Indian Pharma Post",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757330720426-df2wmfz3y",
        "type": "form_483",
        "date": "2025-06-23T07:00:00.000Z",
        "title": "Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1 - Indian Pharma Post",
        "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQdTBGaXNDb1ktYURkZ3FfQjhTbmxnTTRvVlN1aWVfWkZwaURpYmNXZjhmNk91c25ZZ0d0dkZLUDRVek9TVG9UbzE4WUFGaGROQkdJY0t6dW1HbkFkTVNLTUJscm9taU5FMU9NazhoZDBvYkhlcXZzQXFULWxualRsdWNJc2haZ1NXVnZDandCRWtfdkpQMEZzWEFadTJ6MGtqVzNMNEJSZWRJbTBpQ2FWeVlzLXF0ay1tMVpTcE1RMnA1TkdSN1RpYUFpVmM2X3NacnhMNzhYSjlKZw?oc=5",
        "source": "Google News - Form 483",
        "summary": "Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1  Indian Pharma Post",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 12,
    "last_updated": "2025-09-08T11:25:20.493Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Granules India scolded over truckloads of torn manufacturing documents after recent FDA inspection",
    "aliases": [
      "Granules India scolded over truckloads of torn manufacturing documents after recent FDA inspection"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-hyu51ycmx",
        "type": "regulatory_news",
        "date": "2024-09-19T07:00:00.000Z",
        "title": "Granules India scolded over truckloads of torn manufacturing documents after recent FDA inspection - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQa0M4b3g4LThibmRENjZLbDVNZXczX2JMc1FLYzIwOWV1dmZ5RE5JUURQdGwzS005c29Vak1qbUhRMXRsV0xkTDFSaENMZGdfaVZUNDNTQ3ZnMXNZQTEycDMzbGVHdVRnbzlQZ3NxT3dGSmNiSjFvaVAwcXpseXRjNlB6QnhGcVIxRkdPT2NYLVR4V1FQSmEtSEJkT2czVXBKZURrcktkWE1VYU5JS3lXaDBzQnJ4dHBXclRwRQ?oc=5",
        "source": "Google News - Form 483",
        "summary": "Granules India scolded over truckloads of torn manufacturing documents after recent FDA inspection  Fierce Pharma",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Syngene International gets 5 USFDA observations for Bengaluru facilities",
    "aliases": [
      "Syngene International gets 5 USFDA observations for Bengaluru facilities"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-q8cs0iyfk",
        "type": "regulatory_news",
        "date": "2025-02-24T08:00:00.000Z",
        "title": "Syngene International gets 5 USFDA observations for Bengaluru facilities - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Syngene International gets 5 USFDA observations for Bengaluru facilities  Medical Dialogues",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "s Raichur units",
    "aliases": [
      "s Raichur units"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-ryf8qqdk0",
        "type": "form_483",
        "date": "2025-03-08T08:00:00.000Z",
        "title": "Shilpa Medicare's Raichur units gets Form 483 with one observation from US FDA - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Shilpa Medicare's Raichur units gets Form 483 with one observation from US FDA  Business Standard",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Biocon Gets FDA Observations At Key Biosimilars Facilities",
    "aliases": [
      "Biocon Gets FDA Observations At Key Biosimilars Facilities"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-6028bqyax",
        "type": "regulatory_news",
        "date": "2024-10-17T19:27:51.000Z",
        "title": "Biocon Gets FDA Observations At Key Biosimilars Facilities - insights.citeline.com",
        "link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPdW9IWHZYMVBWaGRBdUF5OHVFV3pkZ1JDRUFZU2psYWN5NFIzY0VsVDBfaFJqNGViY0wyNllqaDRISUtTWktoSElNemhYQzZGeEdqRzEyTWwtVE5vZUVTUUxNc19SVXlGTEhCaElLTENHcEwwMGZ2a0U5QVdRS1hPNEVkLVhNNFBlR2RzTWJLSWI0ZkllWjYwWVFkRTh3UjA?oc=5",
        "source": "Google News - Form 483",
        "summary": "Biocon Gets FDA Observations At Key Biosimilars Facilities  insights.citeline.com",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "s API plant in Hyderabad",
    "aliases": [
      "s API plant in Hyderabad"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-0tlv26b55",
        "type": "regulatory_news",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "Natco Pharma’s API plant in Hyderabad gets U.S. FDA observation - The Hindu",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Natco Pharma’s API plant in Hyderabad gets U.S. FDA observation  The Hindu",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [
      "Hyderabad, ge"
    ],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "USFDA issues 6 observations for Piramal Pharma Turbhe facility",
    "aliases": [
      "USFDA issues 6 observations for Piramal Pharma Turbhe facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-fie2v7qjq",
        "type": "regulatory_news",
        "date": "2025-02-19T08:00:00.000Z",
        "title": "USFDA issues 6 observations for Piramal Pharma Turbhe facility - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues 6 observations for Piramal Pharma Turbhe facility  Medical Dialogues",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Gland Pharma Gets Three FDA Observations For Visakhapatnam Facility",
    "aliases": [
      "Gland Pharma Gets Three FDA Observations For Visakhapatnam Facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-2wqfzqovc",
        "type": "regulatory_news",
        "date": "2025-02-25T08:00:00.000Z",
        "title": "Gland Pharma Gets Three FDA Observations For Visakhapatnam Facility - NDTV Profit",
        "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNZ24zUm1pbklnbklLbmJGWFZaOE8xV0FKTVFoUmd5VmpaNVJEbVl4Slh6OUlVTVdvMHJ3VlZHYzV2c3ZsbnJBV3NnWUJ0LVNhOW84TjIwMVZRZG0wbHFnV0hvRUE1MzhkS0J0cFM5RjhoNWZZYTJyLV9UR3ltOERod3FUVk5BWjZQci1odVp1N1hwUU84dTBRRG1Zc1JzR2prTGszNnFB0gGrAUFVX3lxTE4tNzhEMGhqdUV4ejVQRDJ4Q2Fqemd6Sk5ISGtEWUhfS0w2Mmt3NVB1LWZnWGQxNWRISXhETVQ0Y0t3OXRQVm5wQ09jUE1CNXdDaXZnTkViQjlldWJ0MDdCa2Mza2pCLUVLblVqYnFwT0ZpMTZvOUN2bi1yTmE4QjJvNlA4MHlGelBUWWxNcFJQOG1iQXZjYzFTU0Z5WDR5Z1pYSVZvbXZsOGN0NA?oc=5",
        "source": "Google News - Form 483",
        "summary": "Gland Pharma Gets Three FDA Observations For Visakhapatnam Facility  NDTV Profit",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "s Bommasandra plant in Bengaluru",
    "aliases": [
      "s Bommasandra plant in Bengaluru"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-laeenkbqd",
        "type": "regulatory_news",
        "date": "2025-05-30T07:00:00.000Z",
        "title": "Cipla's Bommasandra plant in Bengaluru gets single USFDA observation after cGMP inspection - CNBC TV18",
        "link": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNUHZSMS1mSWFQNkZpY2lfN0xoTmViVFJfVkJwVWFqc2lQYVBKNXJtNklyR1pwYWRYSmc2U19pWl9ySTI5ak43Z09tVjY3VndxZmE3QVJZMGtLLURvMFh4bGwzOEV2OWVWTlVXb21sbkkyenNUUy15NzlYYUk0NEZ0NmpUc1o4R3RPdFFmeEtmb2hPUXhmTDNRd3VTdXFBVDd6aE85LU9HUDZ5YmNoeGxqa3IzSnJuelNnVG9ocndwWmc2dnFrVnp2RHdKTHlEZUF5OVR2YWNhQjc4YWR5VTY1dmhHai1Jem_SAewBQVVfeXFMUFRNVUNDbE5OUFU0VnhIS1plSng2eXNHMzZ3MTd0UUxrcFVNeElnX1NIa3cya1N5aWkxaF9pZ01rSzBzWHJNSGwtbTdHcFJhVWxjcWg2V0oyTGhEbHBvcS1TcEpLR092ZXZUclVGbmdhQ3RsRFB6UjRpQzNwNEJ1bXNGbThYUG55dGFLdktiWFlWUm9TZk9fWFdvaWFLX01SU2d2SlluRTE2VWNKNFFyNDZLQmNwZmM3bnRaNkR3M01lZkdOYTRRVGVvUkttWkIwSGY2eTdIUS0xSEJ0Ym00TEl0RDlUZEZwbFFEMGY?oc=5",
        "source": "Google News - Form 483",
        "summary": "Cipla's Bommasandra plant in Bengaluru gets single USFDA observation after cGMP inspection  CNBC TV18",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [
      "Bengaluru gets, si"
    ],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.393Z",
    "monitoring_since": "2025-09-07T14:46:07.393Z"
  },
  {
    "name": "Srikakulam facility",
    "aliases": [
      "Srikakulam facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-ha8y5ifzv",
        "type": "regulatory_news",
        "date": "2025-07-19T07:00:00.000Z",
        "title": "Dr Reddy's Labs gets 7 USFDA observations for Srikakulam facility - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dr Reddy's Labs gets 7 USFDA observations for Srikakulam facility  Medical Dialogues",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "Cipla gets eight observations after FDA inspection at Bengaluru plant",
    "aliases": [
      "Cipla gets eight observations after FDA inspection at Bengaluru plant"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-jkca33dhl",
        "type": "regulatory_news",
        "date": "2024-11-13T08:00:00.000Z",
        "title": "Cipla gets eight observations after FDA inspection at Bengaluru plant - CNBC TV18",
        "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPM2lRTm1SSjR5NXYyZDhMUTR5TENMdmJ6MGgxeXd0VlZSVzVhREE3VUtjUFN2dUVyVXllYWQwWDNlRFNCQm5zY0lHTVdDdTQ2cGVPRXo4QzRKX2hTNXoxcU5DLU9vVVlMVnFFa0p2T3VIdnZRZS1oTF9SYlctNWpWX285T2xXOVZwR09YQ3hOZ0ZMSW14WjVxcVJUeVRFNmVnVGZ3azk5aTlRelQ3S1lPcWkzM2NGeDjSAbwBQVVfeXFMTnE0U0hNSTVMbTJHYWl5bTBmclpzYk1ZQTQ2VktzcTNzYkZpMWFMdVdDUnN6bGNSdVVYQnJpc3pyY0dodmdtamFqM2xzWExFc19pbnlrSDB3R2k2RWxPNTNhS1F0T3pvcG9nbWFhak5RbnFhX3BmcXRDYnBRaG52OUNhdk5kMWRHLU5FZkUxZlNIbGNvdkxORTlnVlZEVU9zLWFEZEFObmlRRHBoRmYyN3ZLeUt5eDNEX3N6OHU?oc=5",
        "source": "Google News - Form 483",
        "summary": "Cipla gets eight observations after FDA inspection at Bengaluru plant  CNBC TV18",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "Apitoria Pharma gets Form 483 with 10 observations from USFDA",
    "aliases": [
      "Apitoria Pharma gets Form 483 with 10 observations from USFDA"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-aptckndp8",
        "type": "form_483",
        "date": "2024-10-01T07:00:00.000Z",
        "title": "Apitoria Pharma gets Form 483 with 10 observations from USFDA - Indian Pharma Post",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Apitoria Pharma gets Form 483 with 10 observations from USFDA  Indian Pharma Post",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "Its Hyderabad Facility",
    "aliases": [
      "Its Hyderabad Facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-q0odgruzv",
        "type": "regulatory_news",
        "date": "2025-02-09T04:03:13.000Z",
        "title": "Dr Reddy’s Laboratories Hit With 10 USFDA Observations For Its Hyderabad Facility - BW Healthcare",
        "link": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOTXY1X3RJYXJGbk1Gb1VPYjZEZlBmOTRmdmFXOVdtdlZEY2ZrMXc5NzRNWkpEb2hLZDFjakJyVXZELUZyTXRjbXBEM1dDb29VMF9MNV92T2xEX1ZQV1FhQjNzWFE4UFVyaG9JdzE5TldUcVJpSnVTSlo0c0xZTFRrTC1ybDBzQ3puYU5PZE9zUzRzSGlqWXpFWEttRzV3bVQ2aWZSbVVBNzA5OG1nMFpNNnVpT0owU1FDTmhXT2hFNkYwNHl2N3hMYVpvYV9yNE10bXNTUg?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dr Reddy’s Laboratories Hit With 10 USFDA Observations For Its Hyderabad Facility  BW Healthcare",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "s Halol facility",
    "aliases": [
      "s Halol facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-ri3uztji1",
        "type": "regulatory_news",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "Sun Pharma’s Halol facility issued eight observations by U.S. FDA - The Hindu",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Sun Pharma’s Halol facility issued eight observations by U.S. FDA  The Hindu",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "FDA slams trio of Indian drugmakers with Form 483 filings after December inspections",
    "aliases": [
      "FDA slams trio of Indian drugmakers with Form 483 filings after December inspections"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-vmj80uus6",
        "type": "form_483",
        "date": "2024-01-03T08:00:00.000Z",
        "title": "FDA slams trio of Indian drugmakers with Form 483 filings after December inspections - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQVS16dVlxMldRdUJWNDJVRG1Sc3QydmtUSDQwOUFqamViaE5ROTBGRjhiNWR4cGpSSmVHVk05Z2I0bE1sQ1Fvd0dMb1pkZkVfOUR3V0pQRlpzdU11RldzN005a2R4aURwZ1BXQlF2cFY0M1h2VXNaUkl2VDl0ZDhXakotWW1DQlpqd054bGZla3F3bW1vMzlyYVFPY2VlMm5fNEp5SHljTkRQendxYWN4LXh3?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA slams trio of Indian drugmakers with Form 483 filings after December inspections  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "Dr Reddys Hyderabad API Plant Gets Seven Observations From USFDA",
    "aliases": [
      "Dr Reddys Hyderabad API Plant Gets Seven Observations From USFDA"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-0u0ybw5b0",
        "type": "regulatory_news",
        "date": "2024-11-19T08:00:00.000Z",
        "title": "Dr Reddys Hyderabad API Plant Gets Seven Observations From USFDA - NDTV Profit",
        "link": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPOHdPRVFnUFU4UkZVdUVoZE9zaGZEdzgza0w3WTFHWnAyM1A3RFk4NTlVOE9tRHNmOThXNnJYTGF1S3F1SmQ0bzc1VjZSWDhTU2lNUnZxU1pRUWV2ejA5NkItRzg3U2FGLXNZVXl2WUlydzdCcjRXWGJsMjJOd0Raei1aa3c3VWZZUWpkbdIBkgFBVV95cUxPLWVDNkd5UGZ5OVRNUG0wT1BoaURWRFBkMUREQlh2aTdxNHBwaWR4emhKY2p6cllfWXJZcnZWYjh2UkdmNV9waWJDZ1p4cG1IWDdnWGV5QWdjelBnRlJjdnVINVVBMnhsYzhLTFltd0xzSkR1MGtCQXZYQVRiVHA0bWhjX2xZYU9iM2JZQ1d6VkJCQQ?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dr Reddys Hyderabad API Plant Gets Seven Observations From USFDA  NDTV Profit",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "FDA flags 10 observations in another Form 483 for a Zydus plant",
    "aliases": [
      "FDA flags 10 observations in another Form 483 for a Zydus plant"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-5akrd4ti7",
        "type": "form_483",
        "date": "2024-05-06T07:00:00.000Z",
        "title": "FDA flags 10 observations in another Form 483 for a Zydus plant - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxORTRTdjd0QmlpWWxyOE0xODZHdlVYanJtNkUybmVSTnhoZUtKVUM2ZFRSRXZzX1VmNE5JdHI3TmhZZTk0a193QTdyY0hKVTBSSjY3c21YQkpVTllDSXdUSGlfNV9OQVdXUjM5SU1icDFJWWtWM3BMQVMtSDVGaWtBQ1NkX2t0VXlLY2hzQjhkc25LNFFFcmZ0WnNTQ2JCQQ?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA flags 10 observations in another Form 483 for a Zydus plant  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "USFDA issues one observation for Cipla Bommasandra facility",
    "aliases": [
      "USFDA issues one observation for Cipla Bommasandra facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-kp247p1td",
        "type": "regulatory_news",
        "date": "2025-05-31T07:00:00.000Z",
        "title": "USFDA issues one observation for Cipla Bommasandra facility - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues one observation for Cipla Bommasandra facility  Medical Dialogues",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "Cipla Gets Eight Observations After FDA Inspection",
    "aliases": [
      "Cipla Gets Eight Observations After FDA Inspection"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-cl10sic8j",
        "type": "regulatory_news",
        "date": "2024-11-13T08:00:00.000Z",
        "title": "Cipla Gets Eight Observations After FDA Inspection - NDTV Profit",
        "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxOQUpOdEJ6NDlNQ1pSTFMyYUc3ZWlKdkNjcE8tX2F5OXc5aDhIVm12aEVVS3BVMTZmWG1KbGxBUjBSQ1JKMHFNQjJFeXoxWTU1ODluelVMcVdZM2hUY1BtVmoxeEo1STBiV1hNQnIzcDJsUjJmRW1SbUZYWXlCa1Z6Y3g1U2h2S1REOWZsajBCaWJZQWZYSVZZVndRNE9NQdIBowFBVV95cUxOUzMxWUtNZEhGSGo1QVZSd3dja3dZOXRVOE1nRXl4aTRnNFBXTHBSTVIyeURLZ1psZXFkM05kUVpVdmpIX01PVTBWX0RtemJDdzA4MWJTQlA1RmZ1WGdteXZ6Q05mWWFjTko4Q0cydHg0czRiWDhaSEhFSnV4bU1ScWdMLXYxQW1KNGFoMnBuenh5YnFlbHVQM213aDh2Ukp2dU1Z?oc=5",
        "source": "Google News - Form 483",
        "summary": "Cipla Gets Eight Observations After FDA Inspection  NDTV Profit",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "Alembic hit with Form 483, citing 4 observations at Panelav plant in India",
    "aliases": [
      "Alembic hit with Form 483, citing 4 observations at Panelav plant in India"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-jwyf1u9bv",
        "type": "form_483",
        "date": "2022-10-20T07:00:00.000Z",
        "title": "Alembic hit with Form 483, citing 4 observations at Panelav plant in India - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNVlBZemFGZmV0cjBwZ3ptbEUxbGhoSnJ6bmZESXNQS2xPR2FzOHNkMGNhT0IzLUZHSjc4eGx2SEg4QVV1N2hWNmswa0F4V0dEdkFLZjdfRFhTTDkyZ1BNWnh1cFgteG9BXzNJQXltUW5EbFQwMVR4MmNKNzdQMzZxT2xQTlk3WDdhSzk4MmRKZjUzcDJxcGhHbmRac1FHZE9RTW9hS3E3dURoT3Vwa2RZWEZLTGJXNVZYVnc?oc=5",
        "source": "Google News - Form 483",
        "summary": "Alembic hit with Form 483, citing 4 observations at Panelav plant in India  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [
      "India  Fierce, Ph"
    ],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "Shilpa Medicare slips after US FDA issues four form 483 obersvations to Bengaluru facility",
    "aliases": [
      "Shilpa Medicare slips after US FDA issues four form 483 obersvations to Bengaluru facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-vusr5fdtt",
        "type": "form_483",
        "date": "2024-10-31T07:00:00.000Z",
        "title": "Shilpa Medicare slips after US FDA issues four form 483 obersvations to Bengaluru facility - Business Standard",
        "link": "https://news.google.com/rss/articles/CBMiggJBVV95cUxNMHlFWHRaQ21iNW9tNGFpaHhtSExkZ3JXcHhjS2p2UW9NV1VJdFlrd1NUR3RWbU9jRXJWX2gyWXFPa0NMUGdGMS1WdmJ6eE1aem4xd25mMTVCbkhwOVFQU2JnM0JGWUhTYjEtU1dIZkFFMnY4LWdwMW9wOEx0U1FwSHBwTDdIOGlWYlZKbmpCeEZ1SUU0RU5iNUhWaFB3cEhPQ2dCR1JVWHRjbmEyU1FnbkZkN3ZGRVp4T19ueHVFZ2I5WDBjUG40a3BydnhGYTNPR0ptNkgzUV81UmlyNnJWWkZmQ1I4YkFkMGdqZGhIazduWXhUTmpBYngyRlZWZEx1b0HSAYcCQVVfeXFMTkIzbG9YNUdUZDA1TDdyc3hZdFVaWkh6RGJIWWRYU0txWmo0Y0t4VzBQTEpxeHQ5eDNZMDlvb0trWUgzZmhaU05YY0t5VVhBd2picUdQLVV1WlN2YkVqVWQ1Z01ScjlOWlBxTEZzcHNrTE9oMWRJV3lXX1kyUVo1a1EzUGFyYi1VZU9ZQVRfM3NUVExQc0xCSUYxSzF6MDFHM2NLWEFyUkZxbjJWcjl4S3ZVazBPMTZwQUJDaVdlRkw4NVhzSkFjMXREaHRwRXJFTll3YXc3dEVobk90LU52Q194MURWNDlpemRFSDBjcVd4X1BGenJXTFRBYmdVeExEWWE3T0lYMUU?oc=5",
        "source": "Google News - Form 483",
        "summary": "Shilpa Medicare slips after US FDA issues four form 483 obersvations to Bengaluru facility  Business Standard",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "FDA Enforcement Trends",
    "aliases": [
      "FDA Enforcement Trends"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-bd5ab7k9v",
        "type": "regulatory_news",
        "date": "2020-02-12T08:00:00.000Z",
        "title": "FDA Enforcement Trends: Reflecting on 2019 and Looking Onward to 2020 - Crowell & Moring LLP",
        "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOUDdLMVR6SzIwaVhDZFdCR0pnSjlDOWI4NHhUQzBJZFItYWhDUnRMSVZabXgwZXU4RDl1OEYzNVA4blFnRGR3MjB4c3ZGZDQ0alk3V0NoSE9zU0xRWFJIdnpGaXJ3cWgtcFN6NVRrWEdvdmR6VHR4ZVljTTVKQ2V6NDAzQ0lIby1OZUJuTWtqYXFDZmZJR1N6MTNrZFlNUi1EZ1VudlkwcFBLSy1WWE9aWjk4NVZ6ZjFnOFRZWUF3ZXBlZlg3Unc5bFFGZTZTT2N4OXkwMXNPMGE?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA Enforcement Trends: Reflecting on 2019 and Looking Onward to 2020  Crowell & Moring LLP",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "s Mumbai facility",
    "aliases": [
      "s Mumbai facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-mlgr2vyat",
        "type": "regulatory_news",
        "date": "2025-02-18T08:00:00.000Z",
        "title": "Piramal Pharma's Mumbai facility gets 6 observations from US FDA inspection - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Piramal Pharma's Mumbai facility gets 6 observations from US FDA inspection  CNBC TV18",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "Cipla Goa facility gets one USFDA observation",
    "aliases": [
      "Cipla Goa facility gets one USFDA observation"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-xno1mdisk",
        "type": "regulatory_news",
        "date": "2025-01-21T08:00:00.000Z",
        "title": "Cipla Goa facility gets one USFDA observation - Medical Dialogues",
        "link": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPMUdDS2ljUGlxV0p4dExEanBacGJ2dURReFRtb0hIQmNDcW1TZ1RweXc0Nm40dmNLczJwZFgyWVRqLUdPYjI1REpQSmVfZUsxRUVMM2dEOW5PR1E0OVdFck85cWNyM1hISzZrbWlwdkFTenU1OE9vb29wUWs2MWJVZFJuLXhhOEhtRDdRY2hrNVB6Z3Q2b3dPU3lxQ3hfVG5wQVBF0gGoAUFVX3lxTFBsVk1zTFZQRDdiVV9TU1NJUk13OS1MaEtMQktaRVR1RXZxdGxRVllkNFJYZUFxWWt1LVlGWXNHZGZaQzdEWUNzZG5VcmVzWmhvd2lNamxZTTBaWFBzWTJXc1hPNDloNHVkWUlRbzRfaFYzQ1JvUW1nbmgxdGtXdXJ5YmNFWUFPRWdSR3FRUS1UalhaZ2dQY3V1NHpzS2w5RnNuTFdOUm9zNw?oc=5",
        "source": "Google News - Form 483",
        "summary": "Cipla Goa facility gets one USFDA observation  Medical Dialogues",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "Aurobindo Pharma slips after Andhra Pradesh facility gets 5 observations from USFDA",
    "aliases": [
      "Aurobindo Pharma slips after Andhra Pradesh facility gets 5 observations from USFDA"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-ws8zjzb1j",
        "type": "regulatory_news",
        "date": "2025-02-19T08:00:00.000Z",
        "title": "Aurobindo Pharma slips after Andhra Pradesh facility gets 5 observations from USFDA - Business Standard",
        "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxPYlF4YUtaaTdfRmMyc1Y1Q1hWUDlNbUNvMWNfMnlCbG5BMlpxSmlYZThBdGx5WThORGk0eU1sT1lfTFRxckJnek1tVlRwWGlUcXQwdHpTUzVzMzZSZFJzUEVuQ3lvUjM5NllhYlpOZ2M4Si1WZVgzSHVFbzFqZDU1SnZuY1NyWlJLNGRpYS1lSGlCRVJMaTdHRmdObjBmMVVEbXUxSHh0TkU3NjBORjJ6Wk1QS2ZNeDdfZEdhZXlzQ2dkU2dmaGRQWWVPcUxGaHMtaDlmUF9henE3TnZ6dXU5ZU5taXdyeVMzdWlFeHRUZkJEeGZHVjNpVdIB_gFBVV95cUxOdEt3MktIMVlsTVpHZUo2dVpCX053eUJRZ3hRX3F5SU9xcXNQdVZwT1BFRnVFMFZMVlV5aFFra1EydXBNVHo0OTk5cEVUMFBNQXU0cFJHNVFYYURGSDdqZ1o0S3cxZXZLam9XQkZsMTBPZUJ5SlY1MFNaN2lqcmpXMEVrcGpFbGNBWThZMWQwZHdOZEtkdVlWWlhjbHhmS1FZYmQtVDlwTEZOYjZBbHREV1N1NFBMY1c4RDM0bEV2WU1FX1ljSDd6aXN5dGplY0twVDBUTGNHa0hBYlRfQWlZd1hmR3JkQ19heUhqMmpUemxac0N2cm0wTU5iaC0wdw?oc=5",
        "source": "Google News - Form 483",
        "summary": "Aurobindo Pharma slips after Andhra Pradesh facility gets 5 observations from USFDA  Business Standard",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "FDA puts New Jersey drug ingredients maker Spectrum through the wringer in scathing Form 483",
    "aliases": [
      "FDA puts New Jersey drug ingredients maker Spectrum through the wringer in scathing Form 483"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-ba4arle99",
        "type": "form_483",
        "date": "2023-10-11T07:00:00.000Z",
        "title": "FDA puts New Jersey drug ingredients maker Spectrum through the wringer in scathing Form 483 - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQU0JFWlBzYnRLcHQ4VUNmRHFRbVFlSnBySzhHMllXTlRaelBMdVk1WkpHVGoya0VNWmVVMTFyN1huc2llaTBGZGFBaTJmRWZSTXRxZk10bmF4NGhjTzdESFNhQ2tWbVZhMlk0MjVLUHMwTUtQZ0xMbVB4TUFPRjVyWEF0OWtnRFZyTHVrQ1lYandpRVNvcnBRWjJUbjdXRzFPeVlzdEhrWGxLUFBKdUlqNl9Zbw?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA puts New Jersey drug ingredients maker Spectrum through the wringer in scathing Form 483  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [
      "ingredients maker"
    ],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "Manufacturing operations for Eli Lilly, Rentschler reprimanded by FDA",
    "aliases": [
      "Manufacturing operations for Eli Lilly, Rentschler reprimanded by FDA"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-sc1vn9qa2",
        "type": "regulatory_news",
        "date": "2023-05-04T07:00:00.000Z",
        "title": "Manufacturing operations for Eli Lilly, Rentschler reprimanded by FDA - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNY2JDQ1pBWXJNeXpLZnhPLUpTYnZGYnZudUdDRF9KblE2LUJuVXZKdUF5dG55THVwU1hTdW5vajY4ei1Uc1FBVk5pXy0xRWM2LUpzWmFCVmRpWFZoeTg1S1lueE4wa3VrbzVfWXJoT2xmc1dMOW4xNmRzMEFWRHRsUkdMZFpGZnRKOU0tQTZGOEFkTk52MEFkVWhvZjNHMjA2Z1FOTTY3YWQ4ME5Rc3E1ZU5vVmk5MGxTeGMzc09B?oc=5",
        "source": "Google News - Form 483",
        "summary": "Manufacturing operations for Eli Lilly, Rentschler reprimanded by FDA  Fierce Pharma",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "Granules Indias API Facility In Telangana Gets FDA Observation",
    "aliases": [
      "Granules Indias API Facility In Telangana Gets FDA Observation"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-5ka1wi6gw",
        "type": "regulatory_news",
        "date": "2025-06-20T07:00:00.000Z",
        "title": "Granules Indias API Facility In Telangana Gets FDA Observation - NDTV Profit",
        "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxNMlE1bHc2MFBURzVkdzdIOTY3YTJ1aE5jYmptNmpMM2lZd2hlTTB2Q2oxVDN2MFRWYTFzdXhHRDI1cm52bnBKcklqZWRiaGdFb2hBRDgxSDBJQWR1ZjdsLWJER0xWQ08tU1dDR1BvTmwxWDNrSXRwZkNLYS0ta184TVJpZ1pTMUhoWnJ6UXhOTmhDZU1LVEwySWpIdVBlZ9IBowFBVV95cUxObmVaSjZpdmlKamp5aXlxb29uWWVleXVma0hHelE3THhHVU9LYlFDVVBrYmZIa1plX1VHaFVBelZ1ZF9hNlZrUHRzZk9EQkNub2M3cW5VZnBpRUdZMTZYOWFJOHdmYUo3WXBnek9HMHpEUzE2Q3Z1S1hWY1VLNHJnemx0ZnNldVVzVzFQbzIxZ01uLUR5OEdNbklLSDllSnVyaXBJ?oc=5",
        "source": "Google News - Form 483",
        "summary": "Granules Indias API Facility In Telangana Gets FDA Observation  NDTV Profit",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [
      "Telangana Gets, FD"
    ],
    "risk_score": 0,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "FDA hits UCB facility in Switzerland with Form 483, cites quality control and records issues",
    "aliases": [
      "FDA hits UCB facility in Switzerland with Form 483, cites quality control and records issues"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-rv3iad5bd",
        "type": "form_483",
        "date": "2023-10-26T07:00:00.000Z",
        "title": "FDA hits UCB facility in Switzerland with Form 483, cites quality control and records issues - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQcl84SFlQZVBUYUdSZ1A1ZlBQVWpGTGo3Ui1qel8zT1hFS2dwRDJVa3dUSWdiYzMwUjJMeU5KeTVmLTJCRExnRXRnQTJoYVZvNURHRUVlY0FQbGZRZC1xQXVsWWNUTTFYdkF2ZzkxUTYwUnh0cU51eEswcHhtVXpIWThOa2xBYnRueVk2VnkwdXNVQ3ItTTNyRE9sdlo5djZSM3VjUzkwTkotOVk?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA hits UCB facility in Switzerland with Form 483, cites quality control and records issues  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [
      "Switzerland with, Fo"
    ],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "Piramal API plant in Michigan hit with FDA Form 483 write",
    "aliases": [
      "Piramal API plant in Michigan hit with FDA Form 483 write"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-zh81dkg1y",
        "type": "form_483",
        "date": "2024-02-09T08:00:00.000Z",
        "title": "Piramal API plant in Michigan hit with FDA Form 483 write-up - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOa0NYYjJTU1JqZElDOEs4UmRJajRJSll4TE0weU5Sd2NHNnd3MUoxZW9ubHdUX19vX1dqZ2U5VHRmekpDYU52M2V4cEtzM1FQWnB0VkhRZjIwT01fM0hFcE1Cd1VzT0VLbXp6bklIb2RHVWFOMmlyZy1Ud1N1ek1SNXE3c3RFM2ptNkJDUUhkd3JMM3lad2c?oc=5",
        "source": "Google News - Form 483",
        "summary": "Piramal API plant in Michigan hit with FDA Form 483 write-up  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [
      "Michigan hit, wi"
    ],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "FDA hits Torrent Pharma with a Form 483, citing 5 observations",
    "aliases": [
      "FDA hits Torrent Pharma with a Form 483, citing 5 observations"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757256367324-3xlol05zy",
        "type": "form_483",
        "date": "2023-12-13T08:00:00.000Z",
        "title": "FDA hits Torrent Pharma with a Form 483, citing 5 observations - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQMVRfMW1odTNyNTBRMkR4bnFoZEs5WFdnNXJkX1RrSzMzNjVzVy1hWWRBcktWX1hMQXZnT2h5Ym5LUURrV0JrUGZXa2FPd3ZCc0VQYzhULTdabjZPaG9HdVd1NGQ0Q3RYU3lwN1J1dEFUdWVsU3BWNEszcDJ3VUtvamx1Y0RnRWFHaGVyT2c3amM5Vl83ak5rVWZZUktOTTRmZ0E?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA hits Torrent Pharma with a Form 483, citing 5 observations  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T14:46:07.394Z",
    "monitoring_since": "2025-09-07T14:46:07.394Z"
  },
  {
    "name": "API maker Global Calcium stung with Form 483 filing after FDA inspection of Indian plant",
    "aliases": [
      "API maker Global Calcium stung with Form 483 filing after FDA inspection of Indian plant"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757266612910-p4hrvlar7",
        "type": "form_483",
        "date": "2024-08-29T07:00:00.000Z",
        "title": "API maker Global Calcium stung with Form 483 filing after FDA inspection of Indian plant - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPOGVwY1NZaktiWnJxNDEySjlsRUQ4dS1ENW1maHF5dEN6V2syVjZQQzFVQ3BYclFHcDNGNlBuNmxGeFVRVk1wTjVfOG83Q3FzSUNtdDBJT0RBeUhnN0JaTm5UTXpmOFJEbmRoNlYwcHJvaG45TnJ6Y3RHaDZCeWZ5ZTJVM3hjcl9tVF8zTG1qWXNIUFJid1hObVhaQmFkNnowQ2VrTldtQnB4TVBBNXhuc0s0dw?oc=5",
        "source": "Google News - Form 483",
        "summary": "API maker Global Calcium stung with Form 483 filing after FDA inspection of Indian plant  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T17:36:52.917Z",
    "monitoring_since": "2025-09-07T17:36:52.917Z"
  },
  {
    "name": "Critical FDA Meeting Scheduled",
    "aliases": [
      "Critical FDA Meeting Scheduled"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268001557-o84daf1vx",
        "type": "regulatory_news",
        "date": "2025-09-02T12:00:00.000Z",
        "title": "Critical FDA Meeting Scheduled: Replimune's Advanced Melanoma Treatment Faces Decisive Moment - Stock Titan",
        "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPcjN0dnpXQVJhNmxlNEVPRjBNdmF5bGFnWE84TF9ncFZ5OWpGZktEbWpJNzhGMWRfVC1ld190dG56anBLNGpZXzRBWElMMmpYTVNwU2p6dzRjQzI2Zlk3MTRwNzBmdV9NQ2xJUUFrWlhHaXhSNklYbWhMcXY4WlpNMVdZbGZIcVdscUYwc1pFQ2JMZFNPa09idmpLc1R0dTdMM2ViUnNSRQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "Critical FDA Meeting Scheduled: Replimune's Advanced Melanoma Treatment Faces Decisive Moment  Stock Titan",
        "severity": 5
      }
    ],
    "products": [
      "Faces Decisive"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:00:01.608Z",
    "monitoring_since": "2025-09-07T18:00:01.608Z"
  },
  {
    "name": "FDA Rejects Brain Cancer Drug",
    "aliases": [
      "FDA Rejects Brain Cancer Drug"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268001559-2vvb1nrhy",
        "type": "regulatory_news",
        "date": "2025-04-28T07:00:00.000Z",
        "title": "FDA Rejects Brain Cancer Drug - Oncology News Central",
        "link": "https://news.google.com/rss/articles/CBMiekFVX3lxTE5KalpaMkcyaFE3dE02aDFhcFhDalJjZGFHTWpIYjVyNW9VcGQzcUNEVFFELW01OU9mcjFIb0ZMUmRJU2wwZS1fVV9FanBZeFYzbGNpUjRnRkUzVDVOck04V0I4QndlSG9qbG8yRE93ZXlVcElHcm9zQ0NR?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Rejects Brain Cancer Drug  Oncology News Central",
        "severity": 5
      }
    ],
    "products": [
      "Oncology News"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:00:01.610Z",
    "monitoring_since": "2025-09-07T18:00:01.610Z"
  },
  {
    "name": "A Statement from FDA Commissioner Marty Makary, M.D., M.P.H",
    "aliases": [
      "A Statement from FDA Commissioner Marty Makary, M.D., M.P.H.",
      "A Statement from FDA Commissioner Marty Makary, M.D., M.P.H"
    ],
    "violations": [
      {
        "id": "FDA Press Announcements-1757268364662-1051si9k0",
        "type": "regulatory_news",
        "date": "2025-08-08T15:25:35.000Z",
        "title": "A Statement from FDA Commissioner Marty Makary, M.D., M.P.H.: Announcing Resolution of the IV Saline Solutions Shortage",
        "link": "http://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-marty-makary-md-mph-announcing-resolution-iv-saline-solutions-shortage",
        "source": "FDA Press Announcements",
        "summary": "A Statement from FDA Commissioner Marty Makary, M.D., M.P.H: Announcing Resolution of the IV Saline Solutions Shortage",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:06:05.507Z",
    "monitoring_since": "2025-09-07T18:06:05.507Z"
  },
  {
    "name": "STAT",
    "aliases": [
      "STAT"
    ],
    "violations": [
      {
        "id": "STAT News Pharma-1757268364759-pc0tmx8sw",
        "type": "regulatory_news",
        "date": "2025-09-03T15:10:19.000Z",
        "title": "STAT+: Pfizer’s CEO defends Covid vaccines, suggests Trump may deserve a Nobel Peace Prize",
        "link": "https://www.statnews.com/2025/09/03/pfizer-responds-trump-covid-vaccine-safety-effectiveness/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Pfizer CEO Albert Bourla defended the development of Covid vaccines and suggested President Trump may deserve a Nobel Peace Prize because of Operation Warp Speed.",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757268364759-cm622utq8",
        "type": "regulatory_news",
        "date": "2025-09-03T16:03:08.000Z",
        "title": "STAT+: Why biotech stocks did unusually well yesterday",
        "link": "https://www.statnews.com/2025/09/03/biotech-news-xbi-index-acip-rsv-gilead/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "And more biotech stories brought to you by The Readout.",
        "severity": 5
      },
      {
        "id": "STAT News Pharma-1757268364758-y5ty7a15e",
        "type": "regulatory_news",
        "date": "2025-09-05T13:49:40.000Z",
        "title": "STAT+: Up and down the ladder: The latest comings and goings",
        "link": "https://www.statnews.com/pharmalot/2025/09/05/jobs-biotech-pharma-ladder-sanofi-genmab-merck-icon-iqvia/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:06:05.511Z",
    "monitoring_since": "2025-09-07T18:06:05.509Z"
  },
  {
    "name": "Outlook",
    "aliases": [
      "Outlook"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365419-hbndlw7mn",
        "type": "crl",
        "date": "2025-09-02T21:45:00.000Z",
        "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
        "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268365418-6v8thf0rp",
        "type": "crl",
        "date": "2025-08-28T07:00:00.000Z",
        "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
        "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268365420-eu0us9480",
        "type": "crl",
        "date": "2025-08-28T07:00:00.000Z",
        "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
        "source": "Google News - CRLs",
        "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
        "severity": 9
      },
      {
        "id": "797abb7b22a8a551c2297842b59a1964",
        "type": "regulatory_news",
        "date": "2020-02-21T08:00:00.000Z",
        "title": "Outlook Pharmaceuticals, Inc. - 605071 - 02/21/2020 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPcFg5a2gtSDZrZEh4NDdQZGtzNjZBVVl0bjdXRERQUmVWbVBFOGtybm1WRlZKRjYyVFFERWRadVdOMHhRYTFPb2N6Vk40VllsaF9qUzUxTEFidFhiVEdsd2o0cklkaVVQeHZSTVY3bkhjTVZkYzFHYjNYSEo4Tm94Q3lhYnRxRXZoRmtIRzdFekxkUHJBU01HTkhOMU4yU1JYWWNVV212WFZiVll2akhwM1RCemFkRU5qVTQzNjRaa3VvcnlrMkI5dV9ZS0h6TXNFSmZOTWllNEhKZw?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Outlook Pharmaceuticals, Inc. - 605071 - 02/21/2020  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": null,
    "last_updated": "2025-09-08T12:30:00.607Z",
    "monitoring_since": "2025-09-07T18:06:05.512Z",
    "compliance_score": 55
  },
  {
    "name": "RP1",
    "aliases": [
      "RP1"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365419-htorn016n",
        "type": "regulatory_news",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA Issues CRL for RP1 Plus Nivolumab for Advanced Melanoma - OncLive",
        "link": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQZEl1ZFBnQWVDQlhPSWQ4N1ZwUkJuREc0WHJERS1HUV80emJFRnFmZ2F6NXA1aURxMnBiTUxUYXVtVVVIY3NMWjdWSUlVU1BNUEx3RTlDZlk0WmpUOUZacUhGZGhTTXBBajBfR2VYakhkenE2Wkt2VmpXTHAxWDVZWGJacVRnNFd6cTFHdDIyX3l2Zw?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for RP1 Plus Nivolumab for Advanced Melanoma  OncLive",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268365422-0rq9rv5mg",
        "type": "regulatory_news",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA Issues CRL for RP1 in Advanced Melanoma - Targeted Oncology",
        "link": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPNUp3Q2hzNDdZejRfTHhjYmRhUHpvXzRVYXRUa1JhM2p0X1l2ZUJCZlNEWHlVLTNfM2ZVU2JGZmw1R0RQbEptUS0zRlJ6Z0doQzdEZGMteVFEWndESER6MGpqTXRreHBwd1lFQlJPMG43TjU2dVh6YkFHbXF2X0QteUpR?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for RP1 in Advanced Melanoma  Targeted Oncology",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268365422-ssp386u5g",
        "type": "regulatory_news",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA Issues CRL for RP1 and Nivolumab in Melanoma - Dermatology Times",
        "link": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNVjFfVW80YVZIT1NnUVdMS0ljYU5JTzFQaDExX2JpUmRfMHk2LTZEdjZqV0JoeGhOcmhrTG1wSGZIV1lDcnI2SnBYWDlxVUNGQjJmcXljdEh0WENsYUVTeEpwanNWZndEdnlqa3hVWWFGdXNydEVrbmZxRDBJM01tcWFMS2FJUmJzMndzMUFqcw?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for RP1 and Nivolumab in Melanoma  Dermatology Times",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:06:05.523Z",
    "monitoring_since": "2025-09-07T18:06:05.513Z"
  },
  {
    "name": "Manufacturer",
    "aliases": [
      "Manufacturer"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365422-ztsyub2l5",
        "type": "crl",
        "date": "2025-04-03T07:00:00.000Z",
        "title": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis - Pharmacy Times",
        "link": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNLTlmaDFOclA3OUhtMkdzQjBtQXk3S1JKbl93VzJBM3R2bGRDRUpWQWQxQnZhY05qS0pOTXhNcnJpZE5jTVJnbmlvR1pGa1EweWc2aFkxTldEUEQ2RDZOaTZsS184ZUYxVHN0YmNEOXZlUUt1N3hqNl9VVjJNQ3BKZ19HQkxYbFBRNWdMYnZ1aWJVdlJxb2RweTBfendMM2NQU2I4NVd0MUo1M21Kc3FqS1oyVWwxWE5pZVVzVHVuZUk2dHJiSmhVcGRicDMyMlNVRVE5b1YyRmRIT3BXRzBCOEZDRzA4TWtFNGc?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis  Pharmacy Times",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268365419-zzk0gaxyo",
        "type": "crl",
        "date": "2025-07-02T07:00:00.000Z",
        "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
        "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
        "severity": 9
      }
    ],
    "products": [
      "for CKD",
      "for Dry"
    ],
    "facilities": [],
    "risk_score": 18,
    "last_updated": "2025-09-07T18:06:05.523Z",
    "monitoring_since": "2025-09-07T18:06:05.513Z"
  },
  {
    "name": "Ultragenyx",
    "aliases": [
      "Ultragenyx"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365419-myxpx9esc",
        "type": "crl",
        "date": "2025-07-14T07:00:00.000Z",
        "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
        "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
        "source": "Google News - CRLs",
        "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268365421-ra7ubq0zb",
        "type": "crl",
        "date": "2025-07-11T07:00:00.000Z",
        "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
        "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
        "source": "Google News - CRLs",
        "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
        "severity": 9
      },
      {
        "id": "6d4ea6b915f2c2ad49ec620b693569d2",
        "type": "crl",
        "date": "2025-07-11T07:00:00.000Z",
        "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
        "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
        "source": "Google News - CRLs",
        "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
        "severity": 9,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "for Sanfilippo"
    ],
    "facilities": [],
    "risk_score": null,
    "last_updated": "2025-09-08T12:30:00.067Z",
    "monitoring_since": "2025-09-07T18:06:05.514Z",
    "compliance_score": 55
  },
  {
    "name": "Glofitamab",
    "aliases": [
      "Glofitamab"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365419-1fix7xtcw",
        "type": "regulatory_news",
        "date": "2025-07-18T07:00:00.000Z",
        "title": "FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL - OncLive",
        "link": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPTXJ2V0o3azZmTnIxeTZRclRDS0dwcFUwYWVuMGxyOWVBekJXbzF1WGQ1WUN6TTBwSlpDcTNkUzRXOE1XYk5odDVjQUZaOE1URjJQLURSb3pSMFBpcTd4YUpwcDZvY2laNE9mSzI5Rm5KWGpBV011UWI5d296V0lOejRqVlMtTC1aMWc?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL  OncLive",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268365420-57z4jpj7t",
        "type": "regulatory_news",
        "date": "2025-07-21T07:00:00.000Z",
        "title": "FDA Issues CRL to Glofitamab Plus GemOx in ASCT-Ineligible R/R DLBCL - CancerNetwork",
        "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQQVhucUF6ZTNFTW5XS2hKcGVxRG9HeUFsb2dpR0l0S2tHWi05SXAwaVQyY1JaaWRZTWliM2c0WFFCTGRyVjh4UDNBc3U1TVVZQW04N0JXYkVRRjY4V2pJV28za0R1cG9TMHhzdEhFZ1VVNWVBUjF2V1FKaUpXUnBnQkdTTjZ2bGRZR3BtSy1Kak95c3JlbU02LVBLSHJvSXpGSGFOdVV3?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL to Glofitamab Plus GemOx in ASCT-Ineligible R/R DLBCL  CancerNetwork",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:06:05.517Z",
    "monitoring_since": "2025-09-07T18:06:05.514Z"
  },
  {
    "name": "Replimune",
    "aliases": [
      "Replimune"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757330791536-cilr481un",
        "type": "crl",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment - geneonline.com",
        "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOTHUxdXliYVhkdDUzQTJtZFBuN3oxQzlub3FHaVVtclNlOHQtTHNSdWNPYzhiWXdST2V1VnlMSlBmLVdvSFEwLUsxMXk4WTgzUkE3N1ZSOUp6Mk1tTnZCb0tLY1RITmRoY3YzdS1PVkdBVW5nYkJFV1dDdVdFNzFhWFhSX2QzQ3gxa21vMEhSYWJfZWREMFZRckN2ZFJaTmNGZ01jNHhXc0NIaEZuM0RieV80dnFpZmFNM2J5MHRLODdJYnBJMi1EeDQ5aWs2ZUJ4WW80bkxUaw?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment  geneonline.com",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268365420-wpyf65fne",
        "type": "regulatory_news",
        "date": "2025-07-25T07:00:00.000Z",
        "title": "FDA Crackdown on Trial Design: What July’s CRLs to Replimune and Capricor Mean for Sponsors - Applied Clinical Trials",
        "link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOUlFwSXd5dEk5eHNMYl8xWlk1WS0xby05a1lZNGtmQ1ZXSXRib2lxYzVqb2tWbnMyVlAzalU3eHVBSVpIRUhSQWYyVDNRUkJ3Z1VfUU1VTzRxNXhmbzVUZVpWRVY3cDFQcnA0ZTZHcmsxM1p6cUVvRWIxc2FhV1NBR2d1Z1B3ZXRJVW5NVkcwLUtOWXJRam9JdHFtcjY5STA?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Crackdown on Trial Design: What July’s CRLs to Replimune and Capricor Mean for Sponsors  Applied Clinical Trials",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268365423-fdm66zqnx",
        "type": "crl",
        "date": "2025-08-15T13:11:52.000Z",
        "title": "Replimune receives complete response letter from FDA for RP1 BLA - MSN",
        "link": "https://news.google.com/rss/articles/CBMiygJBVV95cUxNNUIxb2dzdnM4OC1ERlo2MFpMOFZzZl9IaUNJcVhtSFc5cTd0Nkl4Qmd0T1RXanh0alZDQS12MWlwRDZGdWd1WEo1VHRSUFlXZTF0VElxOUdaVDdUQmE2WUJWZzhoSVFORm1BTmdlZFN0S3VzYy1NZWl5dnZ4RWxpSzF2WWQzT1IwOWN6OTVqUDhJck01VGljOVhvM1VhVGI1WnlOSExhNWV1Nnp5SG1xam9DZjZmZWVDdEFUT3owNnltSUdfM0pnREhxVDhCY01GaFlaLTVOdkhsNlhENlRfUzBEa3BZQXJnelRPWl9MMWVyRlVER093blRHV1JObnJBclRSOWRVem83elV4WE1TVElwb2l3REY3WWxINGtYVm03dS1DWE8tUlRBaHlnaXBVUDdwWVEtV2hUS1I0Z3VqQmhHeTBwVjd1UFE?oc=5",
        "source": "Google News - CRLs",
        "summary": "Replimune receives complete response letter from FDA for RP1 BLA  MSN",
        "severity": 9
      }
    ],
    "products": [
      "geneonline"
    ],
    "facilities": [],
    "risk_score": 27,
    "last_updated": "2025-09-08T11:26:31.557Z",
    "monitoring_since": "2025-09-07T18:06:05.515Z"
  },
  {
    "name": "Odronextamab",
    "aliases": [
      "Odronextamab"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365420-qao4ndvjo",
        "type": "regulatory_news",
        "date": "2025-08-01T07:00:00.000Z",
        "title": "FDA Issues CRL for Odronextamab in Relapsed/Refractory Follicular Lymphoma - OncLive",
        "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPU1kxZmpPbjFNMFl6dFd4emhZV2RqLW9NeXd4TFpFNEFMVlhBclIwb2llQVQ1REw0a3loTU96Yk1nUjYza1pGSWJIclhCNXJ0V1ZJMlRMS0Z5UjRIVGpSay1hcHA4dU5tQnhqTTRTeVctRTdWdHZXNDAzVExoWEYyazlBcmNuYWhpUTZHWlppTllRS2pSZ1dyb1BYeWhxQllOR0RCczl3?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for Odronextamab in Relapsed/Refractory Follicular Lymphoma  OncLive",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268365423-h4obp0rze",
        "type": "regulatory_news",
        "date": "2025-08-04T07:00:00.000Z",
        "title": "FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma - CancerNetwork",
        "link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPUC1mb1Z3UGRULXVCa1YyQ2NYbmRQOC05TnFTODg1RmhfcHAwU1hueGRzRG42aVBydTBsOGtJQkk3Skk3LTlpb1l2WnNVT09BVEkzbHRBV0N0NDZVYzFCbVgwRnBKaFMtQXlIQmtDaGdHdUVDSlNkeW1zc2M0bWYzSmRROGExMXhSYUR4QmtTSXFMemR3eVRUR1UzX0NjSk9K?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma  CancerNetwork",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:06:05.524Z",
    "monitoring_since": "2025-09-07T18:06:05.516Z"
  },
  {
    "name": "Previo",
    "aliases": [
      "Previo"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365420-hfssngedp",
        "type": "regulatory_news",
        "date": "2025-07-10T07:00:00.000Z",
        "title": "FDA Releases CRLs for Previous Drug and Biologic Product Applications - OncLive",
        "link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNWVh2d1FXVWZSeWU3b2g2OFpKSTIzdEE4WHU0OVVuQUk1UGUyM2M2T1VmVXhreTllVjJUX3FOdl94clRiZXhtV0l0cE04MjhtaWtMNjdkYzhTT1gwaWt3ZWtLbUpxSXJhZVQ3Y3haSy1qWW1Bb2lZQ2g3MEdwYktZWUNmTkFVai1sR2VweHM5WEJRT2RIMFNEOUVtZm5CUUU?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Releases CRLs for Previous Drug and Biologic Product Applications  OncLive",
        "severity": 5
      }
    ],
    "products": [
      "and Biologic",
      "Applications  OncLive"
    ],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:06:05.516Z",
    "monitoring_since": "2025-09-07T18:06:05.516Z"
  },
  {
    "name": "PTC",
    "aliases": [
      "PTC"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365420-e6ckfufx0",
        "type": "crl",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
        "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
        "source": "Google News - CRLs",
        "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
        "severity": 9
      },
      {
        "id": "Google News - CRLs-1757268365423-hm7zrie13",
        "type": "crl",
        "date": "2025-08-20T18:08:52.000Z",
        "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
        "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 18,
    "last_updated": "2025-09-07T18:06:05.524Z",
    "monitoring_since": "2025-09-07T18:06:05.517Z"
  },
  {
    "name": "Glioma",
    "aliases": [
      "Glioma"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365421-c6a95qmac",
        "type": "regulatory_news",
        "date": "2025-05-01T07:00:00.000Z",
        "title": "FDA Issues CRL to TLX101-CDx for Glioma Imaging - OncLive",
        "link": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOcU9TZGNfSjhtUTZsWTNYQ0NiNUR6YmhGQW5vVjZEY3FSMFg0UmZ1RXBoSWhaSlRzYUtSeXFUcEdNSnVPQ1Nlank3blAtQjhrdlJlSGNzd3Utb0dldUV1dlNFUlZrM1pzNnREWmtTQUhBQUVVdlBJUFdFSkZvZzBKanlR?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL to TLX101-CDx for Glioma Imaging  OncLive",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:06:05.517Z",
    "monitoring_since": "2025-09-07T18:06:05.517Z"
  },
  {
    "name": "Subcutaneo",
    "aliases": [
      "Subcutaneo"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365421-xw5nt5cxj",
        "type": "crl",
        "date": "2024-12-17T08:00:00.000Z",
        "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
        "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T18:06:05.519Z",
    "monitoring_since": "2025-09-07T18:06:05.518Z"
  },
  {
    "name": "Reproxalap",
    "aliases": [
      "Reproxalap"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365421-xjjs3gac2",
        "type": "crl",
        "date": "2025-04-03T07:00:00.000Z",
        "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
        "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T18:06:05.519Z",
    "monitoring_since": "2025-09-07T18:06:05.519Z"
  },
  {
    "name": "Treat",
    "aliases": [
      "Treat"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365421-jc4h28een",
        "type": "crl",
        "date": "2025-09-02T12:56:17.000Z",
        "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
        "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
        "source": "Google News - CRLs",
        "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T18:06:05.519Z",
    "monitoring_since": "2025-09-07T18:06:05.519Z"
  },
  {
    "name": "Complete Response Letter",
    "aliases": [
      "Complete Response Letter"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365421-tgqjpyw22",
        "type": "warning_letter",
        "date": "2025-01-15T08:00:00.000Z",
        "title": "Complete Response Letter, Warning Letter and Shareholder Lawsuit Follow FDA Data Integrity Findings - JD Supra",
        "link": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQUGhhVWRtUDA3TEtVa0p6VElTMGE1eXNMcl9mMG1fY3FsdU1xSFdIODBGNWdMVlUtekUxUVFDbFVtZmpxVTF5WVdEblE0MTI0aFllWHJ2ZEM0UkhRcWNYRUdwbTlibUlJUzdPMmEwOUFRdWlTVXZGc2VMa0tvS3NaRXhRRHM4SGQwZGc?oc=5",
        "source": "Google News - CRLs",
        "summary": "Complete Response Letter, Warning Letter and Shareholder Lawsuit Follow FDA Data Integrity Findings  JD Supra",
        "severity": 8
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 8,
    "last_updated": "2025-09-07T18:06:05.519Z",
    "monitoring_since": "2025-09-07T18:06:05.519Z"
  },
  {
    "name": "Ultragenyx Pharmaceutical Inc",
    "aliases": [
      "Ultragenyx Pharmaceutical Inc"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365422-4hlqbnkq4",
        "type": "crl",
        "date": "2025-07-11T07:00:00.000Z",
        "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
        "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
        "source": "Google News - CRLs",
        "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T18:06:05.521Z",
    "monitoring_since": "2025-09-07T18:06:05.521Z"
  },
  {
    "name": "Astellas",
    "aliases": [
      "Astellas"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365422-snthnbt58",
        "type": "crl",
        "date": "2025-09-04T15:41:33.000Z",
        "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
        "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-07T18:06:05.523Z",
    "monitoring_since": "2025-09-07T18:06:05.523Z"
  },
  {
    "name": "Atara",
    "aliases": [
      "Atara"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365423-gwmk7oo9i",
        "type": "regulatory_news",
        "date": "2025-01-16T08:00:00.000Z",
        "title": "FDA Issues CRL for Atara Biotherapeutics’ BLA for T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD - CGTLive®",
        "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxONG85cUZMcXZGUy1kUEtGY1FWNDNCUDIxRDJ1dmdRVzBOd2tjY2xxZFdUSnFtd1A0ZVItYVZxNDJCMHlxejNFemtSUk8wTlBXUEswUUtIQnk2V01ObVIyQ2tHNG1jZVBSWkozTThySEJDWjRoczFWQTI4SnU2YTU3WC13dGZmOE1OdFJHeE1BQ0huckhhQTNQUU56NElHTktJb29fNkJDclN1R3RveWc?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for Atara Biotherapeutics’ BLA for T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD  CGTLive®",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:06:05.524Z",
    "monitoring_since": "2025-09-07T18:06:05.524Z"
  },
  {
    "name": "Vusolimogene",
    "aliases": [
      "Vusolimogene"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757268365423-53xw0uzhg",
        "type": "regulatory_news",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA Issues CRL for Vusolimogene Oderparepvec in Advanced Melanoma - AJMC",
        "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNM251Q1hxcTBwYmhzMnc3d3V2TWdKbWF5aTdnc0p1QVhnSzFfQTZhTjhYN3p4S0lTQXdoMl9IUlBrc25BMTVtY2x4dHRfVXNNLXYyT3ZFSUVkN2ZwQnpMbFc1cURwc0ZRWVg5eTdrWHpZSlNUVjFGeTJkWXpHZ1JFcENsSkJDeTZQWHVtbDhUcDNwN3V5cXc?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for Vusolimogene Oderparepvec in Advanced Melanoma  AJMC",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:06:05.525Z",
    "monitoring_since": "2025-09-07T18:06:05.525Z"
  },
  {
    "name": "USFDA issues",
    "aliases": [
      "USFDA issues"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365499-6utma301n",
        "type": "form_483",
        "date": "2025-09-05T14:59:30.000Z",
        "title": "USFDA issues Form 483 with 8 observations to Aurobindo's Telangana unit - The Economic Times",
        "link": "https://news.google.com/rss/articles/CBMi_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?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues Form 483 with 8 observations to Aurobindo's Telangana unit  The Economic Times",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757268365502-oxsk9jq91",
        "type": "form_483",
        "date": "2025-02-27T08:00:00.000Z",
        "title": "USFDA issues Form 483 with 3 observations to Gland Pharma's Sterile APIs unit - Indian Pharma Post",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues Form 483 with 3 observations to Gland Pharma's Sterile APIs unit  Indian Pharma Post",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757268365502-tlcb6a2ew",
        "type": "form_483",
        "date": "2025-02-25T08:00:00.000Z",
        "title": "USFDA issues Form 483 with 3 three observations to Gland Pharma's Visakhapatnam unit - The Economic Times",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues Form 483 with 3 three observations to Gland Pharma's Visakhapatnam unit  The Economic Times",
        "severity": 6
      },
      {
        "id": "a2a585573633e7365037fc75ba0dc5af",
        "type": "warning_letter",
        "date": "2024-05-01T07:00:00.000Z",
        "title": "FDA Issues Warning Letters to 14 Online Retailers for Selling Unauthorized E-Cigarettes - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPdU1HSlNGLXo1dVlyX01Ub1Bqam9zNUcxc2lncU9oOWVOdkE2WXhRT3Z4eEhRQWRUU0RxUTBWbEpSUmtkRFpkRmo5LXRUT1BVRmtNRG1mOF9wSE5aLVNQYkxPNjhDYy03d2JEdlRfZ240ZkVLUGpHbHMxTEx1TEN5NEprRGFmZXIzX2p6eTZjSnU1LWE0SXEwVS15MXZHcWcxSnRTVHdnLUwyZ25SS2F0Q1hUaEFMcWRYSWJIYlR5NUlYaE1LT1N2WGNn?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "FDA Issues Warning Letters to 14 Online Retailers for Selling Unauthorized E-Cigarettes  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-05-16T07:00:00.000Z"
      },
      {
        "id": "b49e67a45fe830b1fac48b17e465f3f2",
        "type": "warning_letter",
        "date": "2023-09-12T07:00:00.000Z",
        "title": "FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOc1VHNmJUR3dFN2lEMWtTeXF5eFduR1hpclZHd21OaHJVXzNKNFhucXdIS19LYng4cDNMMl9jd0pibXpleWFDc0Y4ZHJoSE1WUTBrdUYtcUpIZ1RjUU9iX3dqbEVNRDgxYWNjVDNXaHp4dk9HZmVYSjdrQUw1aUNqS0JYdmk3TnFKal9xa0NwY1gxLTNuN0xtdVJPN0ZPbzFOTTVJZVBpMEFvcFNjVVhBU2lwQUNCanVwRUE?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2023-09-27T07:00:00.000Z"
      }
    ],
    "products": [
      "Unapproved Eye"
    ],
    "facilities": [],
    "risk_score": null,
    "last_updated": "2025-09-08T12:30:00.257Z",
    "monitoring_since": "2025-09-07T18:06:05.525Z",
    "compliance_score": 90
  },
  {
    "name": "Novo plant acquired in Catalent buyout faces renewed FDA scrutiny with",
    "aliases": [
      "Novo plant acquired in Catalent buyout faces renewed FDA scrutiny with"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365499-668nmtwat",
        "type": "form_483",
        "date": "2025-08-22T07:00:00.000Z",
        "title": "Novo plant acquired in Catalent buyout faces renewed FDA scrutiny with Form 483: Stat - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNbHR0a3hLWml2bzhKdWl0RWszdXM3ZlQ4THY1LU05SkwzU24tbDdnaHpQeFFOSTRBemxUeFpPVWJWWG5PVWlpYmt2MFpfcXExdGk5MEVOSnFzVElGU2JJaXlEbHVGRUxiVXFvaFdPMzFrUnVMT2ZXc3FDNGJNUmpYTlh2NndnR0ZpTDJHN25TYy1PcHRPTnplVVpQc0ExTl94NHNsVHFUZzNzS2VEeVZDQ0Zjd1liNFlpdVpB?oc=5",
        "source": "Google News - Form 483",
        "summary": "Novo plant acquired in Catalent buyout faces renewed FDA scrutiny with Form 483: Stat  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.525Z",
    "monitoring_since": "2025-09-07T18:06:05.525Z"
  },
  {
    "name": "Capricor says FDA inspection brought",
    "aliases": [
      "Capricor says FDA inspection brought"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365499-2invj7cnn",
        "type": "form_483",
        "date": "2025-06-12T07:00:00.000Z",
        "title": "Capricor says FDA inspection brought Form 483 with several observations - Yahoo Finance",
        "link": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNODRhYzJFMkRaVEpPNHlJa2NFdl81TXdXc0Q5azc3UGJuQ1F6YnI1dnQtWk4xMEswYWNuMDR4VG12RlRpQW9UYmJhZ2ZYZ0dDaTdEaG9UYkxvUEFubzVDLXBhaVRHM0Zwd2tqTjctU1YxM1diaDRZRUZpN3lCMm95N042X1NnV2tpWmc?oc=5",
        "source": "Google News - Form 483",
        "summary": "Capricor says FDA inspection brought Form 483 with several observations  Yahoo Finance",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.526Z",
    "monitoring_since": "2025-09-07T18:06:05.526Z"
  },
  {
    "name": "Aurobindo",
    "aliases": [
      "Aurobindo"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365500-j7v37w21i",
        "type": "regulatory_news",
        "date": "2025-09-05T14:46:24.000Z",
        "title": "Aurobindo Pharma Under US FDA Scrutiny: Eight Observations Made - Devdiscourse",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Aurobindo Pharma Under US FDA Scrutiny: Eight Observations Made  Devdiscourse",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:06:05.526Z",
    "monitoring_since": "2025-09-07T18:06:05.526Z"
  },
  {
    "name": "A Shifting Trend In FDA",
    "aliases": [
      "A Shifting Trend In FDA"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365500-6ki1va0oy",
        "type": "form_483",
        "date": "2025-08-22T21:08:00.000Z",
        "title": "A Shifting Trend In FDA Form 483 Disclosure Obligations - Law360",
        "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNbjc4YTFOYWxET0dKcVZzWWdZd2dVWW55bzN5Q0djRlBYdk9Jd2JnQUl1M2lqalU2TVJ6d3RJbzcwMWthckc1OGFjejRuMEpJM0o0VTRFcVRnclVaVEFQeTJrQnFmUDFSMGROLUV1WmQtbllqVmJ6OW5rMFM1eHd1cHVkVWNfWVlPcVZNNGxVR0lld1RXLUxpTFluNlo2RU8wTFh5a19XTHF3YVVoVGFwRlhFS2stVW_SAXJBVV95cUxNN3ZYQlVIQVgtb2d3MEVsSmZyQmJqaFR2MktlbnF5MGpDVXByQUthaUNqRTFxUGgzZklraTdhLWRHai1vZ0FZS191OFZaWFlNQ1VBZWE2VW4xY1VhSnJ1QVR3SFR6YzgtSG16WThyaXFlbXc?oc=5",
        "source": "Google News - Form 483",
        "summary": "A Shifting Trend In FDA Form 483 Disclosure Obligations  Law360",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.526Z",
    "monitoring_since": "2025-09-07T18:06:05.526Z"
  },
  {
    "name": "The",
    "aliases": [
      "The"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757331001627-chfzsbr0j",
        "type": "regulatory_news",
        "date": "2024-12-05T08:00:00.000Z",
        "title": "Compliance issues at Granules India’s Gagillapur plant - The Times of India",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Compliance issues at Granules India’s Gagillapur plant  The Times of India",
        "severity": 5
      },
      {
        "id": "Google News - Form 483-1757268365500-aypxsdw9l",
        "type": "warning_letter",
        "date": "2025-08-12T07:00:00.000Z",
        "title": "The Warning Letter Wake-Up Call In 2025: What FDA Enforcement Is Really Telling Us - Med Device Online",
        "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPSWFHZV9SUHFlSUYzbS1VQVlBdURxT3dXR0k5QzlYOF9fM3VzOVZ1S250V290cE9FQ21Oa1liS2VWZkliVlVRYUJGcUhJZVFpOE1pWTNpVHZXLUg1TTJSaVU2QlBpWVpTUkZJQmVVN0NsSDBnbDNZLVJZRTRodDRWV1pLZ1E0WVZUNVhuQmdUTFpxd0QwSWd4Q3p2SWlXcm5XMWRMQzFKODBteDZMS0MtRWNLZFV3MXpW?oc=5",
        "source": "Google News - Form 483",
        "summary": "The Warning Letter Wake-Up Call In 2025: What FDA Enforcement Is Really Telling Us  Med Device Online",
        "severity": 8
      }
    ],
    "products": [
      "Online"
    ],
    "facilities": [],
    "risk_score": 12,
    "last_updated": "2025-09-08T11:30:01.639Z",
    "monitoring_since": "2025-09-07T18:06:05.526Z"
  },
  {
    "name": "Dexcom receives",
    "aliases": [
      "Dexcom receives"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365500-f96hq8fgi",
        "type": "warning_letter",
        "date": "2025-03-10T07:00:00.000Z",
        "title": "Dexcom receives warning letter based on FDA inspections of 2 plants - MedTech Dive",
        "link": "https://news.google.com/rss/articles/CBMidEFVX3lxTE1kZDFOS1BEdVY5c3h0X3NBWWxRdWhpUW1VTWRldDRSVXloWDAyUTdGUGZHcDZ0YlFhLVF6TF9vVndpaXVQR3gySWNKeXlFR0t3MG9mRU1uMzRQLXcxcngxbHkwZVZzV2FwekFnZ3JfeEdfeW1t?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dexcom receives warning letter based on FDA inspections of 2 plants  MedTech Dive",
        "severity": 8
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 8,
    "last_updated": "2025-09-07T18:06:05.527Z",
    "monitoring_since": "2025-09-07T18:06:05.527Z"
  },
  {
    "name": "FDA dings Piramal API plant with",
    "aliases": [
      "FDA dings Piramal API plant with"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365500-t8ecqnbqg",
        "type": "form_483",
        "date": "2025-02-26T08:00:00.000Z",
        "title": "FDA dings Piramal API plant with Form 483 detailing problems tied to quality control, equipment cleaning and more - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQUlJZeTVjUGkzaXhRcjcwamh2ZmxIVnFldjgxYVFTMS1TMGhBX2xTZFZQczRkMXhJYVFmNnlTWGpRSkZ2UEN2M1FWb0k4YnJpZERJVE1zQUVpSXVRbnViM1I0OVhTRW1hczdPTDJHMk5MV0VrSUVfWTRDRklkcUYtdEpYWE9HX0Z3V3FyWk9ZU3ZUbDU5bGJQMm5fM0oxcW9Bbm9aOEU3b1cweE80VzdMZFFFWnFES2dESGpN?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA dings Piramal API plant with Form 483 detailing problems tied to quality control, equipment cleaning and more  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.527Z",
    "monitoring_since": "2025-09-07T18:06:05.527Z"
  },
  {
    "name": "Raleigh plant of Aurobindo Pharma arm",
    "aliases": [
      "Raleigh plant of Aurobindo Pharma arm"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365500-ukv70jc0l",
        "type": "form_483",
        "date": "2025-04-11T07:00:00.000Z",
        "title": "USFDA issues Form 483 with 11 observations to Raleigh plant of Aurobindo Pharma arm - The Economic Times",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues Form 483 with 11 observations to Raleigh plant of Aurobindo Pharma arm  The Economic Times",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.528Z",
    "monitoring_since": "2025-09-07T18:06:05.528Z"
  },
  {
    "name": "Aurobindo gets",
    "aliases": [
      "Aurobindo gets"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365500-je74exb7i",
        "type": "form_483",
        "date": "2025-04-14T07:00:00.000Z",
        "title": "Aurobindo gets Form 483 scolding from FDA at North Carolina inhaler plant - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQdUNLZzdXMDZhVExlZlNXeldtWWk5RHpQTHpDQ3l5S1JqckFNNmtOUFpUX3NhU3RnNVB6ZFJ6S1U1VWItNkY5a3NuUFFLaXFENmx1WDByMmd3RkR3cmxGS0xBUkY0ZFNoLW85aG95ZlRDdUZqMzZBQUZTRC1DRGY1MzBMNVUzbFNJUmUzVXlTNmdHa29jTzVQd0lTNWtmQVdUb3FMRDdRNW9pZw?oc=5",
        "source": "Google News - Form 483",
        "summary": "Aurobindo gets Form 483 scolding from FDA at North Carolina inhaler plant  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.528Z",
    "monitoring_since": "2025-09-07T18:06:05.528Z"
  },
  {
    "name": "How to Avoid FDA",
    "aliases": [
      "How to Avoid FDA"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365500-arfoiwuu6",
        "type": "warning_letter",
        "date": "2025-06-17T07:00:00.000Z",
        "title": "How to Avoid FDA Warning Letters - Quality Digest",
        "link": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPUGFtcW8tNVkzQlRvell6cmZ6YU9IWlJYTkV4OHdINlcxTGRudlI1RnFLRWpXbjhYTU9fX25RbFd2UEp4dHRLcGQ2OXczNXE3eS1IWWhGMXVYRlZPS0xHOHZyVDYxQVdma19fSXBEYjhzSl9fSS1UR2dMLXJCREhReXlST2tBLTQxT2dDNGF4Z21SXy01UHZzN0R5Y05GcTI5a3Z3?oc=5",
        "source": "Google News - Form 483",
        "summary": "How to Avoid FDA Warning Letters  Quality Digest",
        "severity": 8
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 8,
    "last_updated": "2025-09-07T18:06:05.529Z",
    "monitoring_since": "2025-09-07T18:06:05.529Z"
  },
  {
    "name": "Dr Reddys Gets",
    "aliases": [
      "Dr Reddys Gets"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365501-2zrbyxuif",
        "type": "form_483",
        "date": "2025-07-18T07:00:00.000Z",
        "title": "Dr Reddys Gets Form 483 With Seven Observations From USFDA After Inspection At Andhra Unit - NDTV Profit",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dr Reddys Gets Form 483 With Seven Observations From USFDA After Inspection At Andhra Unit  NDTV Profit",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.529Z",
    "monitoring_since": "2025-09-07T18:06:05.529Z"
  },
  {
    "name": "Pithampur unit",
    "aliases": [
      "Pithampur unit"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365501-90497prvy",
        "type": "form_483",
        "date": "2025-07-18T07:00:00.000Z",
        "title": "Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2 - Indian Pharma Post",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2  Indian Pharma Post",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.529Z",
    "monitoring_since": "2025-09-07T18:06:05.529Z"
  },
  {
    "name": "Taylor Farms Colorado Springs Facility",
    "aliases": [
      "Taylor Farms Colorado Springs Facility"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365501-ej0ist6kt",
        "type": "form_483",
        "date": "2025-01-14T08:00:00.000Z",
        "title": "FDA Releases Form 483 to Taylor Farms Colorado Springs Facility - Food Safety Magazine",
        "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNTVlWEdUOXJncDJRT2dBZkc2WTZJaEwwVUVob0M1S1liRnZuN3F5U3VGQ3A1QWVSSTF5YklwUkpfbUwyNl9ZVW1wM2k3OGFUVDhaalVPVV9TRkJnenhuaDNFZS04NDdXMk5PT01rT2hXbXZGRWF3MjJYQm52blRJVDlBSk9PNldOM1BjOTBLNWl1bU1CU01XZDFfRUVEX1AxbktGbGpKVzladw?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA Releases Form 483 to Taylor Farms Colorado Springs Facility  Food Safety Magazine",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.530Z",
    "monitoring_since": "2025-09-07T18:06:05.530Z"
  },
  {
    "name": "Turbhe unit",
    "aliases": [
      "Turbhe unit"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365501-ezclgg66t",
        "type": "form_483",
        "date": "2025-02-19T08:00:00.000Z",
        "title": "Piramal Pharma declines after US FDA issues Form 483 with 6 observations to Turbhe unit - Business Standard",
        "link": "https://news.google.com/rss/articles/CBMi_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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Piramal Pharma declines after US FDA issues Form 483 with 6 observations to Turbhe unit  Business Standard",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.530Z",
    "monitoring_since": "2025-09-07T18:06:05.530Z"
  },
  {
    "name": "Japanese",
    "aliases": [
      "Japanese"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365502-7k5ouawze",
        "type": "form_483",
        "date": "2024-09-10T07:00:00.000Z",
        "title": "FDA issues Form 483s to Japanese, Indian drugmakers in wake of plant inspections - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNRFZDZXhpX2U1U2RjMHN1c1B2WGY1aVIyNExmOEo5TGE0VDlQTEJfcVVwejNza0JjdTN2Y1I3Qk1jQnZ4cW4zOTRRWjJDTWVjTTNXbl9JUXU3dW9wNGlYSklOR1BOcFlCT3JRLU5xWC1vTkFSSUw4cDJUbXdlUXVCTy05UG1mMzZEVll0LVQ4SnlSWjgwOHZNbV9KRDkyMjlRd1gtX09nRVhZZTA?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA issues Form 483s to Japanese, Indian drugmakers in wake of plant inspections  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.533Z",
    "monitoring_since": "2025-09-07T18:06:05.533Z"
  },
  {
    "name": "Bonthapally API unit 1",
    "aliases": [
      "Bonthapally API unit 1"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365503-pgohhjhrn",
        "type": "form_483",
        "date": "2025-06-23T07:00:00.000Z",
        "title": "Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1 - Indian Pharma Post",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1  Indian Pharma Post",
        "severity": 6
      },
      {
        "id": "Google News - Form 483-1757330791547-isvqba0gt",
        "type": "form_483",
        "date": "2025-06-23T07:00:00.000Z",
        "title": "Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1 - Indian Pharma Post",
        "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQdTBGaXNDb1ktYURkZ3FfQjhTbmxnTTRvVlN1aWVfWkZwaURpYmNXZjhmNk91c25ZZ0d0dkZLUDRVek9TVG9UbzE4WUFGaGROQkdJY0t6dW1HbkFkTVNLTUJscm9taU5FMU9NazhoZDBvYkhlcXZzQXFULWxualRsdWNJc2haZ1NXVnZDandCRWtfdkpQMEZzWEFadTJ6MGtqVzNMNEJSZWRJbTBpQ2FWeVlzLXF0ay1tMVpTcE1RMnA1TkdSN1RpYUFpVmM2X3NacnhMNzhYSjlKZw?oc=5",
        "source": "Google News - Form 483",
        "summary": "Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1  Indian Pharma Post",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 12,
    "last_updated": "2025-09-08T11:26:31.563Z",
    "monitoring_since": "2025-09-07T18:06:05.533Z"
  },
  {
    "name": "Compliance",
    "aliases": [
      "Compliance"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365504-hxuo8l8xc",
        "type": "regulatory_news",
        "date": "2024-12-05T08:00:00.000Z",
        "title": "Compliance issues at Granules India’s Gagillapur plant - Times of India",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Compliance issues at Granules India’s Gagillapur plant  Times of India",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:06:05.536Z",
    "monitoring_since": "2025-09-07T18:06:05.536Z"
  },
  {
    "name": "Apitoria Pharma gets",
    "aliases": [
      "Apitoria Pharma gets"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365504-r8hef5s5v",
        "type": "form_483",
        "date": "2024-10-01T07:00:00.000Z",
        "title": "Apitoria Pharma gets Form 483 with 10 observations from USFDA - Indian Pharma Post",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Apitoria Pharma gets Form 483 with 10 observations from USFDA  Indian Pharma Post",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.537Z",
    "monitoring_since": "2025-09-07T18:06:05.537Z"
  },
  {
    "name": "FDA slams trio of Indian drugmakers with",
    "aliases": [
      "FDA slams trio of Indian drugmakers with"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365505-zwvkzftwv",
        "type": "form_483",
        "date": "2024-01-03T08:00:00.000Z",
        "title": "FDA slams trio of Indian drugmakers with Form 483 filings after December inspections - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQVS16dVlxMldRdUJWNDJVRG1Sc3QydmtUSDQwOUFqamViaE5ROTBGRjhiNWR4cGpSSmVHVk05Z2I0bE1sQ1Fvd0dMb1pkZkVfOUR3V0pQRlpzdU11RldzN005a2R4aURwZ1BXQlF2cFY0M1h2VXNaUkl2VDl0ZDhXakotWW1DQlpqd054bGZla3F3bW1vMzlyYVFPY2VlMm5fNEp5SHljTkRQendxYWN4LXh3?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA slams trio of Indian drugmakers with Form 483 filings after December inspections  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.537Z",
    "monitoring_since": "2025-09-07T18:06:05.537Z"
  },
  {
    "name": "a Zydus plant",
    "aliases": [
      "a Zydus plant"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365505-egvvii3hu",
        "type": "form_483",
        "date": "2024-05-06T07:00:00.000Z",
        "title": "FDA flags 10 observations in another Form 483 for a Zydus plant - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxORTRTdjd0QmlpWWxyOE0xODZHdlVYanJtNkUybmVSTnhoZUtKVUM2ZFRSRXZzX1VmNE5JdHI3TmhZZTk0a193QTdyY0hKVTBSSjY3c21YQkpVTllDSXdUSGlfNV9OQVdXUjM5SU1icDFJWWtWM3BMQVMtSDVGaWtBQ1NkX2t0VXlLY2hzQjhkc25LNFFFcmZ0WnNTQ2JCQQ?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA flags 10 observations in another Form 483 for a Zydus plant  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.538Z",
    "monitoring_since": "2025-09-07T18:06:05.538Z"
  },
  {
    "name": "Alembic hit with",
    "aliases": [
      "Alembic hit with"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365505-3uojm0whz",
        "type": "form_483",
        "date": "2022-10-20T07:00:00.000Z",
        "title": "Alembic hit with Form 483, citing 4 observations at Panelav plant in India - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNVlBZemFGZmV0cjBwZ3ptbEUxbGhoSnJ6bmZESXNQS2xPR2FzOHNkMGNhT0IzLUZHSjc4eGx2SEg4QVV1N2hWNmswa0F4V0dEdkFLZjdfRFhTTDkyZ1BNWnh1cFgteG9BXzNJQXltUW5EbFQwMVR4MmNKNzdQMzZxT2xQTlk3WDdhSzk4MmRKZjUzcDJxcGhHbmRac1FHZE9RTW9hS3E3dURoT3Vwa2RZWEZLTGJXNVZYVnc?oc=5",
        "source": "Google News - Form 483",
        "summary": "Alembic hit with Form 483, citing 4 observations at Panelav plant in India  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [
      "India  Fierce, Ph"
    ],
    "risk_score": 0,
    "last_updated": "2025-09-07T18:06:05.538Z",
    "monitoring_since": "2025-09-07T18:06:05.538Z"
  },
  {
    "name": "FDA puts New Jersey drug ingredients maker Spectrum through the wringer in scathing",
    "aliases": [
      "FDA puts New Jersey drug ingredients maker Spectrum through the wringer in scathing"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365505-u5a68fx1x",
        "type": "form_483",
        "date": "2023-10-11T07:00:00.000Z",
        "title": "FDA puts New Jersey drug ingredients maker Spectrum through the wringer in scathing Form 483 - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQU0JFWlBzYnRLcHQ4VUNmRHFRbVFlSnBySzhHMllXTlRaelBMdVk1WkpHVGoya0VNWmVVMTFyN1huc2llaTBGZGFBaTJmRWZSTXRxZk10bmF4NGhjTzdESFNhQ2tWbVZhMlk0MjVLUHMwTUtQZ0xMbVB4TUFPRjVyWEF0OWtnRFZyTHVrQ1lYandpRVNvcnBRWjJUbjdXRzFPeVlzdEhrWGxLUFBKdUlqNl9Zbw?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA puts New Jersey drug ingredients maker Spectrum through the wringer in scathing Form 483  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [
      "ingredients maker"
    ],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.539Z",
    "monitoring_since": "2025-09-07T18:06:05.539Z"
  },
  {
    "name": "Piramal API plant in Michigan hit with FDA",
    "aliases": [
      "Piramal API plant in Michigan hit with FDA"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365505-vcy44svl7",
        "type": "form_483",
        "date": "2024-02-09T08:00:00.000Z",
        "title": "Piramal API plant in Michigan hit with FDA Form 483 write-up - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOa0NYYjJTU1JqZElDOEs4UmRJajRJSll4TE0weU5Sd2NHNnd3MUoxZW9ubHdUX19vX1dqZ2U5VHRmekpDYU52M2V4cEtzM1FQWnB0VkhRZjIwT01fM0hFcE1Cd1VzT0VLbXp6bklIb2RHVWFOMmlyZy1Ud1N1ek1SNXE3c3RFM2ptNkJDUUhkd3JMM3lad2c?oc=5",
        "source": "Google News - Form 483",
        "summary": "Piramal API plant in Michigan hit with FDA Form 483 write-up  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [
      "Michigan hit, wi"
    ],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.539Z",
    "monitoring_since": "2025-09-07T18:06:05.539Z"
  },
  {
    "name": "FDA hits Torrent Pharma with a",
    "aliases": [
      "FDA hits Torrent Pharma with a"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365505-9h89nyneu",
        "type": "form_483",
        "date": "2023-12-13T08:00:00.000Z",
        "title": "FDA hits Torrent Pharma with a Form 483, citing 5 observations - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQMVRfMW1odTNyNTBRMkR4bnFoZEs5WFdnNXJkX1RrSzMzNjVzVy1hWWRBcktWX1hMQXZnT2h5Ym5LUURrV0JrUGZXa2FPd3ZCc0VQYzhULTdabjZPaG9HdVd1NGQ0Q3RYU3lwN1J1dEFUdWVsU3BWNEszcDJ3VUtvamx1Y0RnRWFHaGVyT2c3amM5Vl83ak5rVWZZUktOTTRmZ0E?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA hits Torrent Pharma with a Form 483, citing 5 observations  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.539Z",
    "monitoring_since": "2025-09-07T18:06:05.539Z"
  },
  {
    "name": "API maker Global Calcium stung with",
    "aliases": [
      "API maker Global Calcium stung with"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268365505-a7v090ub1",
        "type": "form_483",
        "date": "2024-08-29T07:00:00.000Z",
        "title": "API maker Global Calcium stung with Form 483 filing after FDA inspection of Indian plant - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPOGVwY1NZaktiWnJxNDEySjlsRUQ4dS1ENW1maHF5dEN6V2syVjZQQzFVQ3BYclFHcDNGNlBuNmxGeFVRVk1wTjVfOG83Q3FzSUNtdDBJT0RBeUhnN0JaTm5UTXpmOFJEbmRoNlYwcHJvaG45TnJ6Y3RHaDZCeWZ5ZTJVM3hjcl9tVF8zTG1qWXNIUFJid1hObVhaQmFkNnowQ2VrTldtQnB4TVBBNXhuc0s0dw?oc=5",
        "source": "Google News - Form 483",
        "summary": "API maker Global Calcium stung with Form 483 filing after FDA inspection of Indian plant  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:06:05.539Z",
    "monitoring_since": "2025-09-07T18:06:05.539Z"
  },
  {
    "name": "SC",
    "aliases": [
      "SC"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757330791536-n4hz9mljw",
        "type": "regulatory_news",
        "date": "2024-12-18T08:00:00.000Z",
        "title": "FDA Issues CRL for SC Amivantamab BLA in EGFR+ NSCLC - Targeted Oncology",
        "link": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNNk9hR29fdnIza3V1UVpsUHN0djA2OFlQR01ReUx5U25DNnU4aXh4cTY1OHlsMEZocUxqMjI1LVl2UHpnbU85N010d2JMZ2pQYjM2ZnJzbWtRWEd1VE1NTk9BbUpNMzdUTk1rekxOeC1vanBlRGlLeTZ6RHdSTnczNmwyUU1IY3phWUY2Ug?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for SC Amivantamab BLA in EGFR+ NSCLC  Targeted Oncology",
        "severity": 5
      },
      {
        "id": "Google News - CRLs-1757268589620-avuj4izne",
        "type": "regulatory_news",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "FDA Issues CRL for SC Daratumumab Plus VRd for Transplant-Ineligible or -Deferred, Newly Diagnosed Multiple Myeloma - OncLive",
        "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSFVVVi1aUTFZUDJYMWF3U085ODluNXUyLVNSMENQODNUQ1p5UDU5U21uMVVZZzRwOU1acWxTVlpLWWxqRlEyejFUSlV6cmhnSi05N3F5anNfcldYNDl0al9HSkNmU3JxR1RCSEtWVGJZc1ZXeGIzWnpZT3hhQ3lXQXBRenpDVV9FTGV4S213MTJzWkRmZ05iLXZhM0dpWG5hTnJoOVNkeG5PcTVCcGtKNWcxeFJKQVpyaEJKMVpJUWR1RDA?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for SC Daratumumab Plus VRd for Transplant-Ineligible or -Deferred, Newly Diagnosed Multiple Myeloma  OncLive",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-08T11:26:31.557Z",
    "monitoring_since": "2025-09-07T18:09:49.627Z"
  },
  {
    "name": "the",
    "aliases": [
      "the"
    ],
    "violations": [
      {
        "id": "7a94f95e9c192198d15e1958c385c2ee",
        "type": "warning_letter",
        "date": "2025-08-12T07:00:00.000Z",
        "title": "The Warning Letter Wake-Up Call In 2025: What FDA Enforcement Is Really Telling Us - Med Device Online",
        "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPSWFHZV9SUHFlSUYzbS1VQVlBdURxT3dXR0k5QzlYOF9fM3VzOVZ1S250V290cE9FQ21Oa1liS2VWZkliVlVRYUJGcUhJZVFpOE1pWTNpVHZXLUg1TTJSaVU2QlBpWVpTUkZJQmVVN0NsSDBnbDNZLVJZRTRodDRWV1pLZ1E0WVZUNVhuQmdUTFpxd0QwSWd4Q3p2SWlXcm5XMWRMQzFKODBteDZMS0MtRWNLZFV3MXpW?oc=5",
        "source": "Google News - Form 483",
        "summary": "The Warning Letter Wake-Up Call In 2025: What FDA Enforcement Is Really Telling Us  Med Device Online",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-08-27T07:00:00.000Z"
      },
      {
        "id": "Google News - CRLs-1757268589620-xhwf9e176",
        "type": "regulatory_news",
        "date": "2025-07-16T07:00:00.000Z",
        "title": "FDA’s Published CRLs Deliver Insight Into the Drug Approval Process - OncLive",
        "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxONjFGNFRLejRrYVdvZk5DbWlVVWNZZlZmUlpoZFUwUnBxb2w2bC04LWwxeDlpbDcxZVFoTG50MTNVTEtkWFYyeHZzRHpNOTEyc0RkbHNLcU5qT1hCNFVKM3lwZ05IaXpsb2wwTXJCVEltbHc0LW5hbHdnWmtwLWFScW9WNmcxVHRQWVBPUGxDMnFSeW1OeC1vS0J3RVU?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA’s Published CRLs Deliver Insight Into the Drug Approval Process  OncLive",
        "severity": 5
      }
    ],
    "products": [
      "Approval Process"
    ],
    "facilities": [],
    "risk_score": null,
    "last_updated": "2025-09-08T12:30:00.846Z",
    "monitoring_since": "2025-09-07T18:09:49.627Z",
    "compliance_score": 80
  },
  {
    "name": "quality control",
    "aliases": [
      "quality control"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757268589558-cx9b6sfq7",
        "type": "form_483",
        "date": "2025-02-26T08:00:00.000Z",
        "title": "FDA dings Piramal API plant with Form 483 detailing problems tied to quality control, equipment cleaning and more - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQUlJZeTVjUGkzaXhRcjcwamh2ZmxIVnFldjgxYVFTMS1TMGhBX2xTZFZQczRkMXhJYVFmNnlTWGpRSkZ2UEN2M1FWb0k4YnJpZERJVE1zQUVpSXVRbnViM1I0OVhTRW1hczdPTDJHMk5MV0VrSUVfWTRDRklkcUYtdEpYWE9HX0Z3V3FyWk9ZU3ZUbDU5bGJQMm5fM0oxcW9Bbm9aOEU3b1cweE80VzdMZFFFWnFES2dESGpN?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA dings Piramal API plant with Form 483 detailing problems tied to quality control, equipment cleaning and more  Fierce Pharma",
        "severity": 6
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 6,
    "last_updated": "2025-09-07T18:09:49.635Z",
    "monitoring_since": "2025-09-07T18:09:49.635Z"
  },
  {
    "name": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application",
    "aliases": [
      "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757330720407-06njzkibd",
        "type": "crl",
        "date": "2025-07-14T07:00:00.000Z",
        "title": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application - geneonline.com",
        "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNT0w3NDFEdGlZTG51M1VtMnZhS21xSGlCNjA5U0dTeTZmS01iUDFHbGNvR3R4Szl2LThwcE1ETjVtTmFOUFQ5ZzFZQUdwa3ZSWEZGR2s5YnBOZzVkZHpaNVQ5MHlVRndUaHlCZXRjVXd4cnY0UmhxbVBycjVSX19oaVNKdnI5UmlLQWZwSUllLVBqQ3RvQTNHN3JCUzdxT3M5S0E0X2ZWVEJWelBZR3Fyek9XNUZhcGc?oc=5",
        "source": "Google News - CRLs",
        "summary": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application  geneonline.com",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-08T11:25:20.492Z",
    "monitoring_since": "2025-09-08T11:25:20.492Z"
  },
  {
    "name": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment",
    "aliases": [
      "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757330720407-4idh4osd5",
        "type": "crl",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment - geneonline.com",
        "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOTHUxdXliYVhkdDUzQTJtZFBuN3oxQzlub3FHaVVtclNlOHQtTHNSdWNPYzhiWXdST2V1VnlMSlBmLVdvSFEwLUsxMXk4WTgzUkE3N1ZSOUp6Mk1tTnZCb0tLY1RITmRoY3YzdS1PVkdBVW5nYkJFV1dDdVdFNzFhWFhSX2QzQ3gxa21vMEhSYWJfZWREMFZRckN2ZFJaTmNGZ01jNHhXc0NIaEZuM0RieV80dnFpZmFNM2J5MHRLODdJYnBJMi1EeDQ5aWs2ZUJ4WW80bkxUaw?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment  geneonline.com",
        "severity": 9
      }
    ],
    "products": [
      "geneonline"
    ],
    "facilities": [],
    "risk_score": 9,
    "last_updated": "2025-09-08T11:25:20.492Z",
    "monitoring_since": "2025-09-08T11:25:20.492Z"
  },
  {
    "name": "next month",
    "aliases": [
      "next month"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757330720407-zsm1dj2yf",
        "type": "regulatory_news",
        "date": "2025-08-21T07:00:00.000Z",
        "title": "FDA accelerates Stealth Bio's rare disease application with a decision slated for next month - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQcHpvelRIeWdVRzktOEN6bkRKOUhBaEo3YzJFMkpna1pReW1RSHJyeUFwX280RjhuaVU3QTFVMHhsQ3lXT09ucnB0NjI3M09Sa21OVVlhckh6M00waENmUnJoWWpDd0plODctYnVsOUozeTVEcVlTQkNxNEZpTzlhR0JsaW9RNmVSVFRIZ0hFS3NSZjdNNTZ4WE5GdmtBLUdrS0llQS02YmpFVWR3ZzlPU21IVEN2bFM0OWc?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA accelerates Stealth Bio's rare disease application with a decision slated for next month  Fierce Biotech",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-08T11:25:20.492Z",
    "monitoring_since": "2025-09-08T11:25:20.492Z"
  },
  {
    "name": "FDA Issues CRL for Extended Dosing of Eylea HD",
    "aliases": [
      "FDA Issues CRL for Extended Dosing of Eylea HD"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757330720407-m1mr4jqc7",
        "type": "regulatory_news",
        "date": "2025-04-21T07:00:00.000Z",
        "title": "FDA Issues CRL for Extended Dosing of Eylea HD - Managed Healthcare Executive",
        "link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPWHNrTUNjUEtXVDZaRzNzNi03UFZidUthM09WRzl1Q1B5d0dXTzFGeWJYel9BQVdTTlc2WnRjMW5CdVR5Y3AtVEZkeno0RkZIQXZrclB1RUdibUx2MUFMaGJBRENSb2d0bTF0UjN4aUdWdDhWZmg5NGtuZTA1MmsxUTRNamRRZHk4cF8xYTFtVFlQdF9HcVpraG1B?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for Extended Dosing of Eylea HD  Managed Healthcare Executive",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-08T11:25:20.492Z",
    "monitoring_since": "2025-09-08T11:25:20.492Z"
  },
  {
    "name": "FDA observations, leadership change keep Sun Pharma stock in spotlight on Monday",
    "aliases": [
      "FDA observations, leadership change keep Sun Pharma stock in spotlight on Monday"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757330720425-r9kboyuj8",
        "type": "regulatory_news",
        "date": "2025-06-16T07:00:00.000Z",
        "title": "FDA observations, leadership change keep Sun Pharma stock in spotlight on Monday - The New Indian Express",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA observations, leadership change keep Sun Pharma stock in spotlight on Monday  The New Indian Express",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-08T11:25:20.493Z",
    "monitoring_since": "2025-09-08T11:25:20.493Z"
  },
  {
    "name": "Amneal injectables plant slapped by FDA for sanitary issues, improper working conditions",
    "aliases": [
      "Amneal injectables plant slapped by FDA for sanitary issues, improper working conditions"
    ],
    "violations": [
      {
        "id": "Google News - Form 483-1757330720426-uufzkmhd7",
        "type": "regulatory_news",
        "date": "2023-02-28T08:00:00.000Z",
        "title": "Amneal injectables plant slapped by FDA for sanitary issues, improper working conditions - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNcW5fcmlCVDZ4Vkx1NU9mS2ViNTh3T1M4d0R2LXZwbTZRb3E1ajFJRlB6bndvOURkVnRRVVNsV0JxMkhucmhjaGxyaHV6TV90SGExRWUwc2xobGYybkk4bU9KWEQxRDJNbHV1UWlhVzNzdHgxdVRVdnM5cGx4V3JieFpFVmdJTjZtc3psZ1VTc0VmQ05ycTktZzlOcjR5SkpWT3Y4LVQ2SldMdU0?oc=5",
        "source": "Google News - Form 483",
        "summary": "Amneal injectables plant slapped by FDA for sanitary issues, improper working conditions  Fierce Pharma",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-08T11:25:20.494Z",
    "monitoring_since": "2025-09-08T11:25:20.494Z"
  },
  {
    "name": "Extended",
    "aliases": [
      "Extended"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757330791536-8lsfog1mq",
        "type": "regulatory_news",
        "date": "2025-04-21T07:00:00.000Z",
        "title": "FDA Issues CRL for Extended Dosing of Eylea HD - Managed Healthcare Executive",
        "link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPWHNrTUNjUEtXVDZaRzNzNi03UFZidUthM09WRzl1Q1B5d0dXTzFGeWJYel9BQVdTTlc2WnRjMW5CdVR5Y3AtVEZkeno0RkZIQXZrclB1RUdibUx2MUFMaGJBRENSb2d0bTF0UjN4aUdWdDhWZmg5NGtuZTA1MmsxUTRNamRRZHk4cF8xYTFtVFlQdF9HcVpraG1B?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Issues CRL for Extended Dosing of Eylea HD  Managed Healthcare Executive",
        "severity": 5
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-08T11:26:31.557Z",
    "monitoring_since": "2025-09-08T11:26:31.557Z"
  },
  {
    "name": "Outlook Therapeutics",
    "aliases": [
      "Outlook Therapeutics"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757331502599-4ithq34hh",
        "type": "crl",
        "date": "2025-08-28T07:00:00.000Z",
        "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
        "source": "Google News - CRLs",
        "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-08T11:38:22.746Z",
    "monitoring_since": "2025-09-08T11:38:22.746Z"
  },
  {
    "name": "PTC Therapeutics",
    "aliases": [
      "PTC Therapeutics"
    ],
    "violations": [
      {
        "id": "Google News - CRLs-1757331502601-jrxu3fodu",
        "type": "crl",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
        "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
        "source": "Google News - CRLs",
        "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
        "severity": 9
      }
    ],
    "products": [],
    "facilities": [],
    "risk_score": 0,
    "last_updated": "2025-09-08T11:38:22.747Z",
    "monitoring_since": "2025-09-08T11:38:22.747Z"
  },
  {
    "name": "Synergy Animal Products Inc 712860",
    "aliases": [
      "Synergy Animal Products Inc 712860"
    ],
    "violations": [
      {
        "id": "0199769461948d0192bbc00836e62916",
        "type": "warning_letter",
        "date": "2025-09-08T12:29:37.572Z",
        "title": "Synergy Animal Products, Inc.",
        "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/synergy-animal-products-inc-712860-07162025",
        "source": "FDA Website Direct",
        "summary": "",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-09-23T12:29:37.572Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 85,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.753Z",
    "first_seen": "2025-09-08T12:29:59.752Z"
  },
  {
    "name": "Wisconsin Pharmacal Company Llc 710329",
    "aliases": [
      "Wisconsin Pharmacal Company Llc 710329"
    ],
    "violations": [
      {
        "id": "f5b51bc414d8bd2ee0eb6aac0886621a",
        "type": "warning_letter",
        "date": "2025-09-08T12:29:37.651Z",
        "title": "Wisconsin Pharmacal Company, LLC",
        "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wisconsin-pharmacal-company-llc-710329-08222025",
        "source": "FDA Website Direct",
        "summary": "",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-09-23T12:29:37.651Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 85,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.760Z",
    "first_seen": "2025-09-08T12:29:59.759Z"
  },
  {
    "name": "Supply Center Usa 710859",
    "aliases": [
      "Supply Center Usa 710859"
    ],
    "violations": [
      {
        "id": "47ba1ccd22574ffd89868151c079a93d",
        "type": "warning_letter",
        "date": "2025-09-08T12:29:37.651Z",
        "title": "Supply Center USA",
        "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/supply-center-usa-710859-08252025",
        "source": "FDA Website Direct",
        "summary": "",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-09-23T12:29:37.651Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 85,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.764Z",
    "first_seen": "2025-09-08T12:29:59.764Z"
  },
  {
    "name": "Trew Balance 709880",
    "aliases": [
      "Trew Balance 709880"
    ],
    "violations": [
      {
        "id": "5c45c35f6b764896f0f24daf90cff064",
        "type": "warning_letter",
        "date": "2025-09-08T12:29:37.651Z",
        "title": "Trew Balance",
        "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/trew-balance-709880-08252025",
        "source": "FDA Website Direct",
        "summary": "",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-09-23T12:29:37.651Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 85,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.768Z",
    "first_seen": "2025-09-08T12:29:59.767Z"
  },
  {
    "name": "Homeopathic Educational Services Dba Homeopathic Family Medicine 708635",
    "aliases": [
      "Homeopathic Educational Services Dba Homeopathic Family Medicine 708635"
    ],
    "violations": [
      {
        "id": "7ce9d059413e2d09888a9ec2ae7244c5",
        "type": "warning_letter",
        "date": "2025-09-08T12:29:37.652Z",
        "title": "Homeopathic Educational Services dba Homeopathic Family Medicine",
        "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/homeopathic-educational-services-dba-homeopathic-family-medicine-708635-08252025",
        "source": "FDA Website Direct",
        "summary": "",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-09-23T12:29:37.652Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 85,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.772Z",
    "first_seen": "2025-09-08T12:29:59.772Z"
  },
  {
    "name": "Mel Honey Us 709535",
    "aliases": [
      "Mel Honey Us 709535"
    ],
    "violations": [
      {
        "id": "c68b145ff2d243d986000432fce74b19",
        "type": "warning_letter",
        "date": "2025-09-08T12:29:37.652Z",
        "title": "Mel Honey US",
        "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mel-honey-us-709535-08252025",
        "source": "FDA Website Direct",
        "summary": "",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-09-23T12:29:37.652Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 85,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.778Z",
    "first_seen": "2025-09-08T12:29:59.777Z"
  },
  {
    "name": "Green Vitality Dba Gr33n 710151",
    "aliases": [
      "Green Vitality Dba Gr33n 710151"
    ],
    "violations": [
      {
        "id": "5ecf0deb5d6ae3a660388d222db28971",
        "type": "warning_letter",
        "date": "2025-09-08T12:29:37.652Z",
        "title": "Green Vitality dba Gr33n",
        "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/green-vitality-dba-gr33n-710151-08252025",
        "source": "FDA Website Direct",
        "summary": "",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-09-23T12:29:37.652Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 85,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.782Z",
    "first_seen": "2025-09-08T12:29:59.782Z"
  },
  {
    "name": "My Holistic Honey Co Shenzhen Qanhai Wanb Express Supply Chain Co Ltd 712052",
    "aliases": [
      "My Holistic Honey Co Shenzhen Qanhai Wanb Express Supply Chain Co Ltd 712052"
    ],
    "violations": [
      {
        "id": "ce4b44ff262242a44abd75e7972c711b",
        "type": "warning_letter",
        "date": "2025-09-08T12:29:37.652Z",
        "title": "My Holistic Honey c/o Shenzhen Qanhai Wanb Express Supply Chain Co., LTD",
        "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/my-holistic-honey-co-shenzhen-qanhai-wanb-express-supply-chain-co-ltd-712052-08252025",
        "source": "FDA Website Direct",
        "summary": "",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-09-23T12:29:37.652Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 85,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.791Z",
    "first_seen": "2025-09-08T12:29:59.791Z"
  },
  {
    "name": "Life Enthusiast Co Op 709315",
    "aliases": [
      "Life Enthusiast Co Op 709315"
    ],
    "violations": [
      {
        "id": "bc560082ab5fecc9349df6b57b11c3be",
        "type": "warning_letter",
        "date": "2025-09-08T12:29:37.653Z",
        "title": "Life Enthusiast Co-op",
        "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/life-enthusiast-co-op-709315-08252025",
        "source": "FDA Website Direct",
        "summary": "",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-09-23T12:29:37.653Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 85,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.798Z",
    "first_seen": "2025-09-08T12:29:59.797Z"
  },
  {
    "name": "Amneal Pharmaceuticals Llc 709894",
    "aliases": [
      "Amneal Pharmaceuticals Llc 709894"
    ],
    "violations": [
      {
        "id": "b996e96f77eb78034c7103a61042f80d",
        "type": "warning_letter",
        "date": "2025-09-08T12:29:37.653Z",
        "title": "Amneal Pharmaceuticals, LLC",
        "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amneal-pharmaceuticals-llc-709894-08272025",
        "source": "FDA Website Direct",
        "summary": "",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-09-23T12:29:37.653Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 85,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.805Z",
    "first_seen": "2025-09-08T12:29:59.805Z"
  },
  {
    "name": "Breathing Circuit Set Recall",
    "aliases": [
      "Breathing Circuit Set Recall"
    ],
    "violations": [
      {
        "id": "4450b496f6d814d068afa18c72c81866",
        "type": "recall",
        "date": "2025-08-29T04:00:00.000Z",
        "title": "Breathing Circuit Set Recall: Hamilton Medical, Inc. Removes Coaxial Breathing Circuit Set Due to Possible Inner Blue Tube Cracks That May Impact Ventilation",
        "link": "http://www.fda.gov/medical-devices/medical-device-recalls/breathing-circuit-set-recall-hamilton-medical-inc-removes-coaxial-breathing-circuit-set-due-possible",
        "source": "FDA MedWatch Safety",
        "summary": "Hamilton Medical is recalling certain coaxial breathing sets due to a defect that may cause cracks in the inner tube, risking patient rebreathing exhaled gases.",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 90,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.837Z",
    "first_seen": "2025-09-08T12:29:59.837Z"
  },
  {
    "name": "Manual Resuscitator Recall",
    "aliases": [
      "Manual Resuscitator Recall"
    ],
    "violations": [
      {
        "id": "50a073de243c7b26446a5105be25e029",
        "type": "recall",
        "date": "2025-08-29T04:00:00.000Z",
        "title": "Manual Resuscitator Recall: Ambu Inc. Removes SPUR II Resuscitators Due to Blocked Manometer Port",
        "link": "http://www.fda.gov/medical-devices/medical-device-recalls/manual-resuscitator-recall-ambu-inc-removes-spur-ii-resuscitators-due-blocked-manometer-port",
        "source": "FDA MedWatch Safety",
        "summary": "A blocked manometer port on the Ambu SPUR II resuscitator may delay ventilation or cause barotrauma",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 90,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.844Z",
    "first_seen": "2025-09-08T12:29:59.844Z"
  },
  {
    "name": "Mobile Power Unit Ac Power Cord Recall",
    "aliases": [
      "Mobile Power Unit Ac Power Cord Recall"
    ],
    "violations": [
      {
        "id": "c843f869a4e395844f5d4f8df3881dd0",
        "type": "recall",
        "date": "2025-08-29T04:00:00.000Z",
        "title": "Mobile Power Unit AC Power Cord Recall: Abbott Medical Removes AC Power Cord Associated with HeartMate Mobile Power Unit (MPU) Due to Potential Risk of the Cord Not Locking into Place",
        "link": "http://www.fda.gov/medical-devices/medical-device-recalls/mobile-power-unit-ac-power-cord-recall-abbott-medical-removes-ac-power-cord-associated-heartmate",
        "source": "FDA MedWatch Safety",
        "summary": "Abbott Medical is removing power cords associated with the HeartMate Mobile Power Unit due to a potential risk of the cord not locking into place.",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 90,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.847Z",
    "first_seen": "2025-09-08T12:29:59.847Z"
  },
  {
    "name": "Applicator Recall",
    "aliases": [
      "Applicator Recall"
    ],
    "violations": [
      {
        "id": "bd4ff4908ce8be27cd6254fa49b4d916",
        "type": "recall",
        "date": "2025-08-28T04:00:00.000Z",
        "title": "Applicator Recall: Integra LifeSciences Removes Extended Tip Applicator Due to Potential Sterility and Endotoxin Concerns",
        "link": "http://www.fda.gov/medical-devices/medical-device-recalls/applicator-recall-integra-lifesciences-removes-extended-tip-applicator-due-potential-sterility-and",
        "source": "FDA MedWatch Safety",
        "summary": "Extended Tip Applicator recall due to potential non-sterile product and high endotoxin levels. May cause inflammation or infection if used.",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "and high",
      "sterile"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 90,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.849Z",
    "first_seen": "2025-09-08T12:29:59.849Z"
  },
  {
    "name": "Ventilator Correction",
    "aliases": [
      "Ventilator Correction"
    ],
    "violations": [
      {
        "id": "8b6fe76aa76597bf4343ee6f58cdee00",
        "type": "regulatory_news",
        "date": "2025-08-28T04:00:00.000Z",
        "title": "Ventilator Correction: Hamilton Medical AG Corrects HAMILTON-C6 Due to Risk of Ventilation Interruption from Defective Circuit Board",
        "link": "http://www.fda.gov/medical-devices/medical-device-recalls/ventilator-correction-hamilton-medical-ag-corrects-hamilton-c6-due-risk-ventilation-interruption",
        "source": "FDA MedWatch Safety",
        "summary": "Hamilton is repairing certain HAMILTON-C6 ventilators to replace a defective circuit board that can interrupt ventilation, risking serious injury or death.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.853Z",
    "first_seen": "2025-09-08T12:29:59.853Z"
  },
  {
    "name": "Infusion Pump Correction",
    "aliases": [
      "Infusion Pump Correction"
    ],
    "violations": [
      {
        "id": "e8c6b972292888717acf05fd87913a0c",
        "type": "regulatory_news",
        "date": "2025-08-28T04:00:00.000Z",
        "title": "Infusion Pump Correction: ICU Medical, Inc. Issues Correction for Plum Duo Infusion System Due to Software Possibly Resulting in Pump Becoming Unresponsive",
        "link": "http://www.fda.gov/medical-devices/medical-device-recalls/infusion-pump-correction-icu-medical-inc-issues-correction-plum-duo-infusion-system-due-software",
        "source": "FDA MedWatch Safety",
        "summary": "ICU Medical is correcting the Plum Duo infusion system due to pump software issues that may cause the device to become unresponsive.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.859Z",
    "first_seen": "2025-09-08T12:29:59.859Z"
  },
  {
    "name": "Follow Instructions For Safe Use Of Hyperbaric Oxygen Therapy Devices",
    "aliases": [
      "Follow Instructions For Safe Use Of Hyperbaric Oxygen Therapy Devices"
    ],
    "violations": [
      {
        "id": "aca013822d84114b9cd4bd8639f4aeed",
        "type": "regulatory_news",
        "date": "2025-08-25T04:00:00.000Z",
        "title": "Follow Instructions for Safe Use of Hyperbaric Oxygen Therapy Devices - Letter to Health Care Providers",
        "link": "http://www.fda.gov/medical-devices/letters-health-care-providers/follow-instructions-safe-use-hyperbaric-oxygen-therapy-devices-letter-health-care-providers",
        "source": "FDA MedWatch Safety",
        "summary": "The FDA is reminding the public about the safe use of hyperbaric oxygen therapy devices and is providing recommendations to help reduce potential risks.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "devices and"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.866Z",
    "first_seen": "2025-09-08T12:29:59.866Z"
  },
  {
    "name": "Vascular Stent Recall",
    "aliases": [
      "Vascular Stent Recall"
    ],
    "violations": [
      {
        "id": "46b191ad1b7c6f5ea01b4dd6f2597781",
        "type": "recall",
        "date": "2025-08-22T04:00:00.000Z",
        "title": "Vascular Stent Recall: Boston Scientific Removes Carotid WALLSTENT Monorail Endoprosthesis Due to Risk of Resistance During Device Withdrawal",
        "link": "http://www.fda.gov/medical-devices/medical-device-recalls/vascular-stent-recall-boston-scientific-removes-carotid-wallstent-monorail-endoprosthesis-due-risk",
        "source": "FDA MedWatch Safety",
        "summary": "Boston Scientific Removes Carotid WALLSTENT Monorail Endoprosthesis due to risk of resistance during device withdrawal",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 90,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.869Z",
    "first_seen": "2025-09-08T12:29:59.869Z"
  },
  {
    "name": "Early Alert",
    "aliases": [
      "Early Alert"
    ],
    "violations": [
      {
        "id": "2ecf7bb08cf9ae6e9a4e12c94a285de7",
        "type": "regulatory_news",
        "date": "2025-08-15T04:00:00.000Z",
        "title": "Early Alert: Infusion Pump Issue from Baxter",
        "link": "http://www.fda.gov/medical-devices/medical-device-recalls/early-alert-infusion-pump-issue-baxter-0",
        "source": "FDA MedWatch Safety",
        "summary": "Correction Issued for the Novum IQ Large Volume Pumps, Syringe Pumps",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "c7f62c9f24054d72b51e38dc14d07ebe",
        "type": "recall",
        "date": "2025-08-15T04:00:00.000Z",
        "title": "Early Alert: Cardiac Cannula Issue from Medtronic",
        "link": "http://www.fda.gov/medical-devices/medical-device-recalls/early-alert-cardiac-cannula-issue-medtronic",
        "source": "FDA MedWatch Safety",
        "summary": "This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 85,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.880Z",
    "first_seen": "2025-09-08T12:29:59.875Z"
  },
  {
    "name": "Tandem Diabetes Care Issues Voluntary Medical Device Correction For Select T",
    "aliases": [
      "Tandem Diabetes Care Issues Voluntary Medical Device Correction For Select T"
    ],
    "violations": [
      {
        "id": "dc35df5f6bef8dd8d226ead5e9a9724e",
        "type": "regulatory_news",
        "date": "2025-08-12T04:00:00.000Z",
        "title": "Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps ",
        "link": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/tandem-diabetes-care-issues-voluntary-medical-device-correction-select-tslim-x2-insulin-pumps",
        "source": "FDA MedWatch Safety",
        "summary": "SAN DIEGO – August 7, 2025 – Tandem Diabetes Care, Inc. (Nasdaq: TNDM) has announced a voluntary medical device correction for select t:slim X2 insulin pumps to address a potential speaker-related issue that can trigger an error resulting in a discontinuation of insulin delivery.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.886Z",
    "first_seen": "2025-09-08T12:29:59.886Z"
  },
  {
    "name": "Breathing System Filters Recall",
    "aliases": [
      "Breathing System Filters Recall"
    ],
    "violations": [
      {
        "id": "95c3464f9225855f101dd752b7b8b5d2",
        "type": "recall",
        "date": "2025-08-12T04:00:00.000Z",
        "title": "Breathing System Filters Recall: Draeger Removes SafeStar and TwinStar Filters Due to Risk of Misleading Carbon Dioxide (CO₂) Readings",
        "link": "http://www.fda.gov/medical-devices/medical-device-recalls/breathing-system-filters-recall-draeger-removes-safestar-and-twinstar-filters-due-risk-misleading",
        "source": "FDA MedWatch Safety",
        "summary": "Draeger recalls SafeStar, TwinStar filters due to misleading carbon dioxide waveforms, may result in unnecessary treatment, potentially causing harm or death",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "in unnecessary"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 90,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.890Z",
    "first_seen": "2025-09-08T12:29:59.890Z"
  },
  {
    "name": "Dg Gel Card 125445 125449 125450",
    "aliases": [
      "Dg Gel Card 125445 125449 125450"
    ],
    "violations": [
      {
        "id": "b79fc75e1d2e57dbef4082a44b1fe9d6",
        "type": "regulatory_news",
        "date": "2025-09-02T20:12:24.000Z",
        "title": "DG Gel Card 125445, 125449, 125450 - 125457 ",
        "link": "http://www.fda.gov/vaccines-blood-biologics/dg-gel-card-125445-125449-125450-125457",
        "source": "FDA CBER Biologics",
        "summary": "Product approval information is for:\n•DG Gel 8 AB (x4) card is for the determination of human A and B antigen on the surface of red blood cells in four separate blood samples. For use with the DG Gel System. For in vitro diagnostic use.\n•DG Gel 8 A/B/D card is for the determination of human A, B and",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "approval information"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.914Z",
    "first_seen": "2025-09-08T12:29:59.914Z"
  },
  {
    "name": "Reported",
    "aliases": [
      "Reported"
    ],
    "violations": [
      {
        "id": "f14bcc9ae96bfd0f418d6ee55579b9b1",
        "type": "regulatory_news",
        "date": "2025-09-04T10:33:01.000Z",
        "title": "STAT+: Sanofi shares drop after disappointing trial results",
        "link": "https://www.statnews.com/2025/09/04/sanofi-amlitelimab-immunology-atopic-dermatitis-eczema/?utm_campaign=rss",
        "source": "STAT News Pharma",
        "summary": "Sanofi shares slid Thursday after the company reported underwhelming results from a closely watched trial in the skin condition atopic dermatitis.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.923Z",
    "first_seen": "2025-09-08T12:29:59.923Z"
  },
  {
    "name": "Driving Precision Oncology Development",
    "aliases": [
      "Driving Precision Oncology Development"
    ],
    "violations": [
      {
        "id": "6b385e4facae64588a6fd28c098a4deb",
        "type": "regulatory_news",
        "date": "2025-09-08T09:00:00.000Z",
        "title": "Driving precision oncology development: Integrated biomarker testing solutions that deliver impact",
        "link": "https://www.biopharmadive.com/spons/driving-precision-oncology-development-integrated-biomarker-testing-soluti/759259/",
        "source": "BioPharma Dive",
        "summary": "Driving precision oncology with integrated biomarker testing that delivers results.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.945Z",
    "first_seen": "2025-09-08T12:29:59.945Z"
  },
  {
    "name": "Harnessing The Power Of Ai To Detect Attr",
    "aliases": [
      "Harnessing The Power Of Ai To Detect Attr"
    ],
    "violations": [
      {
        "id": "ea2b3aa571a23cb1728df97a3b696b96",
        "type": "regulatory_news",
        "date": "2025-09-08T09:00:00.000Z",
        "title": "Harnessing the power of AI to detect ATTR-CM",
        "link": "https://www.biopharmadive.com/spons/harnessing-the-power-of-ai-to-detect-attr-cm/758919/",
        "source": "BioPharma Dive",
        "summary": "From accelerating drug discovery to improving disease detection, AI is transforming the way we understand and manage health.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "discovery to",
      "From accelerating"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.950Z",
    "first_seen": "2025-09-08T12:29:59.950Z"
  },
  {
    "name": "Fda Outlines New Review Pathway For Drugs Treating Ultra",
    "aliases": [
      "Fda Outlines New Review Pathway For Drugs Treating Ultra"
    ],
    "violations": [
      {
        "id": "c98eb57ae319d46200598019d6274022",
        "type": "regulatory_news",
        "date": "2025-09-04T16:20:32.000Z",
        "title": "FDA outlines new review pathway for drugs treating ultra-rare diseases",
        "link": "https://www.biopharmadive.com/news/fda-rare-disease-evidence-principles-drug-reviews/759237/",
        "source": "BioPharma Dive",
        "summary": "The agency's two main review offices will work together to flexibly evaluate medicines for serious conditions that affect fewer than 1,000 people in the U.S.",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.961Z",
    "first_seen": "2025-09-08T12:29:59.961Z"
  },
  {
    "name": "Rapport Reveals Promising Open",
    "aliases": [
      "Rapport Reveals Promising Open"
    ],
    "violations": [
      {
        "id": "e13e85e23d5a3067da73c66dcddf573b",
        "type": "regulatory_news",
        "date": "2025-09-08T10:00:35.000Z",
        "title": "Rapport reveals promising open-label study data for epilepsy pill, heads to Phase 3",
        "link": "https://endpoints.news/rapport-reports-promising-open-label-study-data-for-epilepsy-pill-heads-to-phase-3/",
        "source": "Endpoints News",
        "summary": "Rapport Therapeutics has posted topline mid-stage data indicating that its epilepsy pill can cut seizure frequency.\r\n\r\n The biotech's shares {$RAPP} jumped around 130% premarket after the results were announced Monday.  ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.971Z",
    "first_seen": "2025-09-08T12:29:59.971Z"
  },
  {
    "name": "Fda Chief Says Agency Is Probing Covid",
    "aliases": [
      "Fda Chief Says Agency Is Probing Covid"
    ],
    "violations": [
      {
        "id": "ce6dccec125008254b70ab0bef5163d3",
        "type": "regulatory_news",
        "date": "2025-09-05T19:30:39.000Z",
        "title": "FDA chief says agency is probing Covid-19 vaccine deaths in kids",
        "link": "https://endpoints.news/fda-chief-says-agency-is-probing-covid-19-vaccine-deaths-in-kids/",
        "source": "Endpoints News",
        "summary": "FDA chief Marty Makary said the agency is investigating whether the Covid-19 vaccines caused any deaths in kids, building on the government's monthslong effort to question the safety of the products.\r\n\r\n In",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "of the"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.987Z",
    "first_seen": "2025-09-08T12:29:59.987Z"
  },
  {
    "name": "Regenxbio Trumpets One",
    "aliases": [
      "Regenxbio Trumpets One"
    ],
    "violations": [
      {
        "id": "08b75703a4d1307f785855e0c35410e3",
        "type": "regulatory_news",
        "date": "2025-09-05T14:14:19.000Z",
        "title": "Regenxbio trumpets one-year data for Hunter syndrome gene therapy after FDA extended its review",
        "link": "https://endpoints.news/regenxbio-trumpets-one-year-data-for-hunter-syndrome-gene-therapy-after-fda-extended-its-review/",
        "source": "Endpoints News",
        "summary": "Regenxbio released new data that it hopes will get its gene therapy for a rare disease across the regulatory finish line.\r\n\r\n The company said Friday that in a one-year look at 13 patients with Hunter ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "for a"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:29:59.993Z",
    "first_seen": "2025-09-08T12:29:59.993Z"
  },
  {
    "name": "Japan",
    "aliases": [
      "Japan"
    ],
    "violations": [
      {
        "id": "affada21f9ccb6e8fc23424042f84a48",
        "type": "regulatory_news",
        "date": "2025-09-05T13:34:38.000Z",
        "title": "Japan-made generic drugs will be exempt from Trump’s reciprocal tariff ",
        "link": "https://endpoints.news/japan-made-generic-drugs-will-be-exempt-from-trumps-reciprocal-tariff/",
        "source": "Endpoints News",
        "summary": "Generic pharmaceuticals from Japan will be exempt from a 15% reciprocal tariff on the country’s exports to the US, President Donald Trump said in a new executive order.\r\n\r\n The order marks ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.002Z",
    "first_seen": "2025-09-08T12:30:00.002Z"
  },
  {
    "name": "Who Adds Glp",
    "aliases": [
      "Who Adds Glp"
    ],
    "violations": [
      {
        "id": "799cc119a0e185acaa20c78eeecd93e2",
        "type": "regulatory_news",
        "date": "2025-09-05T13:00:18.000Z",
        "title": "WHO adds GLP-1s to essential medicines list",
        "link": "https://endpoints.news/who-adds-glp-1s-to-essential-medicines-list/",
        "source": "Endpoints News",
        "summary": "For the first time, the World Health Organization has added GLP-1s and GLP-1/GIP dual agonists to its registry of essential medicines that should be available “at all times” in functioning health ...",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.005Z",
    "first_seen": "2025-09-08T12:30:00.005Z"
  },
  {
    "name": "Fda Moves To Publish Drug Rejection Letters In Real Time, Releases New Batch Including Replimune's High",
    "aliases": [
      "Fda Moves To Publish Drug Rejection Letters In Real Time, Releases New Batch Including Replimune's High"
    ],
    "violations": [
      {
        "id": "aad818941eb03cdeb718b865c492479b",
        "type": "regulatory_news",
        "date": "2025-09-04T17:45:28.000Z",
        "title": "FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPcThla0JHRzd3ci1sWnVhWUluMmliSWFmeEFQUTdNaG5WREpNU2xQZHRURGNuSFV6ZEpzaTNObDZ2OWkxWHVJS3Bvd2xmS3dfNjhiNUEyb2NKMU9CQUJTd21EbVFiVWFzak5oM1ZCcllXVnNDN2VqNHoxVlFDbDc0TkJQanpNd2FQbDZsZXoyVnhvZTdMRUZiQ1FqX1BqXy1JTkJaZ2FHeUZqdEc5V1RDRWFpVUhmRlN5ZFNhQ2o5ZEJxRkF0?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub  Fierce Biotech",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "rejection letters",
      "to publish"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.035Z",
    "first_seen": "2025-09-08T12:30:00.035Z"
  },
  {
    "name": "Fda Flags Issues In Review Of Telix's Pet Diagnostic Agent For Kidney Cancer",
    "aliases": [
      "Fda Flags Issues In Review Of Telix's Pet Diagnostic Agent For Kidney Cancer"
    ],
    "violations": [
      {
        "id": "6f3b3389e7bbb647e0fcde2caee9f835",
        "type": "regulatory_news",
        "date": "2025-08-28T07:00:00.000Z",
        "title": "FDA flags issues in review of Telix's PET diagnostic agent for kidney cancer - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOem9yN0VVLVNDdDBEbHdycExVVDhVZ1BEZk1JWEJ2X0xab1FFWTdLRXZHWmZYdVdMUWRlWUdwU1RTM21LbnU0bXIwVTBnYkdWSVZPVGJmVDNSc1MwNVhhNkR2SjdzTW03UXk0LTJVVUFnMVcyX1NqUG1BUjV5NjR6VTdPNkZPeHZiYnYtRHpOZm9uS3RtWV9URlIzdVBkMHVkVUYzVXZn?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA flags issues in review of Telix's PET diagnostic agent for kidney cancer  Fierce Biotech",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.043Z",
    "first_seen": "2025-09-08T12:30:00.043Z"
  },
  {
    "name": "Fda Rejects Roche's Columvi In Earlier Diffuse Large B",
    "aliases": [
      "Fda Rejects Roche's Columvi In Earlier Diffuse Large B"
    ],
    "violations": [
      {
        "id": "92eff871929cd512e734197a26c6ccda",
        "type": "regulatory_news",
        "date": "2025-07-18T07:00:00.000Z",
        "title": "FDA rejects Roche's Columvi in earlier diffuse large B-cell lymphoma, citing lackluster US data - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNMmFYcDkzS3FTbVRYZXozazVQU1N6RzAwMjctaXhfQ3Ywak82N25TRmtpRllTbnNQN1ZPaHJELWxRRXNmTF9neFNjTVhRUW9JX2ZNVU9RVFRSRG9VVlpwUk5yMTQ1QkVfM1RpdGxESlVXRm9uOXN0VkdEbmxfeDFNYUdrYk5haU1wSzhwRHlkZVZXajFJUDJoaXJId0NManFmNlB1QVFPMU9uZUV5ZHgyQVZyTHIwcGViZnYyNzF3YnQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA rejects Roche's Columvi in earlier diffuse large B-cell lymphoma, citing lackluster US data  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.057Z",
    "first_seen": "2025-09-08T12:30:00.057Z"
  },
  {
    "name": "Us Fda Declines To Approve Ptc Therapeutics' Oral Drug For Rare Genetic Disorder",
    "aliases": [
      "Us Fda Declines To Approve Ptc Therapeutics' Oral Drug For Rare Genetic Disorder"
    ],
    "violations": [
      {
        "id": "89f42bedc0f5d86e150a3c3a6e2746e6",
        "type": "regulatory_news",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder - Reuters",
        "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOMng1aGpKMmxPMmxqSVN5X3ZFWG5YY19QemEta0l3MVRsMjZBLWE0RWVzQ1hVNTUwTzdaWl9zN0ZUQl85Njg0SVhNZFMwc0dLWGdWaHdFMnJMb0dtTGYyU2plN1lBUWVOTUZHVXBjblRtNVZ4eHRvcldkV3Z5SXdEWTJtX1FjTTMtVkxXelRTdF8xMzV1djN4bV9ON2hBME5CME5aT3IzVXlJdkFaQ2JaVTR4eGw1RmtzY2dnVDYyenhoMGxqcnVtQTNBRG1jYlNWZ0gzV2dKT2dNN2M5?oc=5",
        "source": "Google News - CRLs",
        "summary": "US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder  Reuters",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "for rare",
      "oral"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.063Z",
    "first_seen": "2025-09-08T12:30:00.063Z"
  },
  {
    "name": "Fda Denies Approval For Replimune's Advanced Melanoma Treatment",
    "aliases": [
      "Fda Denies Approval For Replimune's Advanced Melanoma Treatment"
    ],
    "violations": [
      {
        "id": "ccde09e7313efbbc6fb5800220c2c7c3",
        "type": "regulatory_news",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection - Stock Titan",
        "link": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQOXNhTTNEQmVOU18zeVU2RllzaHNkcEN6Q0hLbjdyd2trczhvQXR6QUQtbUc1VkRIVGoyV1YzSWZVNWJrajBENzlvRFNKTHlkMHFyRVpLbGp2N2ZUTFJlT0lyV0tOMlRsalZ3Smp6YjZvUnc2TWhzblVNMzZFcUVFQU5iUmhNSU9ER0NGT1NPZmZ3eGZ2bnZCOG10ZzlGd2E5VnR5TE5qRVAweS1pdUJJNFEtOEQ5QQ?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection  Stock Titan",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Advanced Melanoma"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.070Z",
    "first_seen": "2025-09-08T12:30:00.070Z"
  },
  {
    "name": "Fda Rejection Derails Ptc Therapeutics' Rare Disease Hopeful",
    "aliases": [
      "Fda Rejection Derails Ptc Therapeutics' Rare Disease Hopeful"
    ],
    "violations": [
      {
        "id": "83939944d336ef2d96e54c2906f0b0e4",
        "type": "regulatory_news",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "FDA rejection derails PTC Therapeutics' rare disease hopeful - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOek1NVEJyLTYtTGwzcHlZUzRyUWF6eUtIclc5Zl9vQ1dnUjNvODVrb0xVSmxLbjRZRXB6bklCRlpoOXRCTExIVlU2d3dFcTJMV0xiUzNZeWluaGpab1BjYy12YUFuNjZPeXktTm1jNi1VUmNjQ2xFX3pYeGZVcE5UQ2NfYThRTDBoS2JqNUM4ODFhNmRsOEtSaU1ZdnY?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA rejection derails PTC Therapeutics' rare disease hopeful  Fierce Biotech",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.076Z",
    "first_seen": "2025-09-08T12:30:00.076Z"
  },
  {
    "name": "Replimune's Shares Crater As Fda Rejects Melanoma Drug",
    "aliases": [
      "Replimune's Shares Crater As Fda Rejects Melanoma Drug"
    ],
    "violations": [
      {
        "id": "a04ea06351d3b1fd47223778d0500f64",
        "type": "regulatory_news",
        "date": "2025-07-22T07:00:00.000Z",
        "title": "Replimune's shares crater as FDA rejects melanoma drug - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQSE43LURlWlUxWlJNQmlQRWkyOXdxc3ZkZE9SNVJjZW9xOGtBZjFCRzlwVGxUTS1oNWdpZi1XNzF3eDJKU05zQ3ZibEZwa1ZHRDJFV1JWQ0lzaUtDc1NWTmFpZzJEVDBvNG1YRzhYV2pXR3lrb2NNenA1NEphMVJCbUd6cFN3U0NiVmV6VUVBSFpxNjB6NEtLWldkb3Ytak9JOE1PNlpR?oc=5",
        "source": "Google News - CRLs",
        "summary": "Replimune's shares crater as FDA rejects melanoma drug  Fierce Biotech",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Fierce Biotech",
      "rejects melanoma"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.081Z",
    "first_seen": "2025-09-08T12:30:00.081Z"
  },
  {
    "name": "Fda Accelerates Stealth Bio's Rare Disease Application With A Decision Slated For Next Month",
    "aliases": [
      "Fda Accelerates Stealth Bio's Rare Disease Application With A Decision Slated For Next Month"
    ],
    "violations": [
      {
        "id": "d1c728dd3ec3b4e4e2913f3b85159120",
        "type": "regulatory_news",
        "date": "2025-08-21T07:00:00.000Z",
        "title": "FDA accelerates Stealth Bio's rare disease application with a decision slated for next month - Fierce Biotech",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQcHpvelRIeWdVRzktOEN6bkRKOUhBaEo3YzJFMkpna1pReW1RSHJyeUFwX280RjhuaVU3QTFVMHhsQ3lXT09ucnB0NjI3M09Sa21OVVlhckh6M00waENmUnJoWWpDd0plODctYnVsOUozeTVEcVlTQkNxNEZpTzlhR0JsaW9RNmVSVFRIZ0hFS3NSZjdNNTZ4WE5GdmtBLUdrS0llQS02YmpFVWR3ZzlPU21IVEN2bFM0OWc?oc=5",
        "source": "Google News - CRLs",
        "summary": "FDA accelerates Stealth Bio's rare disease application with a decision slated for next month  Fierce Biotech",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.088Z",
    "first_seen": "2025-09-08T12:30:00.088Z"
  },
  {
    "name": "Empower Clinic Services, Llc Dba Empower",
    "aliases": [
      "Empower Clinic Services, Llc Dba Empower"
    ],
    "violations": [
      {
        "id": "0f678751c51a1d39b0eba7b2ab2c6205",
        "type": "regulatory_news",
        "date": "2025-04-22T07:00:00.000Z",
        "title": "Empower Clinic Services, LLC dba Empower Pharma - 700962 - 04/02/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOQktfRFZKbndkaTc0S292a0tlcmFWQ2JnX0M0bV8zakJpdW50bjFpVDlnTHZYQl9jV3dGLVhPZjY3X3lMVjM3a3VLbkxzMTJob3FCY1hLOHFNRGhZb24ySVhad2MyZlR6eHFRcXBxZjRpaEFlTnBTbmRyR2FVd1p4OWJJNmlONGtPOWo3aGIwZzlMYTRyalMxZXBGVjA0THE4NnNGWWlGOGlxelNlRUVIMGtrZmpOQmNjMUs5bXFzbkN6LWF3LU5QN3FNUmE5Y3JRcHdLbFk5bHdYRWUzeUlLTXdGdnBOazdlU01LYXA1ckxESEU?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Empower Clinic Services, LLC dba Empower Pharma - 700962 - 04/02/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.093Z",
    "first_seen": "2025-09-08T12:30:00.093Z"
  },
  {
    "name": "U.s. Food And Drug Administration",
    "aliases": [
      "U.s. Food And Drug Administration"
    ],
    "violations": [
      {
        "id": "0eadb1f343c44d41a8bd523ab71ef6d2",
        "type": "regulatory_news",
        "date": "2006-06-24T04:02:30.000Z",
        "title": "U.S. Food and Drug Administration - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiN0FVX3lxTE91QXlENXNrYWFFQjFEUHhWUjFwMURtMXROY0FtV0FZcUdsSmhiVmJwaVdqWTh4Zm8?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "U.S. Food and Drug Administration  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Administration  fda",
      "Food and"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.097Z",
    "first_seen": "2025-09-08T12:30:00.097Z"
  },
  {
    "name": "Amneal",
    "aliases": [
      "Amneal"
    ],
    "violations": [
      {
        "id": "07f4a3a68d6fb8a2c52e6c85ebaea27e",
        "type": "regulatory_news",
        "date": "2025-08-27T07:00:00.000Z",
        "title": "Amneal Pharmaceuticals, LLC - 709894 - 08/27/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNd1YwdlVFRDRBZDdQQXVscFdMYjA5bjJHZ2JTaGVQUkl2QTR1dVlKTWJpWnZvRHo0bnJZWWc4X2xTaGpiOG9Yb29STlQ2RkRxZHNEQXluWnEtaTg1OWw2LTlia1BDQjNhcl9KTFVoeE1HVHA3YmpkOW9DU0ZrdEs2bEJCRlVaTjE3UFE2N0lpOUlNdHZEbTh6MDhDakM4VlBhTUI1Vkk1Yk9TMXZxRnJfdWl0WklyNXhsN3c0a3RTZDVqcUc2WktUV0Y1cW1MR0EwMHBzMnFuSVQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Amneal Pharmaceuticals, LLC - 709894 - 08/27/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.100Z",
    "first_seen": "2025-09-08T12:30:00.100Z"
  },
  {
    "name": "Aspartame And Other Sweeteners In Food",
    "aliases": [
      "Aspartame And Other Sweeteners In Food"
    ],
    "violations": [
      {
        "id": "5f124ddb8133123a175706ff86f26a43",
        "type": "regulatory_news",
        "date": "2025-02-27T08:00:00.000Z",
        "title": "Aspartame and Other Sweeteners in Food - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOYzhOdjVRa3VqTmlQWkRfN1pCVGR4OHMxTk9mXzRvNlFsbEpJMFB6U2p0emx6SG41RGh0UGpUMXZPN01zNHZXZlFacm5FUGhpT2hNdElYdTVVSTFhWW90MjVEU2hnTVd4RlBGTlh0cFZvS0VRM2ZvUWFRdHFERkd0Z1BLOThTcVZRR182X2dB?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Aspartame and Other Sweeteners in Food  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.105Z",
    "first_seen": "2025-09-08T12:30:00.105Z"
  },
  {
    "name": "Fda Advises Public Not To Eat, Sell, Or Serve Certain Imported Frozen Shrimp From An Indonesian Firm",
    "aliases": [
      "Fda Advises Public Not To Eat, Sell, Or Serve Certain Imported Frozen Shrimp From An Indonesian Firm"
    ],
    "violations": [
      {
        "id": "14322a22a85d952ec7a89e84de851fd5",
        "type": "regulatory_news",
        "date": "2025-08-19T13:10:09.000Z",
        "title": "FDA Advises Public Not to Eat, Sell, or Serve Certain Imported Frozen Shrimp from an Indonesian Firm - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPZzByTDhrNk1RNzlzVXZ4ZnhZLU82UjdGX2tKazFkbk1aUTNVN3BPbzBuYnItRnFYSkN5RFk5WV9KOTRmNktIV2RuWW9mMjhQSWYzUDNzcUdEaGpESElPajN0SWx4dzZoOU9sTWQxRE5xYTZqVV9ydHBiT3FuSVJBS2EwYU15Q2hxbVFrU040Nl81U3FlZ05MNUptX0gzc1lldkFtZGVmWE5BOGNQYnoyUHFQcERza05OVFdMR29xdlV2ajhFem1NNzZqckpmN19xR2FPU0FKWGxIcFdibnltRU9LYw?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "FDA Advises Public Not to Eat, Sell, or Serve Certain Imported Frozen Shrimp from an Indonesian Firm  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.111Z",
    "first_seen": "2025-09-08T12:30:00.111Z"
  },
  {
    "name": "Fda Notifies Pet Owners That Tests Show H5n1 Contamination In Certain Lots Of Rawr Raw Cat Food Chicken Eats",
    "aliases": [
      "Fda Notifies Pet Owners That Tests Show H5n1 Contamination In Certain Lots Of Rawr Raw Cat Food Chicken Eats"
    ],
    "violations": [
      {
        "id": "678b33fd446936dbb5e07475b040c153",
        "type": "regulatory_news",
        "date": "2025-09-03T00:00:00.000Z",
        "title": "FDA Notifies Pet Owners That Tests Show H5N1 Contamination in Certain Lots of RAWR Raw Cat Food Chicken Eats - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNMDRQQUdMUWcxVTJ2b1Ffa20zcHFxTlZrdXdrSW5PaU9IVlNFVUtBSkxVTWg4dFNPa2ZIUzA4ZVQwYldHRjRnQjlIRmpxd25LVmhqbGJZVXBnVXN0Rl80YUxiNWhyaFUyTjhvTDZUQzY5YVh6aDM5a2psNzB3Ym9VaHF5YmZNbDN0SDJ1NlprbHc2T2VTSHJ0VHUyS3pMWXBrZ2g2TFlnanBGYXMycEJkVE5xUE9LWERWdmFqSEFQblViOWhwbDZSVzJhbVZBZ1hUM3dTMUg0d0N3MzVKbFczTg?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "FDA Notifies Pet Owners That Tests Show H5N1 Contamination in Certain Lots of RAWR Raw Cat Food Chicken Eats  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.115Z",
    "first_seen": "2025-09-08T12:30:00.115Z"
  },
  {
    "name": "Vaccines Licensed For Use In The Us",
    "aliases": [
      "Vaccines Licensed For Use In The Us"
    ],
    "violations": [
      {
        "id": "ea669f463c49a72570e0f1088310c2f3",
        "type": "regulatory_news",
        "date": "2025-05-31T07:00:00.000Z",
        "title": "Vaccines Licensed for Use in the US - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPLXNYWFc5ZTl0U0NhMUdKa0JRVkl6S0FqYi1MNmlnWXZQeXJKTGhaZkpCOXJXLXVsdWFqby04aVIyUUcxUnBjNHRvWjRyenFEc05uSWNIQUFGdDV6eTNialBTSDBMOV9jcjJqLU1oSkhtVGsydjdXcTRuNmdPcWNIRGloeV8tNGJibEVnU3g0S3loQUU?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Vaccines Licensed for Use in the US  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.118Z",
    "first_seen": "2025-09-08T12:30:00.118Z"
  },
  {
    "name": "Dermarite Industries Expands Voluntary Nationwide Recall Due To Potential Burkholderia Cepacia Contamination",
    "aliases": [
      "Dermarite Industries Expands Voluntary Nationwide Recall Due To Potential Burkholderia Cepacia Contamination"
    ],
    "violations": [
      {
        "id": "a128dc9f20b87272114e8fb50d4bc239",
        "type": "recall",
        "date": "2025-08-27T07:00:00.000Z",
        "title": "DermaRite Industries Expands Voluntary Nationwide Recall Due to Potential Burkholderia cepacia Contamination - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQcDlSOTY4Tk13MVJyQTJkQjdrM041bmU5OXdPOHhLY0llbkNUc0lSMUVOYmpRRWFRTjFLLUV2UFlaNERZTEdSVnpVZ0tyNnA2WXI2eVJHQ0JUMWNydzdPTU5ZU0Q3UUZ2aDIwbTQ3QUFyRVZzLVJDZDZiMG55TFJUZ1VOdndZN2l6R3BBaUJLb25CZ0NVcVNzSHQyWGlvbW82RDI1OUduY0pLRlhhMVprMnpLVHAzNy0wUXpwSG9Vdl8xc081QlZqZnlCSzdIM21ZOHEzMFZsU3lZVUFkT2l4V3hXX3lqeE9INEtjb09zMnU?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "DermaRite Industries Expands Voluntary Nationwide Recall Due to Potential Burkholderia cepacia Contamination  fda.gov",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 90,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.124Z",
    "first_seen": "2025-09-08T12:30:00.124Z"
  },
  {
    "name": "Ice Cream Factory Issues Allergy Alert On Undeclared Almond In Vanilla G.nutt Ice Cream",
    "aliases": [
      "Ice Cream Factory Issues Allergy Alert On Undeclared Almond In Vanilla G.nutt Ice Cream"
    ],
    "violations": [
      {
        "id": "339ea7a7bb51dec6c04a9fdf2af05bcc",
        "type": "regulatory_news",
        "date": "2025-09-02T04:00:00.000Z",
        "title": "Ice Cream Factory Issues Allergy Alert on Undeclared Almond in Vanilla G.Nutt Ice Cream - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxONGJZQThsbEIyT2ZtQ0JVcW8tWVhMcFY4cUFjQUkyZ1NPVDVPVlNTQ1g3M0MtcFBLQTMyRTQtSzFraERHNFVkak1fVTZlQ0VDT0E5b1pxTEJJdjc5djB3WU1yc2xuMXdKeXRHQktYT0lhUFBHN2lqMi1YQUV2azRWb2pHdGtHdDl4THRTdzQwbmxRRDN2RWIyTWR6QWFrWWNPd29vb0xsMl9EVXY1cnlpWGRzZVgxSDZxQTNoWDVSVXZ2c2J4Ujkxdlg5Z2Y1cG1fWjM3cUhKbk1UajFROVlyMHhR?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Ice Cream Factory Issues Allergy Alert on Undeclared Almond in Vanilla G.Nutt Ice Cream  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.130Z",
    "first_seen": "2025-09-08T12:30:00.129Z"
  },
  {
    "name": "Updated Release",
    "aliases": [
      "Updated Release"
    ],
    "violations": [
      {
        "id": "22c496ff0ac88067b708359565b4d724",
        "type": "recall",
        "date": "2025-08-29T07:00:00.000Z",
        "title": "Updated Release: Southwind Foods, LLC Recalls Frozen Shrimp Because of Possible Health Risk - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPQ0NVa0VaRVNTMGN2QTNsSkNMQjN2TUloeV8wdjN0a2hlUTQxemdVTldFY0txMTU3a2VyYzYtbEEyNmpoSjVYYzItYVJwbWFpYlV6ZmFlUUxMZWN5WkE5QXo5dWVxOENCNUZxcVI5aVNhVHBuQnNIbGtZNU54THNaX1VvUTJxZ1h4ejVxeWVGWmxNQTdUZEh3azRLRnFrdjFIWDhFOHRIOUtjZlhaZWJld2RtOEpXTHFCUkNSMlUzaFdjYUs4dXBHVnhERGlTR0NFX2hCU1MzS0xZcFhaYmZPQVhjaTl3a29JTHc?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Updated Release: Southwind Foods, LLC Recalls Frozen Shrimp Because of Possible Health Risk  fda.gov",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 90,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.132Z",
    "first_seen": "2025-09-08T12:30:00.132Z"
  },
  {
    "name": "Covid",
    "aliases": [
      "Covid"
    ],
    "violations": [
      {
        "id": "37cb7d59decd3aa1a08fa40f8e168d39",
        "type": "regulatory_news",
        "date": "2025-05-22T07:00:00.000Z",
        "title": "COVID-19 Vaccines (2025-2026 Formula) for Use in the United States Beginning in Fall 2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPZGhnRU9jcmJIOHN2YW90RzNTRHVnZUlvSWd0R2RHXzVYbXdybjhkeVBKYU4yMHFWRTA2bTNhMHRkdWxTYnJrOGJtcVFrSWNqSFdqWGVCUUgyS2t0MDg3RVI0N1o2Mm9Fd241VGcxRXRFWXJDbHBZR25wTG5PTnJfbUd5TDJTTDMtelhaV3ZmR0tFamNxMm40X3lpRUxqVTFNcF9OUzlEam51OGpHcWJpTmVmVUZhVmJ0LXlqUllJVDJTb1BidkhXV1haUkt3SDdTaGpJ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "COVID-19 Vaccines (2025-2026 Formula) for Use in the United States Beginning in Fall 2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.136Z",
    "first_seen": "2025-09-08T12:30:00.136Z"
  },
  {
    "name": "Nicotine Pouch Products Authorized By The Fda",
    "aliases": [
      "Nicotine Pouch Products Authorized By The Fda"
    ],
    "violations": [
      {
        "id": "7bd8c3e9a55470eafe85d18785308c99",
        "type": "regulatory_news",
        "date": "2025-08-19T07:00:00.000Z",
        "title": "Nicotine Pouch Products Authorized by the FDA - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQUkJHN21oX1A5VFZxUkRrQjdPWDJXakFKNTFFMllJZk5TNVRhSTdab0tZMTZYVlJXRWpDZE13dzE0T3pCSXhpR2hXQUFIZHp0NVRDVUZ3NkFZNjBVYmViYXMwTXBnaDlMckJYNHNqbVdhbjhPblJNS05HLVR1ZGNYeUZGSDU2ekJwREJFZG5MakJHLWhyZkdPSVZjOHdYc1BTMERybXJ5N0RNTjZMZGRIeGQwTQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Nicotine Pouch Products Authorized by the FDA  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Nicotine Pouch"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.142Z",
    "first_seen": "2025-09-08T12:30:00.142Z"
  },
  {
    "name": "Fda Approves Expanded Use Of Vonvendi For Von Willebrand Disease, Including For Certain Uses For Children",
    "aliases": [
      "Fda Approves Expanded Use Of Vonvendi For Von Willebrand Disease, Including For Certain Uses For Children"
    ],
    "violations": [
      {
        "id": "262d50ae9edac28bc98392efff184b3c",
        "type": "regulatory_news",
        "date": "2025-09-05T04:00:00.000Z",
        "title": "FDA Approves Expanded Use of Vonvendi for von Willebrand Disease, Including for Certain Uses for Children - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNc25Xa2plaGx0Z0dkRlpVdm9mRjlnbmdQY25SMVYtcnN4RXJ3N21ISHRvajRDZzhXWFUyVl90UjJ6LW5XOS1WVlUydENiTFVUeEVjYy1ranE2Mk1DVkxqbm9SNGpTR2M4dEU0S3NnRi1hUk9Nemk0WDlLMFYzSU5oN2NfZmp2cFpDbUtYM0F0N2wyNnFIdUxFZDZka01xZndoMjF5UzlOdm16eHNTaDl4QXZTQW5Dc2JHVEw0S3ZLUFdMRFh4XzdDUkVsMGFudTFQcnRLc3FXNlE?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "FDA Approves Expanded Use of Vonvendi for von Willebrand Disease, Including for Certain Uses for Children  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.146Z",
    "first_seen": "2025-09-08T12:30:00.146Z"
  },
  {
    "name": "At",
    "aliases": [
      "At"
    ],
    "violations": [
      {
        "id": "20ca8ad5e836ffd7418ae6347b863e63",
        "type": "regulatory_news",
        "date": "2025-06-03T07:00:00.000Z",
        "title": "At-Home COVID-19 Diagnostic Tests: Frequently Asked Questions - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQQWxlR3o5YlZ0UExNc2NjVURMTHd2TDlveFloQjdzOGo2Y0ZMY3pHeF9laU93Z2lkT1QtOTVzWDd1dWhDMkgyX1R6VVRkMk1HQkUtWVZ1STJYTmtJZUU5TkNyeEEyVGNYWFBCb2JiUXdEMWJpZ1hvdTVRZDgwWklWbnVfN1paTmRjU2VVbkxWTnFfMkpKMkJScWlVVTZRWEdMRDJuUnlYdVg4ZUhsd2k3VVVMT0lGemlPcjhHQzhsbnZOaVM1N1FVSm5TRU55bTA?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "At-Home COVID-19 Diagnostic Tests: Frequently Asked Questions  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "6c1eeffa56d84d6fa6ef88a44c354767",
        "type": "regulatory_news",
        "date": "2025-06-03T07:00:00.000Z",
        "title": "At-Home OTC COVID-19 Diagnostic Tests - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNSXVTMmVqQ0Q2M2VPck0zdmxVTGh0czY1X25ZRlNYclRhNnNsMlh2YnBVRWlIT19ZdmZ4Tm5Yekp4bm43VWczM0w3YmQxUDFfcWRTUE1uTlhiQzYweUk0S0IxNG1CQnRSWkV0U2tMOHk3RGtwSnZvTWpXZnFiSkFpZkcxVGEtWjRneDdid0NrMjFIaDlLV1hYb09FRHVWYUw4VDRmM1ZVeWNGTVA1WUliaA?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "At-Home OTC COVID-19 Diagnostic Tests  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 26,
    "compliance_score": 90,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.153Z",
    "first_seen": "2025-09-08T12:30:00.148Z"
  },
  {
    "name": "Drop Off Unwanted Or Unused Medicines At A Drug Take",
    "aliases": [
      "Drop Off Unwanted Or Unused Medicines At A Drug Take"
    ],
    "violations": [
      {
        "id": "a84253c170006e62081df34833170430",
        "type": "regulatory_news",
        "date": "2025-04-16T07:00:00.000Z",
        "title": "Drop off unwanted or unused medicines at a drug take-back location - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOTkxGUFB2bDUwbEs2dnRRbHcxbjNDWlJhMlpfdFB3R1hYazl3ODc0RUY5dm1pRU82My1nUkd6OTkxdkNTWXRRVTcwTFlKXzhCNDJtbUNQMEp0UV9RVzFLSUJuQ05VbkxjODh6STN4SGc1RDlmcGNjSjVXTW9lbE1KblNSOU9xblFHblBOSm5R?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Drop off unwanted or unused medicines at a drug take-back location  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "take",
      "at a"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.151Z",
    "first_seen": "2025-09-08T12:30:00.151Z"
  },
  {
    "name": "Fda Advances Rare Disease Drug Development With New Evidence Principles",
    "aliases": [
      "Fda Advances Rare Disease Drug Development With New Evidence Principles"
    ],
    "violations": [
      {
        "id": "bc7605b566d88381538e458c4ad8f4c5",
        "type": "regulatory_news",
        "date": "2025-09-03T04:00:00.000Z",
        "title": "FDA Advances Rare Disease Drug Development with New Evidence Principles - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNLUJvcWxQNGxCelFnUTZDUHlZUlRETmduY0VPRWxtLTFQa2lKWm5ZOWxFaFJTOWsxYzlncTV5dUpjSzd6dGtYU1YyMmdTYllia3pDRHJoX2NqbEMzTHBFY0dZMnk0V0RtZzc5ZmtKMzhlUjk5STVvcXBwb3owRHdyR29VOFZoVDlLamNxVFRraElGX2RqTkFoQlhITGpBMm9IVWlKMVlwMEQyd3pCSVVVRGV1YzZGYUtSeXc?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "FDA Advances Rare Disease Drug Development with New Evidence Principles  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Development with",
      "Rare Disease"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.158Z",
    "first_seen": "2025-09-08T12:30:00.158Z"
  },
  {
    "name": "Pouches Can Be Dangerous To Kids If They Use, Touch, Chew On, Eat Them",
    "aliases": [
      "Pouches Can Be Dangerous To Kids If They Use, Touch, Chew On, Eat Them"
    ],
    "violations": [
      {
        "id": "e32c3e910cbe3351e1db63c6146e68c5",
        "type": "regulatory_news",
        "date": "2025-09-02T09:00:00.000Z",
        "title": "Pouches Can Be Dangerous to Kids if They Use, Touch, Chew on, Eat Them - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQnpTT28tYmlkcklyRXV3WDVWV1BOclNiVHQtcDEzcTEyYXNSbWZuUU9FbnlpSGNBa2RJNGJVTzl4YnVITlNRNDJrdUVUbmNPX2owVnduN0JRX0hZY3FobnVDcU1aeXpSUkozVGhFYmo1RTM3aW9MZE00bEI3czl4SGlCWG1fNjJrWGdkWUdsN3JpN0E2Ni0zSk5UV2dnTndrOXJ5OE5vWGdXRGswN21NQVRWYVAyY2ZCUFBVN1JTZWpzZw?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Pouches Can Be Dangerous to Kids if They Use, Touch, Chew on, Eat Them  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.163Z",
    "first_seen": "2025-09-08T12:30:00.162Z"
  },
  {
    "name": "Fda Approves Drug To Treat Adults With Persistent Or Chronic Immune Thrombocytopenia",
    "aliases": [
      "Fda Approves Drug To Treat Adults With Persistent Or Chronic Immune Thrombocytopenia"
    ],
    "violations": [
      {
        "id": "c2a3b43276b1af789b46e89792542acb",
        "type": "regulatory_news",
        "date": "2025-09-02T00:00:00.000Z",
        "title": "FDA Approves Drug to Treat Adults with Persistent or Chronic Immune Thrombocytopenia - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPTGg2SkV3VFQ0V2dLOV81Tjk3bW1hUGFDMlpSRng3X2dPM2VYZFhLa2s1Uml1UXppX0J3QTU5SmcxTDhKOEdlQTN6c2Y4M3NrM3gxaFZNU1ZJcF9CdjlEMUZqZmEzcUZxZ1FKdDVBU0ZpR3VmaEtYLV9INHB3dDFNd1hTdkRyZTFKSzUzUDd1ZF9CVUZ1X3M5RWlQUU1FTEpPMVZBeGp5S2ZxX0plMGNmUkZHTVlSZHlqcHNXT1VQSHY4SEtC?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "FDA Approves Drug to Treat Adults with Persistent or Chronic Immune Thrombocytopenia  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "to Treat",
      "FDA Approves"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.169Z",
    "first_seen": "2025-09-08T12:30:00.169Z"
  },
  {
    "name": "Spilling The Beans",
    "aliases": [
      "Spilling The Beans"
    ],
    "violations": [
      {
        "id": "0fadeaf3285e3b5c2266a626d0bc2499",
        "type": "regulatory_news",
        "date": "2024-08-28T07:00:00.000Z",
        "title": "Spilling the Beans: How Much Caffeine is Too Much? - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNc2lvMnJIenNxdUtYYUlXNnctQk9fZ1NaOTNfMGxDZDBuT3lLbDM4ZVlTUnBKMHJkekh1YkdhVmFpQU1ILXR3Ykx6UU5mSjJfOTZDdDNRZ2FwSERPOXN3R2s1aTFwQ2NmMDFEczZRclUwS2VwdmJCMFAwakg0WGdhZXMtZFd4RHd4NUlDRDRMNUdMQQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Spilling the Beans: How Much Caffeine is Too Much?  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.171Z",
    "first_seen": "2025-09-08T12:30:00.171Z"
  },
  {
    "name": "Reduced Or Waived Medical Device User Fees",
    "aliases": [
      "Reduced Or Waived Medical Device User Fees"
    ],
    "violations": [
      {
        "id": "fc25553378aef6ee81e2b6c652e6922d",
        "type": "regulatory_news",
        "date": "2025-07-30T07:00:00.000Z",
        "title": "Reduced or Waived Medical Device User Fees: Small Business Determination (SBD) Program - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMikgJBVV95cUxQWGdjZk9td0VZMkwzRFFTNHQ3NFlIYUJwcjhwM2NZbmtLUHNyVnMxWGtyOEh6ZHJHbkNiUXBsMTczWmVvWnZkSHFXZHFLa24ySWFjeFphdzZISFYxLWw4MXhqLTZTcWl4Q0VkNFh5S0t4bTltYXRMMGU2d0hJeXh5VUN5ZTdvaVdHNWp0RFlBOWJ0UHFPSW1xSVN0V3laOFotUThsUy1wdWp1VzFjc212LWQtVmEwVGVKTS1MQUY4RmV3aHNoZ0tmUHlnSnFYTzhsS1laOThKWEQxTFRteE5DMlBfUTRjSldZWEpONVhMUGxDWUQ0Tmo3Y3EtaVZBQmV4TEFPazV1dWhnS2tTeXdYWkp3?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Reduced or Waived Medical Device User Fees: Small Business Determination (SBD) Program  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.175Z",
    "first_seen": "2025-09-08T12:30:00.174Z"
  },
  {
    "name": "Assessing Novel Efficacy Endpoints In Ophthalmologic Rare Disease Drug And Biologics Development",
    "aliases": [
      "Assessing Novel Efficacy Endpoints In Ophthalmologic Rare Disease Drug And Biologics Development"
    ],
    "violations": [
      {
        "id": "a71806a76f9d20c31c26051f0c6bbf68",
        "type": "regulatory_news",
        "date": "2025-09-02T00:00:00.000Z",
        "title": "Assessing Novel Efficacy Endpoints in Ophthalmologic Rare Disease Drug and Biologics Development - 09/17/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQb1BsYnRhWHlLQ2F6VWFSWGxnUFFXZHVBVThreVdSVW44XzVqZ3JCb1l4dEw4Ymlhc1dYM2hLQ25DNGV1SWRJZERwLTJjN3ZTOWprTTktQlAxSEdMeHhqSkdFMGVuOHl3TnJTZ0gyQnZFSmtYTThUaHhOZW9HeDFuc0ZBOUxPVkQyUHU1STNNUXdRUFJBS1VORnhGTGZkWTRpZGJBbkxpT054VDFLVWU2UlU3ZlU2ckRsb2JuVTdKd3puRjJ6V21KVVMyc1I0dXhSZUZQQzJPX2tWR0E?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Assessing Novel Efficacy Endpoints in Ophthalmologic Rare Disease Drug and Biologics Development - 09/17/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "and Biologics",
      "Rare Disease"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.180Z",
    "first_seen": "2025-09-08T12:30:00.180Z"
  },
  {
    "name": "Fda Purplebook",
    "aliases": [
      "Fda Purplebook"
    ],
    "violations": [
      {
        "id": "e0835e0b9c6cadd231656d7b9a1b8627",
        "type": "regulatory_news",
        "date": "2020-02-24T18:02:48.000Z",
        "title": "FDA Purplebook - FDA Purplebook (.gov)",
        "link": "https://news.google.com/rss/articles/CBMiSEFVX3lxTFBBN0o5aVRWVFBSaDdMS0xjUnFlRG9mdVljN1VKdEV4WHpjVFFrNDJOVkJtaU43NVV3UksyNXg5Mzhqb2l6ckstMg?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "FDA Purplebook  FDA Purplebook (.gov)",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.183Z",
    "first_seen": "2025-09-08T12:30:00.183Z"
  },
  {
    "name": "New Manna Food",
    "aliases": [
      "New Manna Food"
    ],
    "violations": [
      {
        "id": "30597efc911445c86a8ac9f488ecda56",
        "type": "regulatory_news",
        "date": "2023-07-11T07:00:00.000Z",
        "title": "New Manna Food - 652996 - 06/12/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQaHMyQVJJTXNiMDJIWEZXbl9IWFptdTFzOGoxdGJsaFZqZkRCYzJTMjhpaG1fakNjVWNFRWU4QU1kR1ppU196dVAxNGdNRmdyaTQ1Q2Z2d2daV2hITGpXY0d3TVhXZXB6ZUVlZHh6MDJ5OTVxWnRvN25fSWF5XzJidU5DaWJtS3JtX0xJbEx3eHFEeWpPWjI4NUtMdVV2SEZVZHBMdmxRQ1N1bmVMcGNJckxmM0FEMnJOY3BuTTRmV3V3Q0c1UjhqUQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "New Manna Food - 652996 - 06/12/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.185Z",
    "first_seen": "2025-09-08T12:30:00.185Z"
  },
  {
    "name": "Rontis Hellas S.a",
    "aliases": [
      "Rontis Hellas S.a"
    ],
    "violations": [
      {
        "id": "b42f16f4d6201bb5432f6bb39d8dac45",
        "type": "regulatory_news",
        "date": "2024-10-28T07:00:00.000Z",
        "title": "Rontis Hellas S.A. - 695160 - 10/28/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPbG1Fd3VGRGpVR0trRXNtQjM3Um9hU2FtdDQ1U3dHQmJqSWJPU0w4WC1KNlA4cWkwaDBIOTFMTnFuUlZsaEExUXM1MDAxdTlQZ1dMMGNiMHR3S2dVTFllRU1iY0hTb1Y5SDZDelA0N05BM0JGcHZsMnhUZEVSeUFpakZMeTg4VFIzLXF5OEdTalRIbndmaEQza3oxWDNSeE50cXpSUHpxNWpUNm5UQk5qbGlHbUYyZzFLRTltTUM2S0dXU0JpOFJQY1ZLMA?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Rontis Hellas S.A. - 695160 - 10/28/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.187Z",
    "first_seen": "2025-09-08T12:30:00.187Z"
  },
  {
    "name": "Cutera",
    "aliases": [
      "Cutera"
    ],
    "violations": [
      {
        "id": "89d1128bc689b959d806ca89b74146b9",
        "type": "regulatory_news",
        "date": "2024-10-18T07:00:00.000Z",
        "title": "Cutera, Inc. - 639552 - 03/09/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQek9qNEhCT3BQNDE2SDBpUzJRcF9sOGQ4ZnhhRml1MjhFZlhaWVY0aHE1bUJBS0FnVld5Rml0OXdwSGNBMFBPTGJxN3RYdjI5R3ZiVFhXVzlxaWpvNlNtVWpfS0JmTkdLOFV2bUt2RFdDSU12OFJYSkxQNTdKT2hCczVfSTRpSnhsanVOaFBoU2drMVE1aFlxUVJzb1h1amxsUXJZODItUk5IR3BQcWpVOUZwVndHQzY1TXRTeWVJQ0JtZXc?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Cutera, Inc. - 639552 - 03/09/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.188Z",
    "first_seen": "2025-09-08T12:30:00.188Z"
  },
  {
    "name": "Shree Jaya Laboratories Pvt.",
    "aliases": [
      "Shree Jaya Laboratories Pvt."
    ],
    "violations": [
      {
        "id": "b45221f4d6c567547bc15c59e14d106e",
        "type": "regulatory_news",
        "date": "2025-02-28T08:00:00.000Z",
        "title": "Shree Jaya Laboratories PVT. LTD. - 698690 - 02/28/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOQUxXaXQzSHdCRGlJeDJfVWpuNVNuY2REOEF5Q1Blc1pZTlBqamZEelFfdXh4RUNCUTFrM1k4S2tnT3JJMjJJVkdyYzRwMGxOX0NvQVNXLTFiWjZCWEhkQjZEcjlyZkhfNkhXZnFrRG5aaktmblE3OGM1ZEZlTW43WUVCNWs1UnV0d2F2bTVhOWlxOWEtM2tiS3otNHJLRUhrcEU4QWNyWFlLNWFvM1RQUl9NN2dpT2R0RXprclRfUS00NE5wZ3p0SUJTaWFCUUYyTXlBUl9qTGYxZTZld004?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Shree Jaya Laboratories PVT. LTD. - 698690 - 02/28/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.192Z",
    "first_seen": "2025-09-08T12:30:00.191Z"
  },
  {
    "name": "Suprimo Imports",
    "aliases": [
      "Suprimo Imports"
    ],
    "violations": [
      {
        "id": "3b9f41ad05f3da6b4a6b7dd267024292",
        "type": "regulatory_news",
        "date": "2023-06-22T07:00:00.000Z",
        "title": "Suprimo Imports - 657631 - 06/22/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOSE0zLTVtaWlCNUVaNzZ0X1JScDU1Q3FlNHNGNkVXNXRvYnhKZWtUYmdPaDhTUko3em10QndjYWVEbGFKNkt2QkRCNnhLb2lWM2VaVThOTTlCaWp1azh3NVN1bFJCSWlBUVA2NGxJTFdlQ1ZRWUgtalJsVXc3NzEwbU1SWEJMOEVkM1dsYUlXVTh5RXE4TDRkVGhJQVptYnNSX2pfdzNYV0JMNVI0TXZ2TWZWMC1ZeG5OMG5ZR0g1M0VTcEFzLVpPX1hn?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Suprimo Imports - 657631 - 06/22/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.195Z",
    "first_seen": "2025-09-08T12:30:00.195Z"
  },
  {
    "name": "Fresenius Kabi",
    "aliases": [
      "Fresenius Kabi"
    ],
    "violations": [
      {
        "id": "a92bb0cdb3450c4a7aacdddf175c5456",
        "type": "regulatory_news",
        "date": "2024-03-05T08:00:00.000Z",
        "title": "Fresenius Kabi AG - 671249 - 01/04/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPTHh1TFJvc2VJNG5SMDQzRGw2eEtxZkRNdFBoNTN4SWNzZll5aTRrVm9nOEZVQVRYM1ZEUnNWMmQxRHZGQkl2ZGxsa2hQdl9UWG56SUJ4SGlaUVVZa0hCUmNWOEVwSExzX1dsbFNKbGxja1lZRVhwcjNWT3dxUEhHSldaeGVQV2Y0amVpM2VtMXdMeEhJXzB5RTNrWVRWNEhkZ1pGWnpobEJBeWxoN3BWSVZpZ2U0Tm5LcFBvM29sazZWOGtpNXJRSTFPOE4?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Fresenius Kabi AG - 671249 - 01/04/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.198Z",
    "first_seen": "2025-09-08T12:30:00.198Z"
  },
  {
    "name": "Isothrive",
    "aliases": [
      "Isothrive"
    ],
    "violations": [
      {
        "id": "c56b5c53867a714e3de6c358f30d361c",
        "type": "regulatory_news",
        "date": "2025-02-04T08:00:00.000Z",
        "title": "ISOThrive, Inc. - 688547 - 02/04/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOa08zNFRjaHpsZWw0eXJ4eEh4VVQ4bUhsZUFZbUxZNTZLOURtNTVPWGl3QXM2NVRETDBuUElBakV1X2IwOEVUQkVCWWFtVUtTdHhpUnY1bGk0Y0dJck5jNXY1U1NXX1Q4NnpuTnZZT2NZME1haFA1V0s1cmRZUGtxOTJQc3FWR1V1QURJcE42Mm96VE5Gdkp0Wk1uR0N1QU11N2t4bHBySVZvd3B1RWJCYUpqbDY5NEdLZDRNa2JrMnF5RFhMWUo4?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "ISOThrive, Inc. - 688547 - 02/04/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.201Z",
    "first_seen": "2025-09-08T12:30:00.201Z"
  },
  {
    "name": "Namita A. Goyal, M.d",
    "aliases": [
      "Namita A. Goyal, M.d"
    ],
    "violations": [
      {
        "id": "cbd0dfd443a1da73380684b1d390353c",
        "type": "regulatory_news",
        "date": "2024-10-22T07:00:00.000Z",
        "title": "Namita A. Goyal, M.D. - 677324 - 10/10/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOTFR0SU9vQzZMNkF3NkJzOVNkX1NYQkpNd2QxWkRNbHRGVTZEUHJzVlJ5MExlM29LeEZDMkhTRFRBa09jekZ0T0ttdGJ1a2xielJqOG1OOHZUbmViU016SUtEQkM4bkdsb3FjY3JveXZUSVJXNnNaS3d0TjBtM0R6cmRYQ1Q3SWItQk1TRjlWeGFIUVdfTnpVSmhZTVhxNkwxNGVLTlZOcmRRVVNoQkFaWTVFVkhGanB6cld0TDVjTDB2MDdwNXlGZzJn?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Namita A. Goyal, M.D. - 677324 - 10/10/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.204Z",
    "first_seen": "2025-09-08T12:30:00.204Z"
  },
  {
    "name": "Fda Warns Online Retailers For Selling Unauthorized Disposable E",
    "aliases": [
      "Fda Warns Online Retailers For Selling Unauthorized Disposable E"
    ],
    "violations": [
      {
        "id": "c73d3dd434aba914ce190f277ecb5ebd",
        "type": "regulatory_news",
        "date": "2024-02-01T08:00:00.000Z",
        "title": "FDA Warns Online Retailers for Selling Unauthorized Disposable E-Cigarette Brands Popular Among Youth - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNYXBCaVd6Z0FtX3lXOXBYNm43aUZTSFRqUGpZM19JUlNpekk0UlgwcGI0aWJmcUZnVlFUQmppd0c5QzNqejQxUmd5Z213VmV4dnNid3hEUEJ2MmJYV25qN2tscGFvUWhfMlZlbTRrSE1LMTFraHByODNWQ2ZuUEtIQm5yNzZLNWUtcl9Uall6Mlk3VG9udDZUUXZHMGRDUG9lelhHOFFTVWRKUHh5WmNxdXhramFYbzVfM3VVQ3BsdVBKV1FjVjN1Z1M2RnVtMVJSb1lXcUpYc3FLZjFRdzdhUw?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "FDA Warns Online Retailers for Selling Unauthorized Disposable E-Cigarette Brands Popular Among Youth  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.210Z",
    "first_seen": "2025-09-08T12:30:00.210Z"
  },
  {
    "name": "Biostem Life",
    "aliases": [
      "Biostem Life"
    ],
    "violations": [
      {
        "id": "b1e95c3d0c91fcadd7457f7d096ef708",
        "type": "regulatory_news",
        "date": "2025-02-04T08:00:00.000Z",
        "title": "BioStem Life Sciences - 673788 - 01/17/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOeXRQZXVGSWdvbmhQV2pDa0xyS0lZYUxXMHVQWFMtVmlpbWRONnhTYjVwbm1DT1I1NEVkOEkybXhIVzQ3N2dzZkdGZXo4RTlXVHVGenFoZmtsc0wxYXNWZ1BhNXlYa2FhMGtjUmRPeFhaYmhCLVN5cGNfY0lEZmpUc3dGWTZYclpiaWFmNjR4ZEh0azQxbUMtaFFUY2FmVUdLZUtKQWczQ2JYODAyejA1UU44MUsxUWtUOGVCX2JsbGJnY2JUbzJ6TDdCNGY3U2RSVGc?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "BioStem Life Sciences - 673788 - 01/17/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.215Z",
    "first_seen": "2025-09-08T12:30:00.215Z"
  },
  {
    "name": "Pinnacle Transplant Technologies",
    "aliases": [
      "Pinnacle Transplant Technologies"
    ],
    "violations": [
      {
        "id": "0d11483aa088839a040e0f5c16b7c530",
        "type": "regulatory_news",
        "date": "2024-10-01T07:00:00.000Z",
        "title": "Pinnacle Transplant Technologies, LLC - 646783 - 10/01/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNNEw2UmJCamF2bVdCcV83Q0Q5empYQlpNRmhubFhsUjJiVzk4T0h4d3RiV1dzRUFkZ3RfdzVOZWVsUjBJTXlVX1FONllZbDU0WWpHbUtRMVdQeEM2ZzJzbk0ybzZYUzVNVkVFNWI2RGVWLXdJWHBzOFkxcUxjMTdSZkNRRWJyNGJ5NVpHUlp1a1FCUElMX2xYSEtTMGtfQzRmaVpkTGV0UjZLd010blQ1OXJNbkFNQlZCa1V3ZU5iT3J1NzV5YkFoQ1BPd1RtZXNnVmtWOVBlVHhERHBfbXV4OWVobF83UQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Pinnacle Transplant Technologies, LLC - 646783 - 10/01/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.218Z",
    "first_seen": "2025-09-08T12:30:00.218Z"
  },
  {
    "name": "Marshalls Traditional Healthcare Cc",
    "aliases": [
      "Marshalls Traditional Healthcare Cc"
    ],
    "violations": [
      {
        "id": "0834acdfbfaae5ceac6cbc7f1bd52c7c",
        "type": "regulatory_news",
        "date": "2025-02-10T08:00:00.000Z",
        "title": "Marshalls Traditional Healthcare CC - 697697 - 02/10/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOdHpSdktYWWh5WGpZc2VmS0NSZFBndzVNNFF6aU8yNm5VRkllQVJfRzJFRE9Gcm1RYWJMYXdVQ0R0clF6cDNzTk80dHdIOGpid24zbHhwNC1GYTZxU0RkR1RZRm5hbW5tSkNFT2szTkh5U1hEWGN2TmVuRW9naEVWTWZUWE1pQUxndzItUXJCOVhjbGI0dkhULTV4YlBjRUF4QnIyT2Z4aFA1NzNBWlQyZWMyWVdlUHJOVkxFWWZQS0JzS1NQMnN2cWctNHU3dWRkMklncjk5X2FCQWIxdExGanEyWUk?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Marshalls Traditional Healthcare CC - 697697 - 02/10/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.223Z",
    "first_seen": "2025-09-08T12:30:00.223Z"
  },
  {
    "name": "Vegewax Candleworx",
    "aliases": [
      "Vegewax Candleworx"
    ],
    "violations": [
      {
        "id": "8a80b8b534dc30dfcb373e6e09ae32cf",
        "type": "regulatory_news",
        "date": "2025-03-18T07:00:00.000Z",
        "title": "Vegewax Candleworx Ltd. - 675099 - 06/14/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNNENkRFJFbUY3OXdvakhYR3dmc2ZCWHB3UjFFRkdjZkFDMl9Zdzc1eTc2SHN3UjgtWTJEdjJneldUUWh5RUhMREdCaDQwMjkyRFBROHpWLUc5TXFBSVNoMjJya0V3THAxVFljTnIxbkw2dTU4ajQyMUVfUkNOUm4zdndaeVJiR1NrcmNOT2RYQ2VnMDlsd2JvVW1MRmIxZF9XZzYxR0dSdVlMUHZER0JlQmNPeEhCOFJKVlZwa1dyeGxXVnExSTVPUG5QN3lBQW9mbzNR?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Vegewax Candleworx Ltd. - 675099 - 06/14/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.227Z",
    "first_seen": "2025-09-08T12:30:00.226Z"
  },
  {
    "name": "Carsgen",
    "aliases": [
      "Carsgen"
    ],
    "violations": [
      {
        "id": "95c87b0bbcb039a0306fc1ba7d68db3d",
        "type": "regulatory_news",
        "date": "2024-08-27T07:00:00.000Z",
        "title": "CARsgen Therapeutics Corporation - 686504 - 07/26/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNdEFKYXpFT1ZoT05ENjJmcVpyWEJPWFJYTWtIdWVEbzlkMmFJeEdVUk0tNGl4TTBlSnJWYkNTV0Z2elUtc0lCQ1lJVFlUaTV4N1BKUTZObXJaZ19VdFZkZG5qZ3ZWb01PelFhRmE3aGRqc0JCX0VvT1RCdWZBTkdtelpRY2JyODhpNGFObklqTGh0UXowMUpGc2RYSmtrMFJCb0pJM1h2RnY1Z2hBN0pmajd2NEx4dkxzdDMteTlkVXFleDczZE1fMDV6LVhvSjJTQ1Q5N25zZWxtb2VpZHpnRg?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "CARsgen Therapeutics Corporation - 686504 - 07/26/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.230Z",
    "first_seen": "2025-09-08T12:30:00.230Z"
  },
  {
    "name": "Pharmedica Usa",
    "aliases": [
      "Pharmedica Usa"
    ],
    "violations": [
      {
        "id": "b8a08f3b5fd2ddd7e7f8a64ab6872e02",
        "type": "regulatory_news",
        "date": "2023-05-16T07:00:00.000Z",
        "title": "Pharmedica USA, LLC - 648269 - 04/28/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQeUlfaENOV2YwdFZXNlh2TklxcC1yZ1FnTXRvZDhLM1pQeWY5ZEdmLS04QnRtVUdZY2ZxN3ZkLWFfeGdhS2QxMGpobktkelhvZ2YxWVJiWkVaOE1kcTduc1dqSGtBMjR5bXdUb3hYdUdsSlRZTFpJNUYxdi1jUTlNcHhDLXI1NW5xZlBLcFZlNWwtQkFqVFUyWjIzX3pMb0cyREpoeEd3Yy0xM3VKWnNrRXVOaUpIZGJMODAxbW84QmpKTHJ5a2UzaF94TXpWQQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Pharmedica USA, LLC - 648269 - 04/28/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.232Z",
    "first_seen": "2025-09-08T12:30:00.232Z"
  },
  {
    "name": "Abr Laboratory",
    "aliases": [
      "Abr Laboratory"
    ],
    "violations": [
      {
        "id": "aacb699877169e327fb49a9cfce92dce",
        "type": "regulatory_news",
        "date": "2025-02-10T08:00:00.000Z",
        "title": "ABR Laboratory LLC - 696872 - 02/10/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOWHVCZ0o0R19oMEk2UGNlU2NQMWt3Y2tPSzlOWGlHRDA2Qlp6aVRXNUlPaWxOUnlTNDVHTllyY0l3WjFsX0FwSXBPcFQtcHdiWjBmWEllSG9Sa3k0eTdPWjVXSy1zNUpodzJuYzB5Wk04cndVVnh1eThET19tc1RleXhIQ2JlWUdPT3djR3VWOEYwTkRyWWxVSlBXb19tRkt4cEx4NDB3Qlg4ODluVEx0dkJuaEFOMERfRk14UE1EbnlmemdLT1ZPcUhoQVFIQQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "ABR Laboratory LLC - 696872 - 02/10/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.235Z",
    "first_seen": "2025-09-08T12:30:00.235Z"
  },
  {
    "name": "University Fertility Laboratory",
    "aliases": [
      "University Fertility Laboratory"
    ],
    "violations": [
      {
        "id": "799f83e15c924f13d982f9e798c4c24a",
        "type": "regulatory_news",
        "date": "2023-08-03T07:00:00.000Z",
        "title": "University Fertility Laboratory, Inc. - 577584 - 08/03/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNMFFrb19CaEhpdFNEVDZFYm9LaEdLTEFya1VkS1hrblBZZzhwMDN3NHNvYWhIZC1PQlVKM05nTVdsVEZPam9hbG1XVWwtVVpTdlF2VFcxWHJKNmtWZlVnTi1QM0dRYWxfUEk3bEtlZndMWkN4ZHZubkl6VndRbE84V3NwNFdEZ21obk53bjBxWkVhd1YyNXdSSFNHYzZ5cndVYmNhYXhab2dqWnBXYUU2Zkp4REpvNUdiYm80YXRGOF8zdUZ5OGNuOHNwbDZhZl9haEFTR2hCd2h4VzR4YXV1Z3FoOGc?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "University Fertility Laboratory, Inc. - 577584 - 08/03/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.238Z",
    "first_seen": "2025-09-08T12:30:00.237Z"
  },
  {
    "name": "St. Louis Calco",
    "aliases": [
      "St. Louis Calco"
    ],
    "violations": [
      {
        "id": "85845a7b0c793995a62570bd6fa15890",
        "type": "regulatory_news",
        "date": "2024-09-17T07:00:00.000Z",
        "title": "St. Louis Calco, LLC - 669917 - 03/21/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOaVJySGFhVGVqeG1TZURPRWtqckRBM0VYMGNxYmpfeHIwU1V2a3YyWEJsNDUxNDlpTEJQdHZkTkZGalNLcFRBbzNQLUpYUzEyYkVCaTEyVG5RbXdEOXk5bUlzdV9KWm9WajZqdHhiUTU4Z1U3cXpocGRRUEZKcTFud3dwS25iVkxJMENXLTAtLUs2SHpiRmVJT3VmWExLOVM3U09UVklITGZBQWYwNWVWNXpzWWthdGh0YmxIZm0zNktxRV9ySzJ4OXJxMUdHZw?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "St. Louis Calco, LLC - 669917 - 03/21/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.242Z",
    "first_seen": "2025-09-08T12:30:00.241Z"
  },
  {
    "name": "Indoco Remedies Limited",
    "aliases": [
      "Indoco Remedies Limited"
    ],
    "violations": [
      {
        "id": "d09e21f5a7aa1a2149721a9a84b3142a",
        "type": "regulatory_news",
        "date": "2025-01-07T08:00:00.000Z",
        "title": "Indoco Remedies Limited - 691594 - 12/16/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPUkxUVHF0NkRHaHJHaVVvWWNLaXR2dGhwU1ZYZm9vT3ZUc0RBRk0wSlBlSm9fQjJYVlZ4Y1dDUTB3M1lnOVBqcXZERkJlVmZ5WHZPa1FiWEpXZ1FVRkV4NmpNOUpEZ1BwcUdhWl9qODE0NmdjNnpUbjE3c28xWm9pQ1pUVUw2RjJCR3N2RlRiSTJTbHJLTzZ1ZmN4TDY3OTNLeGJ0b0NabDh1eEhvS2czR0oyRDNtU2czd1hZaGhCTTl3OHp6bVBMdjM5SllfbXVNM042Rw?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Indoco Remedies Limited - 691594 - 12/16/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.246Z",
    "first_seen": "2025-09-08T12:30:00.246Z"
  },
  {
    "name": "Micro Orgo Chem",
    "aliases": [
      "Micro Orgo Chem"
    ],
    "violations": [
      {
        "id": "554448a393e320969dedcf08708e9f45",
        "type": "regulatory_news",
        "date": "2024-12-17T08:00:00.000Z",
        "title": "Micro Orgo Chem - 686458 - 12/03/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPNjJQaG9SeWZib0NDeWZxZGdSRTRZWmNFOU5iSW9xMW96MktnMFVmNGxHYlU4VEpzYm9UNEx0dHFFYTBoZHJDVGxZcU5OTU5ZNlFrNEE5VkFHbHljVDVvd1FFV0kzelR0ZGUxNVpoVU5id2Q4ZVlEbm5VUzZ5UW5qeXBlMGp0SHdYb0l5WjVBMUZiSVlnZmIyWWdSWUxIMDUxMEZNVVVEbTRLR3BkNHdueDhSNnZadkRoWnVFblRSZEVlUl9Wa0FDMUd3?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Micro Orgo Chem - 686458 - 12/03/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.249Z",
    "first_seen": "2025-09-08T12:30:00.249Z"
  },
  {
    "name": "Washington Fertility Center",
    "aliases": [
      "Washington Fertility Center"
    ],
    "violations": [
      {
        "id": "5db35775efbf2f1fd98914b6be872dcc",
        "type": "regulatory_news",
        "date": "2024-04-30T07:00:00.000Z",
        "title": "Washington Fertility Center - 678931 - 04/30/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQWk9EQVpXaENhWDQ3TXNsdWR5anhLMlF3S1haUHhBTmxTa3B0QnJXTUp3a1FOdkw1OVdUcHNzbmZidWRfSWphZ3ZFdjdaUjRCeE9ZQlNaYXVuWHlxcl9WcFFJQ1JkMTZFVlZoTEpYUmtvRy0tMXBjd1RrVE5weXpiUUlXVndkUTY2Z2wwa3ZWVTQ5ZVRxTkdYTmVPdUNOb3FNenNpdk5hNlRuUnhoNk15Nmw3UExhQjBTMHNaa2VONE9IOTNTWlpGenFsQ0p2UUVoN04yNzFvTGUydw?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Washington Fertility Center - 678931 - 04/30/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.253Z",
    "first_seen": "2025-09-08T12:30:00.253Z"
  },
  {
    "name": "Donggang Wanrui Food Co.",
    "aliases": [
      "Donggang Wanrui Food Co."
    ],
    "violations": [
      {
        "id": "bf2b4bda1eea5561703fc7e761a32f4c",
        "type": "regulatory_news",
        "date": "2024-07-16T07:00:00.000Z",
        "title": "Donggang Wanrui Food Co., Ltd. - 678557 - 06/25/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNeEVxMVM2VmZLbUpjek5ycFBUai0wQTJiZ3JIYkVLWnFDRWlVYWRlVFV5R3pNUkx1RmZaakdKYnZocHBDdlN2WGphdGlDZHVGY2dVSTFNM3ZOcDBsWXVNbmhGMW1jNENFbENuODRrbkdkWVloSFFybzJJMHpPaUlxaVA0alotVzk5dlhUZW1BXzF5R3hoVTBQUUg3Zlo4OEpQeVVIOEM1UnVfVGNlV01KM2h2UnN5LXpzRERQMUxYdHVsRTV1SmF2WlJ1N0RqRjZoMFY1UjVjZmhRQQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Donggang Wanrui Food Co., Ltd. - 678557 - 06/25/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.255Z",
    "first_seen": "2025-09-08T12:30:00.255Z"
  },
  {
    "name": "Accra",
    "aliases": [
      "Accra"
    ],
    "violations": [
      {
        "id": "81c42010e693176dcb5585d3ac0e7cd6",
        "type": "regulatory_news",
        "date": "2023-04-20T07:00:00.000Z",
        "title": "Accra-Pac, Inc. dba Voyant Beauty - 643600 - 04/20/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOa1lsaGsxR181Snl0NnE0anBxQ1V3UkItU2o4S1EtZU5qTjc1Uzl2SXdWcTRydkVRWV9abnhHRkt3ZzJJdHYybHhCYmdZY2VzcGFyaTdRTzIzeHVfck43QXNDQk5jeTRRWFZ3UEx2ZENDOVNGbVdKemVGZElNOTF0WDQxQ1djeHlOV3JuY1k2V05MUENyMmJuLTY3dUJSdG01dWhVVVpjdkdnaU0yUjhwajF6RUdKeTE0aWtqSU9vWjJDak8wdGpqY0lvMlprMzdDREdaUW02Mzl3aVZCUVpZ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Accra-Pac, Inc. dba Voyant Beauty - 643600 - 04/20/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.260Z",
    "first_seen": "2025-09-08T12:30:00.260Z"
  },
  {
    "name": "Wittman",
    "aliases": [
      "Wittman"
    ],
    "violations": [
      {
        "id": "27d09823bc4d6e3f8c2c0e4a91d360aa",
        "type": "regulatory_news",
        "date": "2024-09-24T07:00:00.000Z",
        "title": "Wittman Pharma, Inc. - 683081 - 08/06/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOUHMyS1pYSU12Q202VWNGckJkTmZDN3NPZjVjVHpOYnZPVC0wU2o2N1FPTWkyWVFpd1VhNnVxZHJTSDVRcXUwZHV0dzZRRnljWnIycS1HNElDNXRYelloUVNDbVdFejlYeHlGbW05VjJVaVRPU2J1Yl9lWE9Xbk1RX3BJQUxneVhEZVU4dEJyZ1VIRzlReGhJa1hNblZKWFdjX2tKMmc3V0lGNmJ0S1RUX3NDalhvbFFveVQ2Y3lxU0VNdWgxczM1TVNTdGJVUQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Wittman Pharma, Inc. - 683081 - 08/06/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.264Z",
    "first_seen": "2025-09-08T12:30:00.264Z"
  },
  {
    "name": "Adventure Innovations",
    "aliases": [
      "Adventure Innovations"
    ],
    "violations": [
      {
        "id": "2c3352273f9fe6da025106458f7f2c6c",
        "type": "regulatory_news",
        "date": "2024-08-28T07:00:00.000Z",
        "title": "Adventure Innovations LLC - 676842 - 08/07/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOTTZaX2JMbUNlTjRMNnFkWmhsbmUwQmllZ05lWEM3X0tNdm02R3FycmUtSnJEWnZhZDNpQTB6LTVUNFlpd3hBOURjMWNYYTR1SnY3UUtpS0hvVTBvN0NhYURaNFhIRFVEUXFjcVItYy0ta3hld2dfbkl4ejVZUzNTQTFhRmJCWWVtRXBaS3hCNkd0RmFTcElleFhDdUo4UGdVajM0dzNadGRzNUU5ZkJsSzZ6MkdDNDlUd2RCRWQtSmRONUJURTRwM2RxbG55Ri1MS0lfT0RJZw?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Adventure Innovations LLC - 676842 - 08/07/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.266Z",
    "first_seen": "2025-09-08T12:30:00.266Z"
  },
  {
    "name": "Icu Medical",
    "aliases": [
      "Icu Medical"
    ],
    "violations": [
      {
        "id": "03dca3af293bc7975b5ef873fa904e2c",
        "type": "regulatory_news",
        "date": "2025-04-04T07:00:00.000Z",
        "title": "ICU Medical - 702535 - 04/04/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOVzVicUdpbFU5YXI1elZlcGZHS0pyb3gyX1RzaVE1VU96d09tbUhJR3FCMS1CM1FyazdPaEZRaVpWYXNtS01LdzFCWS1FdEVfbFZIb0JJdmZ4YTg0N0NHWDdFQVBENGtGSWV2cjAwR0ZrTUVGdGFqV0FycXJ4YzJFdlZkSThOS2pkRWdVMmI1OFdmV0RZSGJZYUFqTUJiWDMzLUVUSmN1UmY2THNTTlpyTDRFR0NORDliOGZSdnpGVDd6WDRU?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "ICU Medical - 702535 - 04/04/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.268Z",
    "first_seen": "2025-09-08T12:30:00.268Z"
  },
  {
    "name": "Mg Infusions",
    "aliases": [
      "Mg Infusions"
    ],
    "violations": [
      {
        "id": "3f1e046888042f18614cfe9285bcc25a",
        "type": "regulatory_news",
        "date": "2025-03-18T07:00:00.000Z",
        "title": "MG Infusions - 696890 - 03/10/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOSjZicXNMRjd0bFhpNUExWTZEQzB1cXRPOTRaemRjTlI2T1IxVkRmVjMxMmpXZ3BtazVpbWFyTkVmWU1RaS1TMjNCREh2TGhtTXVZa1JBRnMtTzdhbGtvMDlSQk1EdzFBQU91ckxKTXVka3B3S0ZRNkZ1Sk1FdnVObFdISkFHSVBCdk82Y0Z5NkN5OXpqVDlfamZaZmJMb0xOQkJOdlBIc20xcm9WUldUaVVKSUxPSVptbGh1dF9id2ZqaUItUVE?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "MG Infusions - 696890 - 03/10/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.271Z",
    "first_seen": "2025-09-08T12:30:00.270Z"
  },
  {
    "name": "Colgin",
    "aliases": [
      "Colgin"
    ],
    "violations": [
      {
        "id": "231be083fd8700eed66f52b46a0ae736",
        "type": "regulatory_news",
        "date": "2024-03-05T08:00:00.000Z",
        "title": "Colgin, Inc. - 670332 - 01/25/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxONF9kRHAwTlhHeDQzU284U0Q0WFFuTjZlcXRpSC1TaVd0VmZmRGpGSm9yaUtSZVREQkdwRUV4NHpkWGpmdFVOMURQS25hSnp5Z0lvMEY4OFVyNURBZXh0R01Gb2R4LW93a3lNLV9SbjdldmpJZFkzalZ1b1dLVG1mZHRrT3FvZVRBQ19JNXlfQ3JHUTlkQjcyR1EzRmY2eWRUSF80T0p1TEprQnFmVEdGWU41Tkt0bWxIdERzNkFuNlhnb1k?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Colgin, Inc. - 670332 - 01/25/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.272Z",
    "first_seen": "2025-09-08T12:30:00.272Z"
  },
  {
    "name": "Apollo Future Technology",
    "aliases": [
      "Apollo Future Technology"
    ],
    "violations": [
      {
        "id": "d61ddf2f0255a0324bd210bd9c05ef1f",
        "type": "regulatory_news",
        "date": "2024-08-27T07:00:00.000Z",
        "title": "Apollo Future Technology, Inc. - 690452 - 08/16/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNZUhvNGFGaWRsUm5tTlFwZkd1c1ByOEI0bS0wdnBub19IbFZvblFTZ09wY0dDWWpGMUxyMktIY2hRSFlTc3BUZzJxVlRhOG9LUWEwYlNkWDJQX1JMZ1kya0VTZWdqc3RhaFhvaGM4a2RzWF9RTGRmRHN2S3I5aThNRWluNUJPTl9CRDRWbHZ0eTF5M3pHV3l6NnhfQ1puV3FldXc2S2tsWUpvTTc2ZmZlVFlMVDhIb1hFTlYyUjRQcklxTVp1b0g2RzZBN29qbm0yVllnRHVHWENvX3M?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Apollo Future Technology, Inc. - 690452 - 08/16/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.276Z",
    "first_seen": "2025-09-08T12:30:00.276Z"
  },
  {
    "name": "Outin Futures",
    "aliases": [
      "Outin Futures"
    ],
    "violations": [
      {
        "id": "705514551a65620f40e7ae3eeadc39e2",
        "type": "regulatory_news",
        "date": "2024-10-15T07:00:00.000Z",
        "title": "Outin Futures Corp. - 684688 - 09/25/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNS3ZuUFFMNzdyb1hFamFvempVYjFkSnQ4ZWRqRzMtZkN3SGdrdld1WnRvbG9PVUhLX0JoejhnRENDZXZ6b2xub1JGZ25NRzVQcXVXUHRSSWlkSlpLYlc3ZFQxd1F1cnRfSDZZOW9DN2JDYW50TGxtV1owX1FOZld2dG5NYTd4NVMxVnBFYWtvQUE0dlR2bXRWQzZBcjM3ZGtSUzVPNTBBXzMwbGtvb2tNX1JEYl9LZ2pGaTZERFNTTlQ3Qk5SVEo3bGpUZ0stUQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Outin Futures Corp. - 684688 - 09/25/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.278Z",
    "first_seen": "2025-09-08T12:30:00.278Z"
  },
  {
    "name": "Akt Trading",
    "aliases": [
      "Akt Trading"
    ],
    "violations": [
      {
        "id": "98f0db391d19a46acf6713aea94bef72",
        "type": "regulatory_news",
        "date": "2024-07-02T07:00:00.000Z",
        "title": "AKT Trading Inc. - 676865 - 06/10/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNcGZYcGlMNkl6SlFLajQteTZnSmpJd280Y0Q3SmFqbnVpLVBPcE94U3AwWVAtUUk3dGpwamVtRkxWSmNyLTNoXzRILTdaMlZYbVI0OGd4SUUxMTBWallQVS1VV0xuMENXMUxnNzhBVG11R3RTZ05MZHNtV0xSVlhFTm9ZVzI5Rk8zWVRsbC00VjlPZGFDY1BIcFRfUE14UHk1S3ZJZVJ3T08tM0otc2lkUUl0T1E2ZHdFZUpJeHV4VW91cENKZERQV1R3?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "AKT Trading Inc. - 676865 - 06/10/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.280Z",
    "first_seen": "2025-09-08T12:30:00.280Z"
  },
  {
    "name": "Wisetrade",
    "aliases": [
      "Wisetrade"
    ],
    "violations": [
      {
        "id": "4d26c9cd7f4526d4ba8e7fbd69f21300",
        "type": "regulatory_news",
        "date": "2023-07-18T07:00:00.000Z",
        "title": "Wisetrade Corporation - 657707 - 06/30/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPdlJwQ0J3VDNTZm16MzRIX0g3WmlzTW84dzFPaFdNT25wRUxDeVhLR0NmOEFKcUR4bzdkcVd3Z3dKM1pxcEgxQ0ZGWXNXWXRBOVoyN1lnUlJqZ2QzSTZSSTJfY0o0a2E5NWRadTY2RENNbTJtWGpOeENreldtb1Y2Uk9GTWJaVGlYczhPYktqdnN6NXJyYU9Ea1U5UzBzc0R3bmtXVE1zNDZkcHpzekVHbW56TEVDVFdIQmFZa1BjdHN6Z1NrVXBXanY2eTlVTHJ0MWc?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Wisetrade Corporation - 657707 - 06/30/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.282Z",
    "first_seen": "2025-09-08T12:30:00.282Z"
  },
  {
    "name": "Makra Kozmetika D.o.o",
    "aliases": [
      "Makra Kozmetika D.o.o"
    ],
    "violations": [
      {
        "id": "4581b99b78e174f8fa3ae14e8f9c704e",
        "type": "regulatory_news",
        "date": "2024-09-26T07:00:00.000Z",
        "title": "Makra Kozmetika D.O.O. - 684125 - 09/26/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPZkRXbVNQckdqbzdTaGpIdHZ1a2VPLUlqWXNlMXRrZWdZdnRScDNhbklOQ3VETnZLbU9iaDJvd1hCa0p4RjAtZG9VdXhpS2daTU1MOEx4OTNIYTExNGNSbmVzSFpBZE9oRnNWblZGSTJfaTRQUWY3MGNndFlSb29vSDQwSGIyeEE4elFhTjVkaks4TzdxalVZWjM0Qmx1MkRNa0kxV3ZaT1ZWaUxrOG1QOXZoRG5nM2hCeDBnUXV2SW9uY1g5RGhNVTVlZkJONTg?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Makra Kozmetika D.O.O. - 684125 - 09/26/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.285Z",
    "first_seen": "2025-09-08T12:30:00.284Z"
  },
  {
    "name": "Diamond Chemical Co.",
    "aliases": [
      "Diamond Chemical Co."
    ],
    "violations": [
      {
        "id": "0aa84e07ebb897c27e2176bbcd97f077",
        "type": "regulatory_news",
        "date": "2024-10-01T07:00:00.000Z",
        "title": "Diamond Chemical Co., Inc. - 687078 - 09/06/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOYW12eTAwOGp2UGRHdE8tNXd3cVRiR3l5bi0zd1J0cDBDb2pmRWV2MWpJZ2x3SU1PM1p4OVZCYUpEZVV4MWJLaF9MUFJ4S2ZHMHA2Rk55UnMzQjFLa2JxZDFON3M0ellseFo1eGxyZXc3ajZEMGZtbEZuMDB6WUJfV2xMQWlyS0p6UVoxLUM0ZzZxS3ZjaHdwSDA1LUFsek93a0huVU9mTzlBbDdNM2t4V09IRFdLMVZLN2pXRmk2R2R1dlFlbzBvYkJDSEZndlZqOTdzSw?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Diamond Chemical Co., Inc. - 687078 - 09/06/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.287Z",
    "first_seen": "2025-09-08T12:30:00.287Z"
  },
  {
    "name": "Sohgave",
    "aliases": [
      "Sohgave"
    ],
    "violations": [
      {
        "id": "da5f8ba6cd3c042edf138a61dd7761a0",
        "type": "regulatory_news",
        "date": "2024-12-31T08:00:00.000Z",
        "title": "Sohgave LLC - 646874 - 12/16/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOOVRJa2dNbDNBVWFYY2cteENJZEl4aXVCaF8wZDhCMDhSQTRSeWJqUnBpc25wTk5ZdWNaYm1fVG0xXzJfWERfX2VQRVBxbWlJLUViSlpQbmZQWWpCcmFzbGtpYkRyQjlTLWRucFYxbXRxdkVBQ0t0TXVnMmxVblhIUUFrMW1oRFFndTV2YnpIeVg1NGYxOWVYZ1o3dXVjVVlROGtRSkNHdDUxUk9aV1lacS1MRWFfdmVNcnpkMFRpTUQ2TzJZ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Sohgave LLC - 646874 - 12/16/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.289Z",
    "first_seen": "2025-09-08T12:30:00.289Z"
  },
  {
    "name": "Champaklal Maganlal Homeo Pharmacy Private Limited",
    "aliases": [
      "Champaklal Maganlal Homeo Pharmacy Private Limited"
    ],
    "violations": [
      {
        "id": "7ca2783e8feca8fdf50f289e0d91a6e5",
        "type": "regulatory_news",
        "date": "2023-05-18T07:00:00.000Z",
        "title": "Champaklal Maganlal Homeo Pharmacy Private Limited - 656743 - 05/18/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxPQzBXVGtVeG5TSGplOFlRWGpCZDkxWEczakZvbC1wM3R1RkFTb3lsNThuNkp2bnF4LWlCTVRoeFl1dE5KX1Y1NUdfcURReVpkcUJYb2MzYmFiNTB3TG9OMnRXQkFTcDNEblNKR21hZTlGN1JmVDlSTG1mVUFSMzRsUFRFOWgtaFo3VTRuR2JKRjNnNTJGUVUyc2w4ZXRTeTlPN0d1U0E1Um1jUmt0RUk2S2szN051Tk9QbVBWUUxvbmt6RkRFYVZNZm5oTXhYN2N0VTYxYWExMEV1VUJhUU9XLS1EWU1JVzR6T2gwRVJjbld2S0FvNDRaQg?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Champaklal Maganlal Homeo Pharmacy Private Limited - 656743 - 05/18/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.294Z",
    "first_seen": "2025-09-08T12:30:00.293Z"
  },
  {
    "name": "Zen Enterprises",
    "aliases": [
      "Zen Enterprises"
    ],
    "violations": [
      {
        "id": "ceb78b1f597fc101f612000737051def",
        "type": "regulatory_news",
        "date": "2024-04-18T07:00:00.000Z",
        "title": "Zen Enterprises LLC - 678407 - 04/18/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNM3JlU2JhOEVsd1puQmxwcHlDbzUtZlF0aUdxRlY4TVQ2WVdTSFE4ZWl4a1BGWVM1azlaaWRTb1lKVUpPNmloeHktUmJiOERtVV9nMnZubXp2azRpdlpZSDFJZG41ZHI4TmhOVE1XY3pZYjBVdU9qekw5VmxJOUhjdUFoM2dMb1pWY2dkYXcyOVNxdmpIRHBaS3NwanVRY0F3YTU1d2FWLXhBcEtBdExUc09BN0E5V3BMLXNkX1ZKaGk4MnhDUEdlclFVZWJYV28?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Zen Enterprises LLC - 678407 - 04/18/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.297Z",
    "first_seen": "2025-09-08T12:30:00.297Z"
  },
  {
    "name": "Angela D. Ritter, M.d",
    "aliases": [
      "Angela D. Ritter, M.d"
    ],
    "violations": [
      {
        "id": "14c010448f574a9665b0a6a7b22a39bc",
        "type": "regulatory_news",
        "date": "2024-06-18T07:00:00.000Z",
        "title": "Angela D. Ritter, M.D. - 681999 - 06/07/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPY3RJZG55SjM1NklIcHFPaFg2MkJIMlNvNDgwcFpncHQ4ejJYcGg1UXQ4Vlp5VWpPM3dZcTQ0RngwY1hIWVpzSnAyaG01SzZSOWY3SGkzS0Z3Nk5jRWc5T1k1X2M4dEJTbTQ3U1V1a1ZyTVlKM3l1Z3EyLWR2SURKVi1YQ0k4cEp3VUd2WThvQzhpYnRZQks0OUY1NzhvbjJjWFJJZGdsOHIxUjZ1QWZDTF9pcDdOUXAxcjNpRTZSOXU2aWdYTzhYZkxXRmszQQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Angela D. Ritter, M.D. - 681999 - 06/07/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.299Z",
    "first_seen": "2025-09-08T12:30:00.299Z"
  },
  {
    "name": "Fda Warns Five More Online Retailers For Selling Unauthorized E",
    "aliases": [
      "Fda Warns Five More Online Retailers For Selling Unauthorized E"
    ],
    "violations": [
      {
        "id": "90a389bfd48aaca808733736011bd4db",
        "type": "regulatory_news",
        "date": "2024-02-28T08:00:00.000Z",
        "title": "FDA Warns Five More Online Retailers for Selling Unauthorized E-Cigarettes Popular with Youth - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQOTc2WWt4WnlTc2N3OUxxeWpLQzh0M3liQTl1ZERTb1FMYXJfZXd6MW9ubERBeUFDQVNXVDhZcFB5c2dMTFdSUXdxWnpkUGFxWXE4ZTZkX2ZFaDVGakNsZUtPOHhLOTVLRUtYSjFKYWQ5alBLNy0wam9uVVE2eWdrQ1Q1bEpJSXlGSjdjRkJXelJSaFFxUV8tY1AwekxMbEcydUxuNmFfY3ZVV1dpc0pQYVJwcjhFR2RtQ1I4eTRjNDl6dnBGQ0locHpsa1BKa0U?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "FDA Warns Five More Online Retailers for Selling Unauthorized E-Cigarettes Popular with Youth  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.304Z",
    "first_seen": "2025-09-08T12:30:00.304Z"
  },
  {
    "name": "Accupack Midwest",
    "aliases": [
      "Accupack Midwest"
    ],
    "violations": [
      {
        "id": "cccc1956a0e50b6059de5caa59a72085",
        "type": "regulatory_news",
        "date": "2024-09-24T07:00:00.000Z",
        "title": "Accupack Midwest, Inc. - 680228 - 08/15/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOOGxvOGNQN09xeTVxbWQwa0lqTkVKQVk1RTJSY1JQcTBYLUNyNmR5U2ZmYVNzTldGTEhsel9sR3NoVXduOXV2Y2J1dXFnN05jMGl0T0U5RW5vWklNSE1qMzZRSjFHb2IxWTNIV0JRTV9NWTdQTFpKTm9sLWFNOWV6SHB0eHU5QWZ5cjRuRDF4ZWZxdHNHeTBJQlpGV2dFYUJkbE1zV3dqMGNqaXBhclB3N1JOQnpFMG5pLW5OaXlxSFU1Yl9ib0xCdVFsR29ERFAw?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Accupack Midwest, Inc. - 680228 - 08/15/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.306Z",
    "first_seen": "2025-09-08T12:30:00.306Z"
  },
  {
    "name": "Fagron Compounding Services, Llc Dba Fagron Sterile Service",
    "aliases": [
      "Fagron Compounding Services, Llc Dba Fagron Sterile Service"
    ],
    "violations": [
      {
        "id": "1dbcaa46aa7274bd4a6959974bfa01bf",
        "type": "regulatory_news",
        "date": "2025-02-04T08:00:00.000Z",
        "title": "Fagron Compounding Services, LLC dba Fagron Sterile Service - 698861 - 12/19/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMigwJBVV95cUxOV3BiRUYyR25vT1R5NnNid1AyUVRKeDl6ay1PbE5odFYwdXE4d2lfRWRQdHJUVFJ1NmFtaXVqLW01UUxOdk5zSW9MMzFHTmpUQXByUExoX0JjUzBURnItTjdITE9KUmFWYnJZVU5rb1A1OHFDZTdIZElzT2huZ3ZTd2Qxa0F3QW1EbXZ2dDVGcFh6RkQyQVhncURSOUhKSFpQbHAtZDdlV3haM1V2ZnFFRzRndHBPR2RhQVRXSlpxYnNzVnQtVnBxUkZkc3VWQ3haOW5ibmdmYmV0YV9IQkYySGgwa3pwZTBaaS1mblYyN0NqSW5zdVZHVFBwTmY0SXRyUjBB?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Fagron Compounding Services, LLC dba Fagron Sterile Service - 698861 - 12/19/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.311Z",
    "first_seen": "2025-09-08T12:30:00.311Z"
  },
  {
    "name": "Appleton City Feed Service",
    "aliases": [
      "Appleton City Feed Service"
    ],
    "violations": [
      {
        "id": "d661a5e14462bcbf241713f452a42be5",
        "type": "regulatory_news",
        "date": "2024-04-16T07:00:00.000Z",
        "title": "Appleton City Feed Service LLC - 662279 - 11/01/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOaFJMa3k0MGpZZXdMQmpyWHFRMnktbmFQcDJqMVl0dl9LM1Z2U0pGV3hENFphQWV0eWNZUVNvMEdGdHdpQ2c2Ukx6dHg3SUpxVDdTaGEtTU1iMHJscWt5UHpZeERZeUxqNkJaUzJXOVhBU2RtN3NyQThrTkZlM01NV0JzdmJWcDBuWFY0VzlfLWlxQzBHMTF0YnVZa29XNkN6WWtzV3VDQXpwd3A0S25sVHpraWhGV0phOWdaVG9LYUdPbWpqYVVXNmdheXhmc1VKdzIxcU9MeXZjcURRLXc?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Appleton City Feed Service LLC - 662279 - 11/01/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.314Z",
    "first_seen": "2025-09-08T12:30:00.314Z"
  },
  {
    "name": "Master Paints & Chemicals",
    "aliases": [
      "Master Paints & Chemicals"
    ],
    "violations": [
      {
        "id": "0283a15002fe9193caadfd9245ee3b74",
        "type": "regulatory_news",
        "date": "2024-04-16T07:00:00.000Z",
        "title": "Master Paints & Chemicals Corp. - 672462 - 03/13/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNQk5Ic2hmR3NxVWtDVmVFaGdQbE0xV1huSkpDamx1X0I2LU1EU1d2R1RUdHMyZGl4QnlYQkZUXzkxcWl0MjNzaGdRemRocHNxVWxZNFI0NUhQdjE4WHdNM1VnOFpUek81aUZHekhTTWstRkt6YkdTQnplV3hLc2F3UlVocGoxNjB2Z2h2emNoenA5ZVRsZFpxVEZtcUVYeDd4Y3hfcU1aVVI3NkdlVnNSUEEwZW5DQlhzcmRncVQ3UmNNU2JtVUJpLWF1OUFYU0RTN19MYnNvV1lrRTA?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Master Paints & Chemicals Corp. - 672462 - 03/13/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.316Z",
    "first_seen": "2025-09-08T12:30:00.316Z"
  },
  {
    "name": "Strukmyer Llc Dba Strukmyer Medical",
    "aliases": [
      "Strukmyer Llc Dba Strukmyer Medical"
    ],
    "violations": [
      {
        "id": "165e0310f28819ab5d3f1c3cb74d6501",
        "type": "regulatory_news",
        "date": "2025-01-30T08:00:00.000Z",
        "title": "Strukmyer LLC dba Strukmyer Medical - 692686 - 01/30/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQUExPQVM4Z1JfYXlPdzk5SXQ2ckhyakgwYXhla3lQczlwY0J4QkpfOHB3V1Y4Tmc5dXlnVmVESlZwa00wdGR2X1RpRG9jNnBqZnNGVi0wRF9ocTdhUFBJSXhDWVJUOE1VVlpGd09jU20zUTZWLXVkbkZrYmxsVnZhU0xPN2hpdENxUEdZbHZJRGpLTWE2WVNVS2FyMDR2a0RBR0JsZGNDeWpSRFlZaXZWOE9mTXR1WWdRYXhjUWVRSnRiYmlheUhvdTI3eGFPXzJIVVI0TU9hcE4xQ0VqS3ZKeEtGRGc?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Strukmyer LLC dba Strukmyer Medical - 692686 - 01/30/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.319Z",
    "first_seen": "2025-09-08T12:30:00.319Z"
  },
  {
    "name": "G&fire",
    "aliases": [
      "G&fire"
    ],
    "violations": [
      {
        "id": "0d0586b754317afef9337a051a038758",
        "type": "regulatory_news",
        "date": "2024-07-15T07:00:00.000Z",
        "title": "G&FIRE INC - 688176 - 07/15/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNckxjSXJXR3pGOHhlbFJuc0Y3bWh4aFgxa2phQVp4Z0FweFl4TS1fcTJhZzV6X2tlRjV6Ml9QUm8zZmVLS2JCNEl5bDlNV3MxcG9OY0o5ZFdYSFp2d2ZFc2tYZkZzb01iLXhnMkc5bTFqMGpjVWV1VU9Oa0RucndQY3BzZjBCRFYxRGlmM1lOUzRLNk9XcjdYTktLN2dneDRJNHQ0Y2ZueWEyY2lHOUFaV090b0M2ZGdGSmZjSHJqSHdOQQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "G&FIRE INC - 688176 - 07/15/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.321Z",
    "first_seen": "2025-09-08T12:30:00.321Z"
  },
  {
    "name": "Quicksilver Scientific",
    "aliases": [
      "Quicksilver Scientific"
    ],
    "violations": [
      {
        "id": "dadfa57a30b9e52ea925fca4ac872ee5",
        "type": "regulatory_news",
        "date": "2024-09-30T07:00:00.000Z",
        "title": "Quicksilver Scientific, Inc. - 612476 - 09/30/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxORXZPNEF0a0xsYWVabzkzeWtaTks4b0dYMTZBTklVdmU3aDRyVFozN2pVazlfMmR6U3VnSDIwN3NZSnFiMGxHMVlsWFE5T2ROR0xsNVRqam9FcUYxMzAtY3J2LXRsblI3R1hCR1A5SXhCN0RhNXZ2dkg1bnRERWJDSDc0bkRXbllyY2NJZUNqUVN4eHkyekRlNFhnbDRsamhyWFdOLTBNdmNPdTNXSVJ0Mkk2RThZcTJVRW54V3gwQk5xQzAwS1EyeVY0akYtSURMTWlQaTYyMTI?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Quicksilver Scientific, Inc. - 612476 - 09/30/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.324Z",
    "first_seen": "2025-09-08T12:30:00.323Z"
  },
  {
    "name": "Sambrosa Care",
    "aliases": [
      "Sambrosa Care"
    ],
    "violations": [
      {
        "id": "b3445a0c37712cdc83d482f3a164965d",
        "type": "regulatory_news",
        "date": "2024-01-24T08:00:00.000Z",
        "title": "Sambrosa Care Inc. - 673321 - 01/24/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNMnBlbkQtRkYtYk5nZi1vNkp0ZktVMU5JRF9iTC1xbUNFOUs2MXE2NjNZd05XREplYXctSUJWZzd6aFo3X29ycjFkMU9sMUxEMGxuM0g5Rk03djBWWVpPR0p3dUdadnNYNmJRb0cyVEJTcWF0RktkQm9udGM3dV8zX2piS1VHeXVPbS0yTGJPQUhxaEQ5U3pGWGI0YUg1cFpGa3ZEVWVqbnZzN3VOc3h0dHl5Z0Q1cW5ILWM4ZUhiM0k4RDN0MVhDaDFyWkM?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Sambrosa Care Inc. - 673321 - 01/24/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.327Z",
    "first_seen": "2025-09-08T12:30:00.327Z"
  },
  {
    "name": "K.c.",
    "aliases": [
      "K.c."
    ],
    "violations": [
      {
        "id": "0166708abf91731ac94e9432983abb12",
        "type": "regulatory_news",
        "date": "2023-08-29T07:00:00.000Z",
        "title": "K.C. Pharmaceuticals Inc. - 654986 - 08/03/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNbU10cEZaN291X2FkbFBiR1Y1LUVqR19RNzM4am9ncE5KZ0RzNTBlQVFnZDNSYlQtUTZPaGlxVGNZazBvcVd1c3cxemtvcXUyaS1ocUViekRldVpaYzFkSl92cWpCMVFQZ1pLc1EyVlI0eW9kRnFwS2NodGRxLTNaWVhXMTJ3UVhZNGpyZmJxdDNHSzM0a2lxOG45d29nSmxucGVTS01fRmphZ1hDUDlfNDZBN0VXa3doakNCaWhXeHVwMWtTN1pIM19GX1R6cTZPOElN?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "K.C. Pharmaceuticals Inc. - 654986 - 08/03/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.330Z",
    "first_seen": "2025-09-08T12:30:00.330Z"
  },
  {
    "name": "Art Of Beauty Company",
    "aliases": [
      "Art Of Beauty Company"
    ],
    "violations": [
      {
        "id": "cf9efcff3ad3b01a0d61e4ac6f563fc4",
        "type": "regulatory_news",
        "date": "2024-07-16T07:00:00.000Z",
        "title": "Art of Beauty Company, Inc. - 674144 - 05/22/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQQnpDdjVvUnRJaTNhWXlwdzJrT0oxUFZnbkozQ2lTWEhxTUMzcl9OYUF0b0xlNERxUmtkUi14UUpwODAxM25WYk4tckE2RXlsQVFOT1ZBWmhKbFAzQ1ZzOEVBdW8xcENfQlVsRU9GT1A5dGNUY2o1RGZQUFJOQ3NvenZMdDVMQjY3c0VBUEZQSlpXUUdIaFlNdy1iNTZlWXdZN3N3dG9rNzV4elkyWmt1ZzlnUzMtTW9Wbi11aUR4U0ktNzkydFFRdElGemRNNWFWVm5F?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Art of Beauty Company, Inc. - 674144 - 05/22/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.333Z",
    "first_seen": "2025-09-08T12:30:00.333Z"
  },
  {
    "name": "Yichang Jiayuan Foodstuffs Co.",
    "aliases": [
      "Yichang Jiayuan Foodstuffs Co."
    ],
    "violations": [
      {
        "id": "4094d1ea378ba9dbb15e02567cd2407a",
        "type": "regulatory_news",
        "date": "2023-06-06T07:00:00.000Z",
        "title": "Yichang Jiayuan Foodstuffs Co., Ltd - 655593 - 05/05/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQMG11MTNtbjh3aF9LUWF0ZFhkU3NXaG1CYjVJOHRKXzVuQ0ZxNGExVlVrZWJsMEo5cWJqbWp2WjZyUjJVYVkzTW9iTE1IUzkzLXRfaGM4b2xGU3FnN1VaTUtTUUNNcUsyeDBDQV9qUld1dEotajFvUGJNSmg2aWNtelhaOXB0dWJpMEVDbkVjR1JxV05SMFJ3TlNfVzBXb1N2Q2xfN25kZjh1RE95WjlhdzJmZi0ta0lDdW5hUGZXZkwxZ0hMX0FqSkJwX2tHVDJhYkFMbU9Kdi13QjlJTV9vQ1Bn?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Yichang Jiayuan Foodstuffs Co., Ltd - 655593 - 05/05/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.336Z",
    "first_seen": "2025-09-08T12:30:00.336Z"
  },
  {
    "name": "Abbott",
    "aliases": [
      "Abbott"
    ],
    "violations": [
      {
        "id": "fa33b828e5d3ea3ed9c554931971db37",
        "type": "regulatory_news",
        "date": "2025-01-21T08:00:00.000Z",
        "title": "Abbott Laboratories - 669353 - 12/12/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPeDN5R01rRVBEYVR3dXNSY2ZRc2k1OTlxb0oyU3FSSzVqcWY2Y3JuQzJ5eWRURF9Tc21QYWRSenlmQXpobHRJVHlWLXVqNkF0ZDAzbURKdkJFZTYwa2hoeWJsMUhRX1VGSEg5dHd3V2xzb3dxX0RoWndVWVgtdTlHOGhaRnlteVRUWTRuVXFtemVIeVRUSGFid1VKY25fdDNkVkk0TlFSalNSSlBQa1Zad1VoNC1FSTdqQXZ0aFdXRXpnaWJJTWY5NE5nY0xqZ0k?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Abbott Laboratories - 669353 - 12/12/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.338Z",
    "first_seen": "2025-09-08T12:30:00.338Z"
  },
  {
    "name": "Evolutionary Biologics",
    "aliases": [
      "Evolutionary Biologics"
    ],
    "violations": [
      {
        "id": "bb9cc56adc4bfd3935c0c45f7d3c7451",
        "type": "regulatory_news",
        "date": "2025-01-28T08:00:00.000Z",
        "title": "Evolutionary Biologics Inc. - 681586 - 12/30/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOR21hcEt4b0xxMm5peDRpcFZTem5pbWs3OWhxSmJ5MFpvMDlBRTNBR3FvNUJ4M2ZMQVBrTDFGZWo3TFl4bFNIRjlHYW1tY1FtWXBGNVlCR2ZTY19tYm45aS1VeTE1dTY1X09vQkoxY3Vlb1A2dU1oTWJuX291S1VlenlGOGFPVmRORG9GcU00Sm4xeGhYS25RRWl1OTlxQ2RhYmI2c3Fzckg4TlRFemtxWEhtcUk4VkE4NkllQ0toOElTVGplcGF6alBVUnVTSDVhdE1OWVhsdUs?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Evolutionary Biologics Inc. - 681586 - 12/30/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.341Z",
    "first_seen": "2025-09-08T12:30:00.341Z"
  },
  {
    "name": "Nortec Quimica",
    "aliases": [
      "Nortec Quimica"
    ],
    "violations": [
      {
        "id": "15f4ff14d9f4451aea7b271166652ea7",
        "type": "regulatory_news",
        "date": "2023-10-30T07:00:00.000Z",
        "title": "Nortec Quimica SA - 639894 - 10/23/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNZ25JSjdSWkVWUnFNVVcyWl9laEtLTWk0MndwNWNjTzZtWWFzalJvMWoyRENNVFEwUkNiVFhReW1raHpHTE1SZ09IOG1fdk1ma3NGa1Mxa0RPbnlPQ2NNSGZfaUR1WHJjSjBidEVhWEwyRnFCWHlHckpQWTRuc1RjeUNhalFpQ2xmTktOQ2xrMEtnRGY5SGRydjR5M3NoZVUwdkJ4SXVka1piOXB0NXJJLVFUdVN6NldVZzlnYXl1N2hmbWtuYVRoYm00RDE?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Nortec Quimica SA - 639894 - 10/23/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.344Z",
    "first_seen": "2025-09-08T12:30:00.344Z"
  },
  {
    "name": "The Vapor Club",
    "aliases": [
      "The Vapor Club"
    ],
    "violations": [
      {
        "id": "1710427726149f6925c9017c52668735",
        "type": "regulatory_news",
        "date": "2025-02-27T08:00:00.000Z",
        "title": "The Vapor Club LLC - 700095 - 02/27/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPRDMzdWluMjNfVTNfLWg0UVVKTy1neEthR0paN0VuN3NtREJsbzZTRTJLN0tEazB6VEVaNkE4cDNaSl9TaUVhcDN4anBlLVQxWkxNVmtJRk5MZzZTUmlZTnExcG10dXhxNGpFY0tqLWhMWUxUYmo3VWx4ZzZ1blhTWVhILW5GMWcwRjJ5ZnpEbnZVTzJEc2liMUdYMzJHWGtwUlJVUGUxR3pydWJXS0xpYWFnT2dYY3lWRnlYSGQ1WjJJWGdEcG5xZg?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "The Vapor Club LLC - 700095 - 02/27/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.346Z",
    "first_seen": "2025-09-08T12:30:00.346Z"
  },
  {
    "name": "Nantong Furuida Packaging Products Co.",
    "aliases": [
      "Nantong Furuida Packaging Products Co."
    ],
    "violations": [
      {
        "id": "d4987cfd992e80a772f6a3b8d4cea4c4",
        "type": "regulatory_news",
        "date": "2024-02-06T08:00:00.000Z",
        "title": "Nantong Furuida Packaging Products Co., Ltd. - 667984 - 11/17/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxQOFhwQXhEMHRlOHdweXBqeXdUSDJzY182UDk4S09seXpHNDJ6NkZ1VGlmcDdQbFNicEprNWVRV0cyMThja01HQmI2bHFadXI2OE55TUxYYl9aQWFlcUpFeXFTS3NWUHN2Qi1nUDJreE42Vm5TOVJLSXp6bC1oX3ZteXNiNy1kTlBReE0xOE5xVXVmdlIzeFRJeDlya2JlMWU0TlFGenJ0NDdhekU2RENnOGJMaGh6bzdFNnQxOGdPMHJCcEdmaVlSVUtfWTRTdGY3MXZjTVphbEt5X0h5eks0THUwV0NCLXZ3TUh6Yw?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Nantong Furuida Packaging Products Co., Ltd. - 667984 - 11/17/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Furuida Packaging"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.349Z",
    "first_seen": "2025-09-08T12:30:00.349Z"
  },
  {
    "name": "Natuzen Co.",
    "aliases": [
      "Natuzen Co."
    ],
    "violations": [
      {
        "id": "5209f8bf070f0d67050c36a111a27a54",
        "type": "regulatory_news",
        "date": "2024-05-14T07:00:00.000Z",
        "title": "Natuzen Co., Ltd. - 677942 - 05/03/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQeXhielc2SGk2cmFOOC12U19TWUVFdjJkRkZVb2dWa1pIMG9lR2daMFlxYXIyVzFVYWNaaG9yOUtWMkdvM3FfdThudk12VkhZd2FfWHNheV9rbm0xc0F3em82WEFhYUY0LThxc2k0OGFWX09JMGNvb3NFdEg0aVdXM0VvZndYd0lGbGRGeEd2Q1ZpNXB6dVNjdF9uUURFcS1XUkswQ0JKcDlLYXVrY0twQTRnMnExY0x2MlloVUVpM3VWSGFLZGw5ZQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Natuzen Co., Ltd. - 677942 - 05/03/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.351Z",
    "first_seen": "2025-09-08T12:30:00.351Z"
  },
  {
    "name": "Lipari Foods Operating Company",
    "aliases": [
      "Lipari Foods Operating Company"
    ],
    "violations": [
      {
        "id": "e29c4c7c3cc2133cb1450c0efa61c53f",
        "type": "regulatory_news",
        "date": "2024-04-16T07:00:00.000Z",
        "title": "Lipari Foods Operating Company, LLC - 669083 - 04/09/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxNR0plWG9fU3FNV3M3Q19HRXZxUnVSZEJOZVVnZ2FvZDVRU0dKdlItWmJ2MGlWQ2NnZXQzUWlEZGJpMjhZeVdvZEQ4UWtPU0E3R19jVUVWTzk3N0M1RWdvTXRZWUxTclJ5V2F5ZkhUenBUeGRtd1RoZFJ1dFU2OWYyc3djNThCODkyalhNNzlLaUJYX0daY1I1bU5EME5iYk1WUnJRVWxHNWxVblVndURRYkdZcGh2bXNjbEh6TjVPdWUwb1MwNXpjbW4zOWdscHRKeGZHY0FpaHZVdng5c0ZDQkttUQ?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Lipari Foods Operating Company, LLC - 669083 - 04/09/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.354Z",
    "first_seen": "2025-09-08T12:30:00.354Z"
  },
  {
    "name": "Hacienda Mexican Foods",
    "aliases": [
      "Hacienda Mexican Foods"
    ],
    "violations": [
      {
        "id": "e0671e007c1f3b4f087185b8d8e4c39b",
        "type": "regulatory_news",
        "date": "2024-05-14T07:00:00.000Z",
        "title": "Hacienda Mexican Foods, LLC - 663221 - 04/04/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOT0FCelJSQWhBNEYxczQ2eG9rS3g5WDZlNlUzOG96NTNwdmc4RGhxX2lkSEFGSi1zQm1mcmV5VXE4eGxZYVF1SnBDd0V4TDlwZk15MkxOUERud1NZVlhhcmNOV0dEMHBQRERjT1hiMkNfZS0zNFZHVVRlVFlzd2NpNEQ2dERPQktQTnRFeW1QcnBqMlduallGalhCSnJZMU9EQ1NUV2dabkx0Rl9FWUkzV1Q0bWFFTlRfWWNnMWNWSjlNMmlfRDJmdEFUbWRyXzJjWjdqWDI3QUk?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Hacienda Mexican Foods, LLC - 663221 - 04/04/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.357Z",
    "first_seen": "2025-09-08T12:30:00.357Z"
  },
  {
    "name": "Han C. Phan, M.d",
    "aliases": [
      "Han C. Phan, M.d"
    ],
    "violations": [
      {
        "id": "63ffde78b3372fe68bfaabf7d814e9d9",
        "type": "regulatory_news",
        "date": "2024-12-03T08:00:00.000Z",
        "title": "Han C. Phan, M.D. - 696989 - 12/03/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQbEY5VFFkTWNmeTl6UVE2b3Jzei1iOUFLdjNYSWQ1b05WaE1PdWdVb2hUTDBIdmU4cDlpa0huOGppaDVxaWk5ekszU0wza0N5TWZEVmlyd091Z2NCeURpSlliN3hwdjRCSzdfT2ZwS0k4VkgzVkI0SGRJSzBwVGN2VnJTS2lYbXNnVVNjLXpfb1JVemlxRDFPOWtIaEM1SFJyMUpyUi1ZWGxwTDg5OGc5UGJtUXVhVWV4MWFwZFhhc25oMnMwNzBR?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Han C. Phan, M.D. - 696989 - 12/03/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.360Z",
    "first_seen": "2025-09-08T12:30:00.360Z"
  },
  {
    "name": "Jiangsu Hengrui Pharmaceuticals Co.",
    "aliases": [
      "Jiangsu Hengrui Pharmaceuticals Co."
    ],
    "violations": [
      {
        "id": "126bd6de47ee78c54bdbc672fc653887",
        "type": "regulatory_news",
        "date": "2024-07-11T07:00:00.000Z",
        "title": "Jiangsu Hengrui Pharmaceuticals Co., Ltd. - 679790 - 07/11/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNTmJWcUZ4cUtMV2FsbjBKT3VncERRUVVia3hyZ3VRSHhUVkpsX3FtU1o3NnhaakpWdjMtWlZmY2VpbHdubGp5U1BJUEJLNFhsQXJ2MXFKRkRLZ1JMS3NjaDI2eHVTRVZkMVNvSFlobFRaRGtmSXIzb2tRTXZrS0x3UVJObWJZeGNyZW5McVBuZ1JUeUR6SU41WmE2Uks4N0p4Vko2OHI0ZHFweFQ5amJHYmNqdEFnaHRtTEpDQ2Zha0dWYml3YW4xcUdwLW5ZMnhFLS1FWHVaSnU4RE4yWGk3RG03QWd6Sks1?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Jiangsu Hengrui Pharmaceuticals Co., Ltd. - 679790 - 07/11/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.366Z",
    "first_seen": "2025-09-08T12:30:00.366Z"
  },
  {
    "name": "Linghai Zhanwang Biotechnology Co.",
    "aliases": [
      "Linghai Zhanwang Biotechnology Co."
    ],
    "violations": [
      {
        "id": "c3c960060bf03367a9e251231dd23dcc",
        "type": "regulatory_news",
        "date": "2025-03-11T07:00:00.000Z",
        "title": "Linghai ZhanWang Biotechnology Co., Ltd - 697983 - 02/25/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQOFRVeERwdTF2WEtpVjczTEVBQlV3N3lkWV9fVmZySnBLbnE0cGFVdWk4Yjl0VEdrY0FFNlNwQy1EdTZtc3Z1R2ZjamJtMVFNeUwtZWxjOTVLdVp3clNNRFFPVjNSRGtTc19QSTFnMjR6WkNrTzZOV05ySmgzaTd4TExBeW1BQjQxRGhlNThEelE1azhsdlV4eEdFU0prOFlKd3VlNWRBVC04VjZzZHZFVUg2SUVXa2FYUksxVVRYWktjWlJxMFpVaW5aWGNtSzRfaHZ3a0hmS3JPVWlyOE9VQjF3VkwxZ28?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Linghai ZhanWang Biotechnology Co., Ltd - 697983 - 02/25/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.372Z",
    "first_seen": "2025-09-08T12:30:00.372Z"
  },
  {
    "name": "Colonial Dames Company",
    "aliases": [
      "Colonial Dames Company"
    ],
    "violations": [
      {
        "id": "33a06dff15350c00c84bdda20d0c55e7",
        "type": "regulatory_news",
        "date": "2023-12-26T08:00:00.000Z",
        "title": "Colonial Dames Company, Ltd - 659151 - 12/05/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNU1NKdzBtbEhvb1JBdXpVNVNxYi1yZFN4NUJLSDRoOGFkLUlqN0EzSHJZaG1YbTRjUXRPbmEzTFdVaEdNLTZhdFlwcGxJa2R6LU1RREVjQktFZE54Q1VYMFZ1c2VBWHdDbkhNMkdWWHRQR3pPNjMwc25BVXZLNjYtVUotWTNTREh0STdaeE1SYnhSNlV4b291dlJHYjd0Y25SbWFsSlNiNkRiQ3AzRXl1aGt3WjltYzlVRVNJOHNQTnUwWG9FUm5oMmxWZE9OcWg2d2F1R09FdzY?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Colonial Dames Company, Ltd - 659151 - 12/05/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.378Z",
    "first_seen": "2025-09-08T12:30:00.378Z"
  },
  {
    "name": "Eco Lips",
    "aliases": [
      "Eco Lips"
    ],
    "violations": [
      {
        "id": "7bd43f6d5c75c3f528f07bc4e57e96f7",
        "type": "regulatory_news",
        "date": "2024-08-30T07:00:00.000Z",
        "title": "Eco Lips, Inc. - 631629 - 08/22/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPR0c2aUdrNERmRmYyRVVNN1ljRmtZdGRYb3VwRnljeWY2UFFndmxKblppdzZ4Y1dIaHBUbkhJc2FPdVVGX2ljSmhkLXdDZjRBXzFjYW9WT00yUUZYcVhVcUFzWHdEdXo4RnRENndnZ21QZFBkRWxlMkZDRXJ1bF9RYlBJXzBWSS1Ib3V3NTI5OEZZN3JuYlFfZk90TVBwbS1ReXdhdjZKVXJRVjlXTjczdmZieGpxMnl2ajE1UE5qUFdOLU9hOHc?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Eco Lips, Inc. - 631629 - 08/22/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.383Z",
    "first_seen": "2025-09-08T12:30:00.382Z"
  },
  {
    "name": "Vintage Chemical",
    "aliases": [
      "Vintage Chemical"
    ],
    "violations": [
      {
        "id": "d6a8f8bc1243494061d25c6ec1e46921",
        "type": "regulatory_news",
        "date": "2024-03-27T07:00:00.000Z",
        "title": "Vintage Chemical Inc. - 673930 - 03/27/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPMXF4RjljVElOM2NaZFh5SkY0Y1lKM19uYXBXdXhTSzV2ZExncTA1X1VONWRIY0FYQjVnbGZzOVlSRlJJY042QWUtZHEtTll1X1EzVVpoWDJoNzJFa0xOTnNyaDFsUkRKTFJjVnViVXRxWHZzclN1MGdXeXcyemxndU5EMkVxNTBTY09Lc3UtclU4d2dscU5jY3JUWVlPNFpPcUkxT1JReXJ6MGhzYW5RX3JuQTNLTjBiN0h6bWNpRG44aE45aFlkOHAxaUtyNVlP?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Vintage Chemical Inc. - 673930 - 03/27/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.387Z",
    "first_seen": "2025-09-08T12:30:00.387Z"
  },
  {
    "name": "Untitled Letters And",
    "aliases": [
      "Untitled Letters And"
    ],
    "violations": [
      {
        "id": "e873d3a39e1ba20bf10c1c32f7d1e732",
        "type": "warning_letter",
        "date": "2023-09-28T07:00:00.000Z",
        "title": "Untitled Letters and Warning Letters - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBzR05pWDI5TGtuejJSX1plbVpNa2U5Q3hmdDZjV2ZSS08zS0ZBOTRHdTJYakdzYk1Fa0t1SWcySzhSWEF3TWNnRVVmajNXR2NialQw?oc=5",
        "source": "Google News - FDA Warning Letters",
        "summary": "Untitled Letters and Warning Letters  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2023-10-13T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.390Z",
    "first_seen": "2025-09-08T12:30:00.390Z"
  },
  {
    "name": "Untitled Letter Recorlev",
    "aliases": [
      "Untitled Letter Recorlev"
    ],
    "violations": [
      {
        "id": "48386229ded7c6122c65f61eb90e5934",
        "type": "warning_letter",
        "date": "2023-07-06T07:00:00.000Z",
        "title": "Untitled Letter Recorlev - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1JY2dLc1UwLXlWakpqZUROeVEyU3BFaG9oYkNOelZOblh0eGo2S2xGNFNnaE0xdDN3Q2Y4Sm9QZW9senl4NDZ0NDBTQk9RMGRLUFQ4?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled Letter Recorlev  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2023-07-21T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.393Z",
    "first_seen": "2025-09-08T12:30:00.393Z"
  },
  {
    "name": "Office Of Prescription Drug Promotion Untitled Letters",
    "aliases": [
      "Office Of Prescription Drug Promotion Untitled Letters"
    ],
    "violations": [
      {
        "id": "dbec0b9a8a0b1c14231a8b6ff85a3fde",
        "type": "warning_letter",
        "date": "2023-10-25T20:05:34.000Z",
        "title": "Office of Prescription Drug Promotion Untitled Letters - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPbTF2UUdtQmpZempPSVVJZlhlS1BMMmQ4ZHdCRkpVT01KOWJ4ZEpoX00ydGxLcmJTemZTZGRzRFpMQUNaY09ZZ1FHNzFNNVBjUE92ZFNwYXNVRlNuR1pXZFQway1POGhUaTFOcDY0dElHN0Rpb250TDRsM1hidThXb1JPYXB6MmxUc0dQQ2JsY0xuR2VWT09oUG5wemJIS2FJMndUZEZqcTFodXd5YkJoSHZR?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Office of Prescription Drug Promotion Untitled Letters  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2023-11-09T21:05:34.000Z"
      }
    ],
    "products": [
      "Promotion Untitled",
      "of Prescription"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.397Z",
    "first_seen": "2025-09-08T12:30:00.397Z"
  },
  {
    "name": "Xeomin Untitled Letter",
    "aliases": [
      "Xeomin Untitled Letter"
    ],
    "violations": [
      {
        "id": "b3fe01c34b2ee867bb06579c773f802d",
        "type": "warning_letter",
        "date": "2024-10-31T07:00:00.000Z",
        "title": "Xeomin Untitled Letter - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE05S0tqazhsQklPTVhoYm1sVWVISXJoQXVjUFhETWlpTHZlMDR4R3pJNENqS2pCWmRtcmZRUlQ2MDRjbzk1dFR1Q1pDUVF0bDROeFo0?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Xeomin Untitled Letter  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-11-15T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.399Z",
    "first_seen": "2025-09-08T12:30:00.399Z"
  },
  {
    "name": "Untitled Letter Auvi",
    "aliases": [
      "Untitled Letter Auvi"
    ],
    "violations": [
      {
        "id": "af11823fc09615c26b5b05c666ec7e1a",
        "type": "warning_letter",
        "date": "2024-07-17T07:00:00.000Z",
        "title": "Untitled Letter Auvi-Q - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE12dkF5Vl9GT0NTeFhHNHNmSV9hNDZCUnBkSWlzazRBWUtVcWs0LV9KUjVlTmwzdUxkX2R2a0xUOFhZWUhXdXRQRkpsZllrblRpRHV3?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled Letter Auvi-Q  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-08-01T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.402Z",
    "first_seen": "2025-09-08T12:30:00.402Z"
  },
  {
    "name": "Astrazeneca Pharmaceuticals Lp",
    "aliases": [
      "Astrazeneca Pharmaceuticals Lp"
    ],
    "violations": [
      {
        "id": "a3439103ccd5a35e7d673a4d763e3f0e",
        "type": "regulatory_news",
        "date": "2024-05-29T07:00:00.000Z",
        "title": "AstraZeneca Pharmaceuticals LP - 664789 - 05/29/2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQX0RiY0NVSTBOZGxZYk5PMGpVSUZlTjQzU3hSbzgybG5LcFVBR2c5NzF1RWV6U1lFNEhoaWFRN1ZDM3FpSDBGZmRFZGJpOWk4RG1QSUxYMXMwbDhVZ1J1WXQ5X2lOTlF6am1vU0QybTc1WWNUZFNQVmNOZ01wMTVsSUR3YV9KbTZGclNFQjRvNzlzRjNUeHNuMUJIbi1Nb1lkM3N2aVczNC1qWm5sZ3MxLW12NzFIVVBqRXRxcE5aY21OeW5CMjFrcW52ZWJSb0gwQlY5YzE2Q0U1MzFJdmc?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "AstraZeneca Pharmaceuticals LP - 664789 - 05/29/2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "2f017ee6942bdfa978bd1dd162b0335d",
        "type": "regulatory_news",
        "date": "2023-08-15T07:00:00.000Z",
        "title": "AstraZeneca Pharmaceuticals LP - 664789 - 08/04/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxNR3VHTmJPcU9kVjM1RHJ2TFlfcGRRN294VkRRb01hdlIxYlg5QW4yOTNWWTcyZC1WeUNmT09HNHdVYzFZbnI0T2V2OVpZcHp2d0ctZTBKTWtaUkpPU1JZQ0VlV08xbUtHRi1MRG5ud1p6VjM0YkxGTkZndXJwMFN6anNuYndpMG9ldi1yM2lPN0tDcjVXZ2VJaExxV2U2dE5fTjNINFRvMnotT21LdUtzclhKM1oyWEx6UlhoMUx1cjRsdkVCRDdPUE1FaHRGWF9ScEk1OUZlOWZJdEpwaEE?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "AstraZeneca Pharmaceuticals LP - 664789 - 08/04/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.790Z",
    "first_seen": "2025-09-08T12:30:00.405Z"
  },
  {
    "name": "Untitled Letter Kisqali",
    "aliases": [
      "Untitled Letter Kisqali"
    ],
    "violations": [
      {
        "id": "280d921171e4a089b65b22c2dc7bd138",
        "type": "warning_letter",
        "date": "2024-01-18T08:00:00.000Z",
        "title": "Untitled Letter Kisqali - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1ycENkVW5IWnZVcVNjZlJ5UGJXOXp1dTkyWUxaelNrXzJsTV9xUnFENDgzNExLcmdkQUV4QlVpMVIwWmVkcTVWbmRSNDU3WnBzc0hJ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled Letter Kisqali  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-02-02T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.409Z",
    "first_seen": "2025-09-08T12:30:00.409Z"
  },
  {
    "name": "Hemady Untitled Letter",
    "aliases": [
      "Hemady Untitled Letter"
    ],
    "violations": [
      {
        "id": "782898126ed94c450a018b917e6d86b2",
        "type": "warning_letter",
        "date": "2025-02-03T08:00:00.000Z",
        "title": "Hemady Untitled Letter - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5kdEExSnlhODhtc0RISHdGRFNuZjlyNHNRUVcweUFTNmltY1BzXzlmV05qZkU3S1kydWwzWWEtb3BQLTNVTDQ3VnB5aFlJZFNCeU5j?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Hemady Untitled Letter  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-02-18T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.415Z",
    "first_seen": "2025-09-08T12:30:00.415Z"
  },
  {
    "name": "Untitled Letter Krazati",
    "aliases": [
      "Untitled Letter Krazati"
    ],
    "violations": [
      {
        "id": "757157db88df99fc5e3d9f74a366b77f",
        "type": "warning_letter",
        "date": "2024-08-01T07:00:00.000Z",
        "title": "Untitled Letter Krazati - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9lRk91bnpySjZ5ZnJEQWlzOHNxSm9uS01BVGVrVVFuZVJhTGhVYU1XYXpCU2VrclZCcnRMZm5rSWc0aktIMHZiZ1pLWDRqNWExbXdZ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled Letter Krazati  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-08-16T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.419Z",
    "first_seen": "2025-09-08T12:30:00.419Z"
  },
  {
    "name": "Coopersurgical",
    "aliases": [
      "Coopersurgical"
    ],
    "violations": [
      {
        "id": "74837e1feaf3602352cc2ff132a02a42",
        "type": "regulatory_news",
        "date": "2022-06-22T07:00:00.000Z",
        "title": "CooperSurgical, Inc. - 613339 - 01/19/2022 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPM1ZsaEZ5dWVTTk03QmJjZzExeEJqTGdzTnVERTFqUjJ4YUhVaW9Ya3QzWk5pcGdlaW1DTE1pV2RqTVdPTWtKSGVWamxTR01sd3hPc0JQSTdNdjFoOEhyOWFCSkJFSVpPcF9SNmgyanBIZXBTaVVTTXlfMlV5TFphd2NubnNkeW9WYnRsdmwxVnFkSDhXdk41bWJqOGM3MWhnZTE4LUtMQ2loOVprbF9sd3VHUGdpNVlUWU5jUUw1MXZYMXh1TFhPMTBNbnpNQQ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "CooperSurgical, Inc. - 613339 - 01/19/2022  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "04b482280b9e1719b2b6d45d0c627f6b",
        "type": "regulatory_news",
        "date": "2021-02-23T08:00:00.000Z",
        "title": "CooperSurgical, Inc. - 613339 - 02/12/2021 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPN21QdzhIQnZkVkZmTkdKb2JuUHk3UkVfZU1id0FWS2VsS3RwTmwtMU9kTE1kcFRpRXRjaGR0WXhZQ0J2RTFVX1Q0QlhvN0MwVGhkYnpiQ3QxNUFvaXAzeUR3RnR4cllqTTlRQ2JqZ2locTBKNGsxNkpRMXNsSzdBdlc0RTE3VTV5VGdrVmhBQkp6OHA1czFTb3BiUVljakdqZUwyVXJHOTAtdlZBUDNYMzdGUktjNXYyVG9VTkpXaHdtTk1QazNJTWlOeEFpUQ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "CooperSurgical, Inc. - 613339 - 02/12/2021  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.830Z",
    "first_seen": "2025-09-08T12:30:00.421Z"
  },
  {
    "name": "Marianne Frost, Ma Senior Vice President, Regulatory Affairs Biohaven Pharmaceuticals 215 Church Street New Haven, Ct 06510 Re",
    "aliases": [
      "Marianne Frost, Ma Senior Vice President, Regulatory Affairs Biohaven Pharmaceuticals 215 Church Street New Haven, Ct 06510 Re"
    ],
    "violations": [
      {
        "id": "c0cc205a81e3bd7fd6bb4b339de66401",
        "type": "regulatory_news",
        "date": "2021-03-08T08:00:00.000Z",
        "title": "Marianne Frost, MA Senior Vice President, Regulatory Affairs Biohaven Pharmaceuticals 215 Church Street New Haven, CT 06510 RE: - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE54UlV4VFgtTzAwMHpMdjF6UU1iR1RXRXBNdXBnVjZ6VXhaaUliSUVVU1VkZzRtMjhSajBwM2tJbTQ1UTBwdG9wd09LNnlEcWVCczRJ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Marianne Frost, MA Senior Vice President, Regulatory Affairs Biohaven Pharmaceuticals 215 Church Street New Haven, CT 06510 RE:  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.431Z",
    "first_seen": "2025-09-08T12:30:00.431Z"
  },
  {
    "name": "Lytgobi Untitled Letter",
    "aliases": [
      "Lytgobi Untitled Letter"
    ],
    "violations": [
      {
        "id": "e6c9af4e89e8a99baa305c1244b26571",
        "type": "warning_letter",
        "date": "2025-03-21T07:00:00.000Z",
        "title": "Lytgobi Untitled Letter - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1hbkNVUXl3dGVocUdqdjhfYlFRcnl1ODBPaUFsbTkwRjRaelRCWVJmWjhTcFd6T2FqemZFOS1reTMwb1lpN0RvOWVlai0tdGF1VGMw?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Lytgobi Untitled Letter  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-04-05T06:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 85,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.437Z",
    "first_seen": "2025-09-08T12:30:00.437Z"
  },
  {
    "name": "John F. Weet, Phd Vice President, Regulatory Affairs And Quality Assurance Collegium Pharmaceutical, Inc. 780 Dedham Street, Sui",
    "aliases": [
      "John F. Weet, Phd Vice President, Regulatory Affairs And Quality Assurance Collegium Pharmaceutical, Inc. 780 Dedham Street, Sui"
    ],
    "violations": [
      {
        "id": "78e421f66c106c1007a2fa3b0b6bde98",
        "type": "regulatory_news",
        "date": "2018-02-09T08:00:00.000Z",
        "title": "John F. Weet, PhD Vice President, Regulatory Affairs and Quality Assurance Collegium Pharmaceutical, Inc. 780 Dedham Street, Sui - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9CbzhROVR3anZiYWFieGpxZkhVcHBqRFctVjNWaWxhd2IxQTZDTE1rV3RhdXFrVmFOYVhSZjJKSGl6dnNCRmo0WDI0MFlxMjdaM0s4?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "John F. Weet, PhD Vice President, Regulatory Affairs and Quality Assurance Collegium Pharmaceutical, Inc. 780 Dedham Street, Sui  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.449Z",
    "first_seen": "2025-09-08T12:30:00.449Z"
  },
  {
    "name": "Sprout",
    "aliases": [
      "Sprout"
    ],
    "violations": [
      {
        "id": "26b95ab0254a1d9d50ab15879e302567",
        "type": "regulatory_news",
        "date": "2025-06-10T07:00:00.000Z",
        "title": "Sprout Pharmaceuticals, Inc. - 709942 - 05/29/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQMEdDdXdDMDBVV3FET1FvVlVRM3F1UGV6dklJb29pYk12czQzZFlXNTNTY1lrdHZfVVZ4R2NOcjd4NjI3NXdvUVhkeU8tWU5yZGV0QThjVUZ5eUpRYmV4WGhJQWxxNVRmWTJ2MFAyaU9qYjd5OERsSTVVZi1rYTZuX1d5TVV0dk8ycWtKbzQtT1JiSmlIc3Zockc0SkhQc25sbUpwTEN4V21IbHFjVmlzTFZ0LVhKUDN0aFpEbng2QVFVZHZ4RWsxUURDejRCRmhCNWZDSDMwX1Y?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Sprout Pharmaceuticals, Inc. - 709942 - 05/29/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "be07b0e3619562fd58a0b4b2951c4ed7",
        "type": "regulatory_news",
        "date": "2021-03-15T07:00:00.000Z",
        "title": "Sprout Pharmaceuticals, Inc. - 610569 - 03/15/2021 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPZUdtNmx2cmk1WGpOT19QRHdza2d6azREd3d0c1EycTdTR2F3N0dVNDh1bVRod1BBbDl4N25aUjFTTWJpVWQtR2oxUElvSy1OU0Y1LXlEXzJPd0czME1fUVdIemwzbTN0TV9rTHQyVjhiV0g0eXlXdzBjUGx6UmVNeHRVcUFqeVM5MGw1RmNlYXdoWFlHQWlkY2Yza1RHWnB2TGE5dHdwcG12Q0pBWm5BRHpyMzVDT2xlM3AyRDhtLTk5Qm1hUDhiSWJiS3I3RnUwLW9qSUhMcE0?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Sprout Pharmaceuticals, Inc. - 610569 - 03/15/2021  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "5dfe0acad658cbd98eee9f3c08200614",
        "type": "regulatory_news",
        "date": "2020-08-31T07:00:00.000Z",
        "title": "Sprout Pharmaceuticals, Inc - 610569 - 08/31/2020 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQYmE4dlVicWhyRE5PSzBhWEgweTZFZFZlQktJU1VFckZxWnFVLXhmZy1FVWp1VjVELVRmazVqQVVLU0lWSXVndkcxN1JqY1RCdThaVEx3RFFLX1U5Z3RfdVJhZlBDdXRaWVZ4Y0VhZC1XamQ2T2czLXVjQ2w1MUZhWk95SEJDYzJFTVo4akIxVmx2NC1BNEV5eS1odFRqVGFnREhKd3ltWndMVTdUdGtCdEo4VTJTeXZ5Z3lDa3NPaGJZc002c1pSS1V2VFRKV21CUU9qekVwc18?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Sprout Pharmaceuticals, Inc - 610569 - 08/31/2020  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.802Z",
    "first_seen": "2025-09-08T12:30:00.452Z"
  },
  {
    "name": "Untitled Letter For Ubrelvy",
    "aliases": [
      "Untitled Letter For Ubrelvy"
    ],
    "violations": [
      {
        "id": "0ffe896477dd0947d87a3fb4f4bb1141",
        "type": "warning_letter",
        "date": "2024-08-29T07:00:00.000Z",
        "title": "Untitled Letter for Ubrelvy - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9yalJfd1ZKUUZ3cDNKbjZCdjlxb3kzZEgyWkVuLXM1UGY0UWRNS05fM2c3Zk1neXFCT1JuVDI5bllBNmJTakZSLWRvdGJQNzMyekI4?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled Letter for Ubrelvy  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-09-13T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.455Z",
    "first_seen": "2025-09-08T12:30:00.455Z"
  },
  {
    "name": "Cytodyn",
    "aliases": [
      "Cytodyn"
    ],
    "violations": [
      {
        "id": "cb5adda9cc1dd2a64d6fdf594ec62945",
        "type": "regulatory_news",
        "date": "2023-07-25T07:00:00.000Z",
        "title": "CytoDyn, Inc. - 626957 - 04/27/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQM0VlQ3gxZ3RQZDlZSDVDeDhKSFoxX19JZlhmMkVvaDNVRUVRQ28tOFYxcjRlSWh4TmROTHI0bDZCTXY2cDhpYUZSQnk5Um4yMERvU1d4OFFxV3d2Mi1iakVULTdGU216V0d3TjVrZ0NLYWlNTE1BU2QxbVN0UTdlQ3c1SWRvaFM1aGJIZ29IVk93N2F2bjkweWttd3hUSjBuLTN6aTUwekVoME55NkNlUmlJTi0zdU43U054MFVMZzF1eHM5?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "CytoDyn, Inc. - 626957 - 04/27/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "130b656f567de8f37b80bdf2d41dccc2",
        "type": "regulatory_news",
        "date": "2022-02-11T08:00:00.000Z",
        "title": "CytoDyn, Inc. - 626957 - 02/11/2022 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPTzJVYzRzeWFkRVJnQ01VQlREUFVHN0tQdUphWFJ1MEZqY2J4QlhNUXBSWjRnRkpObTV5ajUteWJmNXZaYTZFM1h0YmJmelNUZnNZY1FpSjZTWklzYkJmX3c2NWFQc2JSdENaYzFsWEZmUDZscWtzdktzQk5OV3BkV1VnTVFHY0lwTElScnpRZWoxaGk1bUVPTEZBOHRQcDFPVEMtaVhxTHZyUWFMRmk3M2lIMXllSjZxUWNWTzZ1bk81RzJJ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "CytoDyn, Inc. - 626957 - 02/11/2022  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.795Z",
    "first_seen": "2025-09-08T12:30:00.461Z"
  },
  {
    "name": "Sarfez",
    "aliases": [
      "Sarfez"
    ],
    "violations": [
      {
        "id": "d47fb7d75f86149d254a11926eca6432",
        "type": "regulatory_news",
        "date": "2025-05-20T07:00:00.000Z",
        "title": "Sarfez Pharmaceuticals, Inc. - 708901 - 04/25/2025 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPS0YtQTRYOThjNmtMWVNIYnVoQVA3ejlUZThxbE1odldFcHZ4ZlhqRF9Qa1otaDhCVW9tajVTOFN2dzdTSHBDSTNKZkFlMGVFeWtHYndVY3RnNVZ1VDcwR2w1emhscFdxMHlMb0t2RU5kWTRTRjBOZzd1Sm9XR1JxUlZpamN4NXpHRzhEcjdVNllhUzZneV9FZTlWSTRpeWNfYjJTVjcxVTM2aC0ya3p4dVEzVDgzakhqQ1BkYXZXcVRteVMwbEZFNlU1bkFlYUhIYW5aSzBIWng?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Sarfez Pharmaceuticals, Inc. - 708901 - 04/25/2025  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.463Z",
    "first_seen": "2025-09-08T12:30:00.463Z"
  },
  {
    "name": "Korie Osborn Director, Regulatory Affairs Azurity Pharmaceuticals Inc. 841 Woburn Street Wilmington, Ma 01887 Re",
    "aliases": [
      "Korie Osborn Director, Regulatory Affairs Azurity Pharmaceuticals Inc. 841 Woburn Street Wilmington, Ma 01887 Re"
    ],
    "violations": [
      {
        "id": "80c8ce02777c2004597db96d91e3bcf2",
        "type": "regulatory_news",
        "date": "2020-11-24T08:00:00.000Z",
        "title": "Korie Osborn Director, Regulatory Affairs Azurity Pharmaceuticals Inc. 841 Woburn Street Wilmington, MA 01887 RE: NDA 208400 X - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5sZ3BXODZQWHFVTkdSWTZBTEhvandSeUd2RGJmREs0TEJ5T2plM2hjQkdIczlMcFN4M3FoS1VLUlVNN0p6ZDM4U2tnRW9Fck1qVzJF?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Korie Osborn Director, Regulatory Affairs Azurity Pharmaceuticals Inc. 841 Woburn Street Wilmington, MA 01887 RE: NDA 208400 X  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.472Z",
    "first_seen": "2025-09-08T12:30:00.472Z"
  },
  {
    "name": "Galt",
    "aliases": [
      "Galt"
    ],
    "violations": [
      {
        "id": "34f728012074b1252e93b6a657072983",
        "type": "regulatory_news",
        "date": "2019-09-13T07:00:00.000Z",
        "title": "Galt Pharmaceuticals LLC - 593156 - 09/13/2019 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQcUNxdFp6NFdnNEJaLXJGM3ZPOUVZbGU5a08zamFVNjRHSGhhbHp2SmtQM2t2VjJfYmgtaTRhRU1FeFJtOHRMSER0a0JCb1lxeFpJQ21sOGR1SzYyYk5qQjZ4X1VoSmQ4SXM2SVA0RzFxaTNHel9VV2VBeWhKQVBuajZ6UXRIX0luaEEyb095cHRzSlU1SGJVVHVOcWhGT1A1dnFaN1ZQazFwQ1RpMTFzQkl4WEFTWktjRUlQLUlCWUhRLU83bGJoeGs1RjJxNUJXeWlKNm1R?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Galt Pharmaceuticals LLC - 593156 - 09/13/2019  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.476Z",
    "first_seen": "2025-09-08T12:30:00.476Z"
  },
  {
    "name": "Untitled Letter For Slynd",
    "aliases": [
      "Untitled Letter For Slynd"
    ],
    "violations": [
      {
        "id": "d9558f08e95d21d6413ecbadd244b9de",
        "type": "warning_letter",
        "date": "2023-08-11T07:00:00.000Z",
        "title": "Untitled Letter for Slynd - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBtUmZzU3BteEN5WktDRHJSYU5YNkMwQzIzbUQyY1lUSHhfZGtERnZFMkZVNl85cXBEUWJIR3NmYXRGQXIzeE5UM3NSUlU4LXhDdnVZ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled Letter for Slynd  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2023-08-26T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.480Z",
    "first_seen": "2025-09-08T12:30:00.480Z"
  },
  {
    "name": "Untitled Letter Rexulti",
    "aliases": [
      "Untitled Letter Rexulti"
    ],
    "violations": [
      {
        "id": "44979da4c2c68730e3453459efabaa9f",
        "type": "warning_letter",
        "date": "2023-10-31T07:00:00.000Z",
        "title": "Untitled Letter Rexulti - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE01TkNQOFZyTXprWkVONXVtYnpiWk03TkMtMnNoUGNJZ3hxSEl6V09XTUtfczJMUFZxMFpwRHFjdFBJWnE3M3hpOVh2Nl9WZURUZjZJ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled Letter Rexulti  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2023-11-15T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.483Z",
    "first_seen": "2025-09-08T12:30:00.483Z"
  },
  {
    "name": "Mandy Edwards, Manager, Regulatory Affairs And Operations Mayne Pharma Llc 3301 Benson Drive, Suite 401 Raleigh, Nc 27609 Re",
    "aliases": [
      "Mandy Edwards, Manager, Regulatory Affairs And Operations Mayne Pharma Llc 3301 Benson Drive, Suite 401 Raleigh, Nc 27609 Re"
    ],
    "violations": [
      {
        "id": "b2035f635cceecb5951892646a2d276e",
        "type": "regulatory_news",
        "date": "2025-04-28T07:00:00.000Z",
        "title": "Mandy Edwards, Manager, Regulatory Affairs and Operations Mayne Pharma LLC 3301 Benson Drive, Suite 401 Raleigh, NC 27609 RE: - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE4zQlMzbjkzLVRhTnpjRmRKcFRlNjVuMVhCcURQMEV6SFlnZWVUWjRUaXNhRVZZR0RSaGZjQm9rQWwwUFBiV2hPY2VMUnB5WFQ1S3BN?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Mandy Edwards, Manager, Regulatory Affairs and Operations Mayne Pharma LLC 3301 Benson Drive, Suite 401 Raleigh, NC 27609 RE:  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.490Z",
    "first_seen": "2025-09-08T12:30:00.489Z"
  },
  {
    "name": "Kyle Hooper Regulatory Affairs Associate Coopersurgical, Inc. 75 Corporate Drive Trumbull, Ct 06611 Re",
    "aliases": [
      "Kyle Hooper Regulatory Affairs Associate Coopersurgical, Inc. 75 Corporate Drive Trumbull, Ct 06611 Re"
    ],
    "violations": [
      {
        "id": "7acbcbc868bd88552b4a34e0d7294ac5",
        "type": "regulatory_news",
        "date": "2019-07-25T07:00:00.000Z",
        "title": "Kyle Hooper Regulatory Affairs Associate CooperSurgical, Inc. 75 Corporate Drive Trumbull, CT 06611 RE: NDA 018680 ParaGard® - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9TSGJ0V1EzVXA5UGlpZ19Gdko2NlFSemNhNXo4Q1oyTGNJaUFNb3dVNjFsZDJRZWxkTEFvNnRSV3M2N1V4bUhURG1qUnJhbmljNjlJ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Kyle Hooper Regulatory Affairs Associate CooperSurgical, Inc. 75 Corporate Drive Trumbull, CT 06611 RE: NDA 018680 ParaGard®  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.497Z",
    "first_seen": "2025-09-08T12:30:00.497Z"
  },
  {
    "name": "Vanda",
    "aliases": [
      "Vanda"
    ],
    "violations": [
      {
        "id": "3bd2b0c6f2ad6c815f2987b05ebef43f",
        "type": "regulatory_news",
        "date": "2019-05-02T07:00:00.000Z",
        "title": "Vanda Pharmaceuticals - 576442 - 11/21/2018 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQVktiQzBibzZJSjFxRUY2YWt6b1FMc2RONEFySUhoa3pRY21PSG5ZbWpPRlBYenhCdGFpZ295NW9LVHJRWnFjUWlWZjFLWDRmWTZ4enZ6eG1OREZDdTFlVkdwSWRmVDhONWRrM1VzX1RPMDhrRmFsNzJvUU9wbDhYNDdNZ3R3Mm9oMWgzb1VwaTVZdjhlRG9LZk9KejlBUENGSTZQU0VvUmczTU91bVNzeXdGZEYyWGt1b2l5STVSTTlaQ2NodWtDS1ZXbGNfdHNnUEE?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Vanda Pharmaceuticals - 576442 - 11/21/2018  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "a8e5fc699871306f76408f86ef32d699",
        "type": "regulatory_news",
        "date": "2018-10-22T07:00:00.000Z",
        "title": "Vanda Pharmaceuticals - 576442 - 10/22/2018 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOU1pKMzhnN0NTcnBuYVRRQy01LU9GTmFJQ3cyN2REQW5aT2RBUmlNZTdIc3R6NkZmT0JNMUdLM2UxQm5mVU4tMmxDOGpOa0xsNzZMb0ROZjFoelRzUDUzWmphRjZfWVdYRGk3ZWMyLTZuVWtjWUcyMlYxREdXcmZFWTVaVWhlRU1LaW1IdGhtY1IyQUptcjVNVkRyOC11RTBNaFN0SXhlNlNZWmg5d25LT09DV2s1aGxOMmFsSDJMTnVjZEhfQW5OT0JTT1c3b09HSFE?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Vanda Pharmaceuticals - 576442 - 10/22/2018  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.517Z",
    "first_seen": "2025-09-08T12:30:00.499Z"
  },
  {
    "name": "Bruce Merchant, Md, Phd Regulatory Contact For Nascent Biotech, Inc. M",
    "aliases": [
      "Bruce Merchant, Md, Phd Regulatory Contact For Nascent Biotech, Inc. M"
    ],
    "violations": [
      {
        "id": "4fad58c6ea865767c1f37267da7b2588",
        "type": "regulatory_news",
        "date": "2019-11-01T07:00:00.000Z",
        "title": "Bruce Merchant, MD, PhD Regulatory Contact for Nascent Biotech, Inc. M - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBQODBJVXI5Q1N5NW5nNkdJYWVPUTNxVkFWTGd5eTVscHgtUWkzcDFaOUVENU5zY3RObVExMUpZVjR3U2Nmdjg4V3VVbGZIZmNBNXVB?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Bruce Merchant, MD, PhD Regulatory Contact for Nascent Biotech, Inc. M  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.503Z",
    "first_seen": "2025-09-08T12:30:00.503Z"
  },
  {
    "name": "Issuance Of Untitled Letters",
    "aliases": [
      "Issuance Of Untitled Letters"
    ],
    "violations": [
      {
        "id": "9444eb0a16504b17b7dc82c17d146f2f",
        "type": "warning_letter",
        "date": "2024-02-07T08:00:00.000Z",
        "title": "Issuance of Untitled Letters - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNUEVmaE1sTE92WWpYLXUxSjE1ckxTR2NMbXVVNUNKS2lzTzVVOHpoVHJ5bHpIZDFMNjNLSjI1ZTQ0dDVRbVoydlE4LW96SnVFd2oxalJnM0VGYTdQOU1VR2lGX1k5TWo3UmVUa1JGZWt1bllOcVVRbjZuVFNrUzJZeWZDc0lIbE1VYUhHTTNaOTdYODd4b2JPTE5BQk52NFpKeWV3eW1acTU1Uk1zRUMwS3huR0E2TVlOV29URTl6SFlvbjdZRWJTR0haX1gtZFhRRTZaZndBa2FWQQ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Issuance of Untitled Letters  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-02-22T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.508Z",
    "first_seen": "2025-09-08T12:30:00.508Z"
  },
  {
    "name": "Untitled Letter Duobrii",
    "aliases": [
      "Untitled Letter Duobrii"
    ],
    "violations": [
      {
        "id": "809cf4466651cb00b7beeeeda62d37d5",
        "type": "warning_letter",
        "date": "2022-03-31T07:00:00.000Z",
        "title": "Untitled Letter DUOBRII - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9yeUFKQVhWNzItMUZyV0lmUkhOM2s5dTVNdGxmTW5qSWM2NE9lSFB5ZVl5RUVIZGZQdkE3WjFua1dIS1daRG5XTG5EX1RzQXdYclBJ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled Letter DUOBRII  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2022-04-15T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.511Z",
    "first_seen": "2025-09-08T12:30:00.511Z"
  },
  {
    "name": "Warning Letter",
    "aliases": [
      "Warning Letter"
    ],
    "violations": [
      {
        "id": "7f9af42eaff823e792d5f0aabe66d355",
        "type": "warning_letter",
        "date": "2020-09-22T07:00:00.000Z",
        "title": "WARNING LETTER - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBYTFRCbFBpYnp2c0JLSDhwRThuajFFZjF3Z0ZtTDl3Si1TM3k1RW9VdDhQcUQ4Q1ZYRDRyd0lqZ1JYdjZyenU0aFZpOWV5VEc2c05F?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "WARNING LETTER  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2020-10-07T07:00:00.000Z"
      },
      {
        "id": "5afe3cf2bbe52ff3235c98db2da76c7d",
        "type": "warning_letter",
        "date": "2019-08-16T07:00:00.000Z",
        "title": "WARNING LETTER - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFA3eGJVXzVDSGxHclRKYTRqRDFqY1dVZE8wcEJTb1FIWW5QSmYybTNJam9vUjRKOUNjaVluRlRYeXlQSHBkNmVOTG94OFZJVnoyTTJF?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "WARNING LETTER  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2019-08-31T07:00:00.000Z"
      },
      {
        "id": "7156ec8315684a97884c8341b50a871c",
        "type": "warning_letter",
        "date": "2018-10-22T07:00:00.000Z",
        "title": "WARNING LETTER - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE10aThhZ3k1N3pKUE9xd1JhazU2dUNaQmlLamxmeWFmZGZKeFZCbGFNYzVYOVJUSFAtVlV3LTI3ZThaejBfYTVMS1hrRnl5ODF0Qzkw?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "WARNING LETTER  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2018-11-06T08:00:00.000Z"
      },
      {
        "id": "9764c88000262f5945105b450cf499ea",
        "type": "warning_letter",
        "date": "2018-10-05T07:00:00.000Z",
        "title": "WARNING LETTER - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE50czRfM05aa2dzMmluM3E0ZVg3T0cyaGppcFczeEZRalVrVWEtN2RlSkJEblFmVGRrTkdjTXlLbURkMXFXcG5BUlN4WUNsMTdVTXEw?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "WARNING LETTER  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2018-10-20T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.689Z",
    "first_seen": "2025-09-08T12:30:00.514Z"
  },
  {
    "name": "Dear Dr. Woodcock, I Am Writing To Bring To Your Attention A",
    "aliases": [
      "Dear Dr. Woodcock, I Am Writing To Bring To Your Attention A"
    ],
    "violations": [
      {
        "id": "c9543d43b6376f0b2cd4222f03cbc1b0",
        "type": "warning_letter",
        "date": "2018-10-22T07:00:00.000Z",
        "title": "Dear Dr. Woodcock, I am writing to bring to your attention a Warning Letter that Vanda received from the FDA on October 22, whic - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE51ZFIybzZCOG0tY3oyWVZrTGpDbEhkODNncUNYYXI0dWU4bDI5TnZYMzFYQjh0eWlNNEV2Y0lGMVUzZ2JTYUVkczE5RTJjM0NGMWtB?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Dear Dr. Woodcock, I am writing to bring to your attention a Warning Letter that Vanda received from the FDA on October 22, whic  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2018-11-06T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.522Z",
    "first_seen": "2025-09-08T12:30:00.522Z"
  },
  {
    "name": "Avanthi",
    "aliases": [
      "Avanthi"
    ],
    "violations": [
      {
        "id": "7a10479cbe8aedf84fb510d1d3ce9794",
        "type": "regulatory_news",
        "date": "2021-04-14T20:49:07.000Z",
        "title": "Avanthi, Inc. - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPRVZxYmR0SE90Q3MyUGoyUm5lcVVqay1ETGljZ0xpaVFMWlNDYklnNmc1QmNHb3EtcDJnVlRKQmpYY3VJUGd1al9ZSkZjTlg1NVgtUExNSXM3akI4Zll3WkdIWklfZF9HMG5Nc1A0dm1JTG5HNTZITGpKQURPU2xDSGNLWW9KQzZ6RGxCblQ0T3pHdWdYLVYyd2hzV0h0eURrZ3FzRDlIMXNpaTN6TzJ2Vk9maEFUYlBKSHVN?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Avanthi, Inc.  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "26c1720ca24ef37c474576622283714b",
        "type": "regulatory_news",
        "date": "2017-12-19T08:00:00.000Z",
        "title": "Avanthi, Inc. - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNU05NLU1acDRuNFZkN1J4ajJ6bWZQNFE2MTdkeUxyTGpmSUF5akVEUFVDWlZGTXAzM3Y5NXljQkYtLVE4RVo3YVI4RGV2QWFaLVVFYTl0dXQ5S2IwT0RLTkM5S25ENkJMSUpfVndtRFhZVXRHSGJiT01Ea2lVS1NiZXYxNm9VNXZ5eEtMWV9sanM1OE5yd2JoUnN6eEtaSWNpM3o0cUROOXh2TTV5anJNZlNlanBNeFhpYWc0?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Avanthi, Inc.  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.572Z",
    "first_seen": "2025-09-08T12:30:00.530Z"
  },
  {
    "name": "Mannkind",
    "aliases": [
      "Mannkind"
    ],
    "violations": [
      {
        "id": "0902556e49d786d6f224c98729bcb8d2",
        "type": "regulatory_news",
        "date": "2018-10-05T07:00:00.000Z",
        "title": "MannKind Corporation - 578282 - 10/05/2018 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPSnBtVno5bzAtTnE1MXNXQ3Zic1RsbmU5aW9ZZ29ISnBVSG1BWVZrVWdWMVJ5OC1MQkZyRzlSdzA3YTU1c0ZvcGZMUFM4Z3FHaThWdXVmRWNRcXhfUHVhN2lIb1pkSVB0ZDRvRGNFMWRxa3lNT2swRDEwRDJsS1V3a2hJQ1dyOHMzTFRTSnVNNG5ndFJQM1NhTHVGX1l2Q0NLQzNqYmVoOTZ0T0lzSm5WNnJXczBmZVlZMnhaVUJYWXFzeEFuQldISzNLMDBwZk1p?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "MannKind Corporation - 578282 - 10/05/2018  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.533Z",
    "first_seen": "2025-09-08T12:30:00.533Z"
  },
  {
    "name": "Emgality Untitled Letter",
    "aliases": [
      "Emgality Untitled Letter"
    ],
    "violations": [
      {
        "id": "017d342c0ae9f23339404f0dd1b851f7",
        "type": "warning_letter",
        "date": "2021-12-13T08:00:00.000Z",
        "title": "Emgality Untitled Letter - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBfN0szeDVZTG1TRXNKa2FhRTJkUFhhTnhmejFKa1Y1NjhYMzZRUnJ5TmI1NFR4MXM3UWxad0R5TW9VM2UyUU1fUW04Z0JtUFNJUlNV?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Emgality Untitled Letter  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2021-12-28T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.538Z",
    "first_seen": "2025-09-08T12:30:00.538Z"
  },
  {
    "name": "Neulasta Letter",
    "aliases": [
      "Neulasta Letter"
    ],
    "violations": [
      {
        "id": "4d7531e686de31fb9df1761ff68ee9f7",
        "type": "regulatory_news",
        "date": "2021-07-07T07:00:00.000Z",
        "title": "Neulasta Letter - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFA1LVNjUmxvNk12alZ2dndfQ3hxVUNhZ0EteENIZFZkLVJvdmhoM2NwX19YdDBjeEpZQ2pqN2d1NEVpVDAySjFhWW8tRVYyVlpKSWlz?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Neulasta Letter  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.543Z",
    "first_seen": "2025-09-08T12:30:00.543Z"
  },
  {
    "name": "Warning Letters And Notice Of Violation Letters To Pharmaceutical Companies",
    "aliases": [
      "Warning Letters And Notice Of Violation Letters To Pharmaceutical Companies"
    ],
    "violations": [
      {
        "id": "a964a9df176feb0711cae095f822acae",
        "type": "warning_letter",
        "date": "2023-10-25T07:00:00.000Z",
        "title": "Warning Letters and Notice of Violation Letters to Pharmaceutical Companies - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQOWhBYlN5dHpxRS13ZXBES2QyLXVfRk90WDBxY2pjSGFBSW5Za3JJN2pVNHJORjVRdmRWTXBGLXFpOHE3WUxjU0hzOW43V04tMjFxUWRoUjBsMk1CdWVuZzhVRVd1VHZkNkZaUW5uN0o0QkszU21KMVRLVUYwaDVFLWJzNWt2c2lTa3h2eUhJQnJ0Sy1CQzVvQ0JpQWRMR1JnRWs1QmlvalhNWXp5ZHlBMFFGVy1lTGNOb1l4RUFscw?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Warning Letters and Notice of Violation Letters to Pharmaceutical Companies  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2023-11-09T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.551Z",
    "first_seen": "2025-09-08T12:30:00.551Z"
  },
  {
    "name": "Acelrx",
    "aliases": [
      "Acelrx"
    ],
    "violations": [
      {
        "id": "664e45baeb1eab351711e6f9c1a5ba9a",
        "type": "regulatory_news",
        "date": "2022-06-22T07:00:00.000Z",
        "title": "AcelRx Pharmaceuticals, Inc. - 613257 - 03/28/2022 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNWDJNTDh4Vm12SF9ENUFJTDFCenhPbHMzRWs1OTZUZWQzeE9RRFh2TXBxRDZkZnpkUmlHRnUyeDIyd0lUNUZ0SXYwbzlnWk1WNWhvamQwRXE0WFRKd3hoanV4OXVkSnRiNTd0b3RWUTVWSU5SdEIza2dpckY1QzZMWURoQUZnUXpMU29ETG9HZDNqdGZXeFZNN0FxZUZSRkZrZzZOVkcwTnJDQXNTOUZKLXNJdmRBSWNjVG9oZVlRNmNfSEp0Q3ZMaWFfQWU1M0lfbEhERXFVakY?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "AcelRx Pharmaceuticals, Inc. - 613257 - 03/28/2022  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "089e0f5c87816d9dd28633a6d03878bc",
        "type": "regulatory_news",
        "date": "2021-02-11T08:00:00.000Z",
        "title": "AcelRx Pharmaceuticals, Inc. - 613257 - 02/11/2021 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNMmdwZG1WTS1HWVhPZ0ZEclJzWjBCa2J1bkpES0NVa25hSXhsaHM3b3ZnaExVN3Z2ekN1aFVTMWJoS2I5WGRNYnl6bEpGOUxLdHdib0JURUxTdXNjUzB2THIyTEIxZ2t5d1NlM0g0SGw2UDZacjcwU1E3V1pTMEF6MWZUeWtKcGpuRmFDSTVjVzhQRlZxZGItSDQ1amZRR3Jxa1RITTRtVF90dTZxRWttUVFLMXhYUDZVcFI3VTlrR3FXYTdRa3dfLTRCOVFzNnlBR0tiaEt1REU?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "AcelRx Pharmaceuticals, Inc. - 613257 - 02/11/2021  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.838Z",
    "first_seen": "2025-09-08T12:30:00.555Z"
  },
  {
    "name": "Untitled Letter Roszet",
    "aliases": [
      "Untitled Letter Roszet"
    ],
    "violations": [
      {
        "id": "aebb984241d9e18b94ae13a6139f7f68",
        "type": "warning_letter",
        "date": "2022-06-02T07:00:00.000Z",
        "title": "Untitled Letter Roszet - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE95R1JUMkZWRmxNU2QyalV1bkgxd1FXdEoyQWhxcGZDa05PUDVkMWp2VF9GVDZMcUZtLTJhY0gweF9tRm9iZm1pU281QUxod3ZrOFJF?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled Letter Roszet  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2022-06-17T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.561Z",
    "first_seen": "2025-09-08T12:30:00.561Z"
  },
  {
    "name": "Opdp Ectd",
    "aliases": [
      "Opdp Ectd"
    ],
    "violations": [
      {
        "id": "464b041289dbcf4c2cc8b5aa11457f03",
        "type": "regulatory_news",
        "date": "2019-09-09T21:40:32.000Z",
        "title": "OPDP eCTD - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQSEZhNTBCVzVwa2R3Q1V3RnplZ0s2X19XTjNlUGZ5cGRBbHJmNC1tSVV3eHpsb25UUFB2T19qa0dQYzcyQWZsTVVIOG41Z0RiVDZ5RnpVODJ0R3B0cEdVZ2ZIWmRYeGRhTTNjT1IzbE5kMS1SeWpzQjVPUzhJcVNQUDNZUERIUDg?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "OPDP eCTD  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.566Z",
    "first_seen": "2025-09-08T12:30:00.566Z"
  },
  {
    "name": "Alkermes",
    "aliases": [
      "Alkermes"
    ],
    "violations": [
      {
        "id": "9446b0851af7eafb9098147c71eac433",
        "type": "regulatory_news",
        "date": "2019-12-02T08:00:00.000Z",
        "title": "Alkermes, Inc. - 597260 - 12/02/2019 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQckllXzMxNXphOFRiMnh2bFZtQjJneVdiM3FZM0o3NV90MmVjUEhYTUtVaEUxTjlYM0xYSU5ZOUpEcldaMnphejFpSldteE5sRmFwckhacmo4aVJ3WXpjc0tIUzhXakZHMGpPQ2lqZHFRMWhYakFWb3JfM19Hd1lsSEVSVXdBRVJZa280UzB5Ri1pVVJ2UmZVSXktNVp5ZWlwNXBnZ1lqUzlsZ2xBb2hRMndVYndfazNmU21LeENKQWNYa3l4V2c?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Alkermes, Inc. - 597260 - 12/02/2019  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.578Z",
    "first_seen": "2025-09-08T12:30:00.578Z"
  },
  {
    "name": "Santosh T. Varghese, M.d. Chief Medical Officer Vivus, Inc. 900 East Hamilton Avenue, Suite 550 Campbell, Ca 95008 Re",
    "aliases": [
      "Santosh T. Varghese, M.d. Chief Medical Officer Vivus, Inc. 900 East Hamilton Avenue, Suite 550 Campbell, Ca 95008 Re"
    ],
    "violations": [
      {
        "id": "023271657d525f6338242b310226b908",
        "type": "regulatory_news",
        "date": "2019-05-22T07:00:00.000Z",
        "title": "Santosh T. Varghese, M.D. Chief Medical Officer VIVUS, Inc. 900 East Hamilton Avenue, Suite 550 Campbell, CA 95008 RE: NDA 022 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1VbjB3LW1zUEVBMjdqN1FqVzRPMDlvU1FjYzA5RTA2SDNxTEJrOTVsOEZDMEhpWU44MTBiOTR1MnE1V3pPYjgxZFhCY296TTdlemZJ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Santosh T. Varghese, M.D. Chief Medical Officer VIVUS, Inc. 900 East Hamilton Avenue, Suite 550 Campbell, CA 95008 RE: NDA 022  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.589Z",
    "first_seen": "2025-09-08T12:30:00.589Z"
  },
  {
    "name": "Colleen Matkowski Senior Director, Regulatory Affairs Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne, Pa 19087 Re",
    "aliases": [
      "Colleen Matkowski Senior Director, Regulatory Affairs Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne, Pa 19087 Re"
    ],
    "violations": [
      {
        "id": "45a55ec70e092ae0c8b95df58d860ef5",
        "type": "regulatory_news",
        "date": "2019-06-14T07:00:00.000Z",
        "title": "Colleen Matkowski Senior Director, Regulatory Affairs Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne, PA 19087 RE: ND - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9GNUI1NFRRS3dGWllTa1NRZmoza0g5V2xCWUJzMy1LSkxJNUoxemdnVlVRd3dubWFCdkM1bnhFU3pfd0h2SXF2Rm5XaktFUTlmZmRF?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Colleen Matkowski Senior Director, Regulatory Affairs Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne, PA 19087 RE: ND  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.602Z",
    "first_seen": "2025-09-08T12:30:00.602Z"
  },
  {
    "name": "Cipher Pharmaceuticals Us",
    "aliases": [
      "Cipher Pharmaceuticals Us"
    ],
    "violations": [
      {
        "id": "29f5ae56f7736cc1d302b8f2afb0e2af",
        "type": "regulatory_news",
        "date": "2017-08-24T07:00:00.000Z",
        "title": "Cipher Pharmaceuticals US LLC - 460380 - 08/24/2017 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPekpKUEx0TFZQODRVcnM4Q1g3cnJ1U3ZpQVVERGZJVjdYRlFsY1c2UXR1RXlUX1FhcmctaVg5NXN5aVhDZ2pyZHhucVZ2RGpuRGhCdmJvRWlrLWFPNjQ5NDJjZF9nNHpyY25abWp1TmEtSTBjZmxUU3NIeDZNRnA1SkdmRzZJb3N2T09fVjZPTTF4R3dlTWpITzFOUVozNUEtQVRSSmU0M0dyQmZhRlZyOUpqdy1SRXV0S2tkMzJMNm1VcS1WcDJHcHRxal9jSlpoMzZ2TGZ0UEdzR0pH?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Cipher Pharmaceuticals US LLC - 460380 - 08/24/2017  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.606Z",
    "first_seen": "2025-09-08T12:30:00.606Z"
  },
  {
    "name": "Untitled Letter Phexxi",
    "aliases": [
      "Untitled Letter Phexxi"
    ],
    "violations": [
      {
        "id": "6e6171cb7743262f9b692f16e48ca17c",
        "type": "warning_letter",
        "date": "2023-10-31T07:00:00.000Z",
        "title": "Untitled Letter Phexxi - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9TdV92Slg0Sm5rYVdQT2RUQk1VeWVQaWxpLURlQ0E4YURvSjF0YmVOQ1dnaF9DbnhSbEI2dzE3eXNRTDZaTW1iZ0xNXzBTeDNNTm40?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled Letter Phexxi  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2023-11-15T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.610Z",
    "first_seen": "2025-09-08T12:30:00.610Z"
  },
  {
    "name": "Cipher",
    "aliases": [
      "Cipher"
    ],
    "violations": [
      {
        "id": "fad2a626c9e018de47e86aaad7d40167",
        "type": "regulatory_news",
        "date": "2017-11-30T08:00:00.000Z",
        "title": "Cipher Pharmaceuticals Inc. - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPdkR0MUhwYW14Rk9GX1FpMkF3Y2h2NFBTVHJubU9kSmV5S0hJSG9ncXowOGlYZDVUZVhiNFFxUDVQTFBCUWl0c0JNUFZhMEpSLUFDb25tTDdMRjZ4c0hoYmx2eVk1ZGpYeEUzYmIyNV96a3ppN1kyZ2dNVS0zbjFPYVJjUGVvV0lUVXg5TmYzOEYzN1ZuSHZfdV9Oc3JKQ01LbmNiZUtuM1FZNlR3cEVVbzlTc3B3dnd3Zko5Wjg1TExRY2IwWE9SeUR3TVRwSzQ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Cipher Pharmaceuticals Inc.  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.614Z",
    "first_seen": "2025-09-08T12:30:00.614Z"
  },
  {
    "name": "Untitled",
    "aliases": [
      "Untitled"
    ],
    "violations": [
      {
        "id": "fa14e04c45265653e7ca969011195b9f",
        "type": "regulatory_news",
        "date": "2017-12-28T08:00:00.000Z",
        "title": "Untitled - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5QMy1pdHo0NG5XVXpSZzZTTS0telR3c1RPTnMyekk1MDJxMU9iVzdqYTlMVDFyaDFBckZNcmZaYnNfWEo5d1lHVjlkTXhNNmlONmtB?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.616Z",
    "first_seen": "2025-09-08T12:30:00.616Z"
  },
  {
    "name": "Nephron Sc",
    "aliases": [
      "Nephron Sc"
    ],
    "violations": [
      {
        "id": "3cbefeca3ed3a3b52d987ddbf29e665c",
        "type": "regulatory_news",
        "date": "2020-09-22T07:00:00.000Z",
        "title": "Nephron SC Inc. - 610867 - 09/22/2020 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQbDZNN3ZrcVc4ZEp4b3I3bFJtSm9DN1ZYLVBycFBHYTdXbVViODRfdXY1eHg5NWFfX0pnR3FUbUxHbGNCWnQ4dW5xMVI3b0hlbV9mOGZrbUIzcnF0aWVwbGgwbWdGdzJxS2llRkF5TWQ4R1M5M1NQR1ljdDlneExmWnhMalVudXlibXlUZmdTX25fWFljeFpac3lRYkRzRTY1RWR2b1o5WEFmd0dEN2Rld3VkbVA2cHpOcUI3NEN1X1NfbHREdVpZLQ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Nephron SC Inc. - 610867 - 09/22/2020  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.619Z",
    "first_seen": "2025-09-08T12:30:00.619Z"
  },
  {
    "name": "Luis Caveda Senior Director Of Regulatory Affairs Rockwell Medical, Inc 30142 South Wixom Road Wixom, Mi 48393 Re",
    "aliases": [
      "Luis Caveda Senior Director Of Regulatory Affairs Rockwell Medical, Inc 30142 South Wixom Road Wixom, Mi 48393 Re"
    ],
    "violations": [
      {
        "id": "eb816ef942d064703e873239596abbeb",
        "type": "regulatory_news",
        "date": "2019-11-18T08:00:00.000Z",
        "title": "Luis Caveda Senior Director of Regulatory Affairs Rockwell Medical, Inc 30142 South Wixom Road Wixom, MI 48393 RE: NDA 206317; - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE91MzJCdldFY2NzYjZYLUlFYzdMV0pkUzJwNUlqX3U4ZUR5OEo4d1c5NUg4T3NFV2tBTTRzYjN5X1JWUV9LYXpBTE1DZHRLX3BNdjdz?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Luis Caveda Senior Director of Regulatory Affairs Rockwell Medical, Inc 30142 South Wixom Road Wixom, MI 48393 RE: NDA 206317;  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.626Z",
    "first_seen": "2025-09-08T12:30:00.626Z"
  },
  {
    "name": "Suzanne Strang, Ph.d. Executive Director, Regulatory Affairs And Quality Assurance Ascend Therapeutics Us, Llc 607 Herndon Parkw",
    "aliases": [
      "Suzanne Strang, Ph.d. Executive Director, Regulatory Affairs And Quality Assurance Ascend Therapeutics Us, Llc 607 Herndon Parkw"
    ],
    "violations": [
      {
        "id": "0f1a750b1e8a9080d9dfaa403f92cef5",
        "type": "regulatory_news",
        "date": "2018-08-16T07:00:00.000Z",
        "title": "Suzanne Strang, Ph.D. Executive Director, Regulatory Affairs and Quality Assurance ASCEND Therapeutics US, LLC 607 Herndon Parkw - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFAtSi1PRjBCZnUwQ1RXYXdUWVV5cnMtT04zbVh3QkxkaU9xUlFOOGlreXBSWTR2ZjNKWTdjWkdxUERXTDlWak13ZFFURFlXUFlidW9r?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Suzanne Strang, Ph.D. Executive Director, Regulatory Affairs and Quality Assurance ASCEND Therapeutics US, LLC 607 Herndon Parkw  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.633Z",
    "first_seen": "2025-09-08T12:30:00.633Z"
  },
  {
    "name": "The Brief Summary October 2023",
    "aliases": [
      "The Brief Summary October 2023",
      "The Brief Summary October 2024"
    ],
    "violations": [
      {
        "id": "7e0c20833eb52c13991079119be2ea30",
        "type": "regulatory_news",
        "date": "2024-10-07T07:00:00.000Z",
        "title": "The Brief Summary October 2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1jcGhkSkt2X3BxT3RwNXlUM2pIaGpqR054X2J4aGtEc1p6ZDBMUjJ2QUlwdVZlNmR4bVB2b3BGWXZRa0FtRU56Q09fWFdRazZOVGhR?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "The Brief Summary October 2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "d9f6c8d822932aabd4b0dc9efedfb891",
        "type": "regulatory_news",
        "date": "2023-10-04T14:03:13.000Z",
        "title": "The Brief Summary October 2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5ZVGViOVNKY2tUNS1SdVRpWGNKcnZTdThaUGd6YkZCTjhNbmNyVUdMdDlUc3psbFh3amo0MUpzUy14RVFpSHJLWEpzeHN6cHpVVTI0?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "The Brief Summary October 2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 26,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.645Z",
    "first_seen": "2025-09-08T12:30:00.637Z"
  },
  {
    "name": "Nada Glavan Senior Director, Regulatory Eisai Inc. 100 Tice Boulevard Woodcliff Lake, Nj 07677 Re",
    "aliases": [
      "Nada Glavan Senior Director, Regulatory Eisai Inc. 100 Tice Boulevard Woodcliff Lake, Nj 07677 Re"
    ],
    "violations": [
      {
        "id": "e0faf4866fa0fc8f1453320de8833ff1",
        "type": "regulatory_news",
        "date": "2018-10-11T07:00:00.000Z",
        "title": "Nada Glavan Senior Director, Regulatory Eisai Inc. 100 Tice Boulevard Woodcliff Lake, NJ 07677 RE: NDA 202834; 208277 Fycompa - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBjMFkzZnRkNlBQWlFlZ1dyQ1BOTFNJR2xXMFI1RktJV0M0UEF5YjFVeU8tclcxTGRhdjktRFV3STJKNDNHNkU1OGZROVhQWEF5ZFJz?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Nada Glavan Senior Director, Regulatory Eisai Inc. 100 Tice Boulevard Woodcliff Lake, NJ 07677 RE: NDA 202834; 208277 Fycompa  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.651Z",
    "first_seen": "2025-09-08T12:30:00.651Z"
  },
  {
    "name": "Auvi",
    "aliases": [
      "Auvi"
    ],
    "violations": [
      {
        "id": "4485c77bf786eb179174207526f2948a",
        "type": "warning_letter",
        "date": "2024-09-27T07:00:00.000Z",
        "title": "Auvi-Q Untitled Letter Close-Out - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFA1NzJybGdldjd1UVhCcmlrOGtieU1wTEJPUlFtR2hYTHItQTJER3VXNXJjeDMtVWlUbGJHcXpoclZjV0pqcUVGSTRlVHI5R0JwazNB?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Auvi-Q Untitled Letter Close-Out  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-10-12T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.653Z",
    "first_seen": "2025-09-08T12:30:00.653Z"
  },
  {
    "name": "Kimberly Skopitz, Rac Director Of Regulatory Affairs Kowa Pharmaceuticals America, Inc. 530 Industrial Blvd. Montgomery, Al 3611",
    "aliases": [
      "Kimberly Skopitz, Rac Director Of Regulatory Affairs Kowa Pharmaceuticals America, Inc. 530 Industrial Blvd. Montgomery, Al 3611"
    ],
    "violations": [
      {
        "id": "48736e60cac5ae85bc7f6286f79c364d",
        "type": "regulatory_news",
        "date": "2019-09-24T07:00:00.000Z",
        "title": "Kimberly Skopitz, RAC Director of Regulatory Affairs Kowa Pharmaceuticals America, Inc. 530 Industrial Blvd. Montgomery, AL 3611 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE50RjcwS0lYeGJfM1QtRmVFUWhQTi1QRmFFUFVTeGNJX1R1bFdQUDNBOWlwQkJLQmVWV2pXUk9DUHJlVzY1SzkyY2xDUmxORm45QU9J?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Kimberly Skopitz, RAC Director of Regulatory Affairs Kowa Pharmaceuticals America, Inc. 530 Industrial Blvd. Montgomery, AL 3611  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.661Z",
    "first_seen": "2025-09-08T12:30:00.661Z"
  },
  {
    "name": "Metuchen",
    "aliases": [
      "Metuchen"
    ],
    "violations": [
      {
        "id": "a365333e974e691e23eb834bad2b266a",
        "type": "regulatory_news",
        "date": "2019-08-16T07:00:00.000Z",
        "title": "Metuchen Pharmaceuticals, LLC. - 590713 - 08/16/2019 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOSzVIeEhKSk1xMHNLbVBsdTJyb0NiUmJlNUMzOXhSVXpwUGdHRUFBMmNENXpEN2NzMlRoV0d0RmtLTkdBZ2cwSFdOeWJwUTFoSGg5ckgtMlg2R1NsdFY0UUcyc3Q3NDlTR2lUNnBfZ1hBa2xmR2RkQWpyUFQ1N0ZKUTN2VDZlYTNNSGVNelBDUnVMdm1uZElqWDlzcGJaMXRPS2w2dDVlSFlKS0EzTl9JcnVTVVhHQzVNanJLVWlJVTc2dHBmZHA0OUUwOVloX0dvSkZCRDlhVjltVmM?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Metuchen Pharmaceuticals, LLC. - 590713 - 08/16/2019  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.664Z",
    "first_seen": "2025-09-08T12:30:00.664Z"
  },
  {
    "name": "Michele Yelmene Vice President, Regulatory And Quality Assurance Xeris Pharmaceuticals, Inc. 180 N Lasalle Street, Suite 1600 Ch",
    "aliases": [
      "Michele Yelmene Vice President, Regulatory And Quality Assurance Xeris Pharmaceuticals, Inc. 180 N Lasalle Street, Suite 1600 Ch"
    ],
    "violations": [
      {
        "id": "f6f44750960a29f5a64c42ed0625c422",
        "type": "regulatory_news",
        "date": "2020-08-14T07:00:00.000Z",
        "title": "Michele Yelmene Vice President, Regulatory and Quality Assurance Xeris Pharmaceuticals, Inc. 180 N LaSalle Street, Suite 1600 Ch - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBWRWFNX0UwQ2RWSTBnRVlqU2VFdjdFbHVMZGFWbk1fREhnTEFtOFl3WjRIMG9QM3ZmcUR3RXByZy12QUtjb2psbnJRdnM0TDBVSXFv?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Michele Yelmene Vice President, Regulatory and Quality Assurance Xeris Pharmaceuticals, Inc. 180 N LaSalle Street, Suite 1600 Ch  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.671Z",
    "first_seen": "2025-09-08T12:30:00.671Z"
  },
  {
    "name": "The Brief Summary Newsletter",
    "aliases": [
      "The Brief Summary Newsletter"
    ],
    "violations": [
      {
        "id": "ccafc63c8b020f39f9f99d9fa95c0813",
        "type": "regulatory_news",
        "date": "2022-03-08T08:00:00.000Z",
        "title": "The Brief Summary Newsletter - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFAycE1qcVRYQlMzaUdsaXFoalNKTUo0X1RSbV8yVlpkSndBbDdaT1JvU2puRmRWMXhXSkRDVmRsWXVBUzNfUWtwMmtXR2luNDl5eTdB?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "The Brief Summary Newsletter  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.679Z",
    "first_seen": "2025-09-08T12:30:00.679Z"
  },
  {
    "name": "The Brief Summary Janaury 2024",
    "aliases": [
      "The Brief Summary Janaury 2024"
    ],
    "violations": [
      {
        "id": "511ce37455593b870f5e8ff72644dc37",
        "type": "regulatory_news",
        "date": "2024-01-17T08:00:00.000Z",
        "title": "The Brief Summary Janaury 2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE03ZUh6R0tmSktLZk1pUTZzZTJsSXNGMEVGRURvT1RaenlDT3RlVmNNeHJ0REdsWGU3OFNZYzF1LTNDNVhlejNWWnk5VjRhSzZGMGVJ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "The Brief Summary Janaury 2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.694Z",
    "first_seen": "2025-09-08T12:30:00.694Z"
  },
  {
    "name": "Untitled Letter Close",
    "aliases": [
      "Untitled Letter Close"
    ],
    "violations": [
      {
        "id": "f94e475a47f56751f296c82634337af4",
        "type": "warning_letter",
        "date": "2024-01-05T08:00:00.000Z",
        "title": "Untitled Letter Close-Out Phexxi | January 2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE81dnlKMHUxSko2dFcxZkp0U3c0azd4WGVfQy1Ecmo1aXFsSWJNSkJxUDdPeW9kd3FHV1hDMHl0RGtKaXgxa2xDdUJaMHlLd2p3Rkl3?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled Letter Close-Out Phexxi | January 2024  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-01-20T08:00:00.000Z"
      },
      {
        "id": "85b8587348e12407a214e2b367147fbb",
        "type": "warning_letter",
        "date": "2023-12-20T08:00:00.000Z",
        "title": "Untitled Letter Close-Out Rexulti - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBDNENpUzJxVnNRYUVhSkM1bFduRUNxXzlRVDlIY00wdWJtejJNbjBPRXlxVGcyN1YzMEhsaWhSc25xQl9oNTNKRlcxeFNQeWVHSnY4?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled Letter Close-Out Rexulti  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-01-04T08:00:00.000Z"
      },
      {
        "id": "edb71a4787fa26ea78a27311641f6b52",
        "type": "warning_letter",
        "date": "2023-08-09T07:00:00.000Z",
        "title": "Untitled Letter Close-Out Recorlev - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBFNk5wOW1xS2JHYVBUTFhNWFBqOHY2el9QR2tYVUx0WWtPUGdDMUZMN3hDRWMwM2FnSXdsVktrQkU3QUNZeko5bmlfcnNWQTVWcjFR?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled Letter Close-Out Recorlev  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2023-08-24T07:00:00.000Z"
      },
      {
        "id": "7912e1a72ff46832beaef58e96c67215",
        "type": "warning_letter",
        "date": "2022-06-15T07:00:00.000Z",
        "title": "Untitled Letter Close-Out Roszet - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9saUNudmY4SUsxcFVCVzY5dFFHZ2w5bzJEcFl0NkEyVEdvWmlOWlZDdzRhZ0RQZ3JKWGozaHF1ZGlQQUJKN3I1Mk9JUUp2NnVEWW9r?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Untitled Letter Close-Out Roszet  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2022-06-30T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 35,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.779Z",
    "first_seen": "2025-09-08T12:30:00.697Z"
  },
  {
    "name": "Ubrelvy Untitled Letter Close",
    "aliases": [
      "Ubrelvy Untitled Letter Close"
    ],
    "violations": [
      {
        "id": "e31205052fc80365c497c8a43e5d0ab8",
        "type": "warning_letter",
        "date": "2024-10-30T07:00:00.000Z",
        "title": "Ubrelvy Untitled Letter Close-Out - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1KRUhxeG5PM0xrZHRsQnQxOFYyc0xQNWNUNVdmYjB4MzE3OGZHZEsxV1BxQjRYenptTnNleXpNYjUwelo0OUdQVk9ET1lQaWxCc2U0?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Ubrelvy Untitled Letter Close-Out  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-11-14T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.701Z",
    "first_seen": "2025-09-08T12:30:00.701Z"
  },
  {
    "name": "Educational Case Studies",
    "aliases": [
      "Educational Case Studies"
    ],
    "violations": [
      {
        "id": "5204b1505d4efb0ec711a1a85385f2b3",
        "type": "regulatory_news",
        "date": "2023-08-22T07:00:00.000Z",
        "title": "Educational Case Studies - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOdmN6MGxjQjhzUUNjOFV3bW15d3JxelBfMnY0NXdhMGNrOVhjVjFlV2hHb0F0c3FkUnVrTmN1X1NmdXZTQUotNzF2cDNrZlpwZ1hlQTQ5ZjhtVnlFZXRmQTFnWXY1SWtxek94dWdqZlAtU3BLNUY2Tk5xNTFoMmZGUzRkaEgyY1pZRjZrOHhB?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Educational Case Studies  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.706Z",
    "first_seen": "2025-09-08T12:30:00.706Z"
  },
  {
    "name": "Kisqali Untitled Letter Close",
    "aliases": [
      "Kisqali Untitled Letter Close"
    ],
    "violations": [
      {
        "id": "6eac5c9de880a18d94fd75bb3f1ae75a",
        "type": "warning_letter",
        "date": "2024-03-15T07:00:00.000Z",
        "title": "Kisqali Untitled Letter Close-Out - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBDbGloT2FuMEozdXVocG9JVzJSNU5MR2E3TDdNN1R3YjE0S1JJNEZPNTR4UlBYY2p6aWJlcUxLYTlVNkJmYk5GVnJXYjlKX0M2MU53?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Kisqali Untitled Letter Close-Out  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-03-30T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.711Z",
    "first_seen": "2025-09-08T12:30:00.711Z"
  },
  {
    "name": "Nalpropion",
    "aliases": [
      "Nalpropion"
    ],
    "violations": [
      {
        "id": "e0eed61d6254e92c632f95fa86e01e6d",
        "type": "regulatory_news",
        "date": "2023-05-10T07:00:00.000Z",
        "title": "Nalpropion Pharmaceuticals LLC - 610942 - 05/10/2023 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPd0Fxczc5V1NDLXdIWEdfcjJPeVREeWNieFVwV09ub25jLWRLOGJ0TGlpckRuQmh1X0lnS0tIaU1TNHNBaEV3Tk1uR0tlZUlyS3E2ZXdhQjBnUDJQejg1a0RhRjk0b2J2d3lCaHBSdG5qclVDMTdYZmNsbW82eFg3RFlFSHQ5R215ZWVwMm5QS2tnbzktcjBna3VERVV6Q01veXBqVDBoSXNFT2RnV2FPWWszdEE5VlJaOUlVaXBxSW9kcFY4bEZYdzl3REhCeGlpM1V6VHN2eWlDZTRtOVE?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Nalpropion Pharmaceuticals LLC - 610942 - 05/10/2023  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "32a941386b55b37206c04e19828a77cd",
        "type": "regulatory_news",
        "date": "2020-09-22T07:00:00.000Z",
        "title": "Nalpropion Pharmaceuticals LLC - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNSWowUHp0MVIxVDJXLWlveDJZbmNFc18xdHh2VU1vSXYyRTF4anhYWFZoT3VXdVRoMG5GTWM4Z2FTNlZvcDRsWE9pZUFvam9KcHpjMkgyX3ZORTJKekc2RjN0THppcXltNzFUQkI4Ty1TZjQxN3V4TmF3bkx5RUIwM3BLTDZuVHltRHp5VzN2ZlJIekM0cWVjR1dwc05iOE94UUQwTXhiVWQ4OTlSclAzcWd4cFEzaUxNUUJrbjU1WUZGaHVKOXg5YW05Um1lRnZ4ZGJFLQ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Nalpropion Pharmaceuticals LLC  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.822Z",
    "first_seen": "2025-09-08T12:30:00.715Z"
  },
  {
    "name": "The Brief Summary April 2024",
    "aliases": [
      "The Brief Summary April 2024"
    ],
    "violations": [
      {
        "id": "0d3fc894cf30ace880786c925828ba23",
        "type": "regulatory_news",
        "date": "2024-04-10T03:40:45.000Z",
        "title": "The Brief Summary April 2024 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE00bjNRcEtSMEh4Qk5yOEZoSFpvZmd5Y2tRd2VMT2JwbjJJM2RWVlpocHZ1d3pqbjRkamhwRlRnQ05qUUQ5MmxmazJRdU0xUmd2Y1dB?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "The Brief Summary April 2024  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.721Z",
    "first_seen": "2025-09-08T12:30:00.721Z"
  },
  {
    "name": "The Bad Ad Program",
    "aliases": [
      "The Bad Ad Program"
    ],
    "violations": [
      {
        "id": "8111c9ae411ad2a61ff3473a8fdd00d1",
        "type": "regulatory_news",
        "date": "2025-03-06T08:00:00.000Z",
        "title": "The Bad Ad Program - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPa3pNLThkTWFSMXNRZ0lxS1c4T3kxRjhUakhHMnBaaURZUHlFYUJjU24wMy1Kc1JVSVppT1JDWE1NbVBiZ3BnUmM1akc0aXpFQVg3N2hoNVpZQ2RzX0dCaEtwYUlCZy1qY2piMWxlWVN2UUxtb1duNWlyanY4NXp1YQ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "The Bad Ad Program  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.726Z",
    "first_seen": "2025-09-08T12:30:00.725Z"
  },
  {
    "name": "Providing Regulatory Submissions In Electronic And Non",
    "aliases": [
      "Providing Regulatory Submissions In Electronic And Non"
    ],
    "violations": [
      {
        "id": "f1c4209191a296b8a2c60d96f69594c6",
        "type": "opdp",
        "date": "2019-06-21T17:04:33.000Z",
        "title": "Providing Regulatory Submissions in Electronic and Non-Electronic Format - Promotional Labeling and Advertising Materials for Hu - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9tZDI3aFBOLWpBSFRNSU13OVBZQkxpVUN1WWpRMFl6VDBOdzRydlRwdWhicTNCRHlNNVpfUG5EbW5UUUNsc3RYcGRBSm1ZQU5xX3gw?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Providing Regulatory Submissions in Electronic and Non-Electronic Format - Promotional Labeling and Advertising Materials for Hu  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": "2019-07-05T17:04:33.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.731Z",
    "first_seen": "2025-09-08T12:30:00.731Z"
  },
  {
    "name": "Drug Labeling And Its Impact On Promotion",
    "aliases": [
      "Drug Labeling And Its Impact On Promotion"
    ],
    "violations": [
      {
        "id": "3f88bf59141411527a8df607716b3cb1",
        "type": "regulatory_news",
        "date": "2015-11-04T08:00:00.000Z",
        "title": "Drug Labeling and Its Impact on Promotion - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPbmpPb05fRTRwa1NKVUpyU0JFVndMdGVJN1Z2UTE5OGZLbVQ0VUdqbV9RVmNlWHNiZ0VkeEJteWhWZjJ0dlhuQU9feXZld2c4RkFYbjNJZ0Nhb1QzWDNWRkpSTUg5bkI1a0FFVjFYdHZBRHMtbW5uN3RwcFowYmpJRnBWb0txX1VLdVFGVUxLNmc?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Drug Labeling and Its Impact on Promotion  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Labeling and"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.736Z",
    "first_seen": "2025-09-08T12:30:00.736Z"
  },
  {
    "name": "Peter Honig, Md, Mph Senior Vice President, Worldwide Safety And Regulatory Pfizer Inc. 235 East 42nd Street New York, Ny 10017",
    "aliases": [
      "Peter Honig, Md, Mph Senior Vice President, Worldwide Safety And Regulatory Pfizer Inc. 235 East 42nd Street New York, Ny 10017"
    ],
    "violations": [
      {
        "id": "603ef4fddbcc866441badfbb6ff997a3",
        "type": "regulatory_news",
        "date": "2018-06-19T07:00:00.000Z",
        "title": "Peter Honig, MD, MPH Senior Vice President, Worldwide Safety and Regulatory Pfizer Inc. 235 East 42nd Street New York, NY 10017 - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBDVDJiNXpEOWJvYXJ5UGRmTmZVLU5sTjlqT2U1cFA3cnBRemlXSU0yY3JiajdiMWJERmdta3NiLV93REJHdlRmZWVfTDdtWEg5OU9J?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Peter Honig, MD, MPH Senior Vice President, Worldwide Safety and Regulatory Pfizer Inc. 235 East 42nd Street New York, NY 10017  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.744Z",
    "first_seen": "2025-09-08T12:30:00.744Z"
  },
  {
    "name": "February 27, 2018 Untitled Letter",
    "aliases": [
      "February 27, 2018 Untitled Letter"
    ],
    "violations": [
      {
        "id": "f5959eaa17305184435cebf2f0fc8b96",
        "type": "warning_letter",
        "date": "2018-02-27T08:00:00.000Z",
        "title": "February 27, 2018 Untitled Letter - IDELVION - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPTU1UV1RVdjlHbENseVIwTXJKdnBHTEtpM1FTUWp1cUd6OVR6d2k5Xzl0RV9FM2xZdEtDT0d6SjBGdEFTbkNWUkxYYU9DdWdQRDdqdFVWamFRWDdYa3VHeWVueGdsNjZrR3RmM05aZk81ck1HOHlGbEFxTmt4UjJOR0N4dVBTSGR6TWVnOWdyU0dJbUxJdUJyRVdFSHJzSVJHamxNMS14cVp3NWRNVFA4c2h4ZEZLMVIxc0Nsb2VOdw?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "February 27, 2018 Untitled Letter - IDELVION  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2018-03-14T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.748Z",
    "first_seen": "2025-09-08T12:30:00.748Z"
  },
  {
    "name": "Opdp's 2020 Achievements, 2021 Goals",
    "aliases": [
      "Opdp's 2020 Achievements, 2021 Goals"
    ],
    "violations": [
      {
        "id": "7fda75880c3cb733f520b932c737aaa9",
        "type": "regulatory_news",
        "date": "2021-01-27T08:00:00.000Z",
        "title": "OPDP's 2020 Achievements, 2021 Goals - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOVGpfbW9UV2lRRDU3ckNLY00zM093UkpYa0tVLTRZRzBWWWRnX3VFMzd6Q0FrRTZEQkJNYzZka1lJR1JySERnR3VvRVh0emR2b2wwT3lvdF9XblZyZFE5SW1tMXk3YlY1TUlBNEx6TG9jZm9nbFhiQVJtMGRpcmVHeHNuVWVMNElnd1c5ZGtxUW1nTmppeG1OMV9BU0RJWnNqclFQOWxvNDUwa0RNWW5EdjVLdE11UG14Tk10MUhfRXpfM2xVNFdoLWpNa2NZUUhIUWFSc21DWTBWS3df?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "OPDP's 2020 Achievements, 2021 Goals  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.754Z",
    "first_seen": "2025-09-08T12:30:00.754Z"
  },
  {
    "name": "Krazati Untitled Letter Close",
    "aliases": [
      "Krazati Untitled Letter Close"
    ],
    "violations": [
      {
        "id": "3192653db5c75c4904ebd11395ddf9cb",
        "type": "warning_letter",
        "date": "2024-12-11T08:00:00.000Z",
        "title": "Krazati Untitled Letter Close-out - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9qUEFwVmhXTDdZVjZqSmRXU2NwNk45MlpFTF9JQzdGeEFwUU9CQXJXS05tMGxMcTRRUXhlNEc0Q1NpMmZKZGVMTTd2VndlcVlUc2Yw?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Krazati Untitled Letter Close-out  fda.gov",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-12-26T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.767Z",
    "first_seen": "2025-09-08T12:30:00.767Z"
  },
  {
    "name": "Mayne Pharma Close",
    "aliases": [
      "Mayne Pharma Close"
    ],
    "violations": [
      {
        "id": "6c8d5ea207f2004f30e27b48c0a2484e",
        "type": "regulatory_news",
        "date": "2025-06-02T07:00:00.000Z",
        "title": "Mayne Pharma Close-Out Letter NEXTSTELLIS - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1lTDRQSlFFSHpXMXl5bTA0djVRU3lfVXBJaXZrQXhQOEdJblE3QWVfeklJUUxoUTdfSjZGVGRDZGhQdDl6MVItRzlYTmxXVFo4Y3pN?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Mayne Pharma Close-Out Letter NEXTSTELLIS  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.783Z",
    "first_seen": "2025-09-08T12:30:00.783Z"
  },
  {
    "name": "Direct",
    "aliases": [
      "Direct"
    ],
    "violations": [
      {
        "id": "1048b8917b1a3256cf4312c930dbc572",
        "type": "regulatory_news",
        "date": "2019-06-15T18:48:25.000Z",
        "title": "Direct-to-Consumer Television Advertisements -- FDAAA DTC Television Ad Pre-Dissemination Review Program - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE55aHlNRTZfcVA4S0dMTmxNMjZVNW1CSnpzdHZsRmIxcFhMNVo2dXZsNlBmQzM3R1FJMFloYXA0LUZTQWRTalVkVElIWjhSMm1jU2c?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Direct-to-Consumer Television Advertisements -- FDAAA DTC Television Ad Pre-Dissemination Review Program  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.806Z",
    "first_seen": "2025-09-08T12:30:00.806Z"
  },
  {
    "name": "About Warning And Close",
    "aliases": [
      "About Warning And Close"
    ],
    "violations": [
      {
        "id": "6f3a1c796af83b19c5faba2c91c688b0",
        "type": "regulatory_news",
        "date": "2024-03-20T07:00:00.000Z",
        "title": "About Warning and Close-Out Letters - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPNGJFd0ZsMjZjTmN3SFJRekRCRmtpVy0wOEF0eWh0eXlOUUN6S0pZU0l6VHluRHdHRUFyaWtIQXk5ckZDRVUyMjE3SHN4b2xzUTgyc1dxSWR4TXdIa1hac2pKVXNLRVJkQkdNbTZtR25VbXFINTRoajVIV1RRTVhyam52TlRNV1J6MVo5NVBGLWEtX3Zqc0w2aXNUeFc2eGhmMDk2U0dkNmt0M0trLTVQV0NMbGVwZkkwLWY4eVJlei1rV1M5M0R1d3NfNHc1N1k?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "About Warning and Close-Out Letters  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.813Z",
    "first_seen": "2025-09-08T12:30:00.813Z"
  },
  {
    "name": "Instructions For Completing Form Fda 2253",
    "aliases": [
      "Instructions For Completing Form Fda 2253"
    ],
    "violations": [
      {
        "id": "4cf46ac9f75040725b01402a451b57e5",
        "type": "opdp",
        "date": "2019-11-01T09:36:26.000Z",
        "title": "INSTRUCTIONS FOR COMPLETING FORM FDA 2253 – TRANSMITTAL OF ADVERTISEMENTS AND PROMOTIONAL LABELING FOR DRUGS AND BIOLOGICS FOR - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFAxNUVsUHFxaVMzYnVkMGZkSVdFRDJzeS13SGFobVVSVVk5TmNyNkpueDJRM0JKY2tqQnVWWlF2a1Fja1BBWlduaDZua0FDWVdsMHVV?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "INSTRUCTIONS FOR COMPLETING FORM FDA 2253 – TRANSMITTAL OF ADVERTISEMENTS AND PROMOTIONAL LABELING FOR DRUGS AND BIOLOGICS FOR  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": "2019-11-15T09:36:26.000Z"
      }
    ],
    "products": [
      "LABELING FOR"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.818Z",
    "first_seen": "2025-09-08T12:30:00.818Z"
  },
  {
    "name": "Advisory Action Letters",
    "aliases": [
      "Advisory Action Letters"
    ],
    "violations": [
      {
        "id": "2f375d7d858ae566568a4dca282f0810",
        "type": "regulatory_news",
        "date": "2023-05-01T07:00:00.000Z",
        "title": "Advisory Action Letters - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMijAFBVV95cUxOUE9Rc1VJUE9idVgyS0lIamdFZ2NfdkVMLXphaVRHTUsxNWlwWGktZnFWYnlXOFdoWC1rc0N6SUx0N01ZZnBPN3JQd24zRU5uSkpfSXJIeENBSFBDSzdGcEo4N0NfTXFCQzBQbnRSRFlESlJIanVrWlk0OVVGb1NDb0doazB3bmdCMU90Wg?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "Advisory Action Letters  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.827Z",
    "first_seen": "2025-09-08T12:30:00.827Z"
  },
  {
    "name": "A Resource For Stakeholders That Contain Correspondence Issued By Cdrh",
    "aliases": [
      "A Resource For Stakeholders That Contain Correspondence Issued By Cdrh"
    ],
    "violations": [
      {
        "id": "280f149d14fe881becaf5496cb43cebe",
        "type": "regulatory_news",
        "date": "2019-04-28T22:02:34.000Z",
        "title": "A resource for stakeholders that contain correspondence issued by CDRH - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNRENfajFwcURvSVlOcEQ0YXp6YWVFYktaX3NXWk5TR250RjUxWGZld3hhcGVvWE9WSUZRbzMyYWI2SmxOeFZ4cGgzSzF2Q2xQblpMaGkxWE5jMDZMZ1RtdDdNQ01UODZxU1lrYWNuVVVIc3ZkYTBfYkJ6YjJ3Q3ZTVjF5WQ?oc=5",
        "source": "Google News - OPDP Letters",
        "summary": "A resource for stakeholders that contain correspondence issued by CDRH  fda.gov",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.835Z",
    "first_seen": "2025-09-08T12:30:00.835Z"
  },
  {
    "name": "Aurobindo's Telangana Unit",
    "aliases": [
      "Aurobindo's Telangana Unit"
    ],
    "violations": [
      {
        "id": "a63f6342253c986100b0587b7fceb6db",
        "type": "form_483",
        "date": "2025-09-05T14:59:30.000Z",
        "title": "USFDA issues Form 483 with 8 observations to Aurobindo's Telangana unit - The Economic Times",
        "link": "https://news.google.com/rss/articles/CBMi_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?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues Form 483 with 8 observations to Aurobindo's Telangana unit  The Economic Times",
        "severity": 6,
        "status": "new",
        "response_deadline": "2025-09-20T14:59:30.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 25,
    "compliance_score": 90,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.844Z",
    "first_seen": "2025-09-08T12:30:00.844Z"
  },
  {
    "name": "Dr Reddy's Ny Api Plant Gets Usfda",
    "aliases": [
      "Dr Reddy's Ny Api Plant Gets Usfda"
    ],
    "violations": [
      {
        "id": "2b75a65f13183659807eac6e29414b00",
        "type": "form_483",
        "date": "2025-05-17T17:34:26.000Z",
        "title": "Dr Reddy's NY API plant gets USFDA Form 483 with 2 observations - MSN",
        "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQbjZjajl3ZjVoRk5BYV9nUkdRQ0twV1hVVFVJYWVmWG9IblJxV1ZQY3BCQklGSDAzWDJYdDJxT0hjLUtGX09fX0dNY2wyUVcwYlMyZzh3TW16ek0yWnhHU0x2cXF0S285WVpSWkZGblVsUU9WR0c3a25yLUpXeF9wVWxudENNaVZNMXd4NFJpd3lDbHZzVGtrajVXek1WbHF0clRHX3ExZjNOQThRZ3cyWk8xQWt5MzlkUXg1RnhVRjdfcmxfcnpMamI5aFVZaHN1RUI2QThUdWx1NFZB?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dr Reddy's NY API plant gets USFDA Form 483 with 2 observations  MSN",
        "severity": 6,
        "status": "new",
        "response_deadline": "2025-06-01T17:34:26.000Z"
      },
      {
        "id": "b66e9e6f7d15f089ada0a77ae73e9a39",
        "type": "form_483",
        "date": "2025-05-17T07:00:00.000Z",
        "title": "Dr Reddy's NY API plant gets USFDA Form 483 with 2 observations - The Times of India",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dr Reddy's NY API plant gets USFDA Form 483 with 2 observations  The Times of India",
        "severity": 6,
        "status": "new",
        "response_deadline": "2025-06-01T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 29,
    "compliance_score": 80,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.917Z",
    "first_seen": "2025-09-08T12:30:00.853Z"
  },
  {
    "name": "Dr Reddys Labs' Manufacturing Facility Gets Two",
    "aliases": [
      "Dr Reddys Labs' Manufacturing Facility Gets Two"
    ],
    "violations": [
      {
        "id": "65c7c5e6ea3146b17206e4b5b012de1d",
        "type": "form_483",
        "date": "2025-05-26T07:00:00.000Z",
        "title": "Dr Reddys Labs' manufacturing facility gets two form 483 observations from US FDA - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dr Reddys Labs' manufacturing facility gets two form 483 observations from US FDA  Business Standard",
        "severity": 6,
        "status": "new",
        "response_deadline": "2025-06-10T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 25,
    "compliance_score": 90,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.859Z",
    "first_seen": "2025-09-08T12:30:00.859Z"
  },
  {
    "name": "Aurobindo Pharma's Aurolife Plant In North Carolina Faces Us Fda Scrutiny, Gets",
    "aliases": [
      "Aurobindo Pharma's Aurolife Plant In North Carolina Faces Us Fda Scrutiny, Gets"
    ],
    "violations": [
      {
        "id": "6b14b2d2837d421d498bd50bafa15c16",
        "type": "form_483",
        "date": "2025-04-11T07:00:00.000Z",
        "title": "Aurobindo Pharma's Aurolife plant in North Carolina faces US FDA scrutiny, gets Form 483 with 11 observations - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Aurobindo Pharma's Aurolife plant in North Carolina faces US FDA scrutiny, gets Form 483 with 11 observations  CNBC TV18",
        "severity": 6,
        "status": "new",
        "response_deadline": "2025-04-26T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [
      "North Carolina, fa"
    ],
    "executives": [],
    "risk_score": 25,
    "compliance_score": 90,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.867Z",
    "first_seen": "2025-09-08T12:30:00.867Z"
  },
  {
    "name": "Natco Pharma's Hyderabad",
    "aliases": [
      "Natco Pharma's Hyderabad"
    ],
    "violations": [
      {
        "id": "3643a7f066ae34092850706846f7ba37",
        "type": "form_483",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit - Business Standard",
        "link": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNV3Y2eS1EMHMzN3JYVmd4VHItZ2xyQllZTW52N0hMaHNlVDZRSjBTb2F1ZzIxYU1USXlMeHNJTEh4QUFzNzctS2ptYURWUFdIN2RtNTVmREpuWFlINHU3VnBHR0lPWHYwYzNXTUF5a0hWVGMzdXgxTTI3NGd3YThONkUzdXVhZWxLYTRBOFNXVENCRmNHSXloUGdEa0RiMG5FSlRtSEVTX0hQcHJNMFBuaWctSUlnQ1RUQ24wTWRVajM3U3hBMF8ta1Qwd1hsS1IzdWxTVUp1VlFkWE8zbVhEeEtSLVQ2T2sxUjhHRGVQZ1RfTjB4OG5ER1BR0gH_AUFVX3lxTE8yTUJ4N0xocHZvdUFXOHR3aEJhdUtPRmJ4WUF0aF80elRXc2RZV0hVMURFeHUwb0QzeGFmNnFOOExyakhJU3djVDNESXR0VXZCY0xxTGVpYjhIYnBFNWNwREhDTEw3M0JDd1FabUVJQ1RiRzEtbEFDU2FkRXRjb044eXN5YmtTTkU4YTZwVXp5ZkpKTXh5OVFhNGxWMF9xakQ0UnhaVmhVd1JYOFBvZ0tKdEdRYUFrVGMybDJqbzM2TG1zVUJFT3BYRGFCV3huRFBQRWhfSm10MnZkWE1LdlNMUm15b253ZFpaTHA3RzlpQzFHTWREYWk5TmZFaUhmdw?oc=5",
        "source": "Google News - Form 483",
        "summary": "NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit  Business Standard",
        "severity": 6,
        "status": "new",
        "response_deadline": "2025-06-29T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 25,
    "compliance_score": 90,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.872Z",
    "first_seen": "2025-09-08T12:30:00.872Z"
  },
  {
    "name": "Lupin's Somerset",
    "aliases": [
      "Lupin's Somerset"
    ],
    "violations": [
      {
        "id": "daf5de7d9ddde210b9e1143f334347e8",
        "type": "form_483",
        "date": "2025-02-03T08:00:00.000Z",
        "title": "Lupin's Somerset -based facility completes US FDA inspection with zero Form 483 observations - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Lupin's Somerset -based facility completes US FDA inspection with zero Form 483 observations  Business Standard",
        "severity": 6,
        "status": "new",
        "response_deadline": "2025-02-18T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 25,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.876Z",
    "first_seen": "2025-09-08T12:30:00.875Z"
  },
  {
    "name": "Cipla's Goa Facility Receives Single Usfda Observation Following Inspection",
    "aliases": [
      "Cipla's Goa Facility Receives Single Usfda Observation Following Inspection"
    ],
    "violations": [
      {
        "id": "441b4b4c4f30b9c8a507fa7831bcff1f",
        "type": "regulatory_news",
        "date": "2025-01-20T08:00:00.000Z",
        "title": "Cipla's Goa facility receives single USFDA observation following inspection - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Cipla's Goa facility receives single USFDA observation following inspection  CNBC TV18",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.881Z",
    "first_seen": "2025-09-08T12:30:00.881Z"
  },
  {
    "name": "Cipla's Goa",
    "aliases": [
      "Cipla's Goa"
    ],
    "violations": [
      {
        "id": "7447415df78d8361372dbe263efe43d5",
        "type": "form_483",
        "date": "2025-01-21T08:00:00.000Z",
        "title": "Cipla's Goa-based facility gets one form 483 observation from US FDA - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Cipla's Goa-based facility gets one form 483 observation from US FDA  Business Standard",
        "severity": 6,
        "status": "new",
        "response_deadline": "2025-02-05T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 25,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.883Z",
    "first_seen": "2025-09-08T12:30:00.883Z"
  },
  {
    "name": "Gland Pharma's Sterile Apis Unit",
    "aliases": [
      "Gland Pharma's Sterile Apis Unit"
    ],
    "violations": [
      {
        "id": "184960fc32a32ec99d901206b43b0418",
        "type": "form_483",
        "date": "2025-02-27T08:00:00.000Z",
        "title": "USFDA issues Form 483 with 3 observations to Gland Pharma's Sterile APIs unit - Indian Pharma Post",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues Form 483 with 3 observations to Gland Pharma's Sterile APIs unit  Indian Pharma Post",
        "severity": 6,
        "status": "new",
        "response_deadline": "2025-03-14T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 25,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.887Z",
    "first_seen": "2025-09-08T12:30:00.887Z"
  },
  {
    "name": "Gland Pharma's Visakhapatnam Unit",
    "aliases": [
      "Gland Pharma's Visakhapatnam Unit"
    ],
    "violations": [
      {
        "id": "d6716cafa522e36ff35674a6603f2d1b",
        "type": "form_483",
        "date": "2025-02-25T08:00:00.000Z",
        "title": "USFDA issues Form 483 with 3 three observations to Gland Pharma's Visakhapatnam unit - The Economic Times",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "USFDA issues Form 483 with 3 three observations to Gland Pharma's Visakhapatnam unit  The Economic Times",
        "severity": 6,
        "status": "new",
        "response_deadline": "2025-03-12T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 25,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.893Z",
    "first_seen": "2025-09-08T12:30:00.893Z"
  },
  {
    "name": "Alembic Pharma's Vadodara Facility Gets One",
    "aliases": [
      "Alembic Pharma's Vadodara Facility Gets One"
    ],
    "violations": [
      {
        "id": "51e43676f8686c76fafc0d87eb56cef6",
        "type": "form_483",
        "date": "2025-03-08T08:00:00.000Z",
        "title": "Alembic Pharma's Vadodara facility gets one Form 483 observation from US FDA - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Alembic Pharma's Vadodara facility gets one Form 483 observation from US FDA  Business Standard",
        "severity": 6,
        "status": "new",
        "response_deadline": "2025-03-23T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 25,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.897Z",
    "first_seen": "2025-09-08T12:30:00.897Z"
  },
  {
    "name": "Laurus Labs' Us Arm Gets",
    "aliases": [
      "Laurus Labs' Us Arm Gets"
    ],
    "violations": [
      {
        "id": "e36538f309b2873acd446850b2d05add",
        "type": "form_483",
        "date": "2025-01-22T08:00:00.000Z",
        "title": "Laurus Labs' US arm gets Form 483 from FDA after 'adverse experience' probe - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Laurus Labs' US arm gets Form 483 from FDA after 'adverse experience' probe  CNBC TV18",
        "severity": 6,
        "status": "new",
        "response_deadline": "2025-02-06T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 25,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.900Z",
    "first_seen": "2025-09-08T12:30:00.900Z"
  },
  {
    "name": "Syngene's Bengaluru",
    "aliases": [
      "Syngene's Bengaluru"
    ],
    "violations": [
      {
        "id": "239940e5deb420746e642bb77e5cbe33",
        "type": "regulatory_news",
        "date": "2025-06-14T07:00:00.000Z",
        "title": "Syngene's Bengaluru-based facility gets 'NAi' status from US FDA - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Syngene's Bengaluru-based facility gets 'NAi' status from US FDA  Business Standard",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.905Z",
    "first_seen": "2025-09-08T12:30:00.905Z"
  },
  {
    "name": "Granules India's Bonthapally Facility Completes Us Fda Inspection With One Observation",
    "aliases": [
      "Granules India's Bonthapally Facility Completes Us Fda Inspection With One Observation"
    ],
    "violations": [
      {
        "id": "5dfd9dacbc650ccdba9a7aace7718a4d",
        "type": "regulatory_news",
        "date": "2025-06-20T07:00:00.000Z",
        "title": "Granules India's Bonthapally facility completes US FDA inspection with one observation - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Granules India's Bonthapally facility completes US FDA inspection with one observation  CNBC TV18",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.931Z",
    "first_seen": "2025-09-08T12:30:00.931Z"
  },
  {
    "name": "Shilpa Medicare's Raichur Units Gets",
    "aliases": [
      "Shilpa Medicare's Raichur Units Gets"
    ],
    "violations": [
      {
        "id": "16b74cf442aaba5a84a70f4ee962964c",
        "type": "form_483",
        "date": "2025-03-08T08:00:00.000Z",
        "title": "Shilpa Medicare's Raichur units gets Form 483 with one observation from US FDA - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Shilpa Medicare's Raichur units gets Form 483 with one observation from US FDA  Business Standard",
        "severity": 6,
        "status": "new",
        "response_deadline": "2025-03-23T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 25,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.937Z",
    "first_seen": "2025-09-08T12:30:00.937Z"
  },
  {
    "name": "Cipla's Bommasandra Plant In Bengaluru Gets Single Usfda Observation After Cgmp Inspection",
    "aliases": [
      "Cipla's Bommasandra Plant In Bengaluru Gets Single Usfda Observation After Cgmp Inspection"
    ],
    "violations": [
      {
        "id": "68af018b9704460fda4b3ec982b28ed8",
        "type": "regulatory_news",
        "date": "2025-05-30T07:00:00.000Z",
        "title": "Cipla's Bommasandra plant in Bengaluru gets single USFDA observation after cGMP inspection - CNBC TV18",
        "link": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNUHZSMS1mSWFQNkZpY2lfN0xoTmViVFJfVkJwVWFqc2lQYVBKNXJtNklyR1pwYWRYSmc2U19pWl9ySTI5ak43Z09tVjY3VndxZmE3QVJZMGtLLURvMFh4bGwzOEV2OWVWTlVXb21sbkkyenNUUy15NzlYYUk0NEZ0NmpUc1o4R3RPdFFmeEtmb2hPUXhmTDNRd3VTdXFBVDd6aE85LU9HUDZ5YmNoeGxqa3IzSnJuelNnVG9ocndwWmc2dnFrVnp2RHdKTHlEZUF5OVR2YWNhQjc4YWR5VTY1dmhHai1Jem_SAewBQVVfeXFMUFRNVUNDbE5OUFU0VnhIS1plSng2eXNHMzZ3MTd0UUxrcFVNeElnX1NIa3cya1N5aWkxaF9pZ01rSzBzWHJNSGwtbTdHcFJhVWxjcWg2V0oyTGhEbHBvcS1TcEpLR092ZXZUclVGbmdhQ3RsRFB6UjRpQzNwNEJ1bXNGbThYUG55dGFLdktiWFlWUm9TZk9fWFdvaWFLX01SU2d2SlluRTE2VWNKNFFyNDZLQmNwZmM3bnRaNkR3M01lZkdOYTRRVGVvUkttWkIwSGY2eTdIUS0xSEJ0Ym00TEl0RDlUZEZwbFFEMGY?oc=5",
        "source": "Google News - Form 483",
        "summary": "Cipla's Bommasandra plant in Bengaluru gets single USFDA observation after cGMP inspection  CNBC TV18",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [
      "Bengaluru gets, si"
    ],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.953Z",
    "first_seen": "2025-09-08T12:30:00.952Z"
  },
  {
    "name": "Dr Reddy's Labs Gets 7 Usfda Observations For Srikakulam Facility",
    "aliases": [
      "Dr Reddy's Labs Gets 7 Usfda Observations For Srikakulam Facility"
    ],
    "violations": [
      {
        "id": "4e12d5e63f06d7a0df5ffd5c7d3bfd24",
        "type": "regulatory_news",
        "date": "2025-07-19T07:00:00.000Z",
        "title": "Dr Reddy's Labs gets 7 USFDA observations for Srikakulam facility - Medical Dialogues",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Dr Reddy's Labs gets 7 USFDA observations for Srikakulam facility  Medical Dialogues",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.964Z",
    "first_seen": "2025-09-08T12:30:00.964Z"
  },
  {
    "name": "Us Fda Ends Alembic Pharma's Vadodara Unit Inspection With One Observation",
    "aliases": [
      "Us Fda Ends Alembic Pharma's Vadodara Unit Inspection With One Observation"
    ],
    "violations": [
      {
        "id": "d8857c90f42db2f12954e9952d6a0b34",
        "type": "regulatory_news",
        "date": "2025-03-07T08:00:00.000Z",
        "title": "US FDA ends Alembic Pharma's Vadodara unit inspection with one observation - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "US FDA ends Alembic Pharma's Vadodara unit inspection with one observation  CNBC TV18",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.977Z",
    "first_seen": "2025-09-08T12:30:00.977Z"
  },
  {
    "name": "Piramal Pharma's Mumbai Facility Gets 6 Observations From Us Fda Inspection",
    "aliases": [
      "Piramal Pharma's Mumbai Facility Gets 6 Observations From Us Fda Inspection"
    ],
    "violations": [
      {
        "id": "9cf84c1d898dadc8a60d9d7a584fd45c",
        "type": "regulatory_news",
        "date": "2025-02-18T08:00:00.000Z",
        "title": "Piramal Pharma's Mumbai facility gets 6 observations from US FDA inspection - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Form 483",
        "summary": "Piramal Pharma's Mumbai facility gets 6 observations from US FDA inspection  CNBC TV18",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.987Z",
    "first_seen": "2025-09-08T12:30:00.987Z"
  },
  {
    "name": "India's Zydus Hit With",
    "aliases": [
      "India's Zydus Hit With"
    ],
    "violations": [
      {
        "id": "d117cf9592c51f8cc71c964a48783b97",
        "type": "warning_letter",
        "date": "2024-09-11T07:00:00.000Z",
        "title": "India's Zydus hit with warning letter as FDA flags glass contamination concerns and more - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPdUJnWl9iUGV2TDhjaVVORHBacVJMdlFzMUYxQ0tYWFJucGdxNE5hQU9NTWhYNUxub21pdEpzTF9CeWMwcldpd3h1a2tyanY4U1d1VVBJSTFpNVdiU3h2QUdTOTFGMVZVUmVLS2MtYjREMTZQdWtXV3hubkRwLTh4RjdEclpDcmhST01FQ0lleVhkdkw2NzJpc0FGUjNoenVfSVp6ZWdKbDhLRVhhSERNcE9oaw?oc=5",
        "source": "Google News - Form 483",
        "summary": "India's Zydus hit with warning letter as FDA flags glass contamination concerns and more  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-09-26T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.993Z",
    "first_seen": "2025-09-08T12:30:00.993Z"
  },
  {
    "name": "Agc",
    "aliases": [
      "Agc"
    ],
    "violations": [
      {
        "id": "6aa4daaf586a3b92a9c942808e20c51c",
        "type": "form_483",
        "date": "2024-01-31T08:00:00.000Z",
        "title": "FDA slams Eugia with Form 483 and posts older reprimands for AGC, Baxter - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQR2lJNDJYc0N5QUMyWi1HdjVMSlRIVUtqOXlDY2l5ZlF6Q3kyd0lEQVFnckRrelhBYmo2N0thblpwTkwxemJmWFRkNlR2NnNrbl9odlpXRmpFYk0weDJ2ckxqUzd4NnhKQ3VNcVR1V0lPZVJrdlczMFk5dC1FN3J4QjVkdGhDWi1IWk9oWW1IR2FTT1BxTVZrTE1zakZDamdWY0hTeWJhZ3Y?oc=5",
        "source": "Google News - Form 483",
        "summary": "FDA slams Eugia with Form 483 and posts older reprimands for AGC, Baxter  Fierce Pharma",
        "severity": 6,
        "status": "new",
        "response_deadline": "2024-02-15T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 25,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:00.999Z",
    "first_seen": "2025-09-08T12:30:00.999Z"
  },
  {
    "name": "Us Fda Tightens Control Over Obesity Drug Ingredient Imports Amid Safety Concerns",
    "aliases": [
      "Us Fda Tightens Control Over Obesity Drug Ingredient Imports Amid Safety Concerns"
    ],
    "violations": [
      {
        "id": "74ec48909f09188d4fadd07f85a391cf",
        "type": "regulatory_news",
        "date": "2025-09-05T19:01:25.000Z",
        "title": "US FDA tightens control over obesity drug ingredient imports amid safety concerns - Reuters",
        "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPNUVkeGR2M2RqYjNiU3VMQlV4eGpCZVR5Q1ZGNGY4REEtS2V1Ukxpd3NBRDNMWGdIQV9VT3BoOUpmazZBcVNlTUpSR2Fya3ZlRVVrclU1QkdFaEhReFlfMjN1SExsOTRRRC1QTGhyX0ItN09SUUtiRFFSckE1ejhWSlQ4aGY5MTlIcnA0RmtqN2NVcDd5bUs1WDczdllFUlYwOExvZ0lQblJxTHJxSHlyZ2c5U3JKWVNaSkpEalZ0WFRPeEQwbVlSeHRzWlpTemFienJkdjNSc1ZNZjlL?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "US FDA tightens control over obesity drug ingredient imports amid safety concerns  Reuters",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "d824acf9d60d3e7561d1267970916bd4",
        "type": "regulatory_news",
        "date": "2025-09-05T16:06:43.000Z",
        "title": "US FDA tightens control over obesity drug ingredient imports amid safety concerns - Yahoo News Canada",
        "link": "https://news.google.com/rss/articles/CBMidEFVX3lxTE5JZjVQcElqc3V2SUFfVFdid1lac1ZXS1ZuWi16ZzNZRE9hQWJ1bEk3QWk2TFQ2amp2YXBfOHRpeEhSSS1fYmFnTzMwaXdOV0hNSkNQUHluT1ZoUXR1dmRaTXliR21wZkw3a3pMamlnS0daWnp2?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "US FDA tightens control over obesity drug ingredient imports amid safety concerns  Yahoo News Canada",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "ingredient imports",
      "over obesity"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 26,
    "compliance_score": 90,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.012Z",
    "first_seen": "2025-09-08T12:30:01.004Z"
  },
  {
    "name": "The Fda Let Substandard Factories Ship These Medications To The U.s",
    "aliases": [
      "The Fda Let Substandard Factories Ship These Medications To The U.s"
    ],
    "violations": [
      {
        "id": "d84f3a5f4efb8eb65a4cf3e10f862869",
        "type": "regulatory_news",
        "date": "2025-08-12T07:00:00.000Z",
        "title": "The FDA Let Substandard Factories Ship These Medications to the U.S. - ProPublica",
        "link": "https://news.google.com/rss/articles/CBMif0FVX3lxTE5OTWtuR3hWVllaRF9Zd1BrcVYtMnBvTlBNMXNWVG1sT1psNmUzdmhkeUhVTWtqSDk4UkNkXzVGeEJqQ1FlOVBYT1hvMm5YQWxET2Y1clBMLU5lZTloREpkclBCY2czQ3paMzVsOWwzZ1k4aTl0ZmpCX2pQUy1iWDg?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "The FDA Let Substandard Factories Ship These Medications to the U.S.  ProPublica",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Ship These"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.021Z",
    "first_seen": "2025-09-08T12:30:01.021Z"
  },
  {
    "name": "Fda Hits Pair Of Indian Api Makers With",
    "aliases": [
      "Fda Hits Pair Of Indian Api Makers With"
    ],
    "violations": [
      {
        "id": "cf58194e310053d6602720471e475e2e",
        "type": "warning_letter",
        "date": "2025-02-20T08:00:00.000Z",
        "title": "FDA hits pair of Indian API makers with warning letters, import alerts - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOcXZfQ0h3UUNRNHloVkowSHFBa1hyblNzMklrdGloN3NtakVTbDhlSjFVYXlxVzR2YmFVaVEyWWwzazQ4dU84RGxGd3hnYWxMVUFmNGNtbEM0T215cTEzd2NtSGZ6TE92b3ZmWGZyUlVkaHVQVktpRDBWWEx5R0lNNzh3ZWExX2NfR1o2OWw0dDlKZGx6bW9rd3BB?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA hits pair of Indian API makers with warning letters, import alerts  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-03-07T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.026Z",
    "first_seen": "2025-09-08T12:30:01.026Z"
  },
  {
    "name": "Fda Puts Two Chinese Api Makers On Import Alert After Failed Inspections",
    "aliases": [
      "Fda Puts Two Chinese Api Makers On Import Alert After Failed Inspections"
    ],
    "violations": [
      {
        "id": "a37837cfe34db546b8635ca0479469fe",
        "type": "import_alert",
        "date": "2025-02-11T08:00:00.000Z",
        "title": "FDA puts two Chinese API makers on import alert after failed inspections - Endpoints News",
        "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNb3gtX0daUzZFT3M3cWFEMjd4YmthbThjWHk3T0p2SXk1NXpLTnZFc19OR3lBSG5XR3B2TmtrbldER0w2ckVqdlc0ZEFxQjFGdkhoOWduWG9IWjdqSkJfZmZoc2p0VXV6ckJ3cmRFTDByY2NYczhmdUpKbEQ5OFY5NV83bWp1WEtsTFduVmhLOHBlNG5PSUpTMk12bHM?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA puts two Chinese API makers on import alert after failed inspections  Endpoints News",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.032Z",
    "first_seen": "2025-09-08T12:30:01.032Z"
  },
  {
    "name": "Another Disappointing Drug Import Alert From India",
    "aliases": [
      "Another Disappointing Drug Import Alert From India"
    ],
    "violations": [
      {
        "id": "89c0e3acb33c48ce64e4d836b07102c0",
        "type": "import_alert",
        "date": "2025-01-13T08:00:00.000Z",
        "title": "Another Disappointing Drug Import Alert from India - The People's Pharmacy",
        "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPMnZ3QTI4ZG5mdy0wd194QXU3TkZYeFVkTlNWc2xIOVNFLXQzOFU0UGFXWFRBTE81TDl5S1B6WWV1RjgtU0k0VXpuTmg0b2l6bFNaUFEyc00weUFPZkdjOXo1cmpwRWRuM2FWRjJ6enBjZ1UwNE9Tb25leFpSRWFORHk3Sk9SZlVrYVBqbjNjb3daYmJNb1E?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Another Disappointing Drug Import Alert from India  The People's Pharmacy",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Import Alert",
      "Another Disappointing"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.036Z",
    "first_seen": "2025-09-08T12:30:01.036Z"
  },
  {
    "name": "Viatris Faces Fda Import Restrictions At Indian Facility",
    "aliases": [
      "Viatris Faces Fda Import Restrictions At Indian Facility"
    ],
    "violations": [
      {
        "id": "c005b7cdc7a59dbdeb1661aa59304f92",
        "type": "regulatory_news",
        "date": "2024-12-24T08:00:00.000Z",
        "title": "Viatris faces FDA import restrictions at Indian facility - The Pharma Letter",
        "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxQel9hWG5uOGoxeXNFZUJyTVBMR0hVSzhRUmJoeUhaNlNJYUJ5SFpNQklTYTREaXJEV2hmYk1RZlR5WENZZ0dqZGZVZ2xRNWV1Y1A3V0N4QUVSVnlXZTZXektuY2ZpTG1rQ1dyYTBEOTBqcTdwOTB1UDVzZ1A0VDNpX3hTZm5TUlh5OU81TzhjYTFDMXVoY05YUUROT3JGQQ?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Viatris faces FDA import restrictions at Indian facility  The Pharma Letter",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.042Z",
    "first_seen": "2025-09-08T12:30:01.042Z"
  },
  {
    "name": "Fda Hands Down Citations To 3 Drugmakers After Inspections Found Contamination, Testing Concerns",
    "aliases": [
      "Fda Hands Down Citations To 3 Drugmakers After Inspections Found Contamination, Testing Concerns"
    ],
    "violations": [
      {
        "id": "db8ab256c3a5bab751ff76b391cf2612",
        "type": "regulatory_news",
        "date": "2025-07-16T07:00:00.000Z",
        "title": "FDA hands down citations to 3 drugmakers after inspections found contamination, testing concerns - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPc3FLZkRYR0xpWXNvdHA0SmxXOGk2LTBkTk5RVGxpUG81d180WjE2Yld4MUVpX2I3dW52YzZHYWJPOHY3M21DaHhVdDZMNFpSOXlBVF9WdTJKdHRDMEw1dTBEeHJzSVVRaFRSdk9vcURMSC1kR2FDUF9fSmJaSDRNR2xkOTlra2twOFAzMWtod3I3RGdUNnFsOEtrLWNZdW1XZlRrNGY4VS1EN3JONjNOWVY0bkdtS2lUSHc?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA hands down citations to 3 drugmakers after inspections found contamination, testing concerns  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.053Z",
    "first_seen": "2025-09-08T12:30:01.053Z"
  },
  {
    "name": "Fda Issues Import Alert, Additional Recommendations Against Using Plastic Syringes Made In China",
    "aliases": [
      "Fda Issues Import Alert, Additional Recommendations Against Using Plastic Syringes Made In China"
    ],
    "violations": [
      {
        "id": "bcc5d13a7cb616fd62521cc2d9d3b432",
        "type": "import_alert",
        "date": "2024-05-17T07:00:00.000Z",
        "title": "FDA issues import alert, additional recommendations against using plastic syringes made in China - American Hospital Association",
        "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOelVWVDlETVIwU1pMbnR4YklmeVBMdVpFbnk2bTQ1b3VySjZuVUR3S3QyWlR3eFJVT1ZoRkhMZFRNOEI0aXpzTXhiMDhvc2l4anFuc2dQYW1FU1ItQTh1aVFFYnIzeEtWWFNJVElhLXIzeU5DandPWUpTT2FzZGU2OWpFQjVJY1FncF9MeXVFTXctM2NJeDhMcVhya0tpMzBaREdyUUUwOG9rMkp0QnZiRGg3LXlndC1vNmlNZkdRTXRubjFBTnBOSkRTdHlrLXNPbmlF?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA issues import alert, additional recommendations against using plastic syringes made in China  American Hospital Association",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.062Z",
    "first_seen": "2025-09-08T12:30:01.062Z"
  },
  {
    "name": "Intas Pharmaceuticals Hit With Another Fda",
    "aliases": [
      "Intas Pharmaceuticals Hit With Another Fda"
    ],
    "violations": [
      {
        "id": "2981fce4b5dd51da214b08340d93b487",
        "type": "warning_letter",
        "date": "2023-11-30T08:00:00.000Z",
        "title": "Intas Pharmaceuticals Hit with Another FDA Warning Letter, Put on Import Alert - BioSpace",
        "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPVVRudEJxcG1NTnJ1c2phcm5nQ3ZDcGRqXzVEeXdXclJMMy1Fendobk1WamNBNDFrZHZRQU9LNWFrRE92TWpUbEhvSS1FTWJCRW9YNFJnamZxN21xcF8tVmdkeFhuNjdyYnpUYkhSaTlTR1YzT3pWSEZnMkNuVWZvWTZsS1M0RkhnRjdjTlJiMG1WMjQ0bUxmMHUtQ05scHRONzVhaQ?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Intas Pharmaceuticals Hit with Another FDA Warning Letter, Put on Import Alert  BioSpace",
        "severity": 8,
        "status": "new",
        "response_deadline": "2023-12-15T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.068Z",
    "first_seen": "2025-09-08T12:30:01.068Z"
  },
  {
    "name": "Sun Pharma Shares In Focus After Us Fda Issues Eight Observations For Halol Facility",
    "aliases": [
      "Sun Pharma Shares In Focus After Us Fda Issues Eight Observations For Halol Facility"
    ],
    "violations": [
      {
        "id": "4969f980b27359acfe5fb32f62930fac",
        "type": "regulatory_news",
        "date": "2025-06-16T07:00:00.000Z",
        "title": "Sun Pharma shares in focus after US FDA issues eight observations for Halol facility - The Economic Times",
        "link": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxQMkxFdk1RLVpQVkdZMkI5VWh1NzVDRW5tMkJKdTZwNVNiTHdNRnZCTEF2amxqNWd1RGlyaTEtOWZyUjk2VVBtelFQc2pSd2VuQk9YU0RRRFpzM0dKbVFmSGZ0OGpfZjBpSVVxc2RCdm9PVXRKd1Zpd2dScG5NcVpBUDZMTXVTb3BCOThhR0lZMFhNRlFSRDBfSkZtVTZkLVRxZjRkWGQzazh2VVFpVlQtSXotZ3BUV2U1T3pVMTZNalhCdjgxS3lYbnU0R2xnNmJsUkVBalJIS2ZzMFUyWDBSR1NzY3ZsSzAtVE9tNWRGZ9IB9AFBVV95cUxOQVpWaDY2QngzVVdVWXZEeUxEczZ1aGZJek1fWmZNU195dW9oRGFRVGJmSzBLOExLTmEzcjBIV2JRMkJFamZqS2k0WWc5NVJLelJkTElURFhZZ196XzRGRHhZX21aaWhmLUhwdE9DTmpyZkxFQXI5aTBTcEVQa0syeFVDVFJIWWo0a0VIRzNuYURSUDc0ZXc0dWRaXzhnampGWFlLTV9ZMFk2U2xFdkpyYjNlck84dHRuMnFuS3NqeHoyS3I3Ym5CR29LRXB4ZWh4aFhoeEtkSnB2UGpsRVpuTzlTV2t5eWJpMGU4TmZ5TV9pb1ls?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Sun Pharma shares in focus after US FDA issues eight observations for Halol facility  The Economic Times",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 95,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.076Z",
    "first_seen": "2025-09-08T12:30:01.076Z"
  },
  {
    "name": "Fda Slaps China",
    "aliases": [
      "Fda Slaps China"
    ],
    "violations": [
      {
        "id": "132f88127217175ca39cad0f2d4621fa",
        "type": "warning_letter",
        "date": "2025-02-11T08:00:00.000Z",
        "title": "FDA slaps China-based API makers with separate warning letters outlining quality, testing shortfalls - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOckJqX1lIckFjTEQ1c3R3YWRlZnp4cVFfb2VtVVRoUC1SeTVMMGxFSGI3WEhXUUR1c0lVN0JHU2JKdGd0Zml6TjhXNy1wZ0hNME85d0cxaFZTemc5dXVTVS10RE9iN1FTUWprRWk0T0ZPRDR4Y3FIQWN5ZVM3Q2Q1dURDQzVTc3lhWVN1V0xxMTktRlhIM3VOSC1tdXNuRWR5UTh5TTBDb1VrOWx2bFpPOEV5TDRKRVVxSGJGWU5HSVJIajRt?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA slaps China-based API makers with separate warning letters outlining quality, testing shortfalls  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-02-26T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.080Z",
    "first_seen": "2025-09-08T12:30:01.080Z"
  },
  {
    "name": "Sun Pharma Gets Fda Import Warning For India Plant, Shares Drop",
    "aliases": [
      "Sun Pharma Gets Fda Import Warning For India Plant, Shares Drop"
    ],
    "violations": [
      {
        "id": "e69f162462ef2eafc19d9aa240b80b30",
        "type": "regulatory_news",
        "date": "2022-12-08T08:00:00.000Z",
        "title": "Sun Pharma gets FDA import warning for India plant, shares drop - Reuters",
        "link": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPZVl2RkZpYVNKUU40NEFxMnZzMTNXUklENzhyLVBNckx3UGc3SERlMmNybTB0bThrX2pmQWgzS3FVY2J2aGVPWjdhUjU0QVRTVWtsUU1paWFNNklSNGx6TnRrQnQ0aS1PZkNwNkpadVFkU1RSTmxYV2FuYmNqSmhHaUV1NmM1Y0RyNm0xV0g5UFdlVkM3RFo1WHVsOXNFTHFCaENEd1hCd21nRWdhS2NqeGptWkh2NmxPdjFaVk1XYmd0VmJlSFpYXzdQd2I2VDdYazBMWDhn?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Sun Pharma gets FDA import warning for India plant, shares drop  Reuters",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.085Z",
    "first_seen": "2025-09-08T12:30:01.085Z"
  },
  {
    "name": "India's Aspen Biopharma Labs Hit With Fda",
    "aliases": [
      "India's Aspen Biopharma Labs Hit With Fda"
    ],
    "violations": [
      {
        "id": "095c8b02b01ece20c54fd5cf591963fc",
        "type": "warning_letter",
        "date": "2025-03-26T07:00:00.000Z",
        "title": "India's Aspen Biopharma Labs hit with FDA warning letter citing infrastructure, contamination and records problems - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWjNlOVMwM2ZqWHVoYWFaRHFrYzd5bGlvNDZiTkYyTGNiaF9odWpQSGJ5RUIwNXI1RTUyRjhCZ2ZLeVVhLUdhRFppeE9XTm1RZjV5aWZTSjBrME9Mc210UXhTRzNFamlpWHYtdHFGWklpYm9qbklkdUFmSHF0NFN2RzhRaTY1T3JFNjlTSExackZHLXJMVVNYdl9zUmF1VldyS3dCNXJjVmpsZnJYZXA1a1N6dVdrZ3NUT1hGNnAxX1BzR0E?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "India's Aspen Biopharma Labs hit with FDA warning letter citing infrastructure, contamination and records problems  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-04-10T06:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 85,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.089Z",
    "first_seen": "2025-09-08T12:30:01.089Z"
  },
  {
    "name": "Viatris Says India Plant Hit With Fda",
    "aliases": [
      "Viatris Says India Plant Hit With Fda"
    ],
    "violations": [
      {
        "id": "036ab6ee76b49acdc57ac8aa3caf7e44",
        "type": "warning_letter",
        "date": "2024-12-23T08:00:00.000Z",
        "title": "Viatris says India plant hit with FDA warning letter, import ban on 11 products - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQU1djX0V1eHMxNzQxTnRva3Zhaldfa2VxN2Z3ckFTS20waFh3TlhfQ1ZoMnlod3pKZzJRSzdZZFA3WUhlWjZ6UlBub01SRFNyc284aTJPN0xNS3locmtnamF3SkVSSEVLdTFXOFRLTF9sYkYzYlNlQkJoY3JNS3h4R0RfY2Y2ekhsVnc2eW4zQ19wRDBrN3MtYW5laWVNTXE2N2g1RHVzaE1aNkdWWXc?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Viatris says India plant hit with FDA warning letter, import ban on 11 products  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2025-01-07T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.097Z",
    "first_seen": "2025-09-08T12:30:01.097Z"
  },
  {
    "name": "Fda Slaps Sun Pharma Plant With Import Alert After Inspectors Find Production Problems",
    "aliases": [
      "Fda Slaps Sun Pharma Plant With Import Alert After Inspectors Find Production Problems"
    ],
    "violations": [
      {
        "id": "d6a63c194a5d6c971d0e3fcd92a0ee3d",
        "type": "import_alert",
        "date": "2022-12-08T08:00:00.000Z",
        "title": "FDA slaps Sun Pharma plant with import alert after inspectors find production problems - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOQTlveWdFcFpoRjd6SERNMzhRU3BpZlZhUVF5ODNuZVY4TFdNVkRyVWl4a0dPRVJ0XzFGelFDZ2NPUWdHeFU0NEp3eU1uWlVVeDI4TXNMQTkyUG1WTEE5N1RuNktiM3NScHMzYVNNdjZid2V0SlhROHdRYlZMY0xYRzF3YWdnOU93bDNDazFnX0g0ZkQ1bVU5aG8xd29FcjlQ?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA slaps Sun Pharma plant with import alert after inspectors find production problems  Fierce Pharma",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "inspectors find"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.111Z",
    "first_seen": "2025-09-08T12:30:01.111Z"
  },
  {
    "name": "Intas On Import Alert As Fda Flags Data Manipulation, Management Failures In",
    "aliases": [
      "Intas On Import Alert As Fda Flags Data Manipulation, Management Failures In"
    ],
    "violations": [
      {
        "id": "dbdb87eb1a9d597826ae08155625eba1",
        "type": "warning_letter",
        "date": "2023-11-29T08:00:00.000Z",
        "title": "Intas on import alert as FDA flags data manipulation, management failures in warning letter - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQLWJaYmJ6bmdjMDU1ZHl4TVU4eWxtcFZwVUhaZnQ2M1BmOEphQ1JFRE82V2NZamFNNVNPUHBNcmZvTDFHbEJkV3NKbzJBN25PTVlaZ2N6OTFZalFmYnA5ai0tcXFnVklLWEtmVjJDRDVEa19mQ2tSMkJQbkhPbmdKME02dWEzc0tfVGVZTU5HbVotTnQzc1A3T3luNkdNbjR0LWFYVnYzUjJ1U1BBZ2s1Rw?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Intas on import alert as FDA flags data manipulation, management failures in warning letter  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2023-12-14T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.120Z",
    "first_seen": "2025-09-08T12:30:01.120Z"
  },
  {
    "name": "Fda Issues Import Alerts Against 2 More Plastic Syringe Manufacturers",
    "aliases": [
      "Fda Issues Import Alerts Against 2 More Plastic Syringe Manufacturers"
    ],
    "violations": [
      {
        "id": "6460fd840759b22ffd48fb253431ef3a",
        "type": "import_alert",
        "date": "2024-05-17T07:00:00.000Z",
        "title": "FDA issues import alerts against 2 more plastic syringe manufacturers - MedTech Dive",
        "link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQQ1h3Y2lyczZScFdHa19neURiS1AtcGpYdjE2Z2QwekRYd0cxanl2VzdvdXo4MEFwdHg0Y0J6eWtQZnFwSTRISjlEWl85d1IwN1BtUFVBTjlCR01ZQ1E3bzM1aVJtVHJFWnRGanQxbU15RmU2Q053ZnNpRk5idmV5bUhiUTRKaE91X0haYVBuY2MtZUhWTjVLWXV3?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA issues import alerts against 2 more plastic syringe manufacturers  MedTech Dive",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.127Z",
    "first_seen": "2025-09-08T12:30:01.127Z"
  },
  {
    "name": "Sun Pharma Facility Under An Import Alert Handed A",
    "aliases": [
      "Sun Pharma Facility Under An Import Alert Handed A"
    ],
    "violations": [
      {
        "id": "45945ea354605707c4cf5803558b5c70",
        "type": "warning_letter",
        "date": "2023-01-11T08:00:00.000Z",
        "title": "Sun Pharma facility under an import alert handed a warning letter - Endpoints News",
        "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxORV8yakNTNHpLTi1La05mSEdOSFYzZkw4Q3EtUXlzcDAzdGxhTEpiRk5vbUd2WEVmYVd6N1FMdmU4RlJYT3BXdjRXTldna1k0bVphLXJObzlyTVFINldjMHI2dkFtUXdiOEJsWnNVTGxtQjlScnRaMk9HUnU4YlZOc2tnby1YWHZ6MWlwdUEwQ2lQckk?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Sun Pharma facility under an import alert handed a warning letter  Endpoints News",
        "severity": 8,
        "status": "new",
        "response_deadline": "2023-01-26T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.136Z",
    "first_seen": "2025-09-08T12:30:01.135Z"
  },
  {
    "name": "Fda Slaps Import Alert On India's Shilpa After Sterile Injectables Issues Multiply",
    "aliases": [
      "Fda Slaps Import Alert On India's Shilpa After Sterile Injectables Issues Multiply"
    ],
    "violations": [
      {
        "id": "24fe386ecddb861a25061b5cc2ac56e3",
        "type": "import_alert",
        "date": "2021-02-19T08:00:00.000Z",
        "title": "FDA slaps import alert on India's Shilpa after sterile injectables issues multiply - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNUmNTS3V2elVTWkVxYkRtSllqLUM2c2Q2TDdsR2pvRngyeG4xQVlwR0xXOE84dTJXNUt5Z1NkSFdPLUppTzlDYkNzaE1TRUxVbjRxWVNaeU03VUZkV1VhYVlaeDVhenlveVVQOWlHeU5VVFhocm5WT3BTdU02UGNxNW1NUWFuaU1BZVdsbHJhMkVSWnJROVVNcENqQmhxd1BuTDI2dEFOV0l1LXh6ZTA3WVVKUThyOVNoS3RqNlBfOVNKWUp5bVE?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA slaps import alert on India's Shilpa after sterile injectables issues multiply  Fierce Pharma",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.146Z",
    "first_seen": "2025-09-08T12:30:01.146Z"
  },
  {
    "name": "U.s. Fda To Restrict Unlawful Import Of Veterinary Tranquilizer Xylazine",
    "aliases": [
      "U.s. Fda To Restrict Unlawful Import Of Veterinary Tranquilizer Xylazine"
    ],
    "violations": [
      {
        "id": "b6e737f7d7745f412b67e57ac6fa4693",
        "type": "regulatory_news",
        "date": "2023-02-28T08:00:00.000Z",
        "title": "U.S. FDA to restrict unlawful import of veterinary tranquilizer Xylazine - Reuters",
        "link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQSFlGUVFsNXkxOEF5NXJCRFpoakhpUERRVm9UREhlTlY5SUU2T2R1QzF0T1ZVbFB5QnVRVWw5dWxYM3hNdjNCckJYYTE0ajJVR2EydmdQUEJxRXBpbEhWRUVxN2F4OWJXRmNCLS1NWkdQTUtLTmpabmVlQ0NSejctT2NXY1lfblM0M3g5Y3RKQ3diWEowbHNFNnZVUHdkRlR4SXJZZE5SdnBnNktrbklCSjlXMkpoZ3NrX0EyWlpRODIzblphLUo3ZXE1U0dqREtIV0E?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "U.S. FDA to restrict unlawful import of veterinary tranquilizer Xylazine  Reuters",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.154Z",
    "first_seen": "2025-09-08T12:30:01.154Z"
  },
  {
    "name": "Mexico's Glinsa Suffers",
    "aliases": [
      "Mexico's Glinsa Suffers"
    ],
    "violations": [
      {
        "id": "c40bdac6cb031a6cce9d788cbae85c78",
        "type": "warning_letter",
        "date": "2022-06-23T07:00:00.000Z",
        "title": "Mexico's Glinsa suffers warning letter and import alert after refusing FDA manufacturing inspection - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPY1NQeEVCRFFGMGdOQXg4R1E4T1pzYmFucmZFZWthX2pvY2I3RTkxQktHTlNSWHRNc2pmbGpEbmVIYUxXUjNlN0tnUFkzTUZLMXRfUDFjUENlclB6Z1hsSUhOcV9fQVlPR09iOUl6d1hoY0ZTLU9HYWVJTXNFNFRUd1ZRMTZGVDdDaXN1cFZpMkVKNDNtNjdZOHBGUUFEa2htYkNBN1BzaW82R0J0eXl3QXZjRnZpdEhFX3pKSGRCbU82N3dC?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Mexico's Glinsa suffers warning letter and import alert after refusing FDA manufacturing inspection  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2022-07-08T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.159Z",
    "first_seen": "2025-09-08T12:30:01.159Z"
  },
  {
    "name": "Sun Pharma Pauses Us Drug Exports From India Plant After Fda Scolding",
    "aliases": [
      "Sun Pharma Pauses Us Drug Exports From India Plant After Fda Scolding"
    ],
    "violations": [
      {
        "id": "da2a80a8f3cb7d7f938f09b94569b654",
        "type": "regulatory_news",
        "date": "2023-04-27T07:00:00.000Z",
        "title": "Sun Pharma pauses US drug exports from India plant after FDA scolding - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxNbHltb3ljeE1IaURpTVNNSWdCSV9xeGxBMmwxTTg0Mk1Hc0Zja3k4RG1RS25Gemlzd2cyU09TbXpPLVpKa3QtV1dodnBIZDRoMlNlMVhSNVhnMDRXWlJla083MTN3eEZaZXREdU1LX3NfTy1yRUotQ2lveTRZVU1Dd3pUYVpxS18xYUQ4MWpmSGx0S1NVTWp6dDk2bERNQQ?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Sun Pharma pauses US drug exports from India plant after FDA scolding  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "exports from",
      "pauses US"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.170Z",
    "first_seen": "2025-09-08T12:30:01.170Z"
  },
  {
    "name": "Us Fda Issues Import Alert Guidance On Pfas Contaminants",
    "aliases": [
      "Us Fda Issues Import Alert Guidance On Pfas Contaminants"
    ],
    "violations": [
      {
        "id": "28fb39e10a9236be4921b157662597a6",
        "type": "import_alert",
        "date": "2024-03-27T18:01:27.000Z",
        "title": "US FDA issues import alert guidance on PFAS contaminants - SeafoodSource",
        "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxObFFmN3N2QmZOUHJ2RGczNTNNbllKRHBnSW8tOV8tN1lTTzBPeUxBLURHcVpVVTltblFlUFdLT0dCODItVGhOT0JfVnZDQkczWlhvWFQxVk5jU0tEaTg3cHNGZVp4cmRTdHg3Y2hTcFBRVXRHd1VzTzZKVWtTb2RHcXBXazhGM2Z2bEhfd3JXeUJYQTB5S0FxbVpuZkVKY3FRdl91QUdqSHVZUy11UzU2dVJYMW43NzdJZk50LVhR?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "US FDA issues import alert guidance on PFAS contaminants  SeafoodSource",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.177Z",
    "first_seen": "2025-09-08T12:30:01.177Z"
  },
  {
    "name": "After Triggering A Global Valsartan Recall 3 Years Ago, Chinese Drug Manufacturer Overcomes Fda",
    "aliases": [
      "After Triggering A Global Valsartan Recall 3 Years Ago, Chinese Drug Manufacturer Overcomes Fda"
    ],
    "violations": [
      {
        "id": "2a701b7007ffe3c18803cafd4720350b",
        "type": "warning_letter",
        "date": "2021-11-15T08:00:00.000Z",
        "title": "After triggering a global valsartan recall 3 years ago, Chinese drug manufacturer overcomes FDA warning letter - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNTktObVVMQXZ2QlMwWVlVNFBPakZkSEVwTDMtaVFPalBrQVA1dDhfSHpobnVMWG1JcFRCSXJubkFFRUtQb2R6UFEtaEJXLUVodnRySENkNXVvNjAteUg0NUhldmVDN3h4NlowTm5PbmxkYTlRS0dIUmlGTjA3RU90Y0tSWEtEaGN1LWsxSHJPaXBkbHZ2WmRmZzAzd0FHaTJ5X3BXeE1XQnpQV0IxbnRlb0xIdHdLa2gwRm5vaG9uMlptZU4t?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "After triggering a global valsartan recall 3 years ago, Chinese drug manufacturer overcomes FDA warning letter  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2021-11-30T08:00:00.000Z"
      }
    ],
    "products": [
      "manufacturer overcomes",
      "Chinese"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.187Z",
    "first_seen": "2025-09-08T12:30:01.187Z"
  },
  {
    "name": "Actually, It's Just One Site",
    "aliases": [
      "Actually, It's Just One Site"
    ],
    "violations": [
      {
        "id": "1f5be265dfe7ba21ff8dd50ac9b2416b",
        "type": "regulatory_news",
        "date": "2018-10-11T07:00:00.000Z",
        "title": "Actually, it's just one site: FDA corrects previous word on embattled valsartan maker's ban - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQTXZJdHBoZ3BwYW5lU0xiU0xCU1hEQWN2MmNqdHVoMmdUWTBwUl9xUU1zQXBOSjAyaXo3TDFnZ2FHbjU4Z2drRXNPRm5rakJlUEVTMVNSUndQazRhTmFNUGhtZF9jdFBoU2VDUW42OUdIdldwV1hyN0NWckZpcmZucEhlMWlUelk0bktSdkdpaHhqcHVHQXd4SzB1UkhrSlVoQ2ExQ1VzM1JPLTlDb19JNThIbVByN2doQjB4Sw?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Actually, it's just one site: FDA corrects previous word on embattled valsartan maker's ban  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.192Z",
    "first_seen": "2025-09-08T12:30:01.192Z"
  },
  {
    "name": "Wockhardt Hit By Fda Import Alert On Drug Plant",
    "aliases": [
      "Wockhardt Hit By Fda Import Alert On Drug Plant"
    ],
    "violations": [
      {
        "id": "ea2bccda41979b77e975bc4b1a2bb5f6",
        "type": "import_alert",
        "date": "2013-05-23T07:00:00.000Z",
        "title": "Wockhardt hit by FDA import alert on drug plant - Reuters",
        "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxObl9TYzFSUVhvSUpTNjhaWkZocmxoNWtqU0EyeHdMZG9oZmY1MzF0ZWhyMUhuT2FMSVFNcW5LUURFVndjNFFJMnFqRmFTR3gwTXh1S0hfdUI5Mmxnb3VzZHZrSS1Za3pSNUJRbFMySmRNT2g2dTR2bmtoNkNNdFQ5REF4VkNqdHNwV3VPZ1pyUXI5TkkydEhaekFtQVplbTVzN2c?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Wockhardt hit by FDA import alert on drug plant  Reuters",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "plant  Reuters",
      "alert on"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.200Z",
    "first_seen": "2025-09-08T12:30:01.200Z"
  },
  {
    "name": "Lost In Translation, Fda Slaps Chinese Drugmaker With",
    "aliases": [
      "Lost In Translation, Fda Slaps Chinese Drugmaker With"
    ],
    "violations": [
      {
        "id": "013953728eadebc3a9dfeba7154d1948",
        "type": "warning_letter",
        "date": "2017-11-08T08:00:00.000Z",
        "title": "Lost in translation, FDA slaps Chinese drugmaker with warning letter for mixing up APIs - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPbXdmN25YWDA2MURzYkhXMFNNS2YxVWRBdkZxQzBHb19oRWxHRklyQ2lJT1NwSXFvZVM3ZWtoTmNHMjc1SUJaTGZUWl9IOHYtLVZrZW9MZ1FPQXVXWVgwMEtSSFBsVXpBODhpcl9TWG1MejA5TXBjNV9WMnMyOXYyNDlBOXVabEpMU3RQVXl3dmktM1VYYVIxank2LS1EX0tvQVJHOEhGWVR6OWRmMExKbDNNUXZJRUdvRS1KVFVn?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Lost in translation, FDA slaps Chinese drugmaker with warning letter for mixing up APIs  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2017-11-23T08:00:00.000Z"
      }
    ],
    "products": [
      "slaps Chinese"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.205Z",
    "first_seen": "2025-09-08T12:30:01.205Z"
  },
  {
    "name": "South Korean Drugmaker Slapped With Fda",
    "aliases": [
      "South Korean Drugmaker Slapped With Fda"
    ],
    "violations": [
      {
        "id": "55ac71ea2cefc498f4ed7bf6e538b965",
        "type": "warning_letter",
        "date": "2017-09-21T07:00:00.000Z",
        "title": "South Korean drugmaker slapped with FDA warning letter, import alert - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNUFc1MzVUdUdrNk5Ud3hFMG5qTjhrdW1uMjlocWRleTZydExIU1RidmRqM21ibjFwUkh1VG5DRXNGYzF1MUh5UmhIZTZrYnBKUEEyaGFidHExZUlTVDNNdVFJWllMZnVMQlBYTEZIbWowaGw5bjJjU2RyNVZMQkJIWUItTFV5MUdTY3hrc1dYS05BRVdXRDRHbTFfcU5iTEVldHl3bzA3MkE?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "South Korean drugmaker slapped with FDA warning letter, import alert  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2017-10-06T07:00:00.000Z"
      }
    ],
    "products": [
      "South Korean"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.210Z",
    "first_seen": "2025-09-08T12:30:01.210Z"
  },
  {
    "name": "Fda Bans A Third Wockhardt Plant",
    "aliases": [
      "Fda Bans A Third Wockhardt Plant"
    ],
    "violations": [
      {
        "id": "1e068372f615d0c890671c3a99a60967",
        "type": "regulatory_news",
        "date": "2016-08-08T07:00:00.000Z",
        "title": "FDA bans a third Wockhardt plant - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPQm9oX2hKMk9yTGxJSVVMMG00anBJeXVoRDRKMmVtRk13MllpTzdVVnBvRG9zSTlRNEtRMVNyWUZ3MVUwV0FVRGZWNHZSZkQtejAwdGNmeDdiRTdGcGVQaEpzQUNla1VTMGZYNkQ1Yy1mTm1PNUlROE9Sck8zV1JSdg?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA bans a third Wockhardt plant  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.217Z",
    "first_seen": "2025-09-08T12:30:01.217Z"
  },
  {
    "name": "Fda Outlines Data Integrity Problems With Chinese Api Maker Under Import Ban",
    "aliases": [
      "Fda Outlines Data Integrity Problems With Chinese Api Maker Under Import Ban"
    ],
    "violations": [
      {
        "id": "3f0cb46e12e3fe8de8f12e38c53b5489",
        "type": "import_alert",
        "date": "2017-06-21T07:00:00.000Z",
        "title": "FDA outlines data integrity problems with Chinese API maker under import ban - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNWUpZYnNQTHJ6bGo0ZE5mZzlfUHd2WFhmbVd4UTRyU2NQX096bzVkOWkwc281OEphVjk1NUxmMG43ZEVOMzFBYnRwYUNBdV93VE8zRjFoMGsxUld5RFFuM2lTa2xfOG85dTBMMXBZZjZYUU1Mbnk3OUd1UWRfcFVSclByRTB2MVo2WTloVlNPdGdqcU55T3hLdWJjRTVJdWZONldkelg2b3lrdjNRc1BBZC1xOE0?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA outlines data integrity problems with Chinese API maker under import ban  Fierce Pharma",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.227Z",
    "first_seen": "2025-09-08T12:30:01.227Z"
  },
  {
    "name": "Fda Blasts Syntec Pharma After Importer Stored Drug Ingredients With Antifreeze, Weedkiller",
    "aliases": [
      "Fda Blasts Syntec Pharma After Importer Stored Drug Ingredients With Antifreeze, Weedkiller"
    ],
    "violations": [
      {
        "id": "316dd6d3217b5a2189e1a205bb06ab24",
        "type": "regulatory_news",
        "date": "2021-08-04T07:00:00.000Z",
        "title": "FDA blasts Syntec Pharma after importer stored drug ingredients with antifreeze, weedkiller - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOVVA4bmJsSGs5Yk9NdjRBeVdnUnJ5cEliRERvUExNbjdUU2RRLWlraXUwakk4RFh2TV9MQVdhVXlqT21KVlJKZnVGdnZ1Uk5lY1pFeXc4Mjdhc0tsMGc3Ry1GUDVBTkJvVDJpWlpOUWpVUHZUYnJMTHRfcnE2SVZSRWd3U1dzVy1vdFpHaDlOVzFIZTBacDBnemo2U1NpTXo2MzdmNnI2WWllUzhMVmd1NG4wUlhLRkptWjl1bm1nakJlS3liT1dB?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA blasts Syntec Pharma after importer stored drug ingredients with antifreeze, weedkiller  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "ingredients with",
      "importer stored"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.234Z",
    "first_seen": "2025-09-08T12:30:01.234Z"
  },
  {
    "name": "India's Mahendra Chemicals Api Plant Put On Fda Import Alert List",
    "aliases": [
      "India's Mahendra Chemicals Api Plant Put On Fda Import Alert List"
    ],
    "violations": [
      {
        "id": "491046b0cfa9445fa583e69e7712b865",
        "type": "import_alert",
        "date": "2017-08-30T07:00:00.000Z",
        "title": "India's Mahendra Chemicals API plant put on FDA import alert list - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQcTFtdmZ0WExmVjRIbE5WM3JJSWxMZlpmX285OTA0Y2pueEJNdi1uMkttX2JiaThBTU4ta01CYXpRcmtORkFzSXVwQ0RNSGZGU1Faa1FIaXA3SWp0NWFIcjlYSmdtSnNVVXBRZENlQkxmWFpieXhsM3ZVR0tTeVJ4MWZja0s3RV9pX29uLVBGVnJnSGJ2V0ktcjI5RFhMT0RYaVA3VzB4SlE?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "India's Mahendra Chemicals API plant put on FDA import alert list  Fierce Pharma",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.243Z",
    "first_seen": "2025-09-08T12:30:01.243Z"
  },
  {
    "name": "Fda Unleashes Multiple",
    "aliases": [
      "Fda Unleashes Multiple"
    ],
    "violations": [
      {
        "id": "67bfacc41d5722851f808b278f1100b5",
        "type": "warning_letter",
        "date": "2024-02-14T08:00:00.000Z",
        "title": "FDA unleashes multiple warning letters targeting insanitary manufacturing and online sales of unapproved Mounjaro, Ozempic - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPaV9WcHBaQ09CSjBXQlpDMmJyVm9SX0hhU205NlRNUlhNNzFYR3dMcWt3OTRoLUdYd1VlVGUxclNTV1B2N0o2djVIcllXQUgxWEhvZGNsckh2ejNoeFdab1E1c3F6ZXY4UU4zcXpyUTJZUTJFSGJTc3Z0OGlTWF82Y2tOMWFRZTlwaEdDOFJuaU5lRnY4SDRTelVaVnNTX1VrZ2xaU1lDd2tLS2t6RXZMeWxab1hiT0NzcW9JdDlYSm91TlZ5?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA unleashes multiple warning letters targeting insanitary manufacturing and online sales of unapproved Mounjaro, Ozempic  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-02-29T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 31,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.248Z",
    "first_seen": "2025-09-08T12:30:01.248Z"
  },
  {
    "name": "Fda Inspectors Find 'Vermin' In Production Areas Of Indian Api Maker",
    "aliases": [
      "Fda Inspectors Find 'Vermin' In Production Areas Of Indian Api Maker"
    ],
    "violations": [
      {
        "id": "24ecdc76be5f788f90c73c97c199f3dd",
        "type": "regulatory_news",
        "date": "2018-03-21T07:00:00.000Z",
        "title": "FDA inspectors find 'vermin' in production areas of Indian API maker - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNbDRtZHV0UEx5dFlRd183SmVCYzFySHFWdGJ5ZUNRY2dab1hSS0V6dzRHWEdSZzdaM0oxc1M1eXRhbXRKeHJyV0ZJMWJFZ2kyQ0tPbEtUd0FzeHdJXzhpQ1Y0NHdMNnV4dzNpd09NTUxOSWcxUzVaZnZzaEZWRmUxLTBtREVKMGU1ZW5wclhYVDE1dVdhWUlIWUR4VDVJaDlsTjFncmt3?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA inspectors find 'vermin' in production areas of Indian API maker  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.259Z",
    "first_seen": "2025-09-08T12:30:01.259Z"
  },
  {
    "name": "Fda Whacks Megafine India Api Plant With Warning For Faked Test Data",
    "aliases": [
      "Fda Whacks Megafine India Api Plant With Warning For Faked Test Data"
    ],
    "violations": [
      {
        "id": "81b9a2ae052d08904abff0a2f187725a",
        "type": "regulatory_news",
        "date": "2016-05-31T07:00:00.000Z",
        "title": "FDA whacks Megafine India API plant with warning for faked test data - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQS1lqVmdYMFkwaG5XcThtRmNuS0J0V1EtQy1JZV9CZDhTVm1yMkVWYThBeWVSZGYyNXM5eVROWlNCclcxNThMS2o3dlRybTQ3eURtaHlVVXZtM3JmOUt2ZlJ0MVpkSzR3cjljQ0FsWHplRjM1YXNJa2VlbzZvMi1GbG5pemJpdnl6ZGoya2dwU2pWVFMySmp6UHFEeTZzc2tXekIxSA?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA whacks Megafine India API plant with warning for faked test data  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.266Z",
    "first_seen": "2025-09-08T12:30:01.266Z"
  },
  {
    "name": "Import Ban Extended As India's Pan Pharma Racks Up Third Fda",
    "aliases": [
      "Import Ban Extended As India's Pan Pharma Racks Up Third Fda"
    ],
    "violations": [
      {
        "id": "cca9471c1a3b43ad9ccba9a84b0a5120",
        "type": "warning_letter",
        "date": "2016-09-07T07:00:00.000Z",
        "title": "Import ban extended as India's Pan Pharma racks up third FDA warning letter - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQS0RQc0FMZm5LYmRKa1dqV1ZPbVJINmxJUGVVX0w1cWJRbFVLcXZJOF9oclcwd3pZNFRZaWFtRGxVd1ZFeGM4azFaLVNKZzFkcmpjODJ6cnVaMGc4RGpFRlRuUlZGSDRhX2k2cFk1Z2hPNndCVjNxRzR5SEg3bVI4RTRoZklNbUxDWTMxZWx6QmpLblcxUXFnclg1Z3BkVkxtR095T2ZyblJpOGs?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Import ban extended as India's Pan Pharma racks up third FDA warning letter  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2016-09-22T07:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.271Z",
    "first_seen": "2025-09-08T12:30:01.271Z"
  },
  {
    "name": "To Avoid Shortages, Fda Allows Imports From 8 Drug Plants Banned For Quality Shortfalls",
    "aliases": [
      "To Avoid Shortages, Fda Allows Imports From 8 Drug Plants Banned For Quality Shortfalls"
    ],
    "violations": [
      {
        "id": "30452096dc548b04ff428eb4f1409324",
        "type": "regulatory_news",
        "date": "2016-07-25T07:00:00.000Z",
        "title": "To avoid shortages, FDA allows imports from 8 drug plants banned for quality shortfalls - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZHVLM3NYTHFaWGJqc2FiNjRmWGFRNHl2aFhwWjQ2azlJUC0yTUtCTVR5UFR4cFMxdGFJaTc5QXdnOGFqa0hpdnU5LWJiNW8zZF9wTGlFbkE1UUg2eko1T3cxaFZ6RS10QXhad0VteXB0eWZYZGhxbDVRSlViS2Q3T0JBcjZGNm1qOUd4RVJQWHdoMkNNVEtYUHVwanRIRDJUUThnVkJ3UG9RUQ?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "To avoid shortages, FDA allows imports from 8 drug plants banned for quality shortfalls  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "plants banned"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.280Z",
    "first_seen": "2025-09-08T12:30:01.280Z"
  },
  {
    "name": "Us Fda Issues Import Alert On Sun Pharma's Halol Facility",
    "aliases": [
      "Us Fda Issues Import Alert On Sun Pharma's Halol Facility",
      "Us Fda Issues Import Alert On Sun Pharmas Halol Facility"
    ],
    "violations": [
      {
        "id": "818f34c7c73cf300e5d622634c5ca6ef",
        "type": "import_alert",
        "date": "2022-12-09T08:00:00.000Z",
        "title": "US FDA Issues Import Alert On Sun Pharmas Halol Facility - Zee Business",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "US FDA Issues Import Alert On Sun Pharmas Halol Facility  Zee Business",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "2a2f1f403de579fc496ad45e3bd4dff0",
        "type": "import_alert",
        "date": "2022-12-08T08:00:00.000Z",
        "title": "US FDA issues import alert on Sun Pharma's Halol facility - The Economic Times",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "US FDA issues import alert on Sun Pharma's Halol facility  The Economic Times",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.474Z",
    "first_seen": "2025-09-08T12:30:01.289Z"
  },
  {
    "name": "Cracking Down On Kratom",
    "aliases": [
      "Cracking Down On Kratom"
    ],
    "violations": [
      {
        "id": "3784450a11dd1007eb327ebbd9ee466f",
        "type": "recall",
        "date": "2018-08-14T03:08:35.000Z",
        "title": "Cracking Down on Kratom: FDA Investigation, Enforcement, Seizure, and Recall of Products Reported to Contain Kratom - Food and Drug Law Institute (FDLI)",
        "link": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxONWJzZElXQmlnek9hcHYzWXdlWE9ham50WUJITzR4NC16OHh0cjllSjF1Slh0bGJ1Qng0RVhOTWpZaU9keV82RmlJOUpGdHdZR2RrRGpNcjBVRUlTaF9hY1dpOFo4Uk5qMk1TbENvX0dvM3VrTW1MWmRFN2VFXzBGNXlOSlVHTFcwOURuX0NnVTAtaDlpQWJmT0pnSl8xa013TV9NeFMzNTRkejdCcjdYZElTelNBRGxRbTB6ckpDWWlqdzctdGE0ekxNc012ZGl4WjNGYUVHSmE1Ym5qaU5mRFN3?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Cracking Down on Kratom: FDA Investigation, Enforcement, Seizure, and Recall of Products Reported to Contain Kratom  Food and Drug Law Institute (FDLI)",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Law Institute",
      "Recall of",
      "Food and"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.294Z",
    "first_seen": "2025-09-08T12:30:01.294Z"
  },
  {
    "name": "Recall Alert",
    "aliases": [
      "Recall Alert"
    ],
    "violations": [
      {
        "id": "676f4a844bae6cb3bae7567cb6068818",
        "type": "recall",
        "date": "2018-08-15T07:00:00.000Z",
        "title": "Recall Alert: FDA Warning About Two Thyroid Medications - CBS News",
        "link": "https://news.google.com/rss/articles/CBMie0FVX3lxTE80UkJodTdPc3pEZ0JTd1o5SjRodjJoYy00RGFGbVQySGtOV185YVF5T3lwUm44WUx6aFp1anU2WUhzUF8zbE1jTVdfRUJSU2xJbUR3S0FkM2tyTGJGSTRyRnJPQUJ6WklqZ2ZqaXVVcm5QZG5JT3V1NWhKdw?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Recall Alert: FDA Warning About Two Thyroid Medications  CBS News",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Two Thyroid"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.297Z",
    "first_seen": "2025-09-08T12:30:01.297Z"
  },
  {
    "name": "Emcure India Plant Banned By The Fda",
    "aliases": [
      "Emcure India Plant Banned By The Fda"
    ],
    "violations": [
      {
        "id": "918a4e3298e6ecd92c012b525e3a9be4",
        "type": "regulatory_news",
        "date": "2015-07-14T07:00:00.000Z",
        "title": "Emcure India plant banned by the FDA - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9fdUFxWFhUSExMbjJ2UC1PU1BKdTVLZmw5aGM5UHEwb1R3QmZsVmpxVklTVGVGWnhHblZlc09kRHg1TzJFMlpMa19XWFJRMi1sUW1JY2IxV0luenF6ODJlVVZodTdnMWt6cXZKYjVUYUM1X3BIbUJZbklZY0g?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Emcure India plant banned by the FDA  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.302Z",
    "first_seen": "2025-09-08T12:30:01.302Z"
  },
  {
    "name": "Fda Bans Imports From Major Indian Api Manufacturer",
    "aliases": [
      "Fda Bans Imports From Major Indian Api Manufacturer"
    ],
    "violations": [
      {
        "id": "68caa50cb84f117f586510597c6cc20b",
        "type": "regulatory_news",
        "date": "2015-10-15T07:00:00.000Z",
        "title": "FDA Bans Imports From Major Indian API Manufacturer - Regulatory Affairs Professionals Society | RAPS",
        "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNbVpxYmVEZVJwUS13MWJrUk9xX3ZUOHJmRk0wVTlGallGaE9KZ2RmU2paZm1XemstTkdIeUMwcWFISmJoZnR2VlB2VWNEQkJXTV8tZHlnZElRT1l4YzhlWEFzak1SVmNkellvbk0yU2oyeXJnVTZ3MDB5ZjFqbm9vVEJXemdyM0Faal9DMHppZEdxT25QbHFncm9DTmxrbFZtN2hyODJYUWRFNVYtVlBWNA?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA Bans Imports From Major Indian API Manufacturer  Regulatory Affairs Professionals Society | RAPS",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.308Z",
    "first_seen": "2025-09-08T12:30:01.308Z"
  },
  {
    "name": "Fda Hits Dominican Republic Drug Manufacturing Plant With",
    "aliases": [
      "Fda Hits Dominican Republic Drug Manufacturing Plant With"
    ],
    "violations": [
      {
        "id": "df6f09c120add98f0e9f461d78aceebd",
        "type": "warning_letter",
        "date": "2018-04-03T07:00:00.000Z",
        "title": "FDA hits Dominican Republic drug manufacturing plant with warning letter - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxONF8yZEliV1J5b1EwNm1ISjc5YUF4VjhSTVdURFdKaDkySEZManc2Um5ic2g1R2ppU2ZTUkUtenlDWlFBemxOYWNDNDJHV0NnSTJxTm13NTZvdUhQRURleko0em9YaDdCWGU3aDNYSkdsWl9WdWJEcnBuQ3lfbWFHWHFNaUJGX0UtWjFnekNmRzg2dWN2U0dhd3hNWVVRS0JrZGZibk1CbFN5S0tmbnJj?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA hits Dominican Republic drug manufacturing plant with warning letter  Fierce Pharma",
        "severity": 8,
        "status": "new",
        "response_deadline": "2018-04-18T07:00:00.000Z"
      }
    ],
    "products": [
      "manufacturing plant",
      "Dominican Republic"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.314Z",
    "first_seen": "2025-09-08T12:30:01.314Z"
  },
  {
    "name": "Fda Slams Intas, Ipca Over Manufacturing Shortfalls At 3 Indian Plants",
    "aliases": [
      "Fda Slams Intas, Ipca Over Manufacturing Shortfalls At 3 Indian Plants"
    ],
    "violations": [
      {
        "id": "7dd997ddd26ec8fcd78cc3f85a8c69c5",
        "type": "regulatory_news",
        "date": "2023-07-07T07:00:00.000Z",
        "title": "FDA slams Intas, Ipca over manufacturing shortfalls at 3 Indian plants - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOVFI4bko4OHpNX3l4LUxaczdsWmUtMmdEVkpuNUQyNzNaT3gxa3FNWWdTLTFESEl4eVNKWXZOaHMzSUlXNUVMVkpFQWZad3ptT2s2YnVNTmhCcW1Oamt1Y3VGbGpwS3R1dEZQZEtGTk4xWUxqMVZMOHRhc09hai1fV2hLeVpuX3h1SGZ3b0FYN1lzcGtJNGJr?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA slams Intas, Ipca over manufacturing shortfalls at 3 Indian plants  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.320Z",
    "first_seen": "2025-09-08T12:30:01.320Z"
  },
  {
    "name": "Fda Warns China Facility Over 'Persistent' Contamination",
    "aliases": [
      "Fda Warns China Facility Over 'Persistent' Contamination"
    ],
    "violations": [
      {
        "id": "9f7f69233243d55ab0fdf89f7722b599",
        "type": "regulatory_news",
        "date": "2016-09-20T07:00:00.000Z",
        "title": "FDA warns China facility over 'persistent' contamination - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxON0JKd0V4Z2JnYjYxb2JHaGhoT3gzSXdOdXk2Z3VjUWRRdllpLU9TYjF3ZFRBSHBiNUsybDcxTVBnNG9CNG9lZnBqb214MHAtMkx4Zi1pX0FEQlRnSmZMdy14MEtabzJjZ19NalJObkY2dWpzN1ZpcWNHQnYyWWlacV80aVJkUlBRN0FIdUZzNjNUQUJFUEdTakg0alZtUQ?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA warns China facility over 'persistent' contamination  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.328Z",
    "first_seen": "2025-09-08T12:30:01.328Z"
  },
  {
    "name": "Rx Import Alert",
    "aliases": [
      "Rx Import Alert",
      "Import Alert",
      "Import Alerts"
    ],
    "violations": [
      {
        "id": "e311ca24748dee13fa815dd82d914f89",
        "type": "import_alert",
        "date": "2024-06-13T07:00:00.000Z",
        "title": "Rx Import Alert: CVS Branded Generic Drugs Singled Out In Bloomberg Report For Most Recalls - Coalition For A Prosperous America",
        "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQSkpGOG5oUF9MNUZ0akJ4MjNiRGFNOUZjUTk5WGxTY0I2SWU5eDJYVkY1TzZxenQxWmhfZ1NJcmRFZmw0bGVEdGlwckxTcmN5YW8yZlpZaWw0U0lQZm9yUFBLWDhQY1hWd085bDVlRFowSlNFVW0zUDFUOGFDbGFZdjdwM0tyTVFhSUZMMmlRVTFqaXdYcVBBUVRLb2twQS0zSm9XeHd6OGNRc2xYak1PZE9WNVE4UlYxcFZZQVpR?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Rx Import Alert: CVS Branded Generic Drugs Singled Out In Bloomberg Report For Most Recalls  Coalition For A Prosperous America",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "e78b52ce8010e6544d46f463131e55cb",
        "type": "warning_letter",
        "date": "2024-04-23T07:00:00.000Z",
        "title": "Import alerts, warning letters, drug recalls — why ‘pharmacy to the world’ is facing US FDA heat - ThePrint",
        "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOaU00YXdhQnlYNDliTWNUd1lCQ2U0ZC05dE9FS3RxbjVhVnppZWtpLV9QUnJvS3hKajVLQWpWbUczcUxlenlwT3hIR3JYVVFDWFAzeXFjLTVHbXFNZXVfQkZkV1RyODBTMmJnUVZMRnZQUHdYdl9BZTBYM3ZyM1FwbGVWOC1lcG00Qi1MbTJEcUw5OWZpTkpzcVhMYTdOQ3lIWDN5TjdheEpuRUpVdU5zd0tmUVJkX1dYbncwTmJUcnExcG1k0gHKAUFVX3lxTFBVdHRMTGxIV2FmRHBqQjRWUkhfZzh6OG8yVS1nXzY2VDJGcjhlcWxyYkdIX3dzS1czTGoxQ2dvb3ZDUTNHZkdtRnM5V2pYYndIb1g0S1BpWlltdDNwdEdWSmJPWlgxUnY2Q1Bzc19WcUZQTnNUdFFPampfOFdySmYxdnhIQk1IXzdCQkdNVk12ZDEyOGkxVWtCVTRraHlfdm56SE5RVGpjWDBjQWhHcWRBNGFuVUJIM3dqckFucXRDTVVrTWgzTEh0dnc?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Import alerts, warning letters, drug recalls — why ‘pharmacy to the world’ is facing US FDA heat  ThePrint",
        "severity": 8,
        "status": "new",
        "response_deadline": "2024-05-08T07:00:00.000Z"
      },
      {
        "id": "39e709ac11f3738856b643aac7de0f58",
        "type": "import_alert",
        "date": "2014-10-12T07:00:00.000Z",
        "title": "Import Alert: FDA Working Toward Consistency, Better Decision Making - insights.citeline.com",
        "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOY1hZTlU4LUNSa25NZVZjZFdSaXVtc055cWV2U1VjWnBlRG5kclVGbDFBU0dUVXY1SmhfU1I3elc5NWo5aWo4VXlhOUw5aGZyVl9IOHVhcDEycDlLcU5GeGpialBxNC12d0ZCYmtiNHFlNllkMVdaQ1J6MU9FZmxpbGFqVWpfVXFpVkRrZHdITVBEcnFIWHRLUE03ajBqNmJZcUMxaHNqZHVwT3BlcmtVQXZCbDhnZ1BlSVBTVE5rekJkcElsb0VhS0V2MkV5Z1Fkc0dv?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Import Alert: FDA Working Toward Consistency, Better Decision Making  insights.citeline.com",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Branded Generic",
      "recalls"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 33,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.398Z",
    "first_seen": "2025-09-08T12:30:01.332Z"
  },
  {
    "name": "Fda Slams Indian Api Firm For Faking Certificates Of Analysis",
    "aliases": [
      "Fda Slams Indian Api Firm For Faking Certificates Of Analysis"
    ],
    "violations": [
      {
        "id": "74e45fd581e9dd9a5076245d787bacaf",
        "type": "regulatory_news",
        "date": "2017-05-03T07:00:00.000Z",
        "title": "FDA slams Indian API firm for faking certificates of analysis - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNdy11MlJ4a2M5c3BtUlpXUFBnWG9qVk1OVndrd2MyY0YxRVFpZU9RUExSYlJlVG9zTUJraE5fUXR1V0hzZlpEYjdpYVZTTlluQzBSZ0tKLV9xOHJSYnR5aktZZEJ2WmFxbHJfTUpfalRJc2hqOE1sS0xfWG5fZWFkejkwSXdaWl9HMndtdHVLMUUxcEtlTExyYWdWMzNuQzlrUm5Z?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA slams Indian API firm for faking certificates of analysis  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.338Z",
    "first_seen": "2025-09-08T12:30:01.338Z"
  },
  {
    "name": "Fda Lifts Import Ban On Chinese Api To Prevent Shortages",
    "aliases": [
      "Fda Lifts Import Ban On Chinese Api To Prevent Shortages"
    ],
    "violations": [
      {
        "id": "847d8ad6d09fc3db82eff3998f97a703",
        "type": "import_alert",
        "date": "2016-03-18T07:00:00.000Z",
        "title": "FDA lifts import ban on Chinese API to prevent shortages - Generics and Biosimilars Initiative (GaBI)",
        "link": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUkwwNjJXOVFRemVmZDhpZFkzSUF5RDVUQVEtMEVzVU0xSXg4MVB5RVYzRGlKZm93NUFERkY4UnlGZFNpX08tcFlNSi1uYlFtNzNhUTNkRzdwZndVejMtTG5ZbkFfbi1XcU9fVy1qMEZnMllkSWczcHF4cl9TejBxWGN4eUNrOEoyUVA4d1UtSzZXVHN4eFpvVW9jVmZXWmZoX0hGMk5BU3lWVWJUMzVrb09uei03djlldHdVQ0RCTFdZRFlMUmZocg?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA lifts import ban on Chinese API to prevent shortages  Generics and Biosimilars Initiative (GaBI)",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.344Z",
    "first_seen": "2025-09-08T12:30:01.344Z"
  },
  {
    "name": "Us Fda Lists Sun Pharma's Halol Unit Under 'Import Alert'",
    "aliases": [
      "Us Fda Lists Sun Pharma's Halol Unit Under 'Import Alert'"
    ],
    "violations": [
      {
        "id": "b7ba114b48620ab8a1d4af0a151a3d6d",
        "type": "import_alert",
        "date": "2022-12-08T08:00:00.000Z",
        "title": "US FDA lists Sun Pharma's Halol unit under 'import alert' - The Economic Times",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "US FDA lists Sun Pharma's Halol unit under 'import alert'  The Economic Times",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.349Z",
    "first_seen": "2025-09-08T12:30:01.349Z"
  },
  {
    "name": "Sun Pharma Clarifies On Us Fda Import Alert On Halol Plant",
    "aliases": [
      "Sun Pharma Clarifies On Us Fda Import Alert On Halol Plant"
    ],
    "violations": [
      {
        "id": "3c1c8afc2824b270d6c3157c767b4897",
        "type": "import_alert",
        "date": "2022-12-08T08:00:00.000Z",
        "title": "Sun Pharma clarifies on US FDA import alert on Halol plant - Moneycontrol",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Sun Pharma clarifies on US FDA import alert on Halol plant  Moneycontrol",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.356Z",
    "first_seen": "2025-09-08T12:30:01.355Z"
  },
  {
    "name": "Sun Pharma Reaches Small Goal In Unburdening Its Regulatory Load",
    "aliases": [
      "Sun Pharma Reaches Small Goal In Unburdening Its Regulatory Load"
    ],
    "violations": [
      {
        "id": "74954386a173d82484d1743ac66e6468",
        "type": "regulatory_news",
        "date": "2017-03-14T07:00:00.000Z",
        "title": "Sun Pharma reaches small goal in unburdening its regulatory load - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOcWFhRVFva2JSYmFLZlFWa21VT3F4LXRKOVFnMVdUVF8zMTRMWjdrMFBlY1d2b2tiOHNFaTNweGllMG1RWHhnN1UwakxpbXhGQkVudDY5RFVNMVF5amR2Qzh1TFkxT3g3Vjl5MHdCWmt2aWJxVFFLRzVyZjdDZ0ItUjh1QzdWU0QwOHIydmJlMVZVT2pmS2o3SktqRWdtUC1PcXZRYmdNcw?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Sun Pharma reaches small goal in unburdening its regulatory load  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.365Z",
    "first_seen": "2025-09-08T12:30:01.365Z"
  },
  {
    "name": "Wockhardt Gets Import Alert From Us Fda",
    "aliases": [
      "Wockhardt Gets Import Alert From Us Fda"
    ],
    "violations": [
      {
        "id": "d86f1204c7d8f2a8f8eb05b21bfc34ab",
        "type": "import_alert",
        "date": "2016-08-06T07:00:00.000Z",
        "title": "Wockhardt gets import alert from US FDA - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Wockhardt gets import alert from US FDA  Business Standard",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.378Z",
    "first_seen": "2025-09-08T12:30:01.377Z"
  },
  {
    "name": "Usfda Issues Import Alert On Glenmark Pharma's Baddi Plant",
    "aliases": [
      "Usfda Issues Import Alert On Glenmark Pharma's Baddi Plant"
    ],
    "violations": [
      {
        "id": "fcfd467d8aa285780e9eb8886d332eaf",
        "type": "import_alert",
        "date": "2022-10-26T07:00:00.000Z",
        "title": "USFDA issues import alert on Glenmark Pharma's Baddi plant - Moneycontrol",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "USFDA issues import alert on Glenmark Pharma's Baddi plant  Moneycontrol",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      },
      {
        "id": "dc9184e11c2970cc2ec151da65c2d2e6",
        "type": "import_alert",
        "date": "2022-10-26T07:00:00.000Z",
        "title": "USFDA issues import alert on Glenmark Pharma's Baddi manufacturing plant - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "USFDA issues import alert on Glenmark Pharma's Baddi manufacturing plant  Business Standard",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:53:02.945Z",
    "first_seen": "2025-09-08T12:30:01.392Z"
  },
  {
    "name": "Sun Pharmaceuticals' Halol Plant Gets 'Import Alert' From Usfda",
    "aliases": [
      "Sun Pharmaceuticals' Halol Plant Gets 'Import Alert' From Usfda"
    ],
    "violations": [
      {
        "id": "ed01e637dfc793084d337809143b61d2",
        "type": "import_alert",
        "date": "2022-12-08T08:00:00.000Z",
        "title": "Sun Pharmaceuticals' Halol plant gets 'import alert' from USFDA - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Sun Pharmaceuticals' Halol plant gets 'import alert' from USFDA  Business Standard",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.407Z",
    "first_seen": "2025-09-08T12:30:01.407Z"
  },
  {
    "name": "Us Fda Inspections In China",
    "aliases": [
      "Us Fda Inspections In China"
    ],
    "violations": [
      {
        "id": "ae06cc11633b61f7dcb474c64151e05e",
        "type": "form_483",
        "date": "2016-02-10T08:00:00.000Z",
        "title": "US FDA Inspections in China: An Analysis of Form 483s from 2015 - Regulatory Affairs Professionals Society | RAPS",
        "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOdmZlN2FoYjk2UlBZNG9JdW9uZENla095VUdGamZtQ0lNelVEOG55UnAtMERuME1GYjVRcFhkQ21Pc0ZobHczUXNVR0p3MldyZjhjSHB4ekJWUEpDX01keUh3N3dKUW9ILWhGTDN0OWhhNGhQZ0xyaHlSc05hbVBndWxFZDhMSktkR1Zla0kzZ3YzRnFtcHpYNXFUX1RoSDdSSmdmX2hJQmR1ckdnb3c?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "US FDA Inspections in China: An Analysis of Form 483s from 2015  Regulatory Affairs Professionals Society | RAPS",
        "severity": 6,
        "status": "new",
        "response_deadline": "2016-02-25T08:00:00.000Z"
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.413Z",
    "first_seen": "2025-09-08T12:30:01.413Z"
  },
  {
    "name": "Us Fda Imposes Import Alert On Ranbaxy Drugs",
    "aliases": [
      "Us Fda Imposes Import Alert On Ranbaxy Drugs"
    ],
    "violations": [
      {
        "id": "ab07901b8d880b5a940c40472a3a08a5",
        "type": "import_alert",
        "date": "2013-09-17T07:00:00.000Z",
        "title": "US FDA imposes import alert on Ranbaxy drugs - BioSpectrum Asia",
        "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNbWJNbFExWXV3eFBCVlBaYmRhVlI4QU54N0g3LWRCT2pHRV93d0ZWVjZaQ1BtRFgtMC1ESk82SUNiTF9DNE02eWQ1SVdTRmxyS3ZVcUIxZjJpei1rdmZkQXB5MVh0SEkyWjRpdUFNaXEtcDdiOTdyZ2ZyU3lmQ3lxRkItQ0QyR0NKaVlGOGNmV0JLczQ1cFY0S0REN2EzeEtiT1E?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "US FDA imposes import alert on Ranbaxy drugs  BioSpectrum Asia",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "on Ranbaxy"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.420Z",
    "first_seen": "2025-09-08T12:30:01.420Z"
  },
  {
    "name": "Divi's Labs Barred From Exports To Us After Fda Import Alert On Vizag Unit",
    "aliases": [
      "Divi's Labs Barred From Exports To Us After Fda Import Alert On Vizag Unit"
    ],
    "violations": [
      {
        "id": "b31dd73529abf94aa4effcdb0f276b29",
        "type": "import_alert",
        "date": "2017-03-22T07:00:00.000Z",
        "title": "Divi's Labs barred from exports to US after FDA import alert on Vizag unit - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Divi's Labs barred from exports to US after FDA import alert on Vizag unit  Business Standard",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.427Z",
    "first_seen": "2025-09-08T12:30:01.427Z"
  },
  {
    "name": "Oops, They Did It Again",
    "aliases": [
      "Oops, They Did It Again"
    ],
    "violations": [
      {
        "id": "913a07c779556c1653e3faa60157ddbe",
        "type": "regulatory_news",
        "date": "2024-07-18T07:00:00.000Z",
        "title": "Oops, They Did It Again: Indian Pharma’s Frequent Flyers on FDA's Naughty List - BioSpectrum India",
        "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQcXhIeFlXdlJhSGdRV18zdWhYRGUyVjQyZms3WFBSVGRoREIxZGZHckhLSXlzdTZ3WkhTVkJub2l0Q2puZkwyWTRKUjN5U01hS1ZUVElRUFRveGkwSVNwSEh1MENxekRFMk8wX0VXYm8xTkpHaG1kVS1MaDV5c2p5eEpiUHZMVXdWU0F1VGh4ZGdHeG1qY0hYaVhPbzhQNXdZWktYNXV6dFNwVEd0eE9wODBsZlE1amZVVFQ2cHlHdHNZZlFTelRCVnNHS1A5ZVFOcElac1FEQTJxdw?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Oops, They Did It Again: Indian Pharma’s Frequent Flyers on FDA's Naughty List  BioSpectrum India",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.432Z",
    "first_seen": "2025-09-08T12:30:01.432Z"
  },
  {
    "name": "Ipca Labs Undergoes Crucial Us Fda Inspection At Ratlam Facility Amid Import Alert",
    "aliases": [
      "Ipca Labs Undergoes Crucial Us Fda Inspection At Ratlam Facility Amid Import Alert"
    ],
    "violations": [
      {
        "id": "424e835f3cefc94212df5e475d92e6bf",
        "type": "import_alert",
        "date": "2023-06-06T07:00:00.000Z",
        "title": "Ipca Labs undergoes crucial US FDA inspection at Ratlam facility amid import alert - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Ipca Labs undergoes crucial US FDA inspection at Ratlam facility amid import alert  CNBC TV18",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.438Z",
    "first_seen": "2025-09-08T12:30:01.438Z"
  },
  {
    "name": "Fda Alert On Ipca Labs, Us Export Halted From Mp Unit",
    "aliases": [
      "Fda Alert On Ipca Labs, Us Export Halted From Mp Unit"
    ],
    "violations": [
      {
        "id": "4489ff94c68c0b66d5f6e232fbc416e7",
        "type": "regulatory_news",
        "date": "2014-07-25T07:00:00.000Z",
        "title": "FDA alert on IPCA Labs, US export halted from MP unit - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA alert on IPCA Labs, US export halted from MP unit  Business Standard",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.445Z",
    "first_seen": "2025-09-08T12:30:01.445Z"
  },
  {
    "name": "Ipca",
    "aliases": [
      "Ipca"
    ],
    "violations": [
      {
        "id": "e550aab9939eb06977022bd88f6a4f00",
        "type": "import_alert",
        "date": "2015-01-27T08:00:00.000Z",
        "title": "Ipca Labs: Under pressure after US FDA import alert on Ratlam plant - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Ipca Labs: Under pressure after US FDA import alert on Ratlam plant  Business Standard",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.448Z",
    "first_seen": "2025-09-08T12:30:01.448Z"
  },
  {
    "name": "Dabur Gets Us Fda Import Alert",
    "aliases": [
      "Dabur Gets Us Fda Import Alert"
    ],
    "violations": [
      {
        "id": "b975ec455ca00046ec60ab70da351d65",
        "type": "import_alert",
        "date": "2013-06-15T07:00:00.000Z",
        "title": "Dabur gets US FDA import alert - Business Standard",
        "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQbFpyaDEySVl0QXRWNWdBZnJJT0VNWGI3bWlpM1RkOHV3ZndVMzdKUTA2S3pac1J6ZFpQZzBCVUxsLTZkYVM4ckJ3ajhkeVFRZWtIcGdNdXRxYnFTbDlscHZoZHNYQlNNaXFIZC1VZkZpM3dUZFgwalptTThEMXJTT3NZX2tVVEJtNlVjX1ljTndLTXlGLVNYZXJ6MHFLN2hiMmlCQtIBqgFBVV95cUxOak5SWjVkSExoS1FYdnlIalFuLWJ4RHh5X3Rjd3M3d3VIb2ZicUdVQkhscEp3S2FYbU1jd0dHLUVId19wODBjamxLMkU0cEtURW1WczNhMW1ZWkJfem1PeUN4Z1lydmVvT1ZPM1J4Z083RHFVUjJDd0RFX3lTam9mR1A2cUZ6UXZQbmotOXc1YW1QQm4xd1AyZ0dfcDNvcTBCck5YMl95QkRaUQ?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Dabur gets US FDA import alert  Business Standard",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.452Z",
    "first_seen": "2025-09-08T12:30:01.452Z"
  },
  {
    "name": "Sun Pharma Says Us Fda To Lift Import Alert On Mohali Drug Plant",
    "aliases": [
      "Sun Pharma Says Us Fda To Lift Import Alert On Mohali Drug Plant"
    ],
    "violations": [
      {
        "id": "92d32597740353a312584ae6bfe2bf1b",
        "type": "import_alert",
        "date": "2017-03-14T07:00:00.000Z",
        "title": "Sun Pharma says US FDA to lift import alert on Mohali drug plant - Mint",
        "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbWpjVU82TE5UQnk1T2t2SmxSaDI5WEhWZnJveV95amNQd1FKd1VVamFmSElUdWxKUE5KbkFSUFZDQnFjV19sZVJGV3NPSnNPZHl4a09Zc3VTelU5RktkYVpraTRFRGJDUHppU0Fsa3RuRTAxTFoyMXQxNkwyTkI4WUxfaGdQVDRadEYydERUZC15bE9pY280Q1JZamlHbXhGNnpIODBDUm5aQU9yWWdPeDh0Ui1NWFd4?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "Sun Pharma says US FDA to lift import alert on Mohali drug plant  Mint",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "plant  Mint",
      "on Mohali"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.460Z",
    "first_seen": "2025-09-08T12:30:01.460Z"
  },
  {
    "name": "Us Fda Ban On Sun Pharma Unit Lifted After Over 3 Years",
    "aliases": [
      "Us Fda Ban On Sun Pharma Unit Lifted After Over 3 Years"
    ],
    "violations": [
      {
        "id": "10b6de809145a6429935e4b5bfb87c8e",
        "type": "regulatory_news",
        "date": "2017-03-15T07:00:00.000Z",
        "title": "US FDA ban on Sun Pharma unit lifted after over 3 years - Business Standard",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "US FDA ban on Sun Pharma unit lifted after over 3 years  Business Standard",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.467Z",
    "first_seen": "2025-09-08T12:30:01.467Z"
  },
  {
    "name": "Usfda Issues Import Alert On Ranbaxy Laboratories' Mohali Plant",
    "aliases": [
      "Usfda Issues Import Alert On Ranbaxy Laboratories' Mohali Plant"
    ],
    "violations": [
      {
        "id": "49223ab418080929f43979fc55efd7cd",
        "type": "import_alert",
        "date": "2013-09-16T07:00:00.000Z",
        "title": "USFDA issues import alert on Ranbaxy Laboratories' Mohali plant - Business Today",
        "link": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNQUo5bThjbnAzeHRxbTN6aXJCMmlyb0RSams5R3hnZm1Dc0N2NnE4eXluTGhubHhSLUd5Vm9vNDRsSWk4Y2ZOM1RBaXo2Q3VmMGZSb2JmaTYtWFVSTVJMVFdRZ1Ffd0lucEExSFFETUNKNDY1VU1TQS1wMUFwYkdLZUo5cl9QeVVtb3dhMVBIbHhuY0MwaGNBWXdxSW1McGxqVDZxbWVjLW4zZDE1SWk0bkZMVnNBV1ozLVNzLTNpNHBfQQ?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "USFDA issues import alert on Ranbaxy Laboratories' Mohali plant  Business Today",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.480Z",
    "first_seen": "2025-09-08T12:30:01.480Z"
  },
  {
    "name": "Boehringer Ingelheim Ohio Subsidiary Enters Consent Decree",
    "aliases": [
      "Boehringer Ingelheim Ohio Subsidiary Enters Consent Decree"
    ],
    "violations": [
      {
        "id": "97937063fdce13f96538e08fbae21c64",
        "type": "consent_decree",
        "date": "2025-05-15T22:05:27.000Z",
        "title": "Boehringer Ingelheim Ohio Subsidiary Enters Consent Decree - CHEManager",
        "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPZ1JmQzNFTXdpY290STRFckRYNDJiS0t4OVF6RVJjYzhvNEtvMS1QT3ZCVEdiN29GbTF1a2xpWFdJUzlINUpGbnY4Sks5cGJQSVhlOTJDSTQ3S1dBM0k3N3kxd18zZ21JdW1pQnJLQ0p3RG00RlpUZzhpSWphVVQ5aXc3Y0dKQ2JkTFNqd3BJWkZZb0FiRzB2SEF6Nm8?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Boehringer Ingelheim Ohio Subsidiary Enters Consent Decree  CHEManager",
        "severity": 10,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 37,
    "compliance_score": 85,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.486Z",
    "first_seen": "2025-09-08T12:30:01.486Z"
  },
  {
    "name": "Fda Obtains Permanent Injunction Against Deltex",
    "aliases": [
      "Fda Obtains Permanent Injunction Against Deltex"
    ],
    "violations": [
      {
        "id": "e623d67ddbfce8ec8814b01989805300",
        "type": "consent_decree",
        "date": "2025-01-18T08:00:00.000Z",
        "title": "FDA obtains permanent injunction against Deltex Pharmaceuticals - Reliable Plant",
        "link": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOVWZ1MFJvdzFsa1dSRmF5TmdRYkYyTzhtTy1LRmlCeFhJaUV1T0hUeTV2Q3h1dl9fQUhrNGZJNTR1bi1aQ09WNXozWS1ORUpGWU12b3habU9SelNvajFDanlyVjE3cU9uV2dUVGd4NXJqR29tN3l4U0c2dFVkTExrOExDbWc?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "FDA obtains permanent injunction against Deltex Pharmaceuticals  Reliable Plant",
        "severity": 10,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 37,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.491Z",
    "first_seen": "2025-09-08T12:30:01.491Z"
  },
  {
    "name": "Deconstructing The Consent Decree",
    "aliases": [
      "Deconstructing The Consent Decree"
    ],
    "violations": [
      {
        "id": "91a4a560a0c4113374e688a57058c53b",
        "type": "consent_decree",
        "date": "2020-11-15T08:00:00.000Z",
        "title": "Deconstructing the Consent Decree: A Primer and Recent Trends for FDCA Injunctions - Food and Drug Law Institute (FDLI)",
        "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNNXUtLWlFQ21fc2hXWF9Eb0VIRUhZRG1meHNSUEo3RXFDdEJ6SUotWEZnUE9oVUlDUXhwZW4xSmNKZkpldlVXS0pvVHJiQ0tmYXpwSDUwNS1IRnFCSnJwZ1cyYXNLZW4zVy1UMlJFV1FWdjJSdzJNNHM3NlFRaXJTUWc5dWdidFhmVjU4SVhqN1VrWGdCX2dmZG1zaExROVhCQ09nTFlGejdiWGlzcnJlQw?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Deconstructing the Consent Decree: A Primer and Recent Trends for FDCA Injunctions  Food and Drug Law Institute (FDLI)",
        "severity": 10,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Law Institute",
      "Food and"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.496Z",
    "first_seen": "2025-09-08T12:30:01.496Z"
  },
  {
    "name": "Experts Discuss Red Flags That Can Trigger Legal Action Against Drug And Device Makers",
    "aliases": [
      "Experts Discuss Red Flags That Can Trigger Legal Action Against Drug And Device Makers"
    ],
    "violations": [
      {
        "id": "aca73c90dbee165cdd4bd433ea0bfcaa",
        "type": "regulatory_news",
        "date": "2023-12-12T08:00:00.000Z",
        "title": "Experts discuss red flags that can trigger legal action against drug and device makers - Regulatory Affairs Professionals Society | RAPS",
        "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOT3FGT1dxR2w0akRBSXBIejBUOExQWXVmOTFtUVRsejNrVDM2aHZmOVlmQTdGYW5ncGFTNEtVLXB3S1VubnQxbnc4bmlwM2ZlT1hqLTdWbFljZmF5NFlwZ3pZdUlGS0hUbDBHM05UR1JNR2xpdW9VVWQ3dnVHRjdMVmpOQUZ0NEZfaUMwaXZ3YVUzVm84aXp2cUVzQWNQbHN5QnVwRWZfeE9WLS1oZ25oVw?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Experts discuss red flags that can trigger legal action against drug and device makers  Regulatory Affairs Professionals Society | RAPS",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "and device",
      "action against"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.503Z",
    "first_seen": "2025-09-08T12:30:01.503Z"
  },
  {
    "name": "Fda Modifies Consent Decree For Xellia On Closed Ben Venue Plant",
    "aliases": [
      "Fda Modifies Consent Decree For Xellia On Closed Ben Venue Plant"
    ],
    "violations": [
      {
        "id": "037c09c51539496d5da6066ee6f7cb51",
        "type": "consent_decree",
        "date": "2016-05-03T07:00:00.000Z",
        "title": "FDA modifies consent decree for Xellia on closed Ben Venue plant - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQN05yeWdUY1hRbS03aFd6V1JzTko5cXhkSk9LWGhvSUNkVV92bWNqUjFVT1ZPQzBhV3ZNS29URXJJc0RMM1RaLVZXQ3lnM3A0Rks0eHFtSzktNEJENXd5bjNJNE9aRy1XZTc5NFlwaTJNQU9HdFJVODRuZ3NqWldJVkYxQVN1T09sLUNvUXVqZzk3WnozUmRLVWlJZzlKSWI0OGk2VmdXYw?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "FDA modifies consent decree for Xellia on closed Ben Venue plant  Fierce Pharma",
        "severity": 10,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.510Z",
    "first_seen": "2025-09-08T12:30:01.510Z"
  },
  {
    "name": "Fda Bans Cantrell From Manufacturing, Distributing Sterile Drugs",
    "aliases": [
      "Fda Bans Cantrell From Manufacturing, Distributing Sterile Drugs"
    ],
    "violations": [
      {
        "id": "086e2ff3cf769436558608514f39668c",
        "type": "regulatory_news",
        "date": "2018-04-24T07:00:00.000Z",
        "title": "FDA bans Cantrell from manufacturing, distributing sterile drugs - BioPharma Dive",
        "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPUG9ZdUNjejNIS3prVUdZbmJIWVR0SlNIbmV2RzQwSnhYai1hWEhhUU9qLUVUSkxWT3kxWHd1YWtlSjd0TDJzd2pSd0hyWUVEdEZEY01WbmdGVkdmRW9ic3BYdzlKS200SkxMZGExTkNnVzByUkJUUENpZVphM2llZnd6NDNzNDZ6SHMzVEhZcnUwTE5GUlc5dmd1d1IwLUlFakxDNGM5djZrdw?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "FDA bans Cantrell from manufacturing, distributing sterile drugs  BioPharma Dive",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "distributing sterile"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.517Z",
    "first_seen": "2025-09-08T12:30:01.517Z"
  },
  {
    "name": "Abbott, Fda Reach Agreement To Reopen Baby Formula Facility In Michigan",
    "aliases": [
      "Abbott, Fda Reach Agreement To Reopen Baby Formula Facility In Michigan"
    ],
    "violations": [
      {
        "id": "fc8a54aa13d12966f832950c3f2e2365",
        "type": "regulatory_news",
        "date": "2022-05-16T07:00:00.000Z",
        "title": "Abbott, FDA reach agreement to reopen baby formula facility in Michigan - Reuters",
        "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPdHZTMFVMT1ZSLUtuMXhSNGRsYzVYZ3h4RlpXTy1FSjlic3ZKRzNpQk5qTEptT3loVk93dXlHQVg0Zmppd25oUF9XenNHcllzQzd4QkZTSDV1VVFPaWV6blp4VTJEMWpENmhmSVNUZTctQmY2ektENFVTbEItNl9qdzh6X3FZQTEzbEdJUUlvLXc4bmRhM19KdGhEc0VwSFVOWC1NU1NBaFJOTlA0TVA4c2NOM0pCZFZLYlRSRDdZRUJpdGxmZkMtclB0MUMzQkVGSmJ5RjFNZENMZlBY?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Abbott, FDA reach agreement to reopen baby formula facility in Michigan  Reuters",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [
      "Michigan, Re"
    ],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.524Z",
    "first_seen": "2025-09-08T12:30:01.524Z"
  },
  {
    "name": "Fda Forces Actavis To Shut Down Plants",
    "aliases": [
      "Fda Forces Actavis To Shut Down Plants"
    ],
    "violations": [
      {
        "id": "331b1e64ddc8ceb36aa90ce948074ac8",
        "type": "regulatory_news",
        "date": "2019-11-21T23:16:15.000Z",
        "title": "FDA Forces Actavis To Shut Down Plants - Manufacturing.net",
        "link": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQQ21qRkRaR2hBSmh5R3NnbEs0eVFwUk1zS3B4QWlDcFExWkpFQmE3bDRuSk51WHBXQWpDNXhyVnc2VXl0cEltWmNhTFJRTWNGa0dyekVySnEyR0c5S09pNFd3VXZpYnpCR05lTGpsVHN6M3REZTRacWhkaHFHb2tJYkpaNWNhb0VwbnNZOEg3bnFka1BNUjRiZA?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "FDA Forces Actavis To Shut Down Plants  Manufacturing.net",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.532Z",
    "first_seen": "2025-09-08T12:30:01.532Z"
  },
  {
    "name": "J&l Grocery Enters Consent Decree With Doj, Fda",
    "aliases": [
      "J&l Grocery Enters Consent Decree With Doj, Fda"
    ],
    "violations": [
      {
        "id": "b7f8cbbd9c2128f9e39e8120d53fcc1d",
        "type": "consent_decree",
        "date": "2019-07-19T07:00:00.000Z",
        "title": "J&L Grocery enters consent decree with DOJ, FDA - Southwest Times Record",
        "link": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPSE94NHkyN2FmbkcwUEFpRG81cjVrak5yaVVDQXRMT2hvZmFjRXRpMDNST3dKRjBhQ3U1dXpwM2dubkQ3NUJIUzhpR2RSUDZjVnhEbmR3VEVIRjZkS05naVN5c2dVSGJPUUN0ZEdDZlFhMTU2LWFYYWdXOGdRY0FmNGpDOUd0d3Yyd1lzd3NuUQ?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "J&L Grocery enters consent decree with DOJ, FDA  Southwest Times Record",
        "severity": 10,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.537Z",
    "first_seen": "2025-09-08T12:30:01.537Z"
  },
  {
    "name": "How A 15",
    "aliases": [
      "How A 15"
    ],
    "violations": [
      {
        "id": "f54e3b6f07e1cffe683c8aa6a8e523b8",
        "type": "regulatory_news",
        "date": "2024-02-26T08:00:00.000Z",
        "title": "How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues - PharmaVoice",
        "link": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNTU4tTnYtcjJSWHBpaVJIYzVVUjNYNTJxQmhXNjlYSkNOTjZKQkp0Z1ZweGJIN3pFaFJyT0I5bW85N2UxY0d4LVkyNnNtR05DSEhaMXYzd2RUUkFMcmhsOURtS3JYQWIwWG5kUFdzM21tUjRheW9OTWtLU3R6UmVoQlFuSUp5NVU?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues  PharmaVoice",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "shortage became",
      "old Genzyme"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.542Z",
    "first_seen": "2025-09-08T12:30:01.542Z"
  },
  {
    "name": "Fda Forces Carlstadt Company To Shut Down",
    "aliases": [
      "Fda Forces Carlstadt Company To Shut Down"
    ],
    "violations": [
      {
        "id": "d8e91f34cb85eb9b31f53af3a880ff7c",
        "type": "regulatory_news",
        "date": "2017-06-18T07:00:00.000Z",
        "title": "FDA forces Carlstadt company to shut down - Bergen Record",
        "link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQUW9xcWtZLTNFRzFMZHhWc0lqOUR3aHNFUWpxdlE0LUFfT2N6UjFtbUtBR21sZzJYNWZzVEJfZDM4UU8xd3VjMjZPRVBlcXdRczJlWE1ENm9VQ19NQjVIaEV0ZVdiS1ZjWUVLMWd6RVdlU2VUUTFEUlpRMlZtcy11OTZiOTU5UC1yU2RFel9wTHNMM1BnM3FTUlVQZ1J2bEpu?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "FDA forces Carlstadt company to shut down  Bergen Record",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.548Z",
    "first_seen": "2025-09-08T12:30:01.548Z"
  },
  {
    "name": "Florida Compounding Pharmacy Punished By Federal Court",
    "aliases": [
      "Florida Compounding Pharmacy Punished By Federal Court"
    ],
    "violations": [
      {
        "id": "ebf41551173cd7544972eabbbf6213a6",
        "type": "regulatory_news",
        "date": "2021-09-28T20:36:46.000Z",
        "title": "Florida Compounding Pharmacy Punished by Federal Court - Medtruth",
        "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNbEZNTTFfTjdIWFd2YzJTQ2JJQmtvSGE0MXBMdi0zQVlwU1Zleks5dVBqN3JIVzNYMUpVeGNIYzlDaDFDbmtUbF9EbjF0MHBCNzB2SWxQcndOWklaUEZOelZtT2M2OVpXY3BZbkszVGtzM0xlTklLeHloeXNmVFBsU3BOdThhTTdpVWxYR2lMN2M5Rmx4ZnFkZlN0cktuRnBIcFE?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Florida Compounding Pharmacy Punished by Federal Court  Medtruth",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.555Z",
    "first_seen": "2025-09-08T12:30:01.555Z"
  },
  {
    "name": "Fda Again Warns Sun Pharma Over Dadra Facility",
    "aliases": [
      "Fda Again Warns Sun Pharma Over Dadra Facility"
    ],
    "violations": [
      {
        "id": "baf4c11d8bb618e6a7b44e3b09042c86",
        "type": "regulatory_news",
        "date": "2024-07-02T07:00:00.000Z",
        "title": "FDA again warns Sun Pharma over Dadra facility - Regulatory Affairs Professionals Society | RAPS",
        "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZVRWX19LcnlWWGFqcWFrS3lORXNfUUR1cS1CdHAySkdBU1FzbFBSN0p1SmtUSmI2OUgxdUJZNENlaWhmeUNSNjFEOFp5d1YwTVNvVnlEWnZJUWpPaHVuak1OZUNQUlQ0QjRoRDRwdmF5aTVmSE9mRUlRZ0VGdHppX3RRVXlET1c3ZVo1TWF5Qm5CWmRwS3BydVhRb2RyVWdsUExTM2V4UFY5UQ?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "FDA again warns Sun Pharma over Dadra facility  Regulatory Affairs Professionals Society | RAPS",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.563Z",
    "first_seen": "2025-09-08T12:30:01.563Z"
  },
  {
    "name": "After Manufacturing Blunders, Pharmasol Is Shuttered By Us Court For Distributing Adulterated Drugs",
    "aliases": [
      "After Manufacturing Blunders, Pharmasol Is Shuttered By Us Court For Distributing Adulterated Drugs"
    ],
    "violations": [
      {
        "id": "1cfa2ae8b805766630313adf9ae60859",
        "type": "regulatory_news",
        "date": "2023-12-18T08:00:00.000Z",
        "title": "After manufacturing blunders, Pharmasol is shuttered by US court for distributing adulterated drugs - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNdThWVXh3R214Rk1MOWFLUGR5OGFuMzlHNUNlajRNN2Y1a1FFNnFBMW5mYkhnUy11cC1CdzhmOUhMR28xLVJ4V2UteU5Vc2VHMGgydDNUZmJNS0l2NVJwdW8wS0xYMTNrZklld1h4RWhmRzlWcllmeUptY3JELXh1am5PR0FBbFl4ZHpIaG5MM0JjVXp3TWUxR3oxUnRNNUIyWFNVUWctbzJXVm9VMC1vNmJjVlV2eHc?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "After manufacturing blunders, Pharmasol is shuttered by US court for distributing adulterated drugs  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "distributing adulterated"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.570Z",
    "first_seen": "2025-09-08T12:30:01.570Z"
  },
  {
    "name": "Philips' Us Sales Of Sleep Apnea Devices Face Years",
    "aliases": [
      "Philips' Us Sales Of Sleep Apnea Devices Face Years"
    ],
    "violations": [
      {
        "id": "bae6638214ec0e35ff6701c8f4e16114",
        "type": "regulatory_news",
        "date": "2024-01-29T08:00:00.000Z",
        "title": "Philips' US sales of sleep apnea devices face years-long halt after FDA deal - Reuters",
        "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQT0pUakJLQXNLeXNaNXd2QUwtd01nRDFMWVI0c0VBNjNXYzhRQWVUVWM5UEtZaW5KLW8zdTlnOWN0ajFjNzN3Q25MeEw5TERLa05feV9CMlRZcnZsaWtfZmd3VW5rTTZzVHFsdFpJNHRnU2JEc2dGRkJHZkdtMUtDOWFPM3FiSGFreGQtbG0xZTRJZklmalF0aVVIUzhJelZ3MUtQUU5lbkVCY1lvcFYxVkZDNERSVHZxSTdTUFNFYU9rOElOdXJsLVZPTHVTMll1WHF1T1h2VQ?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Philips' US sales of sleep apnea devices face years-long halt after FDA deal  Reuters",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.578Z",
    "first_seen": "2025-09-08T12:30:01.578Z"
  },
  {
    "name": "Fda Orders Sun To Hire Manufacturing Consultant For Troubled Plant As Export Pause Persists",
    "aliases": [
      "Fda Orders Sun To Hire Manufacturing Consultant For Troubled Plant As Export Pause Persists"
    ],
    "violations": [
      {
        "id": "47d347678a3f82c6086a5901152197d9",
        "type": "regulatory_news",
        "date": "2023-05-16T07:00:00.000Z",
        "title": "FDA orders Sun to hire manufacturing consultant for troubled plant as export pause persists - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQUWR3SHF6aDhNSTk0TFhUUTJaYzRMZm84QlZwd0ZOZGVoWkpoUlpMRFFHdU1qRlgwNnJsUFZKZXg3T19WanNaZFdpZnByTDRzdjRQZFZTS0RrOHB0QVNRUGhOQzgwSlNkdlVVTk1pS3psMEVvekhXekN5Yk1GRXpaNjQ4NHdsaWtlOFkxUVVhR1p1SU5VMGR6TzZ5dG9sQjg3RTJtUmF0OEo4Z3B4b0NTZjd6dw?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "FDA orders Sun to hire manufacturing consultant for troubled plant as export pause persists  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.586Z",
    "first_seen": "2025-09-08T12:30:01.586Z"
  },
  {
    "name": "An Analysis Of Fda Fy2018 Drug Gmp",
    "aliases": [
      "An Analysis Of Fda Fy2018 Drug Gmp"
    ],
    "violations": [
      {
        "id": "2d8228a87ebffdd7a3efa367af92cbdc",
        "type": "warning_letter",
        "date": "2019-02-01T08:00:00.000Z",
        "title": "An Analysis Of FDA FY2018 Drug GMP Warning Letters - Pharmaceutical Online",
        "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNQV9IQVAxQWhXZnh3ZUN3cWl0aFlWZjNIN3ZmRmNfRVExM0R6U0lWbEk5R3A4OU1sN1BrWDdYazdnLXoxb19tTmJRdWtKUENVLWNnM2JiVXJYbmRRMGV5MFFFYVhFcEVJNGNlSGhMWXZVTVBxTG9fZHVyWERxb1EzNEE3aER1VkRtdnNkbldxdU1fdTNrVGJz?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "An Analysis Of FDA FY2018 Drug GMP Warning Letters  Pharmaceutical Online",
        "severity": 8,
        "status": "new",
        "response_deadline": "2019-02-16T08:00:00.000Z"
      }
    ],
    "products": [
      "GMP Warning"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.592Z",
    "first_seen": "2025-09-08T12:30:01.592Z"
  },
  {
    "name": "Medtronic's Pain Pump Redesign Ok'd By Fda",
    "aliases": [
      "Medtronic's Pain Pump Redesign Ok'd By Fda"
    ],
    "violations": [
      {
        "id": "0baab1d6e5ba3a38bf79ae02fe75d1a5",
        "type": "regulatory_news",
        "date": "2018-01-10T08:00:00.000Z",
        "title": "Medtronic's pain pump redesign OK'd by FDA - Star Tribune",
        "link": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQOXdZOUJjenNsNmZyNUJZang5M2J4YnpRaUYtNW50QlpnTWVRQnZ3SXFwankzRjR4aWxhZm90d1pTYzBNMHAxVTNOb2dnaFM1OVY5eG9GaTdsR21ycFpqM3h1Ync1MEtVN0psdUxGZmdLVVFJRE5qanBLd296UlA2d1NRZk1JMms?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Medtronic's pain pump redesign OK'd by FDA  Star Tribune",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.599Z",
    "first_seen": "2025-09-08T12:30:01.599Z"
  },
  {
    "name": "Fda Blasts California Compounding Pharmacy For Facility 'Contaminated With Filth'",
    "aliases": [
      "Fda Blasts California Compounding Pharmacy For Facility 'Contaminated With Filth'"
    ],
    "violations": [
      {
        "id": "6d1dfc892263d885d3dd3b7f168e2119",
        "type": "regulatory_news",
        "date": "2020-07-02T07:00:00.000Z",
        "title": "FDA blasts California compounding pharmacy for facility 'contaminated with filth' - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNa3lHRmhEcXpDdkdDakVaQmxUNUpuenZnNHZHOW1BNk1NWGMwdkpXZUJ1ZV9PNVNoRXdEZktOeUI5dmpUVGxadG9odzFPNTRtNjk3b2lJalBSVFFISFRyQ2sxNjRhanJwNkxmOUNyVXRMNVhJaF9mNlI5SWJHT0hoaDl1eE44ZHRsYm1BQUtUVmE1Q1k2NGZDQ25vMXY0dDZVc0c2a1JkRlBOQngySWp1dlRIMFV4bHpm?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "FDA blasts California compounding pharmacy for facility 'contaminated with filth'  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.607Z",
    "first_seen": "2025-09-08T12:30:01.607Z"
  },
  {
    "name": "Fda Approves Generic Doxil To Combat Drug Shortage",
    "aliases": [
      "Fda Approves Generic Doxil To Combat Drug Shortage"
    ],
    "violations": [
      {
        "id": "e4415ecd8cdf5e663162b7a5e643da67",
        "type": "regulatory_news",
        "date": "2013-02-04T08:00:00.000Z",
        "title": "FDA approves generic Doxil to combat drug shortage - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQZ2h0eWRrdzR2YVM1QktwRTN4LXNrcWZ1ODBCT0tscmVBdFhVNnF3dTNwNTJGRXpWYjk5UTVfRnhVNjdsWXc3WVo3VnF0M2pzSUNfbF9nRndTcUYtdEVOdmRiN3hCMHdaaXdXTV81WGZWeWVpV25NVi0yMVhOLWJDY0M1cTZEV3hjUmFGbVM0dFo4ZUhDN2tVc296anNCZF9V?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "FDA approves generic Doxil to combat drug shortage  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "shortage  Fierce",
      "to combat"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.614Z",
    "first_seen": "2025-09-08T12:30:01.614Z"
  },
  {
    "name": "Fda Requires Federal Oversight Of J&j Plants After String Of Drug Recalls",
    "aliases": [
      "Fda Requires Federal Oversight Of J&j Plants After String Of Drug Recalls"
    ],
    "violations": [
      {
        "id": "a383ef606d0644e8f76ef294696fa092",
        "type": "recall",
        "date": "2011-03-11T08:00:00.000Z",
        "title": "FDA Requires Federal Oversight of J&J Plants After String of Drug Recalls - AboutLawsuits.com",
        "link": "https://news.google.com/rss/articles/CBMiakFVX3lxTE5rMW1mR001M2hIUnJfd3R1WXprX2xGcE12cW1sclJXYXR0TGJ3MTcxbmRHQkVRTGRObUZ0Q2hJLUs0aTdpZ2t6X1NyaWhEZGp1OVY4U3V5OWM3cWRTaG51T1ZhTU0ycmg2WVE?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "FDA Requires Federal Oversight of J&J Plants After String of Drug Recalls  AboutLawsuits.com",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Recalls  AboutLawsuits",
      "String of"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.620Z",
    "first_seen": "2025-09-08T12:30:01.620Z"
  },
  {
    "name": "Compounding Pharmacy Ordered To Cease Operations",
    "aliases": [
      "Compounding Pharmacy Ordered To Cease Operations"
    ],
    "violations": [
      {
        "id": "198ff6f0830c9b85c0e1e0f936964e75",
        "type": "regulatory_news",
        "date": "2019-05-29T07:00:00.000Z",
        "title": "Compounding Pharmacy Ordered to Cease Operations - Drug Topics",
        "link": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOci01UC1zQldSX0pMWklLbE43M3Zydm1HWjEtWmplZDhoNE85ZWY3Tnd0SkpVdWFpb2NYQ2xUc2NtZ09CdnZrNTlENVZYeklLREU3VTl3SjlfWlJBTzNkdU5YM0hHZEJyT2hkcnlHZVc0ZkRpejJxZF9vUkdONms0ZkVCVQ?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Compounding Pharmacy Ordered to Cease Operations  Drug Topics",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Topics",
      "Cease Operations"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.628Z",
    "first_seen": "2025-09-08T12:30:01.628Z"
  },
  {
    "name": "Fda, Doj Enter Consent Decree Of Permanent Injunction Against Boosted",
    "aliases": [
      "Fda, Doj Enter Consent Decree Of Permanent Injunction Against Boosted"
    ],
    "violations": [
      {
        "id": "58c41d1b7b148a5b1898d3dac1bf99e0",
        "type": "consent_decree",
        "date": "2024-06-17T07:00:00.000Z",
        "title": "FDA, DOJ Enter Consent Decree of Permanent Injunction Against Boosted LLC - CSP Daily News",
        "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPbER3Z0JOVnRaTlZCRjNvYko3akJGN292dmhJRDZvOEhqMnRlWWNXZ09objJNWm9xdlBRMzlmR1ZvY1ExRUFLOTNFU09KRlYtMjNVOVBYWkJXd0RSb3drSXplVVl0SFNhOWNSQ2VBMjZ2Wmhtc2tiLTlYOXQ3NzRRZmhlbnFJbXJwcDd2TFU5V0FxX09uRF9WWkZSeG9yLUFXUkFlQQ?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "FDA, DOJ Enter Consent Decree of Permanent Injunction Against Boosted LLC  CSP Daily News",
        "severity": 10,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 37,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.637Z",
    "first_seen": "2025-09-08T12:30:01.637Z"
  },
  {
    "name": "Fda Grades New Medtronic Synchromed Ii Recall As Class I Event",
    "aliases": [
      "Fda Grades New Medtronic Synchromed Ii Recall As Class I Event"
    ],
    "violations": [
      {
        "id": "8afb48ad482fa124dcc4a556a413d246",
        "type": "recall",
        "date": "2019-12-05T08:00:00.000Z",
        "title": "FDA grades new Medtronic SynchroMed II recall as Class I event - MedTech Dive",
        "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNUmgzVjY2X3VNRV9Mdy1RM3B6MDEzX09oSjJyN3ZfVE91WXFwamZGU1lTeC1Nd043Wk04TUZhTFJQN3c1MjNMaFVEMlVFREtpQ09CY1JQZHAxSHB1bmplZlhxTVJaRnIyMy1uY0NMMzZfb2hGSV91OGxtUnN5YTZZNGxmMGZsZGtDdDZ6Wlc3dW52U2s4Rld1ZzgySFRxYWlScU5Qa1F3?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "FDA grades new Medtronic SynchroMed II recall as Class I event  MedTech Dive",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.646Z",
    "first_seen": "2025-09-08T12:30:01.646Z"
  },
  {
    "name": "Xellia Expects Ex",
    "aliases": [
      "Xellia Expects Ex"
    ],
    "violations": [
      {
        "id": "742bf2500120f5a5886e08e475e9c20f",
        "type": "regulatory_news",
        "date": "2016-11-15T08:00:00.000Z",
        "title": "Xellia expects ex-Boehringer sterile plant to be ready for production in 2018 - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQk52cV8xT2pOemp5V21pRjU0TXIxSFZRb2djTWJIUm5mcTVFdmlpdDM1N2hBSXNVU2gxNzhwaloydFZjQlQyUWFaNUc4N0hiRzNVQXY2SnZXUWdkTVZ3RW9QNmtkanVReFlhNFc5LU51MU5pREVIMEh4S2hRYUp4WWtPTHBCeXcxYXJjbEltYmdTTk5XR0ZFcjR5Y0R1Y2czakQtMEpjc0U5QWZGYTdrSW5XWEpuM2JF?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Xellia expects ex-Boehringer sterile plant to be ready for production in 2018  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "ready for"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.651Z",
    "first_seen": "2025-09-08T12:30:01.651Z"
  },
  {
    "name": "Fda Fy2020 Drug Inspection Observations And Trends",
    "aliases": [
      "Fda Fy2020 Drug Inspection Observations And Trends",
      "Fy2017 Fda Drug Inspection Observations And Trends"
    ],
    "violations": [
      {
        "id": "c0af3076e9b914f05daff2f39170cd4b",
        "type": "form_483",
        "date": "2020-12-09T08:00:00.000Z",
        "title": "FDA FY2020 Drug Inspection Observations And Trends - Pharmaceutical Online",
        "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNSGdpeDRlNmR1U0R3NW5YMkljdHQwNHVkNjRqMHN2M3hCZ2dpdFFuNldVM1c2bmpSOTNjcC0yUW1QVWp4UnN1Y3dYRmFXb0ZDRmotTC1pOXY5Wnh5QkMtbV9iX2FGWUtIRWJGS2xFbHlzY2pIQlFWaWNyc3hIWDAtXy1rSEdjNGVuMFpRQ3FlRm9MUjZKZ3Jv?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "FDA FY2020 Drug Inspection Observations And Trends  Pharmaceutical Online",
        "severity": 6,
        "status": "new",
        "response_deadline": "2020-12-24T08:00:00.000Z"
      },
      {
        "id": "fc88af127809fbac94b7755849e55cb5",
        "type": "form_483",
        "date": "2018-04-18T07:00:00.000Z",
        "title": "FY2017 FDA Drug Inspection Observations And Trends - Pharmaceutical Online",
        "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQQ3BsXzNPcFIzY1Aya1FJcUlWMUhmRVZqV0JvWDNmWkd3VWtyeElVQ0NCdFJHNUVnZnRzWlBPc1c2NXoxS0JPTFNmWjVFb3htTHhieURHazFsTkRIYkR6U0t2dmxsZC0yVk54b05SSkRSU3dndDNZYkhKVW1nZko2QjR3b1d0dDJmVlJmTjE2SGRHUDVIUWw0?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "FY2017 FDA Drug Inspection Observations And Trends  Pharmaceutical Online",
        "severity": 6,
        "status": "new",
        "response_deadline": "2018-05-03T07:00:00.000Z"
      }
    ],
    "products": [
      "Inspection Observations"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.694Z",
    "first_seen": "2025-09-08T12:30:01.656Z"
  },
  {
    "name": "Fabrazyme Litigation Back In Play For Sanofi's Genzyme As Appeals Court Overturns Dismissal Of 2020 Lawsuit",
    "aliases": [
      "Fabrazyme Litigation Back In Play For Sanofi's Genzyme As Appeals Court Overturns Dismissal Of 2020 Lawsuit"
    ],
    "violations": [
      {
        "id": "92c7218b6e3ce3ffab7638abe42a9feb",
        "type": "regulatory_news",
        "date": "2024-02-20T08:00:00.000Z",
        "title": "Fabrazyme litigation back in play for Sanofi's Genzyme as appeals court overturns dismissal of 2020 lawsuit - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQUWwyYWFRcjBhTkdLOWhIOXlqQTl0WFBCR3daNjBRNzJPQmNfckFuTW0yZjdvbllpcXNEVnJhamExdkV4czRlQXlNNlI3cUdSSnV6TzBoQzNUSjNic09WTkk4eUhJR0FhVVU2QlJ5Mnk2Z1Z0aWJTNnJTeGhnMEtwOTJqZ2xYRzlqVWI0S010XzRTY19hUXlzbHgxRnN6STdfTFlEb2ZfOWhjLXduSjZENzFBdHFYNUp5djBuazd4VkNMRG1OTG5B?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Fabrazyme litigation back in play for Sanofi's Genzyme as appeals court overturns dismissal of 2020 lawsuit  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 22,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.666Z",
    "first_seen": "2025-09-08T12:30:01.666Z"
  },
  {
    "name": "Sun Says 'Time Consuming' Remediation Paying Off",
    "aliases": [
      "Sun Says 'Time Consuming' Remediation Paying Off"
    ],
    "violations": [
      {
        "id": "65b2dc15130199907d6e3cd617cf4d43",
        "type": "regulatory_news",
        "date": "2016-08-22T07:00:00.000Z",
        "title": "Sun says 'time consuming' remediation paying off - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNTUxsczk1WjYxOWhtR0pnLWRpaXY0d0NnN2hDcTNKOWhYQ18tNzloOXV3bzFzbzFpOUZvSmU4YkhGWE1OY3JWbUs4R3BUdHhSN3dhUzNNd0JCc3kyZnpDWFdlSXM2QmltcWV0bUs0N0Yzd3RJXzZzOGxONlp2bHFHV3UwVTZZQ1BubDVfVW5PeDRGMmc?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Sun says 'time consuming' remediation paying off  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.672Z",
    "first_seen": "2025-09-08T12:30:01.672Z"
  },
  {
    "name": "Xellia Pharmaceuticals, Fda Reach Agreement On How To Revive Former Ben Venue Complex",
    "aliases": [
      "Xellia Pharmaceuticals, Fda Reach Agreement On How To Revive Former Ben Venue Complex"
    ],
    "violations": [
      {
        "id": "6382f22648b39e85bfb4cff086edd1ff",
        "type": "regulatory_news",
        "date": "2016-04-28T07:00:00.000Z",
        "title": "Xellia Pharmaceuticals, FDA reach agreement on how to revive former Ben Venue complex - Crain's Cleveland Business",
        "link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPVmJKaXR4VzBuZzd0S09sQ25vS1ZvQ3p6SktCUXBDTmpOM1U3dnFfdWN1Z216UWNGR0gyRmNRUkZ0dGg4eFVHWXp1TkhWaDZZaW9vTV9jRUh3NlR4UEk0RE13dWZuTnlRNUtSSkVMQm05eGZzR0ctLWw4ZWdtdHMwSDUzeXRqQWpKdUZwcTZzYjVxOEhscXVsRnVyLWRBY3lVV2k3azNxbWlMN2tkQ04xd1FhSkZYVnlKdmRsUFJVYXZIVDFiVmNSdUl3?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Xellia Pharmaceuticals, FDA reach agreement on how to revive former Ben Venue complex  Crain's Cleveland Business",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.682Z",
    "first_seen": "2025-09-08T12:30:01.682Z"
  },
  {
    "name": "Caraco Pharmaceutical Names New Ceo",
    "aliases": [
      "Caraco Pharmaceutical Names New Ceo"
    ],
    "violations": [
      {
        "id": "173e818e933635fa4952903ee3329d1e",
        "type": "regulatory_news",
        "date": "2010-10-10T07:00:00.000Z",
        "title": "Caraco Pharmaceutical Names New CEO - CBS News",
        "link": "https://news.google.com/rss/articles/CBMifkFVX3lxTE13cVJxdG1scU5Yb0dkc2VkaGhCQmpoX3hVcnRTS2E4YVNMQUJkRWtmT3BsdDdmbWxSalFxWXNyOUtwSnhySEpqUWE2ZFRCSlczR0Ixck11LU5lWU85b2lHazU3a1JfVEJOWVdQc0x1T1R6WkRaVFVJQV8tMTNCQQ?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Caraco Pharmaceutical Names New CEO  CBS News",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.686Z",
    "first_seen": "2025-09-08T12:30:01.686Z"
  },
  {
    "name": "With U.s. Nod, North Little Rock",
    "aliases": [
      "With U.s. Nod, North Little Rock"
    ],
    "violations": [
      {
        "id": "af9513b80582b4bc756197f1538e9d97",
        "type": "regulatory_news",
        "date": "2018-09-26T07:00:00.000Z",
        "title": "With U.S. nod, North Little Rock-based Cantrell Drug reopens - The Arkansas Democrat-Gazette",
        "link": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQVFktbzA4ZWVFaVU4Z3BYN3N2aHM4ZFcxb2JRUUdzekk2cE9OaTE0ZnVFbXNJZWJMRWdSU1JCT1BtOWs1bnBHU1A1SXpFR01IWEdILXNTNVZQOFNqQUJSRWtyUzR5enJsSGR2MnFJS1RQVUxIUUNEREc1OV9pU1pOMEkxa3FJYTZzd1lHejVZdnJrZw?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "With U.S. nod, North Little Rock-based Cantrell Drug reopens  The Arkansas Democrat-Gazette",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "reopens  The",
      "based Cantrell"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.699Z",
    "first_seen": "2025-09-08T12:30:01.699Z"
  },
  {
    "name": "Sun Pharma Shares Fall After Usfda Halts Shipments To The Us From Mohali Facility",
    "aliases": [
      "Sun Pharma Shares Fall After Usfda Halts Shipments To The Us From Mohali Facility"
    ],
    "violations": [
      {
        "id": "df140029a3707aa89c07186534d8871b",
        "type": "regulatory_news",
        "date": "2023-04-24T07:00:00.000Z",
        "title": "Sun Pharma shares fall after USFDA halts shipments to the US from Mohali facility - CNBC TV18",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Sun Pharma shares fall after USFDA halts shipments to the US from Mohali facility  CNBC TV18",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.707Z",
    "first_seen": "2025-09-08T12:30:01.707Z"
  },
  {
    "name": "Actavis Reintroduces Oxycodone In The Us",
    "aliases": [
      "Actavis Reintroduces Oxycodone In The Us"
    ],
    "violations": [
      {
        "id": "03c55fc243dd7fca13b9eda68209efb4",
        "type": "regulatory_news",
        "date": "2009-04-21T07:00:00.000Z",
        "title": "Actavis Reintroduces Oxycodone In The US - Pharmaceutical Online",
        "link": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPYXpvVnowU0M3M2tHWW8tRjhiQzFTa1doZzI3VXBDUnV4cjV3ajlIQlJ4bkFiaG9RODdSTkxiTVVSNHNVejVsVHRRVjNSa3NBV0JKbWVDNloxdzRLcHd3NkF1b0w2QWlQYkNWRE5HUF9zV2dYYlZ1ZWdteThtalFTTHVIeDF2VXpYNjlBNU43OA?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Actavis Reintroduces Oxycodone In The US  Pharmaceutical Online",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.714Z",
    "first_seen": "2025-09-08T12:30:01.714Z"
  },
  {
    "name": "Xellia Kicks Off Budapest Manufacturing Expansion",
    "aliases": [
      "Xellia Kicks Off Budapest Manufacturing Expansion"
    ],
    "violations": [
      {
        "id": "86af4ce5a6ca1668c4f13345b7650b08",
        "type": "regulatory_news",
        "date": "2016-05-25T07:00:00.000Z",
        "title": "Xellia kicks off Budapest manufacturing expansion - Fierce Pharma",
        "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOM3h2QmxseFVscjBzVHNHNWNIYnd2c3JzTUJwNnN4bG1id0Zoa1hXVnJIbVZ0NzJKTElIUko4Y2V1cGNaTGhVZUsyZldHR1lLTXM0N1lVa3V3bFl2OGlKNkUyVllSWWVHSW9FZDVwWkxKcXI0MW1OYWktblN5VEcwc2NGSGVCcUJHTy1XYXF1bDRvbmlTVDhV?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Xellia kicks off Budapest manufacturing expansion  Fierce Pharma",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.720Z",
    "first_seen": "2025-09-08T12:30:01.720Z"
  },
  {
    "name": "Dietary Supplement Manufacturer Abh Pharma Recalls All Products",
    "aliases": [
      "Dietary Supplement Manufacturer Abh Pharma Recalls All Products"
    ],
    "violations": [
      {
        "id": "34edcbc27150d6229c7cbd4591df7cdd",
        "type": "recall",
        "date": "2020-01-22T08:00:00.000Z",
        "title": "Dietary Supplement Manufacturer ABH PHARMA Recalls All Products - Food Poisoning Bulletin",
        "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPSFFCcWcxbHpXTllvczREUmdXTmpfMVZVTkh0MUxZdDFyaEdLZzc1ZFNrSlpTdWE2eXU1V2ZtWFVZa2ZPX0dYYTFBZ1BDMFJFeTRlcDJtbTN0VW9WSExxUXNrNUZPbVpTTDNJOW9rVjBRd2VmZmVSVGlrc3FWZDBUZE1BZ2Z0SDNIZTFBTjk5dDI2YVg5NXZod1haeE56SFdGVHRyZUVn?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Dietary Supplement Manufacturer ABH PHARMA Recalls All Products  Food Poisoning Bulletin",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [
      "Recalls All"
    ],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.728Z",
    "first_seen": "2025-09-08T12:30:01.728Z"
  },
  {
    "name": "We Will Continue To Engage External Consultants, Biocon Assures Usfda",
    "aliases": [
      "We Will Continue To Engage External Consultants, Biocon Assures Usfda"
    ],
    "violations": [
      {
        "id": "a783f475b064685fe43bce82433cf4b7",
        "type": "regulatory_news",
        "date": "2018-04-17T07:00:00.000Z",
        "title": "We will continue to engage external consultants, Biocon assures USFDA - The Indian Express",
        "link": "https://news.google.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?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "We will continue to engage external consultants, Biocon assures USFDA  The Indian Express",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.737Z",
    "first_seen": "2025-09-08T12:30:01.737Z"
  },
  {
    "name": "Sun Pharma Temporarily Halts Shipments From Mohali Facility To Implement Us Fda",
    "aliases": [
      "Sun Pharma Temporarily Halts Shipments From Mohali Facility To Implement Us Fda"
    ],
    "violations": [
      {
        "id": "c59ba8e9a2d178d570079176c3e29428",
        "type": "regulatory_news",
        "date": "2023-04-23T07:00:00.000Z",
        "title": "Sun Pharma temporarily halts shipments from Mohali facility to implement US FDA-mandated measures - Business Today",
        "link": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNTDBEeEg2SkZoY1RISHlTSmNfRFdZbW8yWmJLQm1LYU5PN2NRM2pkeC1PSExQaFFfSk9SXzc4OWFJZXAtQWdBNEVzd3VVR0o1djdLT0FsVjZFWXNTOVVGX21MLWxVai0teGhhOWZUYjBxdklPZHRRYjQwTlM2S1ZQRzR6V3B3QkdIRktFcDFXYzV1VzRWaGNVVGdRMUkxaHFvczhoNWhPTG9qallOQ0RkSDhoN1phdDh4VzI1WnA3Rm9FcGUyV0pqbktXcmlBYUJYSG8yejZKOWtzN2JXaGJqQ1dBV1hod1lXNTI2ajZsaEZnb2prVmRVZWln0gH_AUFVX3lxTFBkTFQyVk9mOHFjS0V0cnZ2NTRfSDdJZkFjeUR0Z0NzZ2JiaUJvYmsxUDUxZGk2YzVYVnhXOUxUeG04TUR4MHc2VWphdjd1aE9DcURLY2FtTkNMWDd4b0NpcU5uZ1Nzc3VKNWZHUy1DSVhpNXhOZU9ISE5oN1FEeUJGX0RVNWhfTFpKVjE1eTRKVVl3a1dMSFJOTWhkdTlxTkxJV3VWVGJTbUxVSm9sbWZpQjFRaXMxaEg5S0N4Vi02ZzI0MHYzX3VnYmlFMWh3Vmh2VGNWcVQxWGtLaHYyblZldm1zT3dtU3VqNTBlcUczeE5OM0dVOG93Szlmak5KNA?oc=5",
        "source": "Google News - Consent Decrees",
        "summary": "Sun Pharma temporarily halts shipments from Mohali facility to implement US FDA-mandated measures  Business Today",
        "severity": 5,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 0,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:30:01.746Z",
    "first_seen": "2025-09-08T12:30:01.746Z"
  },
  {
    "name": "Fda Adds Firms To Import Alert Due To Pfas In Clams",
    "aliases": [
      "Fda Adds Firms To Import Alert Due To Pfas In Clams"
    ],
    "violations": [
      {
        "id": "891cd2070a3306b11ad5661061200018",
        "type": "import_alert",
        "date": "2025-02-18T08:00:00.000Z",
        "title": "FDA Adds Firms to Import Alert Due to PFAS in Clams - fda.gov",
        "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOZmNSWGJXT1lsWUh0UGxTd3ZndHV0Sk9idkJMUElLdHR2dllZOGNja2FRWmZuZm1HWHNsZTdreXVBOWEyWHp4NktXbWxoNGlKeFA3MHFZeWMzaVZnbWU5ZzFNTk9CQXZZZ3N3SnZoUjYyYzZQbkhVeld6aUJmaHBYNEFsUGNKcFZvbS1iTnRkcXJMdWlJdEE?oc=5",
        "source": "Google News - Import Alerts",
        "summary": "FDA Adds Firms to Import Alert Due to PFAS in Clams  fda.gov",
        "severity": 7,
        "status": "new",
        "response_deadline": null
      }
    ],
    "products": [],
    "facilities": [],
    "executives": [],
    "risk_score": 28,
    "compliance_score": 100,
    "response_times": [],
    "last_updated": "2025-09-08T12:40:48.104Z",
    "first_seen": "2025-09-08T12:40:48.103Z"
  }
]